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Abstract 
 The purpose of this thesis was to assess the integrity of the serotonin system, by 
measuring the neurophysiological response to tasks that measure executive functions, and 
neuroendocrine function in ecstasy users and non-users. Each of the proposed executive 
functions outlined in Miyake et al.’s (2000) conceptual framework (inhibition, switching and 
updating) as well as the addition of access to semantic/long term memory made by Fisk and 
Sharp (2004), was assessed using behavioural tasks in combination with EEG and fNIRS.  
Behavioural performance between ecstasy users and various controls (polydrug and 
drug naïve) was equivalent throughout the thesis. However ERP analysis revealed ecstasy-
related atypicalities in cognitive processing during inhibitory control, switching and access. 
Ecstasy users displayed increases in P2 and N2 components during these tasks that reflect 
recruitment of additional resources. A diminished P3 response during the switching task was 
evident for ecstasy users and polydrug users relative to controls. Regression analyses suggest 
that lifetime cannabis use may be an important factor for this function. Results from fNIRS 
suggest that ecstasy users show an increased haemodynamic response during all four 
executive functions relative to non-users, which suggests that ecstasy users are engaged in 
more effortful cognition than controls. Increases in neuronal activation whilst performing at a 
similar level behaviourally are understood as recruitment of additional resources. Again 
during switching cannabis use may have been an important factor. 
 Another aim of this thesis was to assess neuroendocrine function. Ecstasy users 
displayed elevated basal cortisol levels relative to polydrug controls and drug naïve controls. 
The results suggest that ecstasy is detrimental to the integrity of the HPA-axis. 
 This thesis provides support for ecstasy-related damage to the serotonergic system 
and should be used in educating prospective ecstasy users of relative harms.  
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Chapter 1: Overview of thesis 
 Chapter 1 provides a brief overview of each chapter that this thesis comprises. 
Chapter 2 provides a brief introduction to the study of working memory and the fractionation 
of the central executive. It is these theoretical models of executive functioning that form the 
basis for behavioural assessment in this thesis. This chapter briefly introduces the reader to 
the study of ecstasy use and executive function and provides a rationale for studying each 
function separately. 
 Chapter 3 reviews studies into cognition in ecstasy users, briefly starting with 
intelligence and then focusing more in depth on each of the executive functions that are later 
investigated. This chapter reviews the current understanding of how ecstasy affects executive 
functioning and provides a rationale for further clarification in this research area. 
 Chapter 4 defines the theoretical background of the neuroimaging techniques that are 
used in this thesis, including how they work, what the data that they generate may tell us and 
advantages and limitations of each technique. Furthermore this chapter provides a rationale 
for using the two techniques employed in this thesis in a complimentary fashion. 
 Ecstasy is proposed to damage the serotonergic system and is a proposed neurotoxin. 
It is understood that damage to the serotonin system may underlie any observed cognitive 
deficits. As such Chapter 5 reviews the literature on objective measures of serotonergic 
neurotoxicity in human ecstasy users from various functional and structural neuroimaging 
methods. 
 Chapters 6, 7, 8 and 9 are the empirical chapters of this thesis. The first of these 
assesses each of the four executive functions (using function specific tasks) and their 
electrophysiological correlates from ERPs in ecstasy users, polydrug controls and drug naïve 
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controls. Chapter 7 assesses the haemodynamic response to memory updating using fNIRS 
and two updating tasks (letter updating and spatial updating) in ecstasy users, polydrug 
controls and drug naïve controls. Chapter 8 assesses the haemodynamic response to inhibition 
(using a random letter generation task), switching (using the number-letter task) and access to 
semantic memory (using the Chicago Word Fluency Task) in ecstasy users and controls. 
 The results from these three chapters indicate that ecstasy users perform at a similar 
level to controls in the executive functioning tasks employed in each chapter. However they 
show neurophysiological responses that reflect compensatory mechanisms/recruitment of 
additional resources to enable equivalent performance. 
 Chapter 9 investigates the haemodynamic response to multitasking in ecstasy users, 
polydrug controls and drug naïve controls. Importantly, this chapter also investigates the 
integrity of the HPA-axis and the neuroendocrine response to stress, through salivary cortisol 
sampling. 
 Finally Chapter 10 provides a general discussion of the results and places them in the 
context of the existing literature on ecstasy use, executive function and serotonin system 
degradation. This chapter discusses these results in terms of implications for drug users and 
suggestions for future research.  
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Chapter 2: Working memory and the central executive 
2.1 Chapter overview 
This chapter briefly describes Baddeley’s working memory model and more recent 
work that has built upon this model exploring the central executive, executive processing and 
the fractionation of the central executive. This gives the theoretical basis for further 
exploration of executive functions that are discussed in Chapter 3. 
Theory of working memory, executive functioning and ecstasy use. 
Baddeley’s (1986) multi-component model of working memory is a key construct in 
cognitive psychology. Initially proposed as a three component model, this comprises a 
modality free control system, called the central executive, with limited storage capacity that 
is subserved by two “slave” storage systems. The two slave systems are: the phonological 
loop, which is involved in processing sound and language, and the visuospatial sketchpad, 
which processes visuospatial information. A fourth component- the episodic buffer was later 
added (Baddeley, 2000) to bridge the gap between the limited capacity of the initial three 
components and long term memory. This was added after observing an amnestic patient with 
severe damage to long term memory who was able to recall passages of prose that were 
beyond the capacity of the phonological loop or the visuospatial sketch pad. The episodic 
buffer is regarded as the storage component of the central executive (Baddely, 2003), and is 
thought to be involved in transfer of episodic information to and from long term memory 
stores. 
The central executive is an integral component of working memory and is responsible 
for coordinating the processing of information from the subsidiary components. Initially 
understood to operate as a single unit, studies on individual differences (Miyake et al., 2000) 
and patients with frontal lobe damage (Shallice & Burgess, 1991) started to suggest that 
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perhaps the central executive was not a unified construct. Lehto (1996) explored the 
relationship between working memory capacity and a variety of executive functioning tasks 
in a normal 15-16 year old student population. It was observed that performance on complex 
span measures (working memory) had high inter-correlations with memory updating. 
However, although performance on the Wisconsin Card Sorting Task (WCST) correlated 
with working memory measures, performance on two further executive measures (Tower of 
Hanoi and Global Search Test) did not. Perhaps more interesting, is that none of the 
executive measures correlated significantly with one another, which led Lehto to conclude 
that the central executive was not unified.  
Miyake et al. (2000) explored the separability of executive functions further, by 
examining three possible discrete executive functions: mental set shifting (“shifting”), 
information updating and monitoring (“updating”) and inhibition of prepotent responses 
(“inhibition”) and their contributions to the complex neuropsychological tasks used to assess 
executive function. In this study, performance on three tasks, each proposed to target a 
proposed executive function (WCST, Tower of Hanoi –ToH, and random number generation 
- RNG), as well as two other commonly used executive tasks (operation span and dual 
tasking) were correlated. It was observed, from confirmatory factor analysis, that the three 
target executive functions were moderately correlated with one another, but were distinctly 
separable. Furthermore structural equation modelling revealed that each function contributed 
separately to each task, with performance on the WCST relating to the executive function of 
shifting, ToH pertaining to inhibition, operation span to updating and RNG loaded on both 
inhibition and updating.  
Fisk and Sharp (2004) investigated the separability of executive functions in their 
research on age related cognitive impairment and observed findings largely consistent with 
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Miyake et al.’s fractionated components of the central executive. However an additional 
component termed “access” that involves access to long term memory was proposed. This 
addition was proposed due to word fluency tasks often being used as a measure of executive 
function, and apparent impairment of word fluency after damage to frontal brain regions 
(Stuss et al., 1998). Word fluency involves temporary access of long term memory stores and 
does not seem to fit as well with the three initial proposed components of executive function. 
Furthermore Baddeley (1996) postulated that temporary activation of long term memory was 
a key executive process. In this study a battery of executive tests were administered to an 
elderly cohort, including the WCST, Random Letter Generation (RLG), Brooks spatial 
sequences, reading and computation span, word fluency and a measure of dual task 
performance. All of the tasks loaded on at least one of Miyake’s executive processes apart 
from word fluency and the redundancy measure of RLG (the extent to which a letter is 
produced with the same overall frequency), which loaded on their proposed fourth executive 
function of access. 
The study of executive functions is complicated by task impurity, for example the 
WCST, a commonly used task to assess mental set shifting, requires sorting cards based on a 
particular theme (e.g. colour, shape, number) then switching to another theme at the 
experimenter’s request. This not only involves shifting of the mental set, but also perceptual 
and motor cognitive abilities necessary for sorting cards and monitoring verbal feedback 
(Friedman et al., 2008). As such purer tasks of executive function are required. Further work 
into the separability of executive functions has been conducted by Friedman et al. (2006) 
who suggest that the three executive functions identified in Miyake’s model are differentially 
related to intelligence, with updating showing close relations with crystallised and fluid 
intelligence, but shifting and inhibition showing no such relationship. Furthermore Friedman 
et al. (2008) also suggest that the executive functions are correlated by hereditary factors that 
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go beyond speed of processing or intelligence, but are separable due to other genetic factors 
unique to each function. 
This fractionation of the central executive into four discrete components has helped 
the progression of research into the effects of ecstasy/MDMA on cognition. Many earlier 
studies into ecstasy use and working memory refer to the central executive as a single entity, 
and have yielded equivocal results, whereby users show deficits in some tasks but not others. 
For example Halpern et al. (2004) administered a large battery of neuropsychological tests to 
a relatively pure MDMA user group and found that heavy users were impaired on 
performance of a Stroop task (supposed to be related to inhibition), but did not find 
significant performance deficits on many other tasks (including the WCST, Controlled Oral 
Word Association, WAIS-R digit span subtest, WAIS-R digit symbol subtest, the Rey-
Osterrieth complex figure text and the California verbal word learning test). Fox et al. (2001)  
also observed ecstasy users to be unimpaired on the WCST, supposedly pertaining to the 
executive function of shifting, whereas Fox et al. (2002) show evidence of ecstasy-related 
impairment in shifting as well as verbal fluency, and spatial working memory. Morgan et al. 
(2002) conversely report little performance deficits in the Stroop task or word fluency. Due to 
equivocal findings there was no definitive consensus on whether executive functions were 
impaired in ecstasy users or not. As such, Montgomery, Fisk, Newcombe and Murphy (2005), 
applied Miyake et al.’s (2000) and Fisk & Sharp’s (2004) framework to the research on 
ecstasy users, suggesting that ecstasy users display differential impairments in executive 
function. It is argued that a systematic approach is necessary, using “pure” tasks that tap one 
function only, to observe how MDMA affects each component of the central executive. 
Ecstasy-related impairments were observed in the updating and access components of 
executive function, but not in the switching and inhibition components. 
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In light of these findings, this thesis focuses on the separable executive functions and 
uses function-specific tasks to assess each component of executive function in ecstasy users. 
Furthermore neurophysiological measures such as electroencephalography (EEG) and 
functional Near Infrared Spectroscopy (fNIRS) are employed as more sensitive measures of 
cognitive impairment. The literature on the research pertaining to ecstasy-related deficits on 
executive function briefly touched upon here will be reviewed in greater detail in Chapter 3 
whereby each component of the central executive will be reviewed separately. 
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Chapter 3: Review of the literature on cognitive deficits in ecstasy users 
The recreational drug ecstasy/MDMA (3,4-methylenedioxymethamphetamine) is a 
potent indirect monoaminergic agonist, that is structurally similar to amphetamine and 
mescaline (Morgan, 2000). The acute psychological and physiological effects include 
feelings of euphoria and empathy, increased energy, dilated pupils and tight jaw (trismus) 
(Davison & Parrott, 1997) and are thought to result primarily from serotonin and dopamine 
agonsim (McDowell & Kleber, 1994). However ecstasy has been classed under the novel 
pharmacological category of entactogens (from Greek and Latin roots, meaning to produce a 
“touching within” Nichols, 1986) owing to its unique psychoactive profile that can be 
differentiated from classic hallucinogens and stimulants (Morgan, 2000). MDMA increases 
emotional sensitivity and empathy, but does not produce hallucinations, as such it cannot be 
classified as an hallucinogen or psychostimulant (Cole & Sumnall, 2003). Working memory 
deficits, and those particularly associated with higher level executive functioning tasks appear 
to be most prominent. This is particularly salient given the continued prevalence of 
ecstasy/MDMA use; for example the British Crime Survey (2012) states that 3.3% of 16-24 
year olds report use of MDMA in the last year, and the negative psychological consequences 
could have real world functional significance (Montgomery et al., 2010). MDMA related 
changes in cognition are believed to be related to the drug’s effects on the serotonin system 
(Gouzoulis-Mayfrank et al., 2000) and have been shown to be long lasting (Gerra et al., 
2000). Specifically serotonin, understood to be implicated in supporting working memory 
processes, is densely innervated in the prefrontal cortex (Pazos et al., 1987), and as such it is 
integral in executive processing. 
There have been a number of investigations into working memory deficits in human 
ecstasy users compared to drug naïve controls. This chapter reviews the literature of several 
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aspects of cognition that have been investigated including intelligence, and the four executive 
functions outlined in Chapter 2: shifting, inhibition, updating and access. Although many 
publications cover several executive functions, this chapter has been subdivided into sections 
for each component of the central executive, and thus papers may have been cited multiple 
times.  
3.1 Intelligence: 
 As mentioned in Chapter 2, the executive functions are differentially correlated with 
intelligence so this thesis controls for intelligence throughout. Studies on ecstasy and 
cognition do attempt to control for intelligence, often using Raven’s Standard Progressive 
Matrices (SPM), the Weschler Abbreviated Scale of Intelligence (WASI) or a test of 
crystallised intelligence (e.g. The National Adult Reading Test - NART). 
  Gouzoulis-Mayfrank et al. (2000) measured both crystallised and fluid intelligence in 
ecstasy users, cannabis users and non-drug users. Fluid intelligence was assessed using a 
German version of the Weschler Adult Intelligence Scale – Revised (WAIS-R), Mosaic test, 
in which, participants must reproduce complex visual patterns using cubes (this task assesses 
visuomotor performance, planning and problem solving) and the LPS-4 (a problem solving 
test assessing abstract thinking). Crystallised intelligence was assessed with the German 
WAIS-R general knowledge test. Ecstasy users performed significantly worse than both non-
users and cannabis users on all three intelligence measures. Due to the ecstasy user group 
having lower IQ measures, the researchers had to control for intelligence in their subsequent 
analyses. Gouzoulis-Mayfrank et al. (2003) also observed deficits in crystallised intelligence 
in heavy ecstasy users compared to moderate users and non-users, using the WAIS-R General 
Knowledge test. 
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However, not all studies find differences in intelligence. For example using the NART, 
which involves participants reading 50 words of decreasing fluency in the English language, 
with atypical phonology, so that words should not be guessed correctly using standard 
grammatical pronunciation (a measure of crystallised intelligence), Fox et al. (2002) 
observed no significant differences between ecstasy users and non-users. Furthermore 
Morgan et al. (2006) used the NART to assess premorbid intelligence in ecstasy polydrug 
users, non-ecstasy polydrug users and drug naïve controls and observed no significant 
between group differences in their estimated IQ (ecstasy users: 111.8, polydrug controls : 
112.1, drug naïve controls: 111.2). Similarly, using a Dutch variant of the NART (the DART) 
Renememan et al. (2006) transformed the number of correctly read words into an estimate of 
verbal IQ and observed that former ecstasy users (male: 105.9, female: 102.0), heavy current 
users (male: 106.0, female: 104.5), moderate users (male: 111.2, female: 112.2) and non-
ecstasy polydrug users (male: 104.7, female: 106.9) had comparable premorbid IQ regardless 
of gender. Moreover Dafters et al. (1999) observed that level use of ecstasy was not 
correlated with performance on the NART.  
Montgomery, Fisk and Newcombe (2005) used the NART in ecstasy polydrug users 
compared to drug naïve controls and observed no significant between group differences in 
this measure. The same study also found no significant differences between users and non-
users on Raven’s SPM, whereby participants are required to study a series of problems 
presented as a symbolic sequence and select an appropriate response to complete the 
sequence from a choice of 6/8 options. Montgomery and Fisk (2008) again observed no 
differences between ecstasy users and controls on the NART and Raven’s SPM. Raven’s 
SPM has been used frequently in the literature to assess fluid intelligence, and has repeatedly 
yielded no observable significant differences between ecstasy users and non-users (Fisk et al., 
2004; Montgomery, Fisk & Newcombe, 2005). However, Montgomery et al. (2010) found 
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ecstasy users to score significantly lower than non-users on this measure. Furthermore 
Halpern et al. (2011) found performance on Raven’s SPM and WAIS-R digit symbol subtest 
to be significantly reduced in moderate users, but not heavy users in comparison to drug 
naïve controls. However in an earlier study by the same research group (Halpern et al., 2004) 
on a similarly pure ecstasy using cohort, no such differences were observed.  
Verbal intelligence (using the WAIS III vocabulary subtest) and performance 
intelligence (using the WAIS III block design subtest) in ecstasy users was explored in a 
longitudinal study by Zakzanis and Young (2001) to observe whether these measures were 
robust to continuing ecstasy use over time. The tests were administered twice, one year apart, 
with continued ecstasy use in between testing dates. It was observed that there were no 
significant differences in WAIS vocabulary score between the first testing session (mean = 
53.0) and the one year follow up score (mean = 52.1), nor was there significant decline in 
performance in WAIS block design performance between time one (mean = 49.0) and time 
two (mean= 48.4). However there was a significant correlation between frequency of MDMA 
use and performance change (time one – time two score) on the vocabulary subtest, 
suggesting that verbal intelligence is adversely affected by frequency of ecstasy use. 
Thomasius et al. (2003) also explored premorbid intelligence using the German multiple 
choice test of vocabulary knowledge (Mehrfachwahl-Wortschatztest – MWT-B), in their 
initial study (Thomasius et al., 2003) they report that ecstasy users (IQ score – 102.5), former 
ecstasy users (IQ – 106.48), polydrug controls (IQ -104.28) and drug naïve controls (IQ -
104.97) showed no significant differences in IQ, and this remained non-significant in their 
follow up study (Thomasius et al., 2006) (ecstasy users – 101.36, former users – 106.48, 
polydrug controls – 107.91, drug naïve controls – 105.20). Currently abstinent ecstasy users 
were assessed on verbal intelligence using the WAIS-III vocabulary subtest and the NART in 
a study by McCann et al. (2007) and again it was observed that differences between abstinent 
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ecstasy users and drug naïve controls on their estimated baseline intelligence were non-
significant (WAIS- III; MDMA users 44.44, controls 40.39, NART; MDMA users 102.74, 
controls 99.38); it was suggested that these tests provide estimates of verbal intelligence that 
are insensitive to MDMA related neurotoxicity. 
 In summary, it would appear that most studies in this area attempt to control for IQ 
differences, and in the majority of cases there is little difference in IQ between ecstasy using 
populations and controls. In studies that do show between group differences in IQ measures, 
IQ is used as a covariate and statistically controlled for in subsequent analysis. Although one 
longitudinal study (Zakzanis & Young, 2001) observed a negative correlation between 
frequency of ecstasy use and performance on verbal intelligence measures, suggesting that 
ecstasy use could affect intelligence over time, other longitudinal studies have found little 
effect of use on measures of intelligence (Thomasius et al., 2006). However in line with most 
other research in this area, the studies presented in this thesis all have at least one control 
intelligence measure. 
3.2.1 Mental set switching 
Mental set “switching” or “shifting” is the ability to switch attention between task 
types, whereby a switch between tasks is associated with a performance cost, either in 
accuracy or time, compared to completing two tasks in succession (Jersild, 1927). Switching 
reflects cognitive flexibility and is one of the core executive functions outlined in Miyake et 
al.’s (2000) framework. Several tasks have been used in the literature to assess this function 
in ecstasy users, including the WCST, the number-letter task, plus-minus task, and a 
switching variant of the Stroop task. Findings of performance of this executive function in 
ecstasy users are equivocal. 
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 Fox et al. (2001) used a computerised version of the WCST whereby participants 
have to learn a rule in order to sort a pack of 128 cards, along three possible ‘dimensions’ 
(colour, shape or number). After 10 consecutive successful card placements, the rule by 
which the cards were being sorted was changed (switch). There were six switch trials, where 
the rule changed (from colour to shape to number then repeated). In this task participants are 
scored for number of correctly completed trials, number of trials to complete the first 
category, percentages of perseverative (the amount by which they fixated on a rule after it 
had changed) and non-perseverative errors and failure to maintain set. No significant 
performance differences on the task were reported between controls and ‘problem’ or ‘non-
problem users’ (defined as problems attributed to use of ecstasy), furthermore lifetime dose 
of ecstasy (low = < 100 tablets, medium = 100-500 tablets, high = > 500 tablets) had no 
significant effect on performance. The WCST was administered in a neurocognitive test 
battery to current ecstasy users [15 male, mean age = 24.5, mean lifetime dose (MLD) for 
males = 1033.77, females = 600.42 tablets], former users (16 male, mean age = 24.13, MLD 
for males = 987.31, females = 533.80 tablets), polydrug controls (15 male, mean age = 24.41) 
and drug naïve controls (15 male, mean age = 23.13) by Thomasius et al. (2003), planned 
comparisons revealed that the polydrug user group produced a significantly higher amount of 
perseverative errors than both ecstasy using groups. Reneman et al. (2006) compared 15 
moderate MDMA users (9 male, mean age = male 25.6, female 22.7, MLD = male 29.5, 
female, 27.3), 23 heavy MDMA users (12 male, mean age = male 27.1, female 25.0, MLD = 
male 831.8, female 200.9 tablets ), 16 former users (8 male, mean age = male 26.4, female 
24.1, MLD = male 126.9, female 409.3 tablets) and 13 ecstasy naïve, but drug taking controls 
(7 male, mean age = male 29.3, female 23.3) on performance on the WCST and observed 
little difference on any of the performance measures of the task. Similarly Back-Madruga et 
al. (2003) observed no differences in performance on the WCST between recreational ecstasy 
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users (n=22, 14 male, mean age = 37.0, mean lifetime occasions = 74.6) and controls (n=28, 
23 male, mean age = 39.9). Halpern et al. (2004) also observed no significant differences in 
performance on the WCST between 23 MDMA users with minimal exposure to other drugs 
(8 male, median age = 20, median lifetime MDMA episodes = 60) and 16 ecstasy naïve 
comparison individuals involved in rave subculture (9 male, median age = 22). However, 
when the ecstasy user group was further subdivided into light (less than 50 occasions of use) 
and heavy (more than 50 occasions of use) users, heavy users performed worse compared to 
non-users after adjusting for age, sex and family of origin on the “total categories” score of 
the task. However this score does not relate to the executive function of switching in the same 
way as total perseverations does and may not reflect switching deficits. In a follow up study 
(Halpern et al., 2011) with similarly ecstasy pure participants (n=52, 30 male, median age = 
22, median lifetime episodes of MDMA use = 43.5) versus rave subculture matched controls 
(n=59, 38 male, median age = 24) it was again observed that there were no significant 
between group differences in performance on the WCST. However this changed when the 
ecstasy user group was subdivided into heavy and moderate users. This time WCST total 
category score was significantly reduced among moderate, but not heavy users. Results from 
studies administering the WCST as a measure of switching seem to suggest that this function 
is relatively robust to ecstasy use. However as discussed in Chapter 2, this task has been 
criticised for not necessarily being a pure measure of mental set switching. Therefore, it is 
important to consider other tasks that have assessed this function. 
 Fox et al. (2002) compared 20 ecstasy polydrug users (10 male, mean age = 27.3, 
MLD = 172.0 tablets) and 20 ecstasy naïve polydrug users (8 male, mean age = 27.5) on their 
ability to effectively “switch” attention using the 3D IDED (intra-dimensional/extra 
dimensional) attention shift task as well as a switching version of the Go/NoGo task. Based 
on a task in the CANTAB neuropsychological battery, the 3D IDED comprised of eight 
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stages related to forming, maintaining and shifting attentional set. Participants are required to 
learn two alternative forced choice discriminations and their reversals. The stimuli used, 
varied on three possible dimensions (one dimension is relevant and the other two are not). In 
the first and simplest stage (visual discrimination) two stimuli are presented and these vary on 
one of the three dimensions (e.g. colour) and in the reversal stage the previously incorrect 
item becomes the correct item. Following this, there is the compound visual stage in which 
the two stimuli are different on all three possible dimensions. In the intra dimensional shift 
stage, the “relevant” dimension (e.g. colour) remained the same despite the introduction of 
two novel stimuli. Finally in the extra-dimensional shift stage participants are required to 
shift their response set to a previously irrelevant dimension (e.g. shape). Each stage has a 
reversal stage and participants progress to the next stage by achieving six successive 
discriminations. Although increases in errors and reaction time were observed within groups 
as difficulty increased, there were no significant between group differences in performance at 
any stage on non-reversal trials. However on reversal trials the difficulty by group interaction 
was approaching significance, with ecstasy users making more errors on simple and 
compound reversal trials but fewer errors on the extra dimensional reversal condition than 
controls. Furthermore ecstasy users were significantly slower than controls at all levels of 
reversal, indicating performance deficits. In the same study, switching was also assessed with 
a switching variant of the Go/NoGo task with 10 blocks, each containing 18 symbols 
appearing rapidly on the centre of a screen. Half of the symbols were “targets” and half were 
“non-targets” comprising of letters (from A-G) and numbers (2-9). Participants had to press 
the space bar when a target appeared on the screen and were to withhold a response to non-
targets. The targets (either letters or numbers) switched every two blocks. Mean errors were 
calculated (failure to press space bar) as well as mean distractors (pressing space bar when it 
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should not have been pressed) and mean reaction time for correct responses. No between 
group differences were observed on any of the measures analysed on the task. 
 The number-letter task is considered to load on the executive function of switching 
only, and was used by Montgomery, Fisk, Newcombe and Murphy (2005), to assess 
switching performance in 51 ecstasy polydrug users (27 male, mean age 21.96, MLD = 
345.96 tablets) compared to 42 non-user controls (8 male, mean age 20.83). In this task 
(adapted from Rogers & Monsell, 1995), participants are presented with a number-letter pair 
(e.g. “D4”) in one of four quadrants on a computer screen. If the number-letter pair appears in 
one of the top two quadrants of the screen, participants must indicate whether the letter is a 
vowel or a consonant. If the pair appears on the bottom half of the screen participants should 
indicate whether the number is odd or even. In the main three blocks of the task, number-
letter pairs appear 64 times, in the first block they alternate between the two quadrants on the 
top half of the screen. In block two, pairs alternate between the bottom two quadrants. 
However on the third block the pairs rotate clockwise around all four quadrants of the screen. 
As such every second trial in block three requires a switch in categorisation. A switch cost is 
calculated by subtracting the average time taken to complete trials on the first two blocks 
(where no switching is required) from the mean trial reaction time in block three. There were 
no differences between users and non-users in this task, and groups had equivalent age, 
premorbid intelligence, fluid intelligence and years in education. In the same study, the plus-
minus task also measured set switching, and involves three blocks of mental arithmetic; in 
block one participants are given a list of 30 two-digit numbers (10-99) and are required to add 
three to each number, in block two participants are given another 30 two-digit number list 
and are required to subtract three from each. In the final block participants are given a third 
30 two-digit list and participants are to alternate between adding three and subtracting three 
from each number on the list. This final block involves a shift/switch and the switch cost is 
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calculated by subtracting mean completion times for lists one and two from the time taken to 
complete list three. No between-group differences were observed on this task, and the main 
effect of ecstasy use on switching was non-significant.  
Using a modified version of the Stroop task, to assess inhibition and task switching, 
Dafters (2006) compared performance of 18 ecstasy users (12 male, mean age = 23.24, MLD 
= 522.33), 15 ecstasy users who did the task in reversed order (9 male, mean age = 22.93, 
MLD = 475.87), 17 cannabis users (13 male, mean age = 23.19) and 18 controls (10 male, 
mean age = 22.67) whom had never used either drug. The switching component came in the 
fourth phase of the task whereby colour words appeared on a screen and participants were 
required to name the ink colour rather than read the word. On half of the trials the word was 
underlined in black and participants were required to select the colour name rather than the 
ink colour, hence a switch in rule. Reaction times were analysed for the switch trials and it 
was reported that ecstasy users performed worse than both cannabis users and non-drug user 
groups on the switching component of the task, after covarying for other drug use. However, 
the mapping of tasks onto individual executive functions is difficult, and as this task is 
usually implemented to assess inhibition, perhaps this manipulation does not necessarily tap 
switching exclusively. It could be that these results still reflect inhibition deficits (Murphy et 
al., 2009). Dafters et al. (1999) had previously observed dose related impairment in switching 
using a derivative of the WCST called the Behavioural Assessment of the Dysexecutive 
Syndrome (BADS) rule shift cards test, whereby MDMA use was negatively correlated with 
performance on the task. There was, however, no control group in this experiment, and when 
heavy ecstasy (at least 50 MDMA tablets over lifetime)/ cannabis (1680.7 mean lifetime 
joints) users, were compared to light ecstasy (below 50 tablets)/cannabis users (1252.9 mean 
lifetime joints), cannabis only users (1023.1 lifetime mean lifetime joints) and non-drug 
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controls, this task yielded no significant differences between groups after covarying for 
alcohol, amphetamine cocaine and LSD (Dafters et al., 2004). 
von Geusau et al. (2004) assessed cognitive flexibility in 26 ecstasy using first year 
university students (17 male, mean age = 21.4 MLD = 53.82 tablets, 9 female, mean age = 
21.7, MLD = 38.78) and 33 non-user controls (12 male, mean age = 22.0, 21 female, mean 
age = 21.4) using the Dots-Triangles task and the Local-Global task. In the Dots-Triangles 
task participants are presented with a 4x4 grid on a computer screen in which varying 
numbers of dots or triangles appear. When dots appear, participants have to decide whether 
there are more dots in the left half of the screen or the right half, and when triangles appear a 
decision has to be made as to whether there are more triangles in the top half of the screen or 
the bottom half. In blocks one and two, all trials are dots or triangles (randomised), whereas 
in block three it alternates between dots and triangles being presented every four trials. The 
Local-Global task involves participants responding to rectangles and squares. Larger (global) 
rectangles or squares consist of smaller (local) rectangles or squares. Participants respond to 
either the local or global figures only, in the first two blocks of the task. In the third block, the 
rule alternates between local and global every fourth trial, initiating a switch. Male users 
displayed a significantly higher switch cost reaction time than non-users in the dots triangles 
task, although they were also shown to be significantly more accurate. Female users and non-
users were equivalent in performance on this task. Moreover on the Local-Global task male 
users were significantly slower than controls and had a higher switch cost. However there 
was no significant difference in accuracy on this task.  
 In summary, it appears from the literature that the majority of studies suggest that this 
executive function is relatively stable after ecstasy use, although there may be issues with the 
purity of some of the tasks. However there is some evidence to suggest that this executive 
 
 
 
 
27 
 
function warrants further investigation. Although von Geusau et al. (2004) suggests that this 
function is more affected in males, this could be an effect of dose, as the males in this sample 
had a higher mean lifetime dose than females and the range was much larger for males. This 
is interesting to consider given that Dafters et al. (1999) showed evidence of a relationship 
between dose and performance on set switching. Halpern et al.’s (2004) study also showed an 
effect in heavy users compared to light users. However this was contradicted in a follow up 
study (Halpern et al., 2011) with moderate users performing worse than heavy users. 
Furthermore Dafters’ 2006 study showed evidence for deficits in this area. Perhaps the 
addition of neuroimaging techniques in combination with performance on these tasks can 
help to address equivocal findings. As such the effect of ecstasy use on mental set switching 
will be investigated in this thesis both behaviourally and with EEG and fNIRS, using the 
number-letter task in Chapters 6 and 8. 
3.2.2 Inhibitory control 
 Inhibitory control, or response inhibition is one of the executive processes outlined in 
Miyake et al.’s (2000) framework and involves the inhibition of prepotent, or dominant 
responses when they are not necessary. This function has been assessed in ecstasy using 
populations with several tasks, including: the traditional Stroop task, RLG, RNG, ToH, Stop 
Signal and Go/NoGo tasks. 
 The most frequently used task to assess this function in the literature is the Stroop task 
(Stroop, 1935). Conventional Stroop measures involve comparing reaction times of 
participants to name the ink colour of a colour named word (e.g. the word “yellow” written in 
red ink), to naming the ink colour when the stimulus and colour match (e.g. “red” written in 
red ink) or the stimulus is not a word (e.g. an asterisk) (Murphy et al., 2009). Morgan et al. 
(2002) examined performance on the Stroop task in 18 current heavy ecstasy users (9 male, 
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mean age = 23.4, MLD = males 513 tablets, females 93 tablets), 15 former heavy ecstasy 
users (4 male, mean age = 24.7, MLD = males 336 tablets, females 577 tablets, abstinent for 
at least 6 months), 16 ecstasy naïve polydrug controls (8 male, mean age = 22.1) and 15 drug 
naïve controls (6 male, mean age = 22.4). No significant between group differences were 
observed for number of errors made or reaction time. Dafters (2006) used a modified version 
of the Stroop task, in which standard colour-word interference trials were interspersed with 
trials where the target colour was the same as the distractor word from the previous trial. 
Performance was compared between ecstasy users, cannabis users and controls (as described 
in Chapter 3.2.1). After covarying for cocaine, amphetamines, alcohol and tobacco, ANOVA 
revealed no significant between group differences on the magnitude of Stroop interference 
reaction times (pre potent response inhibition). However a difference was observed on the 
magnitude of negative priming, whereby ecstasy users showed a reduced priming effect 
(reduced short term residual inhibition) compared to both other groups. It was suggested that 
these two inhibition types are regulated by separable processes and future work should 
investigate the microstructure of cognitive subcomponents. Back-Madruga et al. (2003) failed 
to observe behavioural differences in the Stroop task between ecstasy users and controls 
matched for age, IQ and education (described in Chapter 3.2.1). Similarly Gouzoulis-
Mayfrank et al. (2000) observed no significant differences on Stroop performance between 
ecstasy users, cannabis users and non-drug users. However Halpern et al. (2004) did observe 
ecstasy-related performance deficits on the Stroop task, after subdividing the ecstasy using 
population into heavy and light users (as described in chapter 3.2.1). Heavy users showed 
significantly longer reaction times and more Stroop errors on interference trials. However, 
these findings were not replicated in a follow up study (Halpern et al., 2011). A longitudinal 
test on 149 new ecstasy users (<5 MDMA use occasions before participating in the study) 
was conducted by Wagner et al. (2012) to examine whether abnormalities in executive 
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function existed prior to drug using. This was followed up one year later with 109 remaining 
participants; Of these, 43 did not use illicit substances other than cannabis over the 1 year 
(classed as non-users for analysis) and 23 took more than 10 MDMA tablets over the one 
year period (mean = 33.6). The remaining participants used MDMA more than once, but had 
taken less than 10 tablets, and so were excluded from follow up analysis. Using a German 
variant of the Stroop task, no significant differences were found in performance between 
groups, or between baseline and follow up sessions. This suggests that performance on this 
task does not decline following continued use in new users over a one year period.  
 Wareing et al. (2000) assessed performance of 10 ecstasy users (mean age = 22.2, 
mean duration of use = 4.1 years), 10 former users (mean age = 22.6, mean duration of use = 
3.9 years, abstinence of at least 6 months) and 10 non-users (mean age = 22.6) on RLG. 
Participants were instructed to speak aloud consonants in random order and to avoid 
repeating letter sequences, producing alphabetical sequences and to try and produce each 
letter with the same overall frequency. Participants were required to produce three sets of 100 
letters, at a different rate (every 4 seconds, 2 seconds or 1 second – presentation randomised). 
This task yields three performance measures; redundancy - the extent to which each letter 
appears with the same overall frequency, number of letters produced at each rate (often due to 
more accelerated rates participants will lapse and produce fewer letters) and number of vowel 
intrusions. A low score on redundancy and vowel intrusions is desirable for good 
performance on this task, whereas a high score on the number of letters produced is indicative 
of good performance. Ecstasy users (both groups) performed worse on the task compared to 
controls, with more vowel intrusions at all three rates, and higher redundancy and lower 
number of letters produced relative to controls at the 1s rate. It is suggested that this function 
is impaired in ecstasy users and this persists after six months, furthermore ecstasy users 
perform worse when greater demand is placed on them. However the sample size here is 
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relatively small and these results were not replicated in a follow up study with a larger sample 
(Fisk et al., 2004) where it was observed that ecstasy users (n=44, mean age = 21.52, MLD = 
343.38 tablets) were unimpaired on all measures of RLG performance relative to controls 
(n=59, mean age = 21.37). Moreover, Montgomery, Fisk, Newcombe and Murphy (2005) 
observed ecstasy users (described in Chapter 3.2.1) to perform better at RLG than non-users 
with users producing significantly more letters than controls. Other measures (alphabetic 
sequences, repeat letters and redundancy) were non-significant. 
RLG was also administered to 15 ecstasy users (3 male, 1 transsexual, mean age = 
24.5, MLD = 364.8 tablets), 12 cannabis only users (6 male, mean age = 21.9) and controls (6 
male, mean age = 19.6) who had never used either drug in a study by Murphy et al. (2011). 
No between group differences were observed in measures of alphabetic sequences or repeat 
sequences (measures of impulsivity) and ecstasy use did not predict performance on these 
measures. However there were between group differences in ‘redundancy’ which the authors 
suggest pertains more to access to long term memory and as such will be discussed in 
Chapter 3.2.4.  
 More recently, Clark et al. (2009), suggested that disrupted ‘reflection’ impulsivity 
may be more related to cannabis use than MDMA use. In this study 46 current ecstasy users 
(33 male, mean age = 24.2, MLD = 609.1 tablets), 14 former ecstasy users (6 male, mean age 
= 27.9, MLD = 1000.8 tablets, abstinence of at least 1 year), 15 cannabis users (5 male, mean 
age = 22.3) and 19 drug naïve controls (12 male, mean age = 24.0) were compared on 
performance of a novel information sampling task (IST). The IST comprised of two 
conditions; the fixed reward (FR) condition and the reward conflict (RC) condition. 
Participants had to make judgements on which colour (out of a choice of two) was most 
frequently contained inside 25 boxes. Participants could open as many boxes as they desired 
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before making the judgement. In the FR condition participants were awarded 100 points for a 
correct response regardless of how many boxes were opened before reaching the decision. In 
the RC condition 250 points were available to win at the start of the trial, which decreased by 
10 points with every box that was opened, creating conflict between reward and certainty 
level. Moreover, 100 points were deducted for incorrect responses. Performance was indexed 
by average number of boxes opened, as well as calculating the probability of a correct 
response at the point of decision [P(correct)]. Post-hoc analysis revealed that cannabis users 
opened significantly less boxes than current ecstasy users, and this difference was 
approaching significance with former users and drug naïve controls. There was also a group 
by gender interaction, and subsequent analysis revealed that male cannabis users had 
significantly reduced information sampling compared to males in all three other groups. This 
difference was not the case in females, despite equivalent cannabis use in males and females. 
However, the results from this study are difficult to interpret given the higher use of cannabis 
(although not statistically significant) in both ecstasy groups compared to cannabis users. The 
authors suggest this study shows evidence against a simplistic pathway from ecstasy 
consumption to elevated impulsivity via serotonin neurotoxicity. 
 The Go/NoGo task, is believed to have specificity for the executive function of 
response inhibition. The literature suggests that ecstasy users are relatively unimpaired on 
this task also. Gouzoulis-Mayfrank et al. (2003) used this response inhibition task in which 
participants are presented with two visual stimuli (e.g. an X and an O) independently, one of 
these is defined as the critical target and every time this stimulus appears on the screen 
participants are to respond to it. Whereas the other stimulus is a non-critical target and 
responses are to be inhibited. Performance is measured by the amount of responses to the 
non-critical target (errors). In this study no significant differences in performance on the task 
were observed between 30 heavy ecstasy users (21 male, mean age = 21.5, MLD = 503.2 
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tablets), 30 moderate users (21 male, mean age = 24, MLD = 39.5 tablets) and non-drug 
controls (21 male, mean age = 25.37). Similarly Roberts & Garavan (2010) assessed 20 
ecstasy users (10 male, mean age = 22.4, MLD = 406.5 tablets) and 20 drug naïve controls 
(10 male, mean age = 22.5) on the Go/NoGo task in an fMRI study. No significant between 
group differences were observed on any of the performance measures (% of successful 
response inhibitions, error of commission reaction times and GO reaction times). However 
between group differences were observed on neurophysiological data which will be discussed 
further in Chapter 5.5. Hanson and Luciana (2010) also observed no MDMA related 
performance deficits in a Go/NoGo task. On the contrary Hoshi et al. (2007) observed 
impaired response inhibition on a Go/NoGo task in current ecstasy users (n=25, mean age = 
28.64, mean lifetime uses = 288.00) compared to former users (n=28, mean age = 29.50, 
mean lifetime uses = 264.86) and drug naïve controls (n=27, mean age = 32.04). However, 
polydrug controls (n=29, mean age = 31.93) were also impaired in this task compared to 
former users and drug naïve controls. The authors concluded that recency of use may play a 
role in response inhibition given that former users do not appear impaired on this function. 
Moreover recent use of cannabis and cocaine may also play a role in inhibition given that 
polydrug controls showed impairments compared to former users and drug naïve controls. 
 The majority of published studies investigating this function using the Stroop task 
have yielded no ecstasy-related effects in terms of performance. Although Halpern et al. 
(2004) did observe differences with this task after subdividing their ecstasy user group to 
heavy and light users. This was, however, not replicated in a follow up study, using similarly 
pure ecstasy users. As such the initial findings should be treated with caution. Wareing et al. 
(2000) observed deficits in ecstasy users (both current and former) compared to non-users 
with RLG, however again this was not replicated. Of the Go/NoGo tasks reviewed, only one 
showed drug related deficits behaviourally, and recent cannabis and cocaine use were 
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implicated here; as such it would appear that this function is relatively robust to MDMA use. 
Nevertheless this thesis intends to provide a complete analysis of MDMA’s effects on 
executive functioning. Therefore performance in this function will be assessed with the 
addition of neuroimaging to provide a more complete understanding of the mechanisms that 
subserve this function. This function will be investigated using the Go/NoGo task and the 
RLG task using EEG and fNIRS in chapters 6 and 8 respectively. 
3.2.3 Updating 
 The updating function of working memory involves the monitoring and coding of 
incoming information for task relevance, and updating the items held in working memory by 
replacing irrelevant information with new incoming relevant information (Miyake et al. 
2000), and appears to be more consistently affected by MDMA use.  
 Montgomery, Fisk, Newcombe and Murphy (2005) assessed this function in 27 
ecstasy users (14 male, mean age 21.70, MLD = 345.96 tablets) versus 34 non-user controls 
(10 male, mean age 21.59) using a letter updating task and a computation span task. In the 
letter updating task participants are presented with a random sequence of between six and 12 
consonants. There are 24 trials and participants are unaware of the list length each time. 
Participants complete six trials at each list length (6, 8, 10 and 12) and in each case need to 
recall the last six consonants. A composite score for updating can then be calculated. In this 
study a second measure of updating was also completed (computation span). Participants are 
given a number of arithmetic problems to solve (e.g. 4 + 7 = ?) and have to circle the correct 
answer from a choice of three possible answers, as well as simultaneously remembering the 
second digit of each presented problem. Following each set of problems, the second digits are 
to be recalled in the order they were presented. The number of arithmetic problems, to be 
solved whilst remembering second digits, increases as the task progresses. For the first three 
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trials, one problem is presented, increasing to two for the next three trials and then increased 
by one every three
 
trials until the participant gives two incorrect answers in a set. 
Computation span is defined as the maximum number of second digits in serial order 
correctly remembered, accompanied by correct arithmetic responses. In this study the authors 
observed no between group differences in background variables such as age, premorbid 
intelligence, number of hours slept per evening, years of education or fluid intelligence (as 
measured by Raven’s SPM) – although this was approaching significance. Ecstasy users did 
however score significantly higher than non-users for subjective daytime sleepiness (as 
measured by the Epworth Sleepiness Scale). It was observed that ecstasy users performed 
significantly worse than non-users on both the letter updating and computation span task 
measures. Letter updating was subsequently investigated again by Montgomery and Fisk 
(2008), with 73 ecstasy users (39 male, mean age = 21.77, MLD = 309.86 tablets) and 73 
non-ecstasy user controls (16 male, mean age = 20.73). Separate analyses were conducted 
according to span length (span = 4, 5 or 6), and it was observed that ecstasy users with simple 
spans of five and six performed worse than non-users. Those with a span of four were not 
significantly different. It is suggested that this may be due to small numbers of participants 
with this span length, thus reducing the statistical power of the analysis. Correlational 
analysis revealed that higher levels of ecstasy use were associated with poorer performance 
on the task, whereas indicators of cocaine and cannabis use were not correlated with updating 
performance. 
Fisk et al. (2004) had previously observed deficits in updating, using the computation 
span task, in ecstasy users (described in Chapter 3.2.2) compared to non-users. Performance 
on this task was significantly worse in the ecstasy using cohort after covarying for cannabis, 
amphetamine and cocaine use, as well as cigarettes smoked per day and units of alcohol 
consumed per week. Similarly Wareing et al. (2004) observed deficits in both current ecstasy 
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users (n=42, 22 male, mean age = 24.69, MLD = 553 tablets) and former users (n=17, 9 male, 
mean age = 26.06, abstinent for at least 6 months, MLD = 385 tablets) compared to non-user 
controls (n=31, 12 male, mean age = 23.39) in computation span. This remained significant 
after statistically controlling for cannabis and other drugs and is suggestive of long lasting 
impairments as the deficits persist after six months abstinence.  
Wareing et al. (2005) measured computation span in 36 current users (mean age = 
21.81, MLD = 591.33 tablets), 12 former users (mean age = 26.83, MLD = 433.36) and 31 
controls (mean age = 23.39). The updating component of spatial working memory was also 
investigated with a maintenance plus type visuo-spatial working memory task. This task 
involved participants being presented with a 4x4 matrix on a computer screen, in which five 
cells would be highlighted for three seconds. The task commenced with one matrix being 
presented three times. On the next three trials two matrices were presented sequentially and 
this kept on increasing by one matrix every three trials up until a maximum of six matrices 
per trial. In each matrix, one of the highlighted cells was filled with 0’s and participants had 
to remember the position of this cell, whist simultaneously indicating whether there were 
more highlighted cells at the top or the bottom of the matrix. After all of the matrices for each 
trial had been presented, participants had to indicate on a blank grid all of the 0 labelled cells 
that had appeared in the trial, in the order that they had appeared. This had to be correctly 
achieved on two out of three trials at each level for acceptance of performance at that level. 
This task is analogous to computation span, as it requires concurrent processing and storage 
of incoming information but without the phonological component. It was observed that 
ecstasy users and former users both performed significantly worse in the computation span 
task. Moreover both groups of ecstasy users performed significantly worse than non-users in 
the spatial working memory task. These differences remained after controlling for spatial 
span and age. Spatial updating was investigated by Montgomery and Fisk (2008) using a task 
 
 
 
 
36 
 
that is analogous to the letter updating task, in which participants are presented with blocks in 
a Corsi type arrangement and a random sequence of spatial locations are highlighted. 
Twenty-four trials (6 at span sequence length, 6 at span+2, 6 at span+4 and 6 at span+6) are 
undertaken whereby the participant is unaware of the number of locations to be highlighted. 
The participant is to indicate the last X amount of blocks highlighted in the order they were 
presented (where X is the participant’s span that had been calculated prior to undertaking the 
updating task). Seventy-three ecstasy users were compared to 73 non-users on task 
performance (as described above) and separate analyses were conducted for each span length. 
It was observed that for those participants with a spatial span of five, ecstasy users performed 
significantly worse than controls. Furthermore heavy ecstasy use was correlated with poorer 
performance. Spatial span and spatial working memory was assessed in 52 polydrug users 
(MDMA use 0-150 tablets) and non-drug controls (< 10 occasions of cannabis use and no use 
of other drugs) by Hanson and Luciana (2010). The Spatial Delayed Response Task (SDRT) 
was used in which participants had to correctly recall a spatial location that had been 
highlighted on the screen after various delay intervals (500ms, 4000ms or 8000ms). Polydrug 
users had poorer spatial memory spans, and were more negatively impacted by increasing 
delay intervals than controls (as measured by the SDRT). However the polydrug user group 
was a mixture of ecstasy polydrug users and ecstasy naïve polydrug users. Exploratory 
correlations showed that the spatial working memory summary score was negatively 
correlated with average number of ecstasy tablets consumed per session, as well as maximum 
number of tablets ever taken in one session. Total lifetime dose (tablets) was not correlated 
with performance suggesting that impairment is associated with the size of an 
average/maximal dose.  
Backward digit span is another measure of updating that has been employed in the 
research on ecstasy use. Participants are required to repeat sequences of digits in the opposite 
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order (backwards) to which they were presented. Sequence lengths increase with successful 
performance and points are gained for sequences that are correctly repeated in order. Reay et 
al. (2006) compared performance in this task between 15 ecstasy polydrug users (9 male, 
mean age = 25, mean ecstasy use = 11.5 tablets per month for the last 4.3 years) and 15 non-
ecstasy polydrug users (7 male, mean age = 21.3, defined as having never used ecstasy); it 
was observed that performance was not significantly different between the two groups after 
controlling for cannabis, cocaine, alcohol and tobacco. Similarly, Gouzoulis-Mayfrank et al. 
(2003) observed no performance differences on this task between heavy ecstasy users, 
moderate users and non-users (as described in Chapter 2.3.2). However in a previous study 
by the same group (Gouzoulis-Mayfrank et al. 2000), it was reported that ecstasy users (at 
least two tablets per month over the previous two years/at least 25 occasions; no heavy 
alcohol use/no other illicit drug use except cannabis) performed significantly worse than non-
drug users and cannabis matched controls, and this remained significant after covarying for 
general knowledge. Backward digit span (and forwards digit span) was also administered to 
11 MDMA users (4 male, mean age = 22.9, MLD = 32.5 tablets), 13 polydrug users (4 male, 
mean age = 23.2) and 13 non-users (4 male, mean age = 23.2), in an EEG study by Nulsen et 
al. (2011), who observed no main effect of group on performance. Moreover, MDMA 
variables did not predict performance in their regression analyses. Croft et al. (2001) also 
used backward and forward digit span as a measure of updating performance to assess the 
relative contributions of ecstasy and cannabis to cognitive impairment (31 drug naïve controls, 
11 MDMA/cannabis users and 18 cannabis users). It was observed from ANCOVA that there 
were no differences between MDMA/cannabis users and cannabis only users on these 
measures. However there were significant differences between drug naïve controls and a 
combined (both MDMA/cannabis users and cannabis only users) drug user group. It was 
suggested that cannabis use was more closely related to performance deficits, as both drug 
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user groups had used cannabis and did not differ on performance. Moreover, covarying for 
MDMA consumption had little effect on results. This highlights the complication of 
concomitant use of other drugs in this research area, and suggests that cognitive deficits 
observed in ecstasy users may be related to cannabis use.  
Halpern et al. (2011) measured backwards digit span in ecstasy users, who report little 
use of other drugs, and non-users (as described in Chapter 3.2.1). Modest differences between 
users and non-users were observed, with ecstasy users scoring lower for correct repeated 
sequences. However it was concluded that differences were sufficiently limited to reject a 
large effect of ecstasy. As such residual cognitive deficits in ecstasy users were not assumed. 
However in a reinterpretation of results, Parrott (2011) suggested that the initial interpretation 
was incorrect and that, these results were in-line with other studies suggesting serotonergic 
neurotoxicity and cognitive impairment in ecstasy users. It was argued that the participants in 
Halpern et al.’s (2011) study were careful drug users, with lifetime rates that were not 
particularly high (especially for the heavy user group) and that usage was not intense. The 
bioenergetic stress model (Parrott, 2006) suggests MDMA damage is greater when taken 
intensely and cumulatively. Parrott (2011) suggests that even under the neuroprotective 
circumstances that users in this sample experienced, cognitive damage is still apparent. 
 Bedi and Redman (2008) assessed backwards digit span in 45 ecstasy polydrug users 
(ecstasy and cannabis use ≥ 10 times), 48 cannabis polydrug users (cannabis use ≥ 10 times, 
with variable other drug use) and 40 legal drug users (namely alcohol, > 5 times cannabis 
use). No differences were observed here on a group level, however hierarchical regression 
suggested that weak negative semi-partial correlations were apparent with lifetime ecstasy 
dose and LSD dose with attention/working memory scores (digit span forward and digit span 
backwards). Other studies that report no ecstasy-related deficits on backwards digit span 
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include Thomasius et al. (2003) and Bhattachary and Powell (2001). Suggesting this task has 
produced more varying results than other tasks that assess updating. Nevertheless a meta-
analysis by Rogers et al. (2009) suggested that generally ecstasy users performed worse than 
controls on common measures of digit span. 
 The N-back task has been used to assess updating in ecstasy users, often in 
association with neuroimaging methods (which will be reviewed in a separate chapter). In 
this task, participants are usually presented with strings of digits (or letters) sequentially, and 
upon instruction are required to recall the “nth” character back in the sequence (where n=0 is 
the last character to be displayed in the sequence). This task can be varied for difficulty 
depending on how far back in the sequence the participant is required to recall. Gouzoulis-
Mayfrank et al. (2003) observed heavy users, moderate users and non-users (as described in 
Chapter 2.3.2) performance on a 2-back task (whereby participants must respond to a 
stimulus if it is the same as one presented two trials earlier), no significant between group 
differences were observed on measures of performance on this task. Daumann, Fimm et al. 
(2003) subjected 11 heavy ecstasy users (8 male, mean age = 27, MLD = 258.18 tablets), 11 
moderate ecstasy users (8 male, mean age = 23.27, MLD = 27.36 tablets) and 11 healthy non-
user controls (8 male, mean age = 25.64) to three n-back tasks consisting of sequential 
presentation of single letters. In the 0-back condition, participants had to respond when a 
stimulus in the sequence matched a target stimulus. In the 1-back condition, participants were 
to respond to stimuli that matched the stimuli immediately preceding it, and in the 2-back 
condition participants had to respond if the stimuli matched a stimulus presented 2 letters 
earlier. Analysis of behavioural data revealed that although there was a main effect of 
difficulty, there were no between group differences in performance on the task. In an 18 
month longitudinal study (Daumann, Fischermann, Heekeren et al., 2004), 30 ecstasy users 
(at time 1, whom had consumed ecstasy regularly twice a month over a six month period, or 
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at least 20 occasions, excluded if they regularly use legal or illegal psychotropic drugs such 
as opiates and benzodiazepines, or regular heavy use of alcohol), which due to various 
exclusion reasons reduced to 21 users (16 male, mean age = 24.93) at time 2, completed three 
n-back tasks (0,1 and 2 back) at time 1 and 2, to observe whether performance deteriorates 
over time with continued/discontinued use. The 21 returning participants were subdivided 
into those who had not consumed any MDMA or amphetamine in the 18 month period (n=8) 
and those who reported continued ecstasy and amphetamine use of at least 20 tablets (n=9). 
The remaining four participants were excluded from analysis due to sporadic MDMA and 
amphetamine use between time 1 and 2. The two groups did not differ in performance at 
baseline or follow up. However both groups tended to respond quicker at time 2 (significantly 
at 2 back for abstinent users and 0-back for continuing users). The results suggest task 
performance was not correlated with drug use patterns.  
 In summary it appears that ecstasy use has a more consistent effect on memory 
updating. Of the studies reviewed here, ecstasy users performed consistently worse than non-
drug controls on letter updating (Montgomery & Fisk, 2008; Montgomery, Fisk, Newcombe 
& Murphy, 2005). Although there was no polydrug control group employed in either study, 
greater use of MDMA was associated with poorer performance. The findings are however, 
more diverse for backwards digit span. No differences between ecstasy users and controls are 
observed in several of the studies reviewed (Bedi & Redman, 2008; Bhattachary & Powell, 
2001; Croft et al., 2001; Gouzoulis-Mayfrank et al., 2003; Nulsen et al., 2011; Reay et al., 
2006; Thomasius et al., 2006). However one of these (Nulsen, et al., 2011) was an EEG study 
with low n numbers, which may have lacked the statistical power to detect behavioural 
differences (this study did show between group differences in electrophysiological measures 
will be discussed in Chapter 5). Another (Reay et al., 2006) failed to detect differences 
between ecstasy users and cannabis users. However, as discussed by Croft et al. (2001), 
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cannabis may play a role in ecstasy-related impairments. Conversely Gouzoulis-Mayfrank et 
al. (2000) showed deficits in ecstasy users compared to cannabis matched controls, so this 
warrants further exploration. Halpern et al.’s (2011) study could be useful in deciphering the 
ecstasy/cannabis contribution to this task due to this ecstasy using population being relatively 
pure. However there is debate about the interpretation of the findings, with Parrott (2011) 
suggesting that the results here show evidence that intensity of dose is related to cognitive 
impairment. Finally Bedi and Redman (2008) observed an MDMA related effect on 
performance on this task with regression analysis, and meta-analysis on this task suggests that 
overall ecstasy use is associated with poor performance. 
 Spatial working memory performance was shown to be associated with intensity of 
MDMA dose (Hanson & Luciana, 2010), and MDMA use was correlated with poor 
performance in this measure by Montgomery and Fisk (2008). Current and former users were 
observed to be worse than non-users (Montgomery & Fisk, 2008), suggesting that this deficit 
is persistent after cessation of use. Moreover the control group here were not drug naïve and 
these results remained after controlling for other drug use. As such it is unlikely that the 
deficit is due to continued cannabis use. Computation span regularly yields observable 
deficits in ecstasy users relative to controls after covarying for other drug use (Fisk et al., 
2004; Wareing et al., 2004) and this has also been observed to be persistent after cessation of 
use (Wareing et al., 2004; Wareing et al., 2005). The N-back task in this review appears to 
have yielded few ecstasy-related deficits. However this may in part be due these 
neuroimaging studies recruiting low numbers of participants (Daumann, Fischermann, 
Heekeren et al., 2004). Moreover, in these studies, the n-back task has not gone beyond a 3-
back difficulty; perhaps deficits may become more apparent with increasing difficulty. 
Further to this, many of these studies have found differences in their neurophysiological 
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response (Daumann Fimm et al., 2003; Daumann, Fischermann, Heekeren et al., 2004) and 
will be discussed further in Chapter 5. 
 Chapters 6 and 7 will investigate ecstasy-related differences in memory updating 
using neuroimaging techniques (EEG and fNIRS). Pure memory tasks that tap this function 
will be used in combination with the neuroimaging measures. For example computation span 
relies heavily on ability to conduct mental arithmetic, which should be avoided. As such the 
n-back task will be used in combination with EEG. Furthermore the difficulty of the task will 
be increased beyond the level that has been used previously in the research. Letter updating 
and spatial updating tasks will be used in combination with fNIRS in Chapter 7, due to these 
tasks consistently yielding behavioural differences. Using these tasks in combination with 
fNIRS will allow the neurophysiological mechanisms underlying performance to be observed. 
3.2.4 Access to semantic/long term memory 
 The fourth component of the central executive - access to semantic/long term memory 
(referred to as ‘access’ from this point on) was added by Fisk and Sharp (2004). This function 
involves word fluency and efficiency of lexical access. Retrieval of words and semantics 
involves the ability to access the long term memory store. The efficiency with which this can 
occur is dependent on areas of the DLPFC (Stuss et al., 1998), amongst other subcortical 
networks. Tasks that have classically been used to study this function in the ecstasy literature 
include RLG and the Chicago Word Fluency Task (CWFT). RLG is understood to load on 
two executive processes, with alphabetic sequences and letter repeats loading on inhibition 
and redundancy loading on access. 
 Murphy et al. (2011) observed that ecstasy users (described in Chapter 3.2.2) 
performed significantly worse than drug naïve controls, but not compared to cannabis only 
users on the redundancy measure of RLG, which is suggested to load on access. The cannabis 
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only group did not have a significantly lower redundancy score compared to drug naïve 
controls. However regression analysis yielded a significant relationship between cannabis use 
and redundancy, whereas MDMA use did not. Furthermore members of the ecstasy user 
group had very high cannabis consumption totals that perhaps contributed to the significant 
divergence from drug naïve controls in the analysis. Wareing et al. (2000) observed that 
current and former ecstasy users performed worse than controls on the redundancy measure 
of RLG, however this result was not replicated with a larger sample by Fisk et al. (2004) or 
by Montgomery, Fisk, Newcombe and Murphy (2005). 
 The CWFT is a measure of word fluency that requires access to semantic long term 
memory. In this pencil and paper task, there are usually two blocks that increase in difficulty. 
In the first block participants are required to write down as many words beginning with the 
letter S, as possible in five minutes. The following block requires participants to write down 
words beginning with C, with the added restriction that they must only use four letter words.  
Furthermore in block two the time in which participants are given to produce words is 
reduced to four minutes. Participants are instructed to avoid place names, people’s names and 
plurals. This task is usually coupled with a semantic fluency task which requires participants 
to name as many animals (including breeds within species) as possible in a four minute 
period. The number of appropriate words is given as the total score for each fluency measure. 
Using these fluency measures Montgomery, Fisk, Newcombe and Murphy (2005) observed a 
main effect of ecstasy use on word fluency. Ecstasy users produced significantly less S letter 
and C letter words than non-user controls. This difference was greatest in the C letter 
category, which places more constraints upon participants and is therefore more demanding. 
Group differences on the semantic fluency measure were not significant. Due to the small 
amounts of illicit drug use in the non-user sample in this study, correlations of performance 
with different measures of ecstasy, amphetamine, cocaine and cannabis use were performed 
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to investigate the influence of other drug use on word fluency. Although measures of ecstasy 
were correlated with word fluency performance, measures of cocaine use were similarly 
correlated and as such it is difficult to attribute the observed effects solely to MDMA use in 
this study. Montgomery et al. (2007) again observed significant performance deficits in 
ecstasy users compared to non-users on a composite measure of word fluency (letter fluency 
– C letter words and S letter words combined) after covarying for semantic fluency and 
controlling for sleep. However, this study was an analysis of participants from several studies 
from this research lab, and so included the data from the 2005 study. Heffernan et al. (2001) 
measured word fluency/semantic fluency in a similar task with 30 ecstasy users (17 male, 
mean age 23.9, mean use = 5.6 tablets per month) and 37 non-user controls (10 male, mean 
age 25.5). In this study, verbal fluency was measured by participants writing down as many C 
letter words as possible in one minute. Semantic fluency was measured by naming as many 
animals as possible in a one minute time frame, and a combined verbal/semantic fluency 
measure was obtained whereby participants had to recall as many household objects 
beginning with T as possible in one minute. Amounts of cannabis, cocaine and alcohol use 
were incorporated into an Analysis of Covariance and it was observed that the ecstasy user 
group performed significantly worse on verbal fluency, semantic fluency and verbal/semantic 
fluency. Fisk and Montgomery (2009) compared performance on the CWFT (S letter words 
and 4 letter C words) in ecstasy users (n=117, 64 male, mean age = 21.68, MLD = 328.55 
tablets), cannabis only users (n=53, 17 male, mean age = 20.96) and non-users of illicit drugs 
(57, 14 male, mean age = 20.91) and observed that after controlling for sleep measures, 
ecstasy users still showed deficits in performance on the CWFT. 
 An oral variant of the CWFT is also frequently used as a measure of word fluency, 
known as the Controlled Oral Word Association task (COWA) or the FAS task, this usually 
involves participants orally producing words beginning with F, followed by words beginning 
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with A and then S in one minute periods. Results using this variant of the task have provided 
less consistent findings. Halpern et al. (2004) observed no performance differences on this 
task between heavy users, moderate users and nonusers (sample described in Chapter 3.2.1). 
Bedi and Redman (2008) found no differences at the group level (45 ecstasy users, 48 
cannabis only users, 40 legal drug users described in Chapter 3.2.3) for COWA, and MDMA 
use variables did not predict word fluency performance in a regression analysis. Morgan et al. 
(2002) used the COWA task with 18 current heavy ecstasy users who also used other illicit 
drugs, 15 abstinent (at least 6 months) heavy ecstasy users, who continued to use other illicit 
drugs, 16 polydrug controls who had never taken ecstasy but had similar pattern of other drug 
use and 15 drug naïve controls (sample described in Chapter 3.2.2). Statistical analysis 
revealed no significant between group differences on this measure of verbal fluency, although 
there was a trend for ecstasy user groups to perform worse on a category fluency task 
whereby participants had 90 seconds to name as many fruits as possible followed by 90 
seconds to name as many vegetables as possible.   
 Bhattachary and Powell (2001) observed ecstasy-related deficits in word fluency 
using the COWA. In this sample, participants were divided into groups of nonusers (n = 20, 
mean age = 22.1), novice users (n = 18, mean age = 23.6, 1-5 lifetime doses) regular users (n 
= 26, mean age = 23.8, modal lifetime doses ≥ 51) and currently abstinent users (n = 16, 
mean age = 24.6, modal lifetime doses ≥ 51). All three MDMA user groups performed 
significantly worse than non-users on this task. Hanson and Luciana (2004) also compared 
ecstasy users (n=26, 14 male, mean age = 21.3, mean occasions of use = 64.3) and 
individuals with no history of MDMA use (n=26, 14 male, mean age = 20.7); Although users 
and non-users had equivalent performance in number of words generated, it was observed 
that ecstasy users produced more rule-breaking errors. Furthermore in an exploratory analysis 
of MDMA users with MDMA abuse/dependence (as described by the DSM-IV) verses non-
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problem MDMA users, it was observed that those with a clinical diagnosis produced 
significantly fewer words than those without. Hanson and Luciana (2010) again assessed this 
function using the COWA in polydrug users and controls observing no between group 
differences on verbal working memory. Due to the polydrug user group in this study also 
containing participants who had never used ecstasy, regression analyses were conducted to 
observe contributions of individual drugs on the neuropsychological measures. It was 
concluded that MDMA did not correlate with performance on verbal working memory. Croft 
et al. (2001) assessed COWA along with word fluency of ‘animals’ in their study on 31 drug 
naïve controls (mean age = 23.5), 11 ecstasy/cannabis users (mean age = 25.7, MLD = 41.9 
tablets) and 18 cannabis only users (mean age = 26.6). No differences were observed between 
drug user groups on this task, however when drug user groups were combined and compared 
to nonusers it was observed that controls performed better on the ‘animals’ component of 
word fluency. After covarying for total cannabis use, total MDMA use, frequency of cannabis 
use and frequency of MDMA use the authors concluded that the effects observed may be 
more related to cannabis use than MDMA use. 
 More recently Raj et al. (2010) assessed 16 polysubstance users (10 male, mean age = 
23.6, 12 with a history of MDMA use, mean episodes of use = 43.33) on a task that probed 
semantic verbal memory in a preliminary fMRI study. This task consisted of a word and 
pseudo-word encoding period and a word and pseudo-word recognition period. During each 
encoding phase participants were required to memorise a group of five English words and or 
a group of five pronounceable pseudo-words. After this they were presented with homophone 
pairs (e.g. prey/pray), one of which was novel, the other of which would have appeared in the 
encoding period. Participants had to identify which of the homophones was previously 
presented. Pseudo-words were Dutch words, and pseudo-word homophone counterparts were 
synthesised English words based on pronunciation. English words in the encoding phase 
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should have a greater semantic association for participants and as such the difference between 
words and pseudo-words should isolate semantic memory. Correlations between drug use and 
performance on task measures (correct responses, omission errors, commission errors and 
reaction time for correct responses) revealed that MDMA was not associated with recognition 
task measures. However total lifetime cannabis joints was significantly negatively correlated 
with accuracy (number of commission errors) on the pseudo word part of the task. Moreover, 
lifetime exposure to cannabis (both episodes and total joints) was significantly negatively 
correlated with reaction time on the word part of the task. However due to the nature of this 
preliminary study and the small sample used, the results need to be treated with caution. The 
results from fMRI will be discussed in Chapter 5. 
 In summary it appears that there is evidence for ecstasy-related deficits in word 
fluency using the written variant of the CWFT. However one of these studies (Montgomery 
et al. 2007) includes data from their 2005 study that observed deficits in this task. The results 
are less consistent when the task takes on an oral format. However using the FAS one minute 
version, does not provide a variant of difficulty like the CWFT does, and as was observed by 
Montgomery, Fisk, Newcombe and Murphy (2005), ecstasy users tend to perform worse in 
more difficult circumstances when greater load is placed on the central executive. Further to 
this, it may be that over a short period of time (1 minute) ecstasy users perform 
comparatively to controls. Perhaps longer periods (such as 4 or 5 minutes in the CWFT) of 
sustained load, on the central executive, may uncover effects of difficulty and load. Using the 
short variant COWA, Hanson and Luciana (2004) observed performance deficits in ecstasy 
users. However this was only with number of rule-breaking errors rather than performance on 
fluency measures. This may reflect ecstasy users’ difficulty in following instructions rather 
than deficits in access. Furthermore these results were not replicated in a follow up study 
(Hanson & Luciana, 2010). The RLG studies reviewed show mixed results, with two 
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suggesting performance deficits in ecstasy users (Murphy et al., 2011; Wareing et al., 2000) 
and others suggesting no such observable differences (Fisk et al., 2004; Montgomery, Fisk, 
Newcombe & Murphy, 2005). Moreover, Murphy et al. (2011) suggest that performance is 
more correlated with cannabis use. Cannabis use was also put forward as a greater predictor 
of performance on the COWA by Croft et al. (2001) and in a novel semantic task by Raj et al. 
(2011), so it would seem that the relationship between this function, MDMA and cannabis 
use needs further exploration. 
 This thesis will fully investigate the role of ecstasy in access to semantic long term 
memory. The addition of neuroimaging techniques may provide valuable insight into the 
nature of processing mechanisms involved in this executive function and untangle the 
inconsistent evidence in the neuropsychological literature. This function is assessed 
behaviourally and with EEG in Chapter 6 and with fNIRS in Chapter 8. 
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Function/Authors Sample Details Task Main Findings 
    
Switching    
    
Fox et al.(2001) 20 ‘problem’ ecstasy users, 20 ‘non-
problem ecstasy users’, 20 polydrug 
controls 
WCST No performance differences between groups, and no 
effect of lifetime dose on performance. 
    
Thomasius et al. (2003) 30 current ecstasy users, 31 former users 
(abstinence of at least 5 months), 29 
polydrug controls, 30 drug naïve controls 
WCST Polydrug controls produced significantly higher amount 
of perseverative errors than both ecstasy groups. No other 
differences observed. 
    
Back-Madruga et al. (2003) 22 ecstasy users, 28 controls WCST No performance differences observed on WCST 
    
Halpern et al. (2004) 23 ecstasy users with minimal exposure to 
other drugs, 16 ecstasy naïve controls 
involved in rave subculture 
WCST No significant performance differences on WCST. 
However after subdividing ecstasy users into heavy and 
moderate users, heavy users performed worse than non-
users on “total categories”. 
    
Halpern et al. (2011) 52 ecstasy users with minimal exposure to 
other drugs, 59 ecstasy naïve controls 
involved in rave subculture 
WCST No significant between groups differences. However 
after subdividing ecstasy users into heavy and moderate 
users, moderate users showed significantly reduced “total 
categories” score compared to controls. 
    
Fox et al. (2002) 20 ecstasy polydrug users, 20 polydrug 
controls 
3D IDED task No between groups differences on non-reversal trials. 
However ecstasy users slower than controls at all levels 
of reversal condition indicating performance deficits. 
    
  Switching Go/NoGo No between groups differences observed on any of the 
measures analysed on the task 
    
Montgomery, Fisk, Newcombe and 
Murphy (2005) 
51 ecstasy polydrug users, 42 non-user 
controls 
Number-Letter task No differences between users and non-users on this task 
  Plus-Minus task No between-groups differences observed on this task. 
    
    
    
    
Table 3.1: Summary of studies involving behavioural assessment of executive function in ecstasy users 
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Dafters (2006) 18 ecstasy users, 15 ecstasy users who 
completed task in reverse order, 17 
cannabis only users, 18 drug naïve 
controls. 
Stroop task Ecstasy users performed worse than both cannabis users 
and non-drug user groups on the switching component of 
the task, after covarying for other drug use 
    
Dafters et al. (1999) 24 recreational drug users BADS rule shift cards 
test 
MDMA use was negatively correlated with performance 
on the task 
    
Dafters et al. (2004) 16 heavy ecstasy (+50 tablets) and 
cannabis users, 19 light ecstasy (-50 
tablets) and cannabis users, 15 cannabis 
only users, 19 drug naïve controls. 
BADS rule shift cards 
test 
No significant differences between groups after 
covarying for alcohol, amphetamine cocaine and LSD 
    
Von Geusau et al. (2004) 26 ecstasy users, 33 non-user controls Dots-Triangles and 
Local-Global tasks 
Male users significantly higher switch cost reaction time 
than non-users in the dots triangles task, although 
significantly more accurate. On the Local-Global task 
male users were significantly slower than controls and 
had a higher switch cost. However there was no 
significant difference in accuracy on this task.  
 
Inhibitory Control    
    
Morgan et al. (2002) 18 current ecstasy users, 15 former ecstasy 
users (abstinent for at least 6 months), 16 
polydrug controls, 15 drug naïve controls.  
Stroop task No between groups differences (error or reaction time). 
    
Dafters (2006) 18 ecstasy users, 15 ecstasy users who 
completed task in reverse order, 17 
cannabis only users, 18 drug naïve 
controls. 
Modified Stroop task No significant between groups differences on the 
magnitude of Stroop interference reaction times (pre 
potent response inhibition). However ecstasy users 
showed a reduced priming effect (reduced short term 
residual inhibition) compared to both other groups. 
    
Back-Madruga et al. (2003) 22 ecstasy users, 28 controls (not 
specified) 
Stroop task No between groups differences observed. 
    
Gouzoulis-Mayfrank et al. (2000) 28 ecstasy users, 28 cannabis users, 28 
drug naïve controls 
Stroop task No between groups differences observed. 
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Halpern et al. (2004) 23 ecstasy users with minimal exposure to 
other drugs, 16 ecstasy naïve controls 
involved in rave subculture 
Stroop task Ecstasy related performance deficits observed after 
dividing users into heavy and moderate users, whereby 
heavy users showed significantly longer reaction times 
and more Stroop errors on interference trials compared to 
controls. 
    
Halpern et al. (2011) 52 ecstasy users with minimal exposure to 
other drugs, 59 ecstasy naïve controls 
involved in rave subculture 
Stroop task No ecstasy related performance deficits on the Stroop 
task. 
    
Wagner et al. (2012) 
 
Longitudinal study on 149 new ecstasy 
users (<5 MDMA use occasions before 
participating in the study). One year follow 
up yielded 43 interim non-users, and 23 
regular ecstasy users. Remaining 
participants excluded from follow up 
analysis 
Stroop task (German 
variant) 
No significant performance  differences between groups, 
or between baseline and follow up sessions 
    
Wareing et al. (2000) 10 ecstasy, users, 10 former users, 10 non-
users 
RLG Ecstasy users (both groups) performed worse than 
controls (more vowel intrusions at all 3 rates, and higher 
redundancy and lower number of letters produced at the 
1s rate). Ecstasy users perform worse when greater 
demand is placed on them 
    
Fisk et al. (2004) 44 ecstasy users, 59 non-users controls RLG Ecstasy users unimpaired on all measures of performance 
relative to controls. 
    
Montgomery, Fisk, Newcombe and 
Murphy (2005) 
51 ecstasy polydrug users, 42 non-user 
controls 
RLG Ecstasy users show improved performance, producing 
significantly more letters than controls. Differences on 
other performance measures on this task were non-
significant. 
    
Murphy et al. (2011) 15 ecstasy users, 12 cannabis only users, 
12 drug naïve controls 
RLG No between group differences observed for alphabetic 
sequences or repeat sequences (measures of impulsivity). 
Ecstasy use did not predict performance on these 
measures. However differences were observed on 
“redundancy” which relates more to access. 
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Clark et al. (2009) 46 ecstasy users, 14 former users 
(abstinence of at least 1 year), 15 cannabis 
users, 19 drug naïve controls 
IST Cannabis users opened significantly less boxes than 
current ecstasy users, and this difference was 
approaching significance with former users and drug 
naïve controls 
    
Gouzoulis-Mayfrank et al. (2003) 60 ecstasy users (30 heavy users, 30 
moderate users), 30 non-user controls 
Go/NoGo Ecstasy users split into heavy and moderate users. No 
performance differences observed between groups on this 
task 
    
Roberts and Garavan (2010) 20 ecstasy users, 20 drug naïve controls Go/NoGo No between groups performance differences observed 
    
Hanson and Luciana 52 polydrug users, 29 non-drug controls Go/NoGo No MDMA related deficits observed for Go/NoGo 
    
Hoshi et al. (2007) 25 ecstasy users, 28 former users, 29 
polydrug controls, 27 drug naive controls 
Go/NoGo Ecstasy users and polydrug users impaired on this task 
compared to former ecstasy users and drug naïve 
controls. 
    
Updating    
    
Montgomery, Fisk, Newcombe and 
Murphy (2005) 
27 ecstasy users, 34 non-users Letter updating Ecstasy users performed significantly worse than controls  
    
  Computation  span Ecstasy users performed significantly worse than controls 
    
Montgomery and Fisk (2008) 73 ecstasy users, 73 non-user controls Letter updating Ecstasy users with simple spans of five and six 
performed worse than non-users. Higher levels of ecstasy 
use were associated with poorer performance on the task, 
whereas indicators of cocaine and cannabis use were not 
correlated with updating performance 
    
  Spatial updating Ecstasy users with spatial span of five, performed 
significantly worse than controls. Heavy ecstasy use was 
correlated with poorer performance 
    
Fisk et al. (2004) 44 ecstasy users, 59 non-users controls Computation span Ecstasy users performed significantly worse than controls 
after covarying for cannabis, amphetamine, cocaine, 
alcohol use and daily cigarette use. 
 
 
 
 
53 
 
    
Wareing et al. (2004) 42 ecstasy users, 17 former users 
(abstinent for at least 6 months), 31 non-
user controls  
Computation span Performance worse for both ecstasy groups compared to 
controls 
    
Wareing et al. (2005) 36 ecstasy users, 12 former users, 31 non-
user controls 
Computation span Ecstasy users and former users both performed 
significantly worse in computation span task performance. 
    
  Spatial updating Both groups of ecstasy users performed significantly 
worse than non-users. 
    
Hanson and Luciana (2010) 52 polydrug users, 29 non-drug controls SDRT Polydrug users had poorer spatial memory spans, and were 
more negatively impacted by increasing delay intervals 
than controls. Working memory summary score was 
negatively correlated with average number of ecstasy 
tablets consumed per session, as well as maximum number 
of tablets ever taken in one session 
    
Reay et al. (2006) 15 ecstasy users, 15 polydrug controls Backwards digit span No performance differences observed after controlling for 
cannabis, cocaine, alcohol and tobacco 
    
Gouzoulis-Mayfrank et al. (2003) 60 ecstasy users (30 heavy users, 30 
moderate users), 30 non-user controls 
Backwards digit span No performance differences between heavy ecstasy users, 
moderate users and non-users 
    
  N-back No between group differences observed 
    
Gouzoulis-Mayfrank et al. (2000) 28 ecstasy users, 28 cannabis users, 28 
drug naïve controls 
Backwards digit span Ecstasy users performed significantly worse than drug 
naïve and cannabis matched controls 
    
Nulsen et al. (2011) 11 ecstasy users, 13 polydrug controls, 13 
non-drug controls 
Backwards (and 
forwards) digit span 
No main effect of group on performance 
    
Croft et al. (2001) 11 ecstasy/cannabis users, 18 cannabis 
only users, 31 drug naïve controls 
Backwards (and 
forwards) digit span 
Significant differences between drug naïve controls and a 
combined (both MDMA/cannabis users and cannabis only 
users) drug user group were observed. No difference 
between ecstasy/cannabis users and cannabis only users. 
Covarying for MDMA consumption had little effect on 
results 
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Halpern et al. (2011) 52 ecstasy users with minimal exposure to 
other drugs, 59 ecstasy naïve controls 
involved in rave subculture 
Backwards digit span Ecstasy users showed modest performance deficits, 
scoring lower for correct repeated sequences. 
    
Bedi and Redman (2008) 45 ecstasy users, 48 cannabis users, 40 
legal drug use controls 
Backwards digit span No between groups differences observed. Lifetime ecstasy 
use showed weak negative semi-partial correlation with 
performance 
    
Thomasius et al. (2003) 30 current ecstasy users, 31 former users 
(abstinence of at least 5 months), 29 
polydrug controls, 30 drug naïve controls 
Backwards digit span No ecstasy related performance deficits 
    
Bhattacharay and Powell (2001) 26 regular ecstasy users, 18 novice ecstasy 
users, 16 currently abstinent ecstasy users 
(abstinence of at least 30 days) and 20 
non-user controls 
Backwards digit span No between groups performance differences 
    
Daumann, Fimm et al. (2003) 11 heavy ecstasy users, 11 moderate 
ecstasy users, 11 non-user controls 
n-back No between groups performance differences 
    
Daumann, Fischermann, Heekeren et al. 
(2003) 
18 month longitudinal study with 30 
ecstasy users at time 1, which reduced to 
21 users at time 2. These were subdivided 
into those who had not consumed MDMA 
or amphetamine in the 18 month period 
(n=8) and those who continued to use 
ecstasy and amphetamine (n=9). The 
remaining four participants were excluded 
from analysis due to sporadic MDMA and 
amphetamine use between time 1 and 2 
n-back No performance differences between groups at baseline or 
follow up. 
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Access    
    
Montgomery, Fisk, Newcombe and 
Murphy (2005) 
27 ecstasy users, 34 non-users CWFT Ecstasy users produced significantly less S letter and C 
letter words than non-user controls. 
    
Montgomery et al. (2007) 36 ecstasy users, 63 non-ecstasy users CWFT Significant performance deficits observed in ecstasy users 
compared to non-users on a composite measure of word 
fluency (letter fluency – C letter words and S letter words 
combined). However, this study included data from the 
2005 study 
    
Heffernan et al. (2001) 30 ecstasy users, 37 non-user controls CWFT and 
verbal/semantic 
fluency 
Ecstasy users significantly impaired in verbal fluency, 
semantic fluency and verbal/semantic fluency 
    
Fisk and Montgomery (2009) 117 ecstasy users, 53 cannabis only users, 
57 non-drug controls 
CWFT Ecstasy users performed worse than both control groups 
in on the CWFT after controlling for sleep measures. 
    
Halpern et al. (2004) 23 ecstasy users with minimal exposure to 
other drugs, 16 ecstasy naïve controls 
involved in rave subculture 
COWA No performance differences observed between heavy 
users, moderate users and non-users 
    
Bedi and Redman (2008) 45 ecstasy users, 48 cannabis users, 40 
legal drug use controls 
COWA No performance differences observed between groups. 
MDMA use also did not predict performance in 
regression analyses. 
    
Morgan et al. (2002) 18 current ecstasy users, 15 former ecstasy 
users (abstinent for at least 6 months), 16 
polydrug controls, 15 drug naïve controls. 
COWA No performance differences observed on the COWA. 
However a trend for ecstasy users to perform worse on a 
category fluency task. 
    
Bhattacharay and Powell (2001) 26 regular ecstasy users, 18 novice ecstasy 
users, 16 currently abstinent ecstasy users 
(abstinence of at least 30 days) and 20 
non-user controls 
COWA All 3 ecstasy user groups performed significantly worse 
than non-user controls 
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Hanson and Luciana (2004) 26 ecstasy users, 26 non-user controls COWA Equivalent performance between groups. However 
ecstasy users produced more rule breaking errors. 
Subsequent analysis between problem and non-problem 
MDMA users showed that problem users produced fewer 
words than non-problem users 
    
Hanson and Luciana (2010) 52 polydrug users, 29 non-drug controls COWA MDMA use did not correlate with performance deficits 
    
Croft et al. (2001) 11 ecstasy/cannabis users, 18 cannabis 
only users, 31 drug naïve controls 
COWA No differences were observed between drug user groups. 
However a combined drug user group (ecstasy user and 
cannabis users) performed worse than non-user controls 
on the ‘animals’ component of word fluency.  After 
covarying for MDMA and cannabis use indices the 
authors concluded that the effects observed may be more 
related to cannabis use than MDMA use 
    
Raj et al. (2010) 16 polysubstance users Semantic verbal 
memory task 
MDMA was not correlated with recognition task 
measures. However total lifetime cannabis joints was 
significantly negatively correlated with accuracy and 
lifetime exposure to cannabis (both episodes and total 
joints) was significantly negatively correlated with 
reaction time 
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Chapter 4: Neurophysiology and neuroimaging as indicators of cognition.  
4.1 EEG 
Physiological Basis of the EEG Signal 
Neurons communicate via action potentials which are discrete voltage spikes 
generated in the cell body that travel down the axon to axon terminals where 
neurotransmitters are then released. Theoretically, two neurons with action potentials that are 
sent simultaneously via parallel axons that end in simultaneous firing would summate for a 
voltage recording at an electrode. However, this rarely happens. Instead, slight differences (at 
the microsecond level) in neuronal firing typically cancel out action potentials in different 
axons and are therefore not detectable from electrodes at the scalp. As such the potentials 
usually observed with an EEG reflect post synaptic potentials (Luck, 2005).  
 Post synaptic potentials are voltages that occur either after an action potential has 
travelled along the axon fibre to an excitatory synapse causing and excitatory postsynaptic 
potential, or an action potential travels along a fibre ending in an inhibitory synapse where 
hyperpolarization occurs, culminating in an inhibitory post synaptic potential (Speckman & 
Elger, 2005). Neurotransmitters bind to the membrane on the post synaptic cell which causes 
the opening or closing of an ion channel, resulting in a change in potential at the cell 
membrane (Luck, 2005). Unlike action potentials, whose durations are only milliseconds in 
length, postsynaptic potentials are longer, potentially lasting hundreds of milliseconds. If 
there is coherence between neurons (i.e. many receiving excitatory neurotransmitter and in a 
similar orientation), then post synaptic potentials may summate and their voltages will be 
measurable at the scalp (Schaul, 1998).  
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EEG recording and processing 
 EEG recording involves the measurement, amplification and recording of differences 
between fluctuating electrical field potentials over time (Kamp et al., 2005). EEG recordings 
should adequately represent the spatial distribution of potentials over the scalp. As such, 
recording from several electrodes simultaneously is imperative. It is routine for a large 
number of electrodes to be placed over the scalp of a participant.  
 During a conventional EEG recording session an electrode cap is fitted to a 
participant’s head and electrodes are placed into standardised positions in the electrode cap. 
A suitable conducting gel is used to form an electrolyte bridge between the participants head 
and each electrode. The placement of the electrodes usually corresponds to the Standardised 
International 10-20 system. This system is based upon internationally recognised anatomical 
landmarks on the skull and allows for consistency of electrode names and locations across 
research laboratories. The electrodes themselves have an input amplifier and measurement of 
electrical field potentials occurs here. The necessity of input amplification is due to relatively 
low signal voltage amplitudes at the scalp. Once the electrodes have acquired the EEG signal 
and it has been amplified it is necessary to convert the signal from a continuous analogue 
voltage to a discrete digital one that is compatible with a computer for display, analysis and 
storage of data (Luck, 2005).  
 As voltage is the potential for a current to move between two points, the signal at an 
electrode represents the difference between the voltage at an electrode site and a predefined 
reference electrode site (Luck, 2005). There are several ways in which a reference can be 
provided, including a common average reference representing the mean of all scalp 
electrodes, linked earlobes or mastoids or the vertex (Hagemann et al., 2001), and Laplacian 
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calculations based on differences between an electrode and it’s ‘nearest neighbour’ electrodes 
(Nunez et al., 1997).  
Event Related Potentials and components 
If EEG as a general method is used to investigate brain reactions to a variety of 
stimuli, then Event Related Potentials (ERPs) can be globally understood as EEG changes 
that are time-locked to a stimulus (Lopes da Silva, 2005). They are defined in the time 
domain as electrical activity from the brain that is caused by a particular event or stimulus. 
As such ERPs are used to quantify the neurophysiological response to a stimulus and 
differences between groups and conditions can be observed (Duncan et al., 2009). 
ERPs have distinct advantages over measurements of speed and accuracy of motor 
responses, the first being that they provide a continuous measure of cognitive processing 
giving rise to the possibility of determining the stage at which processing is affected by 
experimental manipulation (Luck, 2005). The second is that they can provide a measure of 
processing of stimuli in cases where no behavioural response is required. For example 
attended versus ignored stimuli (Luck, 2005) such as that used in a Go/NoGo task. A 
disadvantage however is that functional significance of an ERP is not as clear as that of a 
behavioural response, which is perhaps why it is necessary to observe both. 
Due to ERPs being small, a relatively large number of trials are necessary to measure 
them adequately. However due to the fact that ERPs are time-locked to an event, single ERP 
waveforms can be averaged together to create a grand average (mean) waveform. It is these 
grand-averaged waveforms that are usually presented in research papers, and they reflect 
more clearly defined positive and negative deflections that are understood as components 
(Luck, 2005). 
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ERP components are usually labelled in such a way that refers to their polarity (P = 
positive, N= negative) and their position in the waveform or time (for example P1 would 
refer to the first positive component). Some of these components have been described by 
Luck (2005) for example P1 is a very early positive going component, typically largest at 
lateral occipital electrodes, that usually peaks between 100 and 130ms; this appears sensitive 
to spatial attention and arousal and is not considered to be affected by top down processes. 
The N1 component follows the P1 wave and has two posterior components that peak usually 
around 150-200ms and again reflect spatial attention, although there is suggestion that this 
component is involved in discriminative processing. The second positive component P2 
follows the N1 at anterior and central electrodes. This component is usually larger in trials 
that contain target features which are fairly simple, so this is an early processing stage. The 
P2 wave can be observed at anterior and central sites, and elicits a larger response to simple 
target features that are relatively infrequent (Luck & Hillyard, 1994). This component 
precedes the N2 and is suggested to be involved in the initial inhibition from further 
processing in target stimuli (Hansen & Hillyard, 1988).  
The N2 and P3 components are more widely studied and as such will be described in 
more detail here. The N2 family has several studied components; a basic N2 can be observed 
with a repetitive non-target stimulus. However if other deviant stimuli are presented within a 
repetitive sequence then a larger amplitude of this basic N2 is observed. Task relevant 
deviants evoke a later N2 effect (sometimes referred to as N2b) which appears largest over 
central (for auditory stimuli) and parietal (for visual stimuli) sites; this component is assumed 
to reflect stimulus categorisation processes (Luck, 2005). The N2 component is observed to 
be involved in inhibition as this component has been suggested to reflect stimulus 
discrimination (Ritter et al., 1982) and is therefore an important measure of response 
inhibition. Kok et al. (2004) suggest the N2 component shows greater amplitude in trials 
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where inhibition of response is required (NoGo) than no inhibition (Go) trials. Moreover 
amplitude of N2 is more prominent in unsuccessful inhibition trials. The N2 component is 
associated with errors (i.e. “error negativity” or Ne), and is sensitive to monitoring errors. 
This has been suggested to be a product of activity in medial frontal regions such as the 
anterior cingulate (Bekker et al., 2005).  
 The P3 wave follows the N2 wave, and can be subdivided into a frontally maximum 
P3a component that will increase with unexpected task irrelevant stimuli and P3b component 
that is largest over parietal sites. Usually when studies refer to the P3 component, it is 
actually the P3b that they are referring to. Typically cognitive impairment is associated with 
alterations to the P3 amplitude or latency due to the P3 being involved in higher level 
processing of stimuli. This component encompasses frontal-parieto network activation 
(Gaspar et al., 2011) and in normal populations decreases in the amplitude potential reflects 
increased cognitive load, and diminished P3 reflects cognitive dysfunction. Longer latencies 
and smaller amplitude of the P3 response are indicative of cognitive impairment. The P3 
component is also understood to be associated with the allocation of attentional resources 
necessary for information processing and also memory function (de Sola et al., 2008). 
Strengths and Limitations of EEG 
Due to EEG employing a high sampling rate (usually 512Hz) it has excellent temporal 
resolution that allows tracking of neurophysiological processes at the neuronal rate 
(milliseconds) (Liu & He, 2010). As described earlier this affords a continuous measure of 
cognitive processing and direct understanding of how stimuli are processed and which stages 
of processing are affected by experimental manipulation. Furthermore the EEG signal is 
directly coupled to neuronal electrical activity (Debener et al., 2006), as opposed to inferred 
indirect measurements of neuronal activity in neuroimaging methods that rely on 
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haemodynamic responses such as fMRI and fNIRS. EEG is considered to be much less 
expensive than other techniques (for example fMRI) and is non-invasive (Luck, 2005). 
Furthermore systems such as the one used for data collection in this thesis (Biosemi Ag-AgCl 
active-two electrode system - Biosemi B.V, Amsterdam, Netherlands) contain their own 
preamplifier, minimising electrode impedance, and this system is also portable and does not 
require electrical shielding. 
 A major limitation of EEG is that it has poor spatial resolution in comparison to 
haemodynamic measurement counterparts. This is due to the electrodes being separated from 
the source of the activity in the brain by cerebrospinal fluid, the skull and scalp (Nunez, 
1981). The ambiguity of the location of active neurons is known as the inverse problem 
(Michel et al., 2004). Many complex mathematical algorithms have been developed to 
attempt to solve the so called inverse problem, however many of these are constrained by a 
priori assumptions on the generation of EEG signals (Michel et al., 2004). It is suggested that 
the measurements contain inadequate information about the generators of the activity and as 
such a perfect localization tomography does not exist (Pascual-Marqui, 1999). 
4.2 Functional Near-Infrared Spectroscopy (fNIRS). 
Introduction and Physiological Basis of the Technique 
fNIRS is a novel non-invasive optical neuroimaging technique, that is portable and is 
used to measure the haemodynamic response to brain activation (Leff et al., 2011). This is an 
indirect neuroimaging measurement based on the assumption that neuronal activity and 
cerebral blood flow are tightly coupled (Holper et al, 2009; Villringer & Dirnagl, 1995). 
More specifically fNIRS can be used to measure oxygenation changes to oxygenated 
haemoglobin (oxy-Hb) and deoxygenated haemoglobin (deoxy-Hb) (Jobsis, 1977), by 
shining light in the near infrared range (700 – 900nm) directly onto the tissue of a 
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participant’s forehead. Oxygenated and deoxygenated haemoglobin have characteristic 
optical properties in this light range (Izzetoglu et al., 2004) and chromophores can change in 
concentration with oxy and deoxygenated haemoglobin. Thus, light reflected back to a 
detector will be attenuated by an increase in chromophores. The differences in light 
attenuation can be attributed to the oxygenation changes in the haemoglobin. Typically this 
type of neuroimaging will penetrate to structures around 2-3 mm of the cortex underlying the 
skull (Firbank et al., 1998). Therefore forebrain structures such as the dorsolateral prefrontal 
cortex (DLPFC) can be easily accessed and observed. Due to the DLPFC being prominent in 
higher level processing, and due to these structures being easy to access with this type of 
imaging, it has been used in several studies observing motor control and learning (Leff et al., 
2011), as well as more complex tasks that involve working memory and category 
discrimination (Izzetoglu et al., 2004). 
The Modified Beer-Lambert Law 
 fNIRS raw signals are measurements of light intensity (Ayaz et al., 2011) and optical 
density is measured at two wavelengths (one for oxy-Hb and one for deoxy-Hb). These are 
chosen (within the 700-900nm range) based on intensities whereby oxy-Hb and deoxy-Hb are 
the dominant chromophores (absorb the majority of light) compared to other tissue 
chromophores (Ayaz et al., 2011). The isosbestic point (around 805nm) is the point at which 
oxy-Hb and deoxy-Hb absorption spectrums cross. Hence a wavelength above this is used to 
assess oxy-Hb changes (850nm in this case) and a wavelength below the isosbestic point is 
used to maximally assess deoxy-Hb changes (730nm). The Modified Beer-Lambert Law is 
used to calculate relative changes in oxy-Hb and deoxy-Hb from baseline. It is worth noting 
that levels of oxy-Hb and deoxy-Hb (given as µmolar) are calculations that are relative to 
baseline only, and it is not possible to derive absolute values of concentration with fNIRS.  
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 Optical density at a specific wavelength is calculated using the following formula 
(Modified Beer-Lambert Law): 
 (from Ayaz et al., 2011). 
Whereby wavelength (λ) is equal to the logarithmic ratio of input light intensity (Iin) 
and output (detected) light intensity (Iout). This (optical density – OD) is also related to the 
concentration (c) and extinction coefficient (e) of chromophores, as well as the corrected 
distance between light source and detector (d) and a constant attenuation factor (G) (Ayaz et 
al., 2011). 
Changes in chromophore concentration lead to changes in optical density, thus by 
calculating optical density changes at two wavelengths (850 and 730nm), and by applying 
known extinction coefficients of oxy-Hb and deoxy-Hb at each of those wavelengths, 
concentration changes in oxy-Hb and deoxy-Hb can be determined (Boas et al., 2001).  
Data Collection and Sensor Placement: 
 Conventional fNIRS recording requires a fNIRS headband that has several light 
emitting diodes and sensors embedded in it. This is placed over the participant’s forehead, 
ensuring that the sensors make contact with the skin (any hair preventing contact between 
sensor and skin should be moved) and that there is no ambient light leakage (to this end a 
further headband may be placed over the fNIRS headband to limit light leakage). The 
locations of sensors (voxels) can be observed in Figure 4.1. 
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Figure 4.1. Voxel placement for fNIRS 
 
 
 
 
Fig 4.1: Depicts the sensor placement for the fNIRS headband. Odd numbers correspond to superior parts of the 
PFC, even numbers correspond to inferior parts. Placement at 1 starts over the left side of the brain, with voxels 
1-4 referring to the left DLPFC, voxels 5-8 refer to left medial PFC, voxels 8-12 refer to the right medial PFC 
and voxels 13-16 refer to the right DLPFC.  
 
Advantages and Limitations 
 There are a number of distinct advantages for studying the cortical response to 
behavioural tasks using optical neuroimaging methods such as fNIRS. Firstly, as described 
earlier the prefrontal cortex (PFC) which is understood to subserve executive functions and is 
densely innervated with serotonergic axons, is particularly accessible using fNIRS (Leff et al., 
2011) due to these areas directly underlying the fNIRS sensors (optically accessible). The 
technology is also portable (only a headband is necessary to attach sensors to the forehead) 
and robust to movement artefacts, affording measurement of realistic everyday tasks (Leff et 
al., 2011). Movement artefacts are apparent if there is a sustained dip of the head due to 
gravitational effects on blood flow. However, unlike EEG the data is not affected by blinks, 
body movements or vocalisation. This allows for verbal and written responses to tasks to be 
measured. It is also not as restrictive as other haemodynamic measures (fMRI) that require 
participants to be confined to a set space, and is far less susceptible to movement artefacts 
compared to fMRI. Another important advantage in comparison to fMRI is that fNIRS 
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obtains information about oxygenated haemoglobin as well as deoxygenated haemoglobin, as 
opposed to just deoxy-Hb, as is the case with fMRI (Schecklemann et al., 2010). Although 
deoxy-Hb is more closely linked to the BOLD response, oxy-Hb is understood to be the best 
indicator of activation in fNIRS. Furthermore total haemoglobin (Hbt) can be calculated and 
as such fNIRS gives a multi-dynamic haemoglobin response (Leff et al., 2011). A further 
advantage of fNIRS is that it is relatively low cost, flexible, portable and user friendly 
(Holper et al., 2009).  
 fNIRS does also have several disadvantages, primarily that in comparison to fMRI it 
has relatively poor spatial resolution. Although placement is usually in line with the 
standardised 10-20 system of anatomical landmarks, it measures cortical activation but does 
not provide anatomical information about the brain like fMRI (Leff et al., 2011). Furthermore 
the measurements are confined to relatively superficial cortical areas, as such positioning of 
the device determines the regions that are examined (Ehlis et al., 2008). Moreover fNIRS has 
relatively poor temporal resolution in comparison to EEG (Ehlis et al., 2008).  
Summary 
 In summary, EEG and fNIRS can provide robust data which details neural and 
haemodynamic responses to activation. Each method has considerable strengths which are 
important for the current investigation. The excellent temporal resolution and direct 
measurement of neuronal activity that EEG affords provides much needed information about 
the stages of processing that may be affected. Moreover, haemodynamic response to cortical 
activation in areas of the PFC (which is hypothesised to be damaged with ecstasy use) can be 
explored with fNIRS. Taken together, these techniques will provide a wealth of information 
about how cognitive processing may be affected by use of ecstasy. EEG and fNIRS data are 
implemented in this thesis to investigate functional atypicalities of cognitive processes in 
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ecstasy users relative to controls. ERP analysis is relatively underused for assessing executive 
function in ecstasy users, and as such is implemented to achieve a holistic understanding of 
the contribution of processing deficits in each executive function. fNIRS, to the author’s 
knowledge, has not been used to assess cognitive deficits in ecstasy users, as such this is a 
novel approach to the investigation of executive functions in ecstasy users as well as the 
haemodynamic response to multi-tasking. 
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Chapter 5: Review of Neuroimaging Studies in Ecstasy Users 
 Executive function and other cognitive deficits were reviewed in Chapter 3. Given the 
dense innervation of serotonin neurons in prefrontal areas, it is understood that such deficits 
may be mediated by MDMA related damage to the serotonin system. It is believed that 
repeated use of MDMA will lead to serotonergic neurotoxicity, or down-regulation of 
serotonin receptors. Indeed, in the animal literature MDMA has been observed to be toxic to 
serotonin neurons (see Ricaurte et al., 2000 for a review). In humans direct investigation of 
serotonergic neurotoxicity is difficult. However, various neuroimaging methodologies have 
been employed to investigate the integrity of the serotonin system. This chapter reviews the 
literature from neuroimaging studies in ecstasy users. It is important for this thesis to better 
understand how MDMA use may affect neuronal activity, as atypicalities in neuronal 
function are a more sensitive indicator of potential MDMA related neurotoxicity than residual 
cognitive performance indicators. Each indicator of neuronal activity will be described at the 
outset of each subchapter and the relationship between MDMA use and neuronal integrity 
will be discussed. 
5.1 Single-Photon Emission Computed Tomography (SPECT) 
 Single-Photon Emission Computed Tomography (SPECT) is a neuroimaging method 
that utilises radioligands for the labelling of serotonin transporters (SERT) in the brain, so 
that they can be tracked and densities of these receptors can be assessed. Owing to the 5-HT 
transporter being understood as a structural element of the 5-HT neuron, it is a putative 
reliable marker of the integrity of 5-HT neurons (Reneman, Booij, Majoie et al., 2001). 
Moreover, lower densities of 5-HT receptors observed with SPECT may reflect damage to 
the serotonin system, via MDMA use. 
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 The effect of MDMA use on cortical 5-HT2A receptor densities was assessed using 
SPECT by Reneman, Habraken et al. (2000). In this preliminary study, the radioligand 
[123I]R91150 was administered intravenously to 10 MDMA users (7 male, mean age = 27, 
MLD = 139 tablets, abstinent for at least 2 months), 5 former users (4 male, mean age = 24, 
MLD = 218 tablets), and 10 healthy drug naive control subjects (4 male, mean age = 23). 
Mean cortical 5-HT2A receptor binding ratios were calculated (average of left and right frontal, 
parietal and occipital binding of [123I]R91150) and it was observed that the current MDMA 
user group had significantly lower binding ratios than controls and former users. The 
observed low cortical 5-HT2A receptor densities in the current user group are suggested to be 
due to downregulation of receptors owing to MDMA induced 5-HT release. However the 
increase in cortical 5-HT2A receptor densities (approaching significance) in the former user 
group compared to controls is suggested to be due to upregulation of post synaptic 5-HT2A 
receptors as a result of low synaptic 5-HT caused by MDMA induced serotonergic 
neurotoxicity.  
 The same research group (Reneman, Booij et al., 2000) investigated whether MDMA 
use produced alterations to post-synaptic 5-HT2A receptors and memory function, by 
administering the same radioligand [123I]R91150, as well as a verbal memory test (Rey 
Auditory Verbal Learning Test – RAVLT) to 5 MDMA users (4 male, mean age = 23.6, 
MLD = 218, mean time since last dose = 4.6 months) and 9 age and education matched 
healthy controls (4 male, mean age = 22.8). SPECT imaging results revealed that overall 
binding ratios were higher in the MDMA user group. However this only approached 
significance in the occipital cortex. Again it is suggested that the higher density of 5-HT2A 
receptors, reflects upregulation of postsynaptic 5-HT2A receptors as a result of 5-HT depletion. 
Furthermore, performance on the memory task was significantly reduced in MDMA users 
relative to controls and this was correlated with 5-HT2A receptor binding in the MDMA group. 
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The authors suggest that these results reflect memory deficits that are attributable to MDMA 
induced 5-HT deficits. 
 Serotonin transporter densities were examined in 22 current MDMA users (11 male, 
mean age = 26.2, MLD = 485 tablets, mean time since last use = 2.4 months), 13 former users 
(8 male, mean age = 25.3, MLD = 268 tablets, mean time since last use = 29 months) and 13 
controls (7 male, mean age = 25) by Reneman, Lavalaye et al., (2001). This study used the 
radioligand: iodine 123-labeled 2β-carbomethoxy-3β-(4-iodophenyl) tropane (123 Iβ-CIT). 
SERT and memory function (using the RAVLT) were assessed to observe if there were 
correlations between the two and whether prolonged abstinence could lead to recovery of any 
observed deficits. Current MDMA users displayed lower cortical 123 Iβ-CIT binding than 
controls, however no significant differences in binding were observed between former users 
and controls. Immediate and delayed recall performance on the RAVLT was poorer for both 
ecstasy user groups relative to controls. However this was not correlated with 123 Iβ-CIT 
binding. It was concluded that the lower SERT densities in current MDMA users reflects 
neurotoxic effects, which may be reversible after cessation of use, whereas the effects on 
memory function may be long lasting. The same research group (Reneman, Booij, de Bruin et 
al., 2001) used the same radioligand in a SPECT study to investigate the effects of sex, dose 
and long term abstention from use of MDMA on serotonin neurons. Fifteen moderate ecstasy 
users (9 male, mean age = males 25.6, females 22.7, MLD = 28.6 tablets, mean time since 
last use = 3.6 months), 23 heavy users (12 male, mean age = males 27.1, females 25, MLD = 
530 tablets, mean time since last use = 2.3months), 16 former users (8 male, mean age = 
males 26.4, females 24.1, MLD = 268.1, mean time since last use = 29 months) and 15 
controls (7 male, mean age = males 29.3, females 23.3) participated in this study. There were 
no between group differences in age, verbal intelligence or use of alcohol, tobacco and 
cannabis, although MDMA users reported more use of amphetamines and cocaine than 
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controls. 123 Iβ-CIT binding ratios were significantly lower in female, but not male heavy 
MDMA users compared to controls and this was true for all brain regions analysed. The 
moderate user group showed equivalent binding ratios for males and females compared to 
controls. Females showed significantly lower binding ratios than males in the former user 
group, though this did not differ significantly to controls. Overall SERT binding and log 
transformed previous MDMA use were significantly correlated in females but not in males. 
These results suggest that MDMA use can lead to reductions in serotonin transporters that are 
dependent on gender, and level of use. The study also suggests that MDMA induced 
reductions in SERTs may be reversible after abstention in females.  
Reneman, Booij et al. (2002) investigated the densities of nigrostriatal dopamine neurons in 
29 ecstasy users (15 male, mean age = 26.1, MLD = 324 tablets), 9 ecstasy and amphetamine 
users (6 male, mean age = 22.1, MLD = 358 tablets) and 15 non-user controls (7 male, mean 
age = 26.1) using the radioligand 123 Iβ-CIT. It is understood that MDMA may affect the 
dopaminergic system, and tablets sold as ecstasy may also contain known compounds that 
cause dopaminergic neurotoxicity, such as (meth) amphetamine. Between group comparisons 
revealed that 123 Iβ-CIT binding ratios were significantly higher in the ecstasy user group 
compared to controls, whereas 123 Iβ-CIT binding ratios were significantly reduced in the 
ecstasy + amphetamine group relative to ecstasy only users (but not compared to controls). 
Level use of ecstasy and amphetamine did not correlate with 123 Iβ-CIT binding ratios. The 
authors suggest combined use of MDMA and amphetamine may lead to reduced dopamine 
transporter densities. However this is most likely to result from the amphetamine use, given 
that ecstasy alone does not appear to have an effect on dopamine neurons, whereas 
amphetamine has been observed to be neurotoxic to dopamine neurons in animal studies (e.g. 
Ricaurte et al., 1984).  
 
 
 
 
72 
 
 Chang et al. (2000) used SPECT to assess cerebral blood flow (CBF) in 21 ecstasy 
users (17 male, mean age = 43.4, MLD = 211 tablets) and 21 age, gender and 
socioeconomically matched controls (17 male, mean age = 43.7). MDMA users showed only 
slightly lowered global CBF (2.3%) and mild but not significant reductions in regional CBF. 
Differences in individual regions were not significantly different, and drug use variables 
(frequency, duration or recency) did not correlate significantly with global or regional CBF. 
This study also investigated acute effects of MDMA administration. Eight participants were 
administered MDMA on two separate occasions within one week and were scanned again 2-3 
weeks later. Global and regional CBF SPECT scans post MDMA administration showed 
decreases in CBF in most brain regions compared to baseline and to controls. Decreased 
regional CBF was greatest in the caudate and superior parietal cortices, and right DLPFC. 
These decreases were more pronounced in participants who received larger doses of MDMA 
and most recently. However the data suggest that these effects may be transient. 
 More recently Klomp et al. (2012) suggested that age of first exposure may affect 
serotonin transporter densities. SPECT analysis of 123 Iβ-CIT was conducted in 33 ecstasy 
users stratified for early exposed users (first use at between 14 and 18 years) and later 
exposed users (first exposure between 18 and 36 years). ANOVA revealed a significant effect 
of age at first use in midbrain 123 Iβ-CIT binding ratios (age at scan, gender, duration of use 
and lifetime dose had no effect). There was also a strong significant negative correlation 
between age of first use and midbrain 123 Iβ-CIT binding ratios in the early exposed group, 
but not the late exposed group. These findings suggest that MDMA affects the developing 
brain differently to the mature brain and MDMA’s neurotoxic effect is dependent on the 
developmental stage of SERT and maturity of serotonin transmitter function. 
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 The sustained effect of MDMA on SERT densities in novel ecstasy users was 
assessed by de Win et al. (2008a), using the radioligand 123 Iβ-CIT. In this prospective 
study 188 ecstasy naïve participants with a high probability of ecstasy use were recruited, 
based on participants indicating intention to use in the near future. Participants underwent 
SPECT imaging at baseline and again in a follow up imaging session 12-36 months after 
baseline. By the follow up testing sessions, 59 participants that were still engaged with the 
study had started to use ecstasy. This incidental ecstasy user group had a mean lifetime dose 
of six tablets (range of 0.5-80) with a mean time since last use of 18.7 weeks. From the initial 
cohort of participants, 56 that were still ecstasy naïve were selected as controls, matched with 
the ecstasy group for gender, age and cannabis use. At baseline the two groups did not differ 
significantly in their age, gender, verbal IQ, SERT polymorphism, smoking, alcohol use, or 
use of cannabis, cocaine and amphetamines. However at follow up the novel ecstasy users 
showed significantly increased consumption of alcohol, cannabis, cocaine and amphetamine 
compared to the persistent ecstasy naïve control group. No significant effects of MDMA on 
123 Iβ-CIT binding were observed, with no between group differences at baseline, or follow 
up, and no significant dose response effects of cumulative doses of MDMA on follow up 
outcomes.  
 In summary, the majority of the literature of SPECT imaging in ecstasy users suggests 
changes in SERT binding ratios. The evidence suggests that heavy users are likely to develop 
reductions in subcortical serotonin transporter densities (Reneman, Lavalaye et al., 2001) and 
that there appears to be dose dependent transient reductions in SERT whereby females are 
more vulnerable than males (Reneman, Booij, de Bruin et al., 2001). Reneman, Booij et al. 
(2000) suggest increases in [123I]R91150 binding in ecstasy users, however this study was 
conducted in a small sample of users (n=5) and the results only approached significance in 
one area. Recency of last dose may also be of significance given that Reneman, Habraken et 
 
 
 
 
74 
 
al. (2000), observed lower [123I]R91150 binding ratios in recent ecstasy users compared to 
former users and controls. Moreover, in the subacute effects observed by Chang et al. (2000) 
decreases in CBF after ecstasy use were more pronounced in larger and more recent doses. 
Klomp et al.’s (2012) study suggests that age at first exposure may play a key role in the 
extent of serotonin transporter density reduction and Reneman, Booij et al.’s (2002) results 
suggest that MDMA may be a selective serotonin neurotoxin (with amphetamine more likely 
to be culpable for striatal dopamine receptor reduction). The majority of studies show 
reduced serotonin transporter densities following ecstasy use, which is a putative marker of 5-
HT neurotoxicity. The only study that observed no alteration in SERT binding between 
ecstasy users and non-users (de Win, Jager et al., 2008a) was conducted on novel ecstasy 
users who had received relatively low doses of MDMA in comparison to other studies. 
 Evidence from SPECT studies suggests a reduction in SERT densities as a result of 
serotonergic neurotoxicity. If this is the case and neurotoxicity has occurred in the present 
sample, differences in behavioural performance as well as changes in processing and 
haemodynamic response to task may be observable in this thesis. 
5.2 Electroencephalography (EEG) 
EEG involves the measurement of electrical activity at the scalp, using electrodes that 
are placed all over a participant’s head. Using this technique several methods can be used to 
investigate various neuronal responses. For example Event Related Potentials (ERPs) are an 
aggregate of post synaptic action potentials that are time locked to an event, whereas Event 
Related Synchronisation (ERS) or Event Related Desynchronisation (ERD) reflect increases 
or decreases in amplitudes of specific frequency bands in relation to an event.  
Dafters et al. (1999) investigated the relationship between EEG variables (spectral 
power and coherence) and cognitive/mood variables with level of MDMA use with a 128 
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electrode EEG apparatus on 23 recreational MDMA users (mean age = 24 years). In this 
study, six resting (eyes closed) epochs of 60 seconds were recorded from each participant 
(with 20s re-arousal periods between each recording) for spectral and coherence analysis. 
Spectral analysis was conducted on one relatively artefact free 60s epoch after visual 
inspection. The results from spectral analysis revealed that level of MDMA use is positively 
correlated with an increase in alpha power across left frontal, left posterior and right posterior 
areas of the brain. Use is also positively correlated with beta power in the left posterior region 
and is negatively correlated with relative delta power over the whole scalp. Coherence 
analysis revealed weak but significant negative correlations between MDMA use and sites 
located over visual tracts (O1-T3, O2-T4). The authors suggest that these results (the 
desynchronisation of EEG activity – increased high frequency bands alpha and beta coupled 
with decrease in low frequency band delta) in MDMA users mimic results observed in ageing 
populations. 
Gamma, et al. (2005) assessed the ERP P3 component in response to an inhibition 
task in 16 ecstasy polydrug users (8 male, mean age = 22.6, MLD = 270.2 tablets) and 17 
controls (10 males, mean age = 26.0, less extensive drug use). ERPs were evoked by a 
Continuous Performance Test (CPT A-X), this is analogous to a Go/NoGo task whereby a 
participant in shown letters sequentially on a screen (A, B, C,D, E, F, G, H, J, L, X), and if an 
‘A’ appears followed directly by an ‘X’ participants are to respond (“Go”). The presentation 
of ‘A’ acts as a cue inducing preparation of a motor response. However the response is to be 
inhibited if any letter other than ‘X’ follows. ERPs to the letter following ‘A’ were used for 
analysis and the size of the P3 response was calculated as the mean amplitude between 250 
and 450ms. Midline electrodes Fz, Cz and Pz were used for analysis, as these had been 
shown previously to produce maximal P3 amplitude. The averaged P3 amplitude for the 4 
quadrants of scalp potential field were also compared (using electrodes Fp1, F3, F7, FC5 and 
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FT9 for the anterior left quadrant, the corresponding electrodes on the right side of the scalp 
were used for anterior right quadrant, P3, O1, T5, CP5, TP9 and PO9 were used for the 
posterior left quadrant and the corresponding electrodes on the right side were used for the 
anterior right quadrant). The results showed that ecstasy users displayed a significantly 
reduced P3 in relation to NoGo trials at midline electrodes Fz and Cz. However after 
controlling for age, education and cannabis use, Fz became non-significant (p=.08). Quadrant 
analysis revealed one significant difference; in the posterior right quadrant ecstasy users 
displayed greater P3 positivity than controls – however this again became non-significant 
after controlling for confounders. There were no between group differences in latencies of P3. 
Moreover lifetime use of MDMA and cannabis did not correlate with ERP characteristics or 
performance on the task. Task performance was also equivalent between groups. The authors 
suggest that although lower P3 amplitudes in ecstasy users are consistent with higher levels 
of neuronal disinhibition, other results do not reflect disturbed inhibitory brain mechanisms.  
Cognitive processing of ecstasy users was investigated using EEG by Mejias et al. 
(2005) using a visual oddball task. In this particular “oddball” paradigm, faces (2 women, 2 
men) were presented to participants. These were either, neutral or emotional (happy or 
fearful). The neutral faces were the frequent stimuli (presented 84 times in a block of 100 
trials), and the emotional faces were the infrequent/”oddball” stimuli that were presented 16 
times in a block of 100 trials (8 x fearful, 8 x happy). This enables separation of attentional 
(preparation to process) and response related (preparation to respond) components of an ERP. 
Thus the N2 component (peaking around 250ms at occipital electrodes) indicates a switch of 
attention (to prepare) and the P3(b) component (occurring around 450ms at parietal sites) 
relates functionally to later stages of processing that are conscious, such as decision making 
and premotor responses. ERPs were recorded from 14 MDMA users (mean age = 24.64, 
MLD = 143.07 tablets) and 14 controls (mean age = 25.57, matched for scores for depression 
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and anxiety and cannabis use), whilst performing 16 blocks of the visual oddball task. 
MDMA users were slower than controls to respond to rare stimuli. Furthermore ecstasy users 
who had consumed upwards of 100 tablets were significantly slower to respond to rare 
stimuli than those who had consumed fewer than 100 tablets. A mixed ANOVA revealed that 
ecstasy users showed a greater latency of the P3b component compared to controls for rare 
stimuli. There were no differences in latency in the N2 or P3a components, or amplitudes at 
any measured component. When ERPs for happy vs. fearful faces were compared, there were 
no between group differences (amplitudes or latencies) for happy faces, whereas ecstasy 
users showed a greater P3b latency for fearful faces compared to controls. The authors 
suggest that these results reflect serotonergic neurotoxicity in MDMA users which manifests 
in attentional deficits. These are indexed neurophysiologically by a postponement of 
information processing at the attentional level to the decision level (P3b) in MDMA users. 
Casco et al. (2005) investigated Visually Evoked Potentials (VEPs) to a simple 
discrimination task in eight heavy MDMA users (7 male, mean age = 28, MLD = 1054 
tablets), eight moderate MDMA users (7 male, mean age = 25, MLD = 52.4 years) and 18 
drug free controls (limited drug use, split into 2 sub-groups of 19-23 years n=9, 3 male and 
24-32 years n=9, 5 male). This two-alternative forced-choice task comprised of digits being 
presented on a screen randomly (either 1 or 2); when the sequence is interrupted participants 
indicate whether the last digit that appeared on the screen was a 1 or a 2. There were no 
between group differences on performance on the task, although pairwise comparisons 
showed that heavy MDMA users made significantly more errors compared to drug free 
controls. Amplitudes and latencies of the following components; P100, N150, P200, N250, 
P300 and N400 were measured at electrodes Oz and Fz. Heavy MDMA users showed 
significantly reduced P200 and P300 amplitudes at Oz compared to controls. Moderate users 
also showed significantly reduced P300 amplitude relative to controls. No such differences 
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were found in latencies at this site. At Fz the P300 was significantly reduced in both heavy 
and moderate users compared to controls. Moreover the N250 component was significantly 
reduced in heavy users relative to controls (this was also approaching significance in 
moderate users). Latency was not significantly different at any component for this electrode. 
Since the groups do not differ in latencies of components it is suggested that processing speed 
is not affected in these ecstasy users. However reductions in amplitude at middle (exogenous) 
and late (endogenous) stages of processing are suggested to be evidence of altered cortical 
activity associated with low level cognitive processing. It was concluded that recreational use 
of MDMA is sufficient to cause neurotoxicity that is associated with subtle low-level 
cognitive deficits in humans. 
Auditory ERPs and cognitive performance were assessed in a longitudinal study by de 
Sola et al. (2008). Fourteen ecstasy polydrug users (6 male, mean age = 25.2, mean total 
lifetime use = 207.4 at baseline) 13 cannabis users (5 male, mean age = 25.1, daily cannabis 
use or at least 25 times in lifetime) and 22 drug naïve controls (7 male, mean age = 24.3) 
were recruited. Three ecstasy users, four cannabis users and one drug naïve control had 
dropped out by the follow up experiment. ERPs were evoked by an auditory oddball 
paradigm and participants were required to count the infrequent stimuli. Grand averaged P3 
amplitudes and P3 latencies were obtained at time 1 and 12 months later at time 2. There 
were no significant between group differences for P3 amplitude or P3 latency at time 1 or 
time 2. Correlations between MDMA use and P3 response were not significant at time 1 or 
time 2. However a significant correlation was observed between lifetime cannabis use and P3 
latency at time 1, which was approaching significance at time 2 whereby greater cannabis use 
improved neuronal processing speed. Conversely a marginally significant correlation between 
cannabis use and P3 amplitude suggested increased lifetime dose is associated with lower P3 
amplitude. Although reduced P3 amplitude and increased P3 latency in ecstasy users 
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compared to controls was consistent across time 1 and time 2, the results were marginal and 
non-significant and fail to provide evidence for neurotoxicity associated with MDMA use, 
though it is suggested that executive functioning tasks are more likely to be impaired at the 
cognitive level than simple attentional orientation tasks. 
More recently Burgess et al. (2011) investigated verbal episodic memory ERPs in 15 
ecstasy polydrug users (7 male, mean age = 24.1 mean lifetime MDMA uses = 138), 14 
cannabis users (7 male, mean age = 21.9) and 13 non-illicit drug users (6 male, mean age = 
22.3). Participants undertook two recognition memory tasks, which were identical apart from 
the type of stimuli; words (verbal) and faces (non-verbal). Over 90 trials participants had to 
indicate whether the presented stimulus was new (presented first time in the sequence) or old 
(had been repeated). The tests consisted of 40 stimuli that were repeated and 10 items that 
were shown only once. No between groups differences were observed on performance on the 
task. However for the word recognition memory task, Partial Least Squares (PLS) analysis on 
the ERP data identified a single latent variable that discriminated between correct new 
responses and correct old responses. A significant repetition effect was observed, with a more 
positive-going ERP for repeated words centred on the left parietal area maximal in the 500-
700ms interval. There was a significant difference between groups in latent variable scores 
with ecstasy/polydrug users showing significantly reduced amplitude compared to non-drug 
controls, and this difference was approaching significance with the cannabis user group. This 
latent variable consisted of two ERP components that were extracted using singular value 
decomposition. These were identified as a left parietal recollection effect and a midline 
frontal familiarity effect. Component scores were compared between groups, the recollection 
component revealed a significantly reduced late positive ERP over left parietal sites in 
ecstasy users compared to both other groups. No between group differences were observed 
for the familiarity component. Latent component analysis on the face recognition task did not 
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provide any between group differences. It is suggested that ecstasy/polydrug users showed an 
attenuation of a neuronal response that is associated with the ‘pure’ cognitive process of 
verbal recollection.  
 Nulsen et al. (2011), observed differences in EEG activity in a cohort of 11 MDMA 
users (4 male, mean age = 22.9, MLD = 32.5 tablets), 13 polydrug users (4 male, mean age = 
23.2) and non-users (4 male, mean age = 23.2), whereby during forward and backwards digit 
span tasks (described in Chapter 3.2.3), both control groups displayed a significantly reduced 
P3b in the digit backwards task (more difficult aspect of the task) than the digit forwards task. 
However the MDMA user group did not show this difference, yet this group displayed the 
greatest discrepancy between digit backward span and digit forward span. These results 
suggest that the ecstasy user group found this part of the task more demanding. The authors 
suggest that ecstasy users’ performance was suppressed more by concurrent processing 
demands of the working memory task than controls, and the ERP data reflect this, showing a 
reduction in the cognitive resources allocated to processing. 
 On the whole, the majority of the studies reviewed reflect differences in 
electrophysiological data that are suggestive of alterations to cognitive processing associated 
with MDMA use. However there are several studies that fail to show ecstasy-related ERP 
atypicalities (de Sola et al., 2008; Gamma et al., 2005). Some studies have observed 
differences in latencies of a P3 component (Mejias et al., 2005). Others have observed 
reductions in P3 amplitude associated with ecstasy use, despite equivalent behavioural 
performance (Casco et al., 2005). Conversely, Nulsen et al. (2011) failed to observe 
reductions in P3 amplitude despite observing performance deficits. Other studies have shown 
alterations to late ERP components reflective of altered cognitive processing (Burgess et al., 
2011). The full extent of MDMA’s effect on electrophysiological indices requires 
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clarification and there is a paucity of EEG data relating specifically to executive processes. 
As such this thesis aims to observe differences between MDMA users, polydrug controls and 
drug naïve controls on each executive function, on three well defined components of an ERP; 
the P2, N2 and the P3(b). 
5.3 Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging (MRI) is a non-invasive neuroimaging method that 
relies on a large cylindrical magnet to create a magnetic field around a subject’s head. When 
a magnetic field is created, protons (mainly from H+ hydrogen ions that are abundant in 
living tissue) align with the same direction as this field (Weishaupt et al., 2008). Radio 
frequency pulses are then sent to target nuclei (H+ ions) causing them to fall out of alignment 
(resonance). Following this, protons immediately begin to realign with the magnetic field. 
The realignment causes a radio frequency which can be received by the scanner. These are 
known as T1 scans and parameters can be adapted to obtain a high contrast between grey and 
white matter. As such these scans can provide valuable structural information. MRI is unable 
to measure neuronal activity, however functional MRI (fMRI) involves parameter 
manipulation to allow for brain function to be imaged whilst an action is being performed 
(Kennedy et al., 2002) (this will be discussed in more detail in chapter 5.5). 
Chang et al. (1999) conducted MRI scans in a 1.5 T scanner on 21 subjects with a 
history of MDMA use (15 male, median age = 43, mean duration since last use = 4 months, 
average lifetime dose of 13.1 g) and 37 ‘normal’ controls (22 men, median age = 38), and 
observed all images for MDMA users and controls to be normal with no significant brain 
atrophy or white matter lesions. Similarly Chang et al. (2000) observed normal MRI scans for 
21 MDMA using subjects and 21 controls (as described 5.1) in a 1.5 T scanner. 
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Structural MRI scans of 31 MDMA polydrug users (5+ uses of MDMA and abstinent 
for at least 3 weeks) and 29 non-MDMA users (age and sex matched that had used a variety 
of drugs but not MDMA) were compared using voxel based morphometry (VBM) in a study 
by Cowan et al. (2003) to investigate regional brain grey and white matter concentration. It 
was hypothesised that ecstasy users may show reduced neocortical grey matter as a result of 
loss of serotonergic trophic effects on cortical cells. Using a 1.5 T scanner T1 weighted scans 
revealed multiple areas of reduced grey matter concentration in MDMA users relative to 
controls. The neocortical regions displaying significantly reduced grey matter concentrations 
included bilateral Brodmann Area (BA) 18 in the occipital lobe, BA 21 in the temporal lobe, 
and left BA 45 in the frontal lobe, as well as a midline region of the brain stem and bilateral 
areas of the cerebellum. These findings are interesting to observe if we consider the proposed 
functionality of these areas. Both BA 45 and BA21 in the neocortex are suggested to play an 
important role in semantic memory retrieval. This therefore has direct relevance to the current 
thesis, as this function will be examined with further neuroimaging techniques.  
Reneman, Majoie et al. (2001) assessed eight ecstasy users (7 male, mean age = 27.6, 
MLD = 154 tablets, mean duration since last use = 14.6 weeks) and six non-users (3 male, 
mean age = 22.3 years) on conventional T1 and T2 weighted scans as well as diffusion and 
perfusion imaging (the results from which will be discussed in chapter 5.6). Perfusion MRI is 
conducted to assess the vasculature of the brain by calculation of cerebral blood volume 
(rCBV). Intravenous bolus injections of gadopentetate dimeglumine were administered to 
participants prior to T2 weighted echo planar scans to provide an endogenous tracer of 
arterial blood entering the brain (Keston et al., 2003). No oedematous changes in the brains 
of ecstasy users compared to controls were observed. However the perfusion MRI data 
provide more interesting results, with ecstasy users having overall higher mean rCBV values 
than controls. This difference approached statistical significance in the globus pallidus. The 
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rCBV ratio in the globus pallidus also correlated significantly with extent of previous drug 
use, and did not correlate with age, sex or IQ values. The authors suggest that increased 
rCBV in the globus pallidus is a result of vasodilation that occurs in the absence of serotonin 
controlled vasoconstriction due to serotonergic depletion. 
Schouw et al. (2012) conducted Pharmacological MRI to assess 5-HT dysfunction in 
ecstasy users (10 male; 50+ lifetime tablets; 7 healthy controls) by examining the 
haemodynamic response to injection of a selective serotonin reuptake inhibitor (SSRI – 
citalopram). MRI was conducted using a 3.0T scanner with pre-infusion anatomical 3DT1 
weighted scans conducted for registration with pharmacologically labelled (post infusion) 
scans. Subtraction of post infusion/citalopram labelled arterial spin labelling (ASL) images 
from pre infusion/control ASL images yielded whole brain perfusion weighted images. 
MDMA users displayed a significant cerebral blood flow reduction in response to the 5-HT 
challenge, most prominent in the left thalamus. A significant decrease in CBF was also 
observed in the right occipital cortex and the right frontal cortex. Significant CBF increases 
were observed in the left globus pallidus and left frontal cortex. Controls showed minimal 
differences between the two scans. Mean whole brain CBF was significantly increased in 
ecstasy users compared to controls, and CBF was significantly decreased in the left thalamus 
and bilateral occipital lobe compared to controls after citalopram infusion. It is suggested that 
ecstasy users showed citalopram evoked haemodynamic changes in cortical regions and 
subcortical grey matter areas that contain high densities of serotonin receptors in normal 
populations, as a result of possible neurotoxicity. 
Overall it appears that structural MRI scans have yielded little evidence for MDMA 
related changes to white matter areas (Chang et al., 1999; Chang et al., 2000; Cowan et al., 
2003) perhaps suggesting that this measure is not sensitive enough to observe a physical 
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alteration to brain composition after MDMA use. However, reductions in neocortical grey 
matter have been observed in ecstasy users compared to controls in structural scans, typically 
in areas that are important for semantic retrieval (BA 21 and 45). Perfusion MRI was 
successful in identifying increases in cerebral blood volume in the globus pallidus in ecstasy 
users (Reneman, Majoie et al., 2001). This is a substructure of the basal ganglia, which has 
been highlighted for its role in access to semantic memory (Copeland, 2003). Furthermore 
alterations of cerebral blood flow were also observed in this area in ecstasy users from 
pharmacological MRI (Schouw et al., 2012), as well as CBF reductions in cortical regions 
and subcortical grey matter areas. 
5.4 Magnetic Resonance Spectroscopy (MRS) 
 Proton Magnetic Resonance Spectroscopy (
1
H MRS) is another non-invasive 
technique, that is similar to MRI in that it measures signals from hydrogen protons. However 
rather than structural information, MRS provides information about relative concentrations of 
CNS metabolites associated with structural brain integrity (Cowan et al., 2007). These 
include the neuronal marker N-acetylaspartate (NAA) and the putative glial marker 
myoinositol (MI). 
 Chang et al. (1999) used MRS to evaluate neurochemical abnormalities in 21 MDMA 
users and 37 controls (as described in Chapter 5.3). Using a 1.5 T scanner, MRS was 
performed in mid-occipital (grey matter), mid frontal (grey matter) and right parietal (white 
matter) brain regions. The results showed that metabolite concentrations of NAA, creatine 
(CR) and choline compounds (CHO) were comparable in all three brain areas measured 
between ecstasy users and non-users. However ecstasy users showed elevated MI and MI to 
CR ratios in parietal white matter as well as MI and MI/CR in parietal white matter. 
Furthermore occipital grey matter positively correlated with MDMA use. The authors suggest 
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that the lack of NAA change (which is a marker considered sensitive to death or damage to 
neurons) could reflect down regulation of 5-HT neurons rather than damage, or potentially 
neuronal recovery. Similarly Liu et al. (2011) observed no significant increases in NAA 
between MDMA users (n = 25, 20 male, mean age = 25.04, MLD = 158.12 tablets) and drug 
naïve controls (n = 27, 17 male, mean age = 27.04) in the basal ganglia, whereas MDMA 
users displayed increases in MI concentrations. Correlations between CR concentration and 
MDMA dose were observed in the right basal ganglia. 
 Reneman, Majoie et al. (2002) investigated NAA/Cr, NAA/CHO and MI/Cr ratios in 
midfrontal grey matter, mid occipital grey matter and right parietal matter using (
1
H MRS) in 
15 male MDMA users (MLD = 723 tablets, mean time since last use – 12 weeks) and 12 age 
matched controls. Ecstasy users showed significantly reduced NAA/Cr and NAA/CHO ratios 
in frontal grey matter compared to controls. Frontal grey matter binding ratios were 
negatively correlated with MDMA use. No differences were observed in mid occipital grey 
matter or right parietal white matter between the two groups. These findings are difficult to 
reconcile with those reported by Chang et al. (1999) and suggest that reduced NAA/Cr and 
NAA/CHO ratios in the frontal cortex reflect neuronal abnormality. As the ecstasy users in 
Reneman, Majoie et al., (2002) had a higher lifetime dose than Chang et al., (1999), this 
could be an effect of dosage.  
Obergreisser et al. (2001) investigated MDMA use on the hippocampus using (
1
H 
MRS) in 6 ecstasy users (having at least 100 doses from 3-6 years, range = 120-350) and 5 
age matched (26.6 years) controls. It was observed that there were no differences in 
hippocampal NAA or choline compounds between ecstasy users and non-users, consistent 
with Chang et al.’s (1999) findings. Daumann, Fischermann, Pilatus et al. (2004) conducted 
1
H MRS in the left hippocampus, midfrontal and midoccipital cortex of 13 regular ecstasy 
 
 
 
 
86 
 
users (10 male, MLD = 324.54 tablets, mean time elapsed since last use = 47.38 days) and a 
non-MDMA control group (n=13, 10 male) that were matched for age, sex, level of education 
and cannabis use. No significant between group differences were observed in NAA/Cr ratios 
in any brain region observed. Furthermore there were no meaningful correlations between 
NAA/Cr ratios and drug use, or memory performance. It was concluded that 
1
H MRS was a 
less sensitive measure of neurotoxicity in ecstasy users than cognitive measures. Similarly, de 
Win et al. (2008a) observed no significant effects of MDMA on brain metabolites (cohort 
and experiment explained in more detail in Chapter 5.1) in a longitudinal study, nor in a 
prospective cohort study on sustained effects of low dose ecstasy use on the brain in new 
ecstasy users (de Win et al., 2007) (this study will be described in more depth in chapter 5.6) 
 Cowan et al. (2007) investigated absolute concentrations of NAA and MI in the 
occipital lobe in 9 MDMA users (at least 5 occasions of use, aged 18-35) and 7 non-MDMA 
controls matched for age and sex and had used a variety of other drugs. In this study a higher 
field proton strength MRS of 4T was used in an attempt to gain a more sensitive measure of 
neuronal disturbance. There were no statistical differences in absolute NAA or absolute MI 
levels in the occipital cortex between MDMA users and non-users. The authors concluded 
that these findings are not supportive of MDMA induced alterations to neurons or glia in the 
occipital cortex of this small sample of moderate MDMA users. 
 In summary, MRS studies suggest MDMA has little effect on NAA, which is an 
indirect measure of neuronal damage. However the samples in these studies are relatively 
small, furthermore the one study which did yield ecstasy-related differences had a cohort of 
MDMA users with far greater MDMA exposure than the other studies (Reneman, Majoie et 
al., 2002). MRS has also been criticised for perhaps not being sensitive enough to detect 
small changes in NAA that are associated with low level recreational doses of MDMA, or 
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detect changes to 5-HT terminals only (Chang et al., 1999). Although increasing the field 
power made little difference in the study by Cowan et al. (2007) perhaps more work is 
necessary with larger samples of heavier MDMA users. 
5.5 Functional Magnetic Resonance Imaging (fMRI) 
 Similar to MRI this functional technique relies on magnetic fields being created 
around a participant’s head. However rather than T1 weighted scans (that have a high spatial 
resolution to give clear structural information) this technique relies on T2 weighted scans at a 
lower resolution to assess Blood Oxygen Level Dependent (BOLD) signal changes (Kennedy 
et al., 2002). In basic terms radio frequencies that are delivered to cause transverse 
magnetisation (falling out of alignment of protons) also cause the spin axes of nuclei to tilt 
(precess) in phase. When the pulse is stopped, this phase precess will relax, and the time 
taken for all ions to fall out of phase is called T2. Increases in duration of time to repeat (time 
between radio frequency pulses and T2) and time to echo (time between radio frequency 
pulses and signal reception) give T2 weighted scans. T2 weighted scans favour imaging of 
water, as such by using paramagnetic contrast agents in the blood (deoxy-haemoglobin) 
blood flow and blood volume changes can be assessed (Huettel et al., 2004).  
 Daumann, Fimm et al. (2003) investigated the cerebral activation during a working 
memory task using fMRI with 11 moderate ecstasy users (8 male, MLD = 27.3 tablets, mean 
time since last dose =330.09 days), 11 heavy users (8 male, MLD = 258.18 tablets, mean time 
since last use = 89.27 days) and 11 healthy controls, all matched for age, sex and level of 
education. Participants conducted an n-back task (behavioural results discussed in Chapter 
3.2.3) in combination with fMRI. The fMRI results showed that all three groups showed 
significant and localised haemodynamic changes in prefrontal, parietal, occipital and 
cingulate brain regions. However there were no group differences in activation at any level of 
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the task at a conservative significance level (p<0.05 corrected). Whereas using a more liberal 
significance level (p<0.01, and p<0.001 uncorrected) heavy users showed weaker BOLD 
responses in left frontal and temporal regions on the most difficult level of the task (2-back) 
relative to the other two groups. Also, both user groups showed increased activation in the 
right parietal cortex with 1 and 2 back tasks. However extent of previous drug use did not 
correlate with BOLD signal changes. It is suggested that these results may reflect subtle brain 
functioning alterations associated with MDMA use, but to treat these results with caution. In 
a similar fMRI/n-back study, Daumann, Schnitker et al. (2003) studied BOLD activation in 8 
pure ecstasy users (no regular use of any other drugs, mean age 25.30, MLD = 74.50 tablets), 
8 polyvalent ecstasy users (concomitant use of ecstasy and amphetamines and cannabis, mean 
age = 26.41, MLD = 56.25 tablets) and 8 healthy controls (mean age = 25.55) in an attempt to 
control for concomitant use of other drugs. Performance on the n-back task was equivalent 
between the three groups and all groups showed typical cortical activation patterns during the 
task. However pure MDMA users showed reduced BOLD activation in the temporal gyrus 
and angular gyrus in the 1-back task compared to controls (polyvalent users did not differ 
significantly from controls). Moreover pure MDMA users had lower signal changes 
compared to polyvalent users in the striate cortex and higher BOLD response in the premotor 
cortex. At the more difficult 2-back level of the task, pure MDMA users showed lower 
activation than both other groups in the angular gyrus. It is concluded from these results that 
MDMA is associated with neuronal alterations that may reflect MDMA-induced 
neurotoxicity and that altered fMRI patterns are not associated with concomitant use of other 
drugs. 
 The same research group (Daumann, Fischermann, Heekeren et al., 2004) conducted 
an 18 month longitudinal fMRI study, again using the n-back task in 30 ecstasy users (at time 
1, this reduced to 21 users by time two). This ecstasy using cohort was then subdivided into 
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two groups based on their drug use in the interval between testing at time 1 and time 2; a 
group that were abstinent during the interval period (n=8, 6 male, mean age =24.50 MLD = 
31.50 tablets, mean time since last dose = 487.5 days) and a group that continued to use 
ecstasy during the interval period (n=9, 5 male, mean age = 25.67, MLD = 149.44 tablets, 
mean time since last dose = 15.67 days). The results of the fMRI scan at time 1 suggest no 
differences in cortical activation between the two groups. At time 2 cortical activation 
patterns did not alter significantly for any level of the n-back task from baseline in the interim 
abstention group, whereas the continuing users showed increased activation from baseline in 
two clusters in the parietal cortex during the most difficult level of the task (2-back). 
Furthermore correlational analysis revealed that the increase in haemodynamic activation 
between time 1 and time 2 in the two clusters in the parietal cortex for the continuing users 
was associated with higher one night dose of MDMA. These results suggest that higher 
nightly doses may result in higher risk of neuronal damage. The authors also offer that 
neuronal damage in ecstasy users is long lasting, as the interim abstinent group did not differ 
(or improve) in their activation at time 2 compared to time 1, assuming that activation at time 
1 was atypical. 
 Moeller et al. (2004) used fMRI to study activation during a working memory task in 
15 MDMA users (12 male, mean age = 24.7, mean lifetime uses = 193.5, mean time since 
last use = 37 days) and 19 controls (11 male, mean age = 25.4). Participants undertook an 
fMRI scan whilst completing an immediate and delayed memory task. SPM99 random effects 
analysis showed that ecstasy users displayed significantly greater BOLD activation in three 
clusters of brain regions compared to controls in the delayed memory task. These clusters 
were; 1- left medial and superior frontal gyri with extending activation to the right medial 
superior frontal gyri, bilateral anterior cingulate gyri, and right middle frontal gyrus. 2- left 
thalamus extending to left caudate and putamen, left parahippocampal gyrus, left 
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hippocampus and left insula. 3- right hippocampal gyrus extending to the right hippocampus, 
right thalamus, right lentiform nucleus, right putamen, right insula, and right temporal cortex. 
Most of these effects remained after controlling for other drugs. However after controlling for 
cannabis, the effect was no longer significant in the prefrontal cortex. The authors suggest 
that the observed increase in activation of the BOLD signal could be due to MDMA users 
being less “efficient” at the working memory task, resulting in an increase in neuronal 
activity to perform at a similar level as controls. They also argue that increased BOLD fMRI 
activation in the hippocampus may be MDMA specific. Valdes et al. (2006) used the same 
subjects as those used by Moeller et al. (2004) and compared fMRI data with scores on the 
Barrat Impulsivity Scale. There was a significant correlation between activation in two 
clusters of the DLPFC and scores on the BIS. However there was no group by BIS interaction 
with DLPFC activation, suggesting that this activation is related to impulsivity independently 
of MDMA use. In line with Moeller et al. (2004), hippocampal dysfunction was observed in 
adolescent MDMA users, in an fMRI study by Jacobsen et al. (2004). Selective and divided 
attention and verbal working memory was assessed concurrently with fMRI in 6 adolescent 
MDMA users (average of 10 episodes of MDMA use, mean age at first use = 15.8, little use 
of other drugs other than cannabis and alcohol, mean age = 17.3) and 6 adolescents with no 
history of MDMA use (matched for age and gender). The two groups did not differ with 
regards to consumption of cigarettes, cannabis, years of education, estimated intelligence or 
self-reported depression or anxiety. Performance on tasks was equivalent, although MDMA 
users had significantly longer reaction times. MDMA users displayed significantly lowered 
hippocampal activity relative to controls during the working memory task. Correlational 
analysis revealed that time since last use was negatively correlated with left hippocampal 
activity. The authors suggest that abnormal hippocampal function in ecstasy users could be 
the result of damage to serotonin neurons that normally modulate inhibitory circuits. 
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Moreover the negative relationship between hippocampal activity and time since last use 
suggests that function of inhibitory circuits in the hippocampus may recover after long 
periods of abstinence. 
 Jager et al. (2008) assessed the concomitant use of other drugs in 71 participants 
recruited on the basis of variations in the amount and type of drugs that they used. Thirty-
three heavy MDMA users (MLD = 322 tablets) and 38 non users (both groups showing 
considerable variation in the type and amounts of drugs they were using) completed tasks of 
working memory, attention and associative memory tasks in association with fMRI 
procedures. Analysis of fMRI revealed no significant effects of ecstasy or any other drugs on 
brain activity relating to working memory (modified Sternberg task) and attention (SAT task). 
However in the associative learning task ecstasy use predicted lower activity in the left 
DLPFC and higher activation in the right middle occipital gyrus. Moreover these effects 
appeared to be independent of cannabis and alcohol use, as well as amphetamine cocaine and 
tobacco use. The authors suggest these results reflect sustained – possibly even long term 
adaptation or compensatory reorganisation of a fronto-visual network. 
 Cowan et al. (2006) investigated the BOLD fMRI response to visual cortex activation 
in ecstasy users. In this study 20 MDMA users (who reported MDMA use on at least 4 
occasions, mean age = 20.8, 8 male) and 23 non-users (13 male, mean age = 25.3) were 
administered photic stimulation using specially constructed fibre optic goggles, whilst an 
fMRI scan was undertaken. MDMA users had reported significantly greater lifetime use of 
alcohol, amphetamine, cannabis, cocaine, hallucinogens, opiates, sedatives and phencyclidine 
than non-users. However there were no differences in visual cortical activation between the 
two groups. Nevertheless a within subjects analysis in the MDMA user group revealed that 
degree of prior MDMA exposure was correlated with number of activated pixels for photic 
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stimulation. Conversely MDMA exposure was not correlated with BOLD signal change, 
whereas lifetime alcohol, hallucinogens, sedatives and cannabis were all inversely correlated 
with % BOLD signal change, but not with number of activated pixels. As such the results are 
inconclusive with regard to the neurophysiological response to visual cortex activation in 
ecstasy users. 
 More recently Raj et al. (2010) observed reduced BOLD signal change during a 
semantic recognition task in ecstasy polydrug users. In a cohort and task described in Chapter 
3.2.4 it was observed that there were statistically significant correlations of MDMA use and 
BOLD signal change in left BA 9, 18 and 21/22, but not BA 45 during a semantic recognition 
task. Lifetime episodes of MDMA use and lifetime dose were both inversely correlated 
with %BOLD signal change at BA 9. Lifetime episodes of use was inversely correlated with 
BOLD signal change in BA 18 and 21/22, though no such correlations were observed for the 
encoding phase of the task, suggesting that MDMA affects verbal recognition but not 
encoding. These results were complicated by inverse correlations between lifetime cocaine 
use and BOLD signal activation in left BA 9 and 18 as well as a statistically significant 
inverse correlation between cannabis use and activation in left BA 9. Nonetheless, after 
controlling for lifetime cocaine and cannabis use, the association between MDMA use and 
BA 9 activation remained statistically significant. The findings in this study are consistent 
with findings of other neuroimaging and behavioural studies suggesting that access to 
semantic memory may be adversely affected by MDMA use.  
 Neurophysiological correlates of impulse inhibition were explored in 20 ecstasy users 
and 20 drug naïve controls (as described in Chapter 3.2.2) by Roberts and Garavan (2010). 
fMRI data showed that ecstasy users displayed greater activity in right middle and inferior 
frontal gyri, right middle frontal gyrus and right inferior parietal lobule, during successful 
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response inhibitions (STOPS) on a Go/NoGo task, compared to controls. Ecstasy users also 
displayed greater error activation in the right middle and inferior temporal gyri. Deactivation 
in the left medial frontal gyrus and left posterior cingulate was significantly greater for 
controls on error trials. It is suggested that the increased activation displayed by ecstasy users 
despite behaviourally silent differences in performance, shows increased neuronal 
recruitment to inhibit in this group. Recruitment of additional resources to maintain 
performance, suggests a subtle functional impairment that would have not been exposed with 
behavioural measures alone. 
The results from fMRI warrant further exploration, although it appears that ecstasy 
use is generally associated with reductions in the BOLD response in frontal and temporal 
regions (Daumann, Fimm et al., 2003; Daumann, Schnitker et al., 2003) the DLPFC (Jager et 
al., 2008), hippocampus (Jacobsen et al., 2004) and BA 9 (Raj et al., 2010). These reductions 
may reflect neuronal loss or damage. Increases in BOLD have also been observed in several 
areas including the thalamus and hippocampus (Moeller et al., 2004) and right middle 
occipital gyrus (Jager et al., 2008). However, the authors of these studies suggest that this 
may reflect compensatory mechanisms due to task inefficiency. Furthermore some increases 
in BOLD have been observed in MDMA users in the parietal cortex and are also correlated 
with higher nightly doses. These effects may be more pronounced in younger users who have 
yet to complete neurodevelopment upon initiation of use (Jacobsen et al., 2004). There is also 
evidence to suggest that ecstasy-related alteration of neuronal activity is long lasting 
(Daumann, Fischermann, Heekeren et al., 2004). However further exploration of use on 
executive function is warranted.  
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5.6 Diffusion Tensor Imaging (DTI) 
 Diffusion Tensor Imaging (DTI) is an MRI technique that enables diffusional motion 
of water molecules to be assessed (de Win et al., 2007), and allows imaging of tissue 
structures at the microscopic level, providing information about neural tissues and changes 
associated with damage and acute brain ischemia (Le Bihan, 2003). Diffusion in the brain 
white matter is anisotropic, and motion is restricted by cellular structures (for example axons) 
(de Win et al., 2007). Damage to axons may cause cytotoxic oedema, causing the cells to 
swell and hence restrict diffusion motion further, resulting in decreased apparent diffusion 
coefficient (ADC). Conversely, chronic damage to axons, may lead to increases in 
extracellular water concentrations, subsequently leading to decreases in fractional anisotropy 
(FA) and therefore increased ADC (de Win et al., 2007). This neuroimaging technique is 
used to visualise anatomical functional connectivity between different areas of the brain by 
mapping the orientation of white matter tracts (Le Bihan, 2003). 
 In a prospective study (de Win et al., 2007), DTI scans were performed on 188 
ecstasy naïve participants who were selected on the basis that there was a high probability of 
them using ecstasy in the near future. Thirty participants (12 males, mean age 22.5 years, 
cumulative dose of ecstasy was 1.8 tablets, with an average of 7.7 weeks since last use) were 
scanned soon after their first ecstasy use. These scans revealed a 0.9% significant increase in 
FA of white matter in the centrum semiovale as well as a significant decrease (3.4%) of ADC 
in the thalamus post ecstasy use. However after correction for multiple comparisons and 
exclusion of participants with continued cocaine use, the increase in FA was no longer 
significant. The authors suggest that this does not provide evidence of structural neuronal 
damage. However the sustained decreases in ADC may indicate prolonged vasoconstriction 
in certain areas even after low doses of ecstasy, although it is not known whether these 
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effects are permanent. This study was followed up by the same research group (de Win et al., 
2008a), using the same initial sample. At the time of this study a total 59 participants had 
used ecstasy (MLD = 6 tablets). These were compared against 56 controls matched for age, 
gender and IQ, although the ecstasy users had now used significantly more cannabis, 
amphetamine, cocaine and alcohol than controls. Ecstasy users showed a significant decrease 
in FA in the thalamus and fronto-parietal white matter. They also showed an increase in FA 
in the globus pallidus and ADC in the thalamus relative to controls. It is suggested that 
decreased FA and increased ADC in the thalamus reflects axonal damage, given that axonal 
cells are understood to be the main cause for restriction of water diffusion and axonal damage 
leads to the observed changes in FA and ADC. 
 The globus pallidus was also indicated as an area of interest in a diffusion MRI study 
by Reneman, Majoie et al. (2001). In this preliminary study 8 MDMA users (described in 
Chapter 5.3) and 6 non-ecstasy controls undertook diffusion MRI scans. It was observed that 
ecstasy users displayed a significant increase in ADC in the globus pallidus relative to 
controls. However, no significant correlations were observed between extent of previous 
ecstasy use and ADC values. This increase in ADC is attributed to possible axonal injury or 
loss and not due to an increase in water content in the extracellular space, as local brain 
oedema was not detected on T2 weighted scans. 
 Moeller et al. (2007) compared FA, mean diffusivity (Dₐᵥ), and longitudinal (diffusion 
along the direction of fibres) and transverse (perpendicular to the fibre tract axis) diffusivities 
between 12 MDMA users (10 male, mean age = 27.3, 181 mean occasions of use) and 20 
healthy controls (13 male, mean age = 25.5), in six regions of the corpus callosum (Genu, 
Rostral body, Anterior Midbody, Posterior Midbody, Isthmus and Splenium). Results from 
DTI showed that MDMA users had significantly reduced longitudinal diffusivities in the 
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rostral body of the corpus callosum relative to controls, consistent with axonal damage in 
MDMA users. No significant differences in FA, Dₐᵥ or transverse diffusivity were observed. 
 Conversely to de Win et al. (2008a), Liu et al. (2011) observed significant increases 
in FA in the bilateral thalami in 25 ecstasy users relative to 27 drug naïve controls (as 
described in Chapter 5.4). In this whole brain DTI study; MDMA users showed clusters with 
significantly increased FA in posterior parts of bilateral thalami and the retrolenticular parts 
of internal capsules. Decreased FA was observed in MDMA users in the genu of the corpus 
callosum which is consistent with findings from Moeller et al. (2007). Furthermore MDMA 
users showed significant decreases in ADCs in the bilateral thalami, posterior internal capsule 
and corona radiata along the bilateral corticospinal tracts, as well as significantly increased 
ADC in the bilateral anterior internal capsule, the bilateral superior longitudinal fasiculus and 
the splenium and genu of the corpus callosum. Decreased ADCs in bilateral thalami and 
increased FA is consistent with de Win et al.’s (2007) initial findings suggesting that integrity 
of axons in the basal ganglia-thalamocortical circuit may be compromised by MDMA use. 
 Neurotoxic effects of ecstasy on the thalamus were explored further using DTI by de 
Win et al. (2008b) using a sample of 71 polydrug users (33 of which were defined as heavy 
MDMA users, MLD = 322 tablets) correlations were conducted between drug use variables 
and DTI values. Extent of MDMA use was significantly correlated with decreased FA in the 
thalamus although no significant effect of MDMA on ADC in the basal ganglia was observed. 
5.7 Positron Emission Tomography (PET) 
 Positron Emission Tomography (PET) is another haemodynamic functional 
neuroimaging technique that involves participants receiving injections of a radioactive tracer 
(radioligand). PET scanners are then able to monitor the distribution of the tracer in the brain, 
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which indexes cerebral blood flow, and thus is an indirect measure of neural activity (Cabeza 
& Nyberg, 1997). 
 PET may also be used to measure SERT densities, similar to SPECT by using radio 
ligands that selectively label the 5-HT transporter. McCann et al. (1998) used the radioligand 
carbon-11-labelled McN-5652 to observe differences in SERT binding between 14 MDMA 
users (9 male, mean age = 26.6, mean use = 228 occasions, mean usual dose = 386mg, mean 
duration since last use = 19 weeks) and 15 controls (9 male, mean age = 28.3). The 
distribution volumes ratios (DVR) for binding of the radioligand were significantly globally 
decreased in MDMA users relative to controls, suggesting that users had lower densities of 
SERT sites than controls. Moreover, decreases in SERT binding correlated significantly with 
extent of previous drug use, suggesting MDMA exposure may lead to loss of 5-HT terminals. 
 The same radioligand was used in a much larger sample by Buchert et al. (2003). 
Thirty current ecstasy users (15 male, mean age = 24.5, MLD = 831 tablets, mean duration 
since last use = 25 days), 29 former users (15 male, mean age = 24.4, MLD = 793 tablets, 
mean duration since last use = 520 days), 29 ecstasy naïve drug users (15 male, mean age = 
24.4) and 29 drug naïve controls (14 male, mean age = 23.2) were compared for SERT 
availability in SERT rich areas of the brain including: mesencephalon, putamen, caudate and 
thalamus. The results showed that ecstasy users had significantly lower DVR in the 
mesencephalon than all other groups. Ecstasy users had significantly reduced DVRs in the 
caudate relative to polydrug users and in the thalamus, ecstasy users’ DVRs were 
significantly reduced compared to polydrug users and drug naïve controls. The mean DVRs 
over all areas were lowest in current users. However, DVRs for former users and drug naïve 
controls were similar across all areas, suggesting possible recovery. There were no 
differences between groups in DVRs in the white matter, where there are no SERTs, 
suggesting that the effects are serotonin specific.  
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Using the same sample, Buchert et al., (2004) observed that current MDMA users had 
significantly reduced DVRs in the posterior cingulate gyrus, left caudate, thalamus, occipital 
cortex, medial temporal lobes including the hippocampus and parahippocampal regions and 
brainstem with mesencephalon and pons compared to all three control groups. These 
differences were more pronounced in females than males, suggesting that females may be 
more susceptible to MDMA related serotonergic changes. Interestingly, there were no 
significant differences in SERT availability between former users and the two other control 
groups, suggesting that these effects may be reversible after long periods of abstention. This 
is also supported by the finding that DVRs and MDMA abstention periods were positively 
correlated in the brainstem with mesencephalon and pons and the basal forebrain. SERT 
appeared to normalise in this follow up study, with no significant differences between groups 
in the mesencephalon. The authors suggest that there were reductions in ecstasy use, which 
may account for normalising SERT levels. These findings coupled with normal SERT levels 
in former users suggest that ecstasy-related effects of SERT availability may be reversible. 
The effects of MDMA use on cortical serotonin function in females was explored 
further in a PET study by Di lorio et al. (2012) using the 5-HT2A receptor specific radioligand 
[
18
F]setoperone. Fourteen female MDMA users (mean age = 21.64, mean lifetime MDMA 
consumption = 14000mg) were compared with 10 female controls (mean age = 21.60). 
MDMA users had significantly increased 5-HT2A receptor binding in occipital-parietal, 
temporal, occipito-temporal-parietal, frontal and fronto-parietal regions. Lifetime use was 
also significantly correlated with binding increases in fronto-parietal, occipito-temporal, 
fronto-limbic, and frontal regions. There were no significant effects of duration of abstinence 
on binding here, suggesting chronic 5-HT neurotoxicity in females. 
 Thomasius et al. (2003) used [
11
C]McN5652 to assess serotonin transporter density in 
30 current ecstasy users (15 male, mean age = 24.5, MLD = 1033.77 tablets, time since last 
 
 
 
 
99 
 
use = male - 21.6 days, female – 24.73 days), 31 former users (16 male, mean age = 24.13, 
MLD = 600 tablets, time since last use = male – 485.40, female – 545.13 days) 29 polydrug 
controls (15 male, mean age = 24.41) and 30 drug naïve participants (15 male, mean age = 
23.13). Current MDMA users showed significantly reduced DVRs in the mesencephalon in 
relation to all other groups. Furthermore typical number of ecstasy exposures was the best 
predictor of DVRs in the thalamus and caudate nucleus, and number of ecstasy tablets taken 
in the year leading up to testing was the best predictor of DVRs in the mesencephalon. The 
authors conclude that these results are in line with the hypothesis that MDMA use may lead 
to reductions in SERT availability in the central serotonergic system. However these 
alterations may be reversible after abstention.  
 McCann et al. (2005) used first and second generation SERT ligands [11C]McN5652 
and [
11
C]DASB to investigate MDMA induced brain serotonin neurotoxicity in 23 MDMA 
users (13 male, mean age = 22.04, mean number of exposures = 96.96, mean usual dose = 
1.79 tablets, time since last dose = 4.71 months) and 19 controls (8 male, mean age = 26). 
Consistent with previous findings, global reductions in DVRs were observed in MDMA users 
compared to controls with both radio ligands. Correlational analysis also revealed that with 
both radioligands, global DVRs correlated with duration of abstinence, suggesting that 
abstention may lead to partial recovery. Global SERT binding DVR was also inversely 
correlated with typical monthly MDMA dose (for both radioligands) suggesting that loss of 
SERT is associated with MDMA use intensity. The same research group (McCann et al., 
2008) conducted PET using [
11
C]DASB to investigate SERT binding, alongside [11C]WIN 
35,428 to investigate dopamine transporter (DAT) binding. The MDMA users in this study 
(n=16, 8 male, mean age = 23.5, mean number of uses = 195.3) had all reported having 
sequential doses of MDMA (2 or more doses over a 3-12 hour period). Subjects also 
underwent formal neuropsychiatric testing (tests of memory, attention and executive 
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function). The results indicated that SERT binding was significantly reduced in multiple 
brain regions for MDMA users relative to controls (occipital cortex, parietal cortex, temporal 
cortex, anterior cingulate cortex, posterior cingulate cortex, DLPFC and hippocampus). The 
reductions were greatest in cortical regions (especially the occipital cortex) and there were no 
significant differences in SERT binding in subcortical regions. However, no differences were 
observed between users and controls in DAT binding in the caudate or putamen, and no 
relationship was found between measures of MDMA use and DAT binding. There was, 
however, a significant negative correlation between SERT availability in the hippocampus 
and duration of MDMA use. These results reflect the specificity of MDMA as a selective 
serotonin neurotoxin and suggest that sequential dosing is associated with lasting decreases in 
SERT. Memory performance was also correlated with SERT binding in the DLPFC, 
orbitofrontal cortex and parietal cortex, across groups. However this was not significant in 
MDMA users alone, suggesting that MDMA use disrupts this relationship. 
 More recently Sudhakar et al. (2009) investigated SERT binding using [
11
C]DASB in 
12 former MDMA users (all male, mean age = 28.2, mean lifetime occasions = 243.75, 
typical session dose = 2.75, time since last use = 2.74 years), 9 polydrug user controls (all 
male, mean age = 35.6) and 19 drug naïve controls (mean age = 30.5). No significant 
differences were observed in cerebellar DVR between the three groups and there were no 
correlations between variables of MDMA use and SERT binding suggesting no long lasting 
serotonin neuron damage in recreational users. 
 Presynaptic (5-HT transporter, SERT) and postsynaptic (5-HT2A receptor) markers of 
serotonin transmission in neocortical areas were investigated in a PET study using the SERT 
ligand [
11
C]DASB and the 5-HT2A receptor ligand [
11
C]MDL by Urban et al. (2012). Thirteen 
current users (8 male, mean age = 30.8, 5.7 weeks mean abstinence, 142 mean MDMA 
sessions) and 13 matched healthy controls were compared. Presynaptic SERT availability 
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was reduced overall in ecstasy users compared to controls for cortical but not subcortical 
regions. The most pronounced differences were observed in the medial prefrontal cortex, 
occipital cortex and temporal cortex. As predicted, decreased SERT was regionally 
associated with upregulated 5- HT2A receptor binding. It is suggested that these results reflect 
MDMA induced damage to 5-HT neuron terminals innervating the cortex. Kish et al., (2010) 
observed SERT binding of [
11
C]DASB in cortical and subcortical areas using voxel based 
analysis with 49 chronic MDMA users (28 male, mean age = 25.9, range of cumulative 
lifetime tablets = 2 – 922, variable use of other drugs) and 50 controls (25 male, mean age = 
26, low use of other drugs). ANOVA revealed highly regional-specific decreases in 
[
11
C]DASB binding in ecstasy users compared to controls that was restricted to the entire 
cerebral cortices and hippocampus with the most marked reduction (-46%) in the occipital 
cortex. No changes were observed in the SERT rich striatum (Caudate, putamen and ventral 
striatum), thalamus, global pallidus or midbrain. These findings suggest that SERT binding 
reduction is regionally specific and is unlikely to be explained by recent use of other 
stimulant drugs, hormonal levels, SERT promoter gene polymorphisms or structural brain 
changes (as observed from regression analysis). 
 [H2 
15
O]-PET was used to assess cerebral blood flow after a single dose of MDMA 
(1.7mg/kg) or placebo in 16 MDMA naïve participants by Gamma et al. (2000). It was 
observed that MDMA produced acute increases in regional cerebral blood flow in the 
ventromedial, frontal and occipital cortex, inferior temporal lobe and cerebellum, as well as 
decreases in the motor and somatosensory cortices, left amygdala, insula, cingulate cortex 
and thalamus. 
 To sum up, the literature on SERT binding in MDMA users as assessed by PET seems 
to consistently suggest that use is associated with lower SERT availability (McCann et al., 
1998; McCann et al., 2005) globally. However this is usually more pronounced in SERT rich 
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areas such as the mesencephalon, caudate and thalamus (Buchert et al., 2003; Buchert et al., 
2004; Thomasius et al., 2003). Findings of decreased DVRs in SERT rich areas coupled with 
no such differences in white matter (Buchert et al., 2003) reflect that potential neural damage 
is serotonin specific. This is also reflected by lack of observed differences in dopamine 
transporter binding between MDMA users and non-users (McCann et al., 2008). There is 
evidence to suggest that MDMA’s effects on serotonin terminals are more pronounced in 
female users (Buchert et al., 2004; Di lorio et al., 2012). Furthermore the majority of studies 
reviewed suggest that the effects observed may be reversible. Sudhakar et al. (2009) observed 
no differences in SERT between former users and controls and other studies have shown 
correlations between period of abstention and SERT availability (Buchert et al., 2004; 
McCann et al., 2005). 
Chapter Summary 
The evidence from neuroimaging studies suggests that ecstasy does adversely affect 
the serotonin system. Although it is clear that some methods are not as sensitive as others at 
detecting perhaps mild cognitive aberrations (MRI, MRS) associated with low recreational 
doses. Other methods (SPECT, PET, fMRI) consistently show alterations to neuronal 
activation/ SERT binding that reflect degradation of the serotonin system that is associated 
with MDMA use. Abstention also appears to play an important role with regards neuronal 
changes, as many studies suggest that SERT availability returns to normal levels after periods 
of abstention. However, some of the behavioural deficits noted in chapter 3 have been shown 
to be long lasting. All participants in this thesis will be required to be abstinent from MDMA 
use for at least 7 days prior to testing, to observe long lasting effects of drug rather than an 
acute residual intoxication effect. Other neuroimaging studies that have been coupled with 
behavioural tasks have observed differences in their neurophysiological performance despite 
having undetectable behavioural deficits, suggesting neuroimaging techniques are more 
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sensitive to cognitive impairment than behavioural measures alone. As such all of the studies 
in this thesis will combine behavioural assessments with assessments of neurophysiological 
indices. Furthermore after conducting a literature search for fNIRS studies with MDMA users, 
it has been concluded that this neuroimaging technique has never been used for assessment of 
cognitive performance in MDMA users previously. As such the application of this technique 
to this research area is novel, and will provide valuable information about haemodynamics in 
the PFC of MDMA users.
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Measure/Authors Methodology Findings 
   
SPECT   
   
Reneman, Habraken et al. (2 000) Structural analysis, using radioligand [123I]R91150 to 
assess cortical 5-HT2A receptor binding in 10 MDMA 
users, 5 former users and 10 drug naïve controls 
Current MDMA users had significantly lower binding 
ratios than controls and former users over an average of 
left and right frontal, parietal and occipital areas. 
   
Reneman, Booij et al. (2000) Structural analysis using radioligand [123I]R91150 to 
assess post-synaptic 5-HT2A receptor binding in 5 
MDMA users and 9 non-user controls 
Overall binding ratios higher for MDMA users. However 
this only approached significance in the occipital cortex. 
   
Reneman, Lavalaye et al. (2001) Structural analysis using radioligand 123 Iβ-CIT to 
assess cortical SERT binding in 22 current MDMA 
users, 13 former users and 13 controls 
Current MDMA users displayed lower cortical SERT 
binding than controls. No significant differences in 
binding observed between former users and controls. 
   
Reneman, Booij, de Bruin et al. (2001) Structural analysis using radioligand 123 Iβ-CIT to 
assess cortical SERT binding in 15 moderate ecstasy 
users, 23 heavy users, 16 former users and 15 controls 
Binding ratios significantly lower in female heavy users 
compared to controls for all brain regions analysed. 
Overall SERT binding and log transformed previous 
MDMA use were significantly correlated in females but 
not in males. 
   
Reneman, Booij et al. (2002) Structural analysis using radioligand 123 Iβ-CIT to 
assess nigrostriatal dopamine neuron densities in 29 
ecstasy users, 9 ecstasy and amphetamine users and 15 
controls. 
 123 Iβ-CIT binding ratios significantly higher in the 
ecstasy user group compared to controls. 123 Iβ-CIT 
binding ratios significantly reduced in the ecstasy + 
amphetamine group relative to ecstasy only users. 
   
Chang et al. (2000) Functional analysis, assessing cerebral blood flow in 21 
ecstasy users and 21 controls 
Ecstasy users showed slightly lowered global CBF 
(2.3%) and mild but not significant reductions in regional 
CBF compared to controls. 
    
Klomp et al. (2012) Structural analysis using radioligand 123 Iβ-CIT to 
assess SERT binding ratios in 33 ecstasy users stratified 
for early (14-18 years) and late (18-36 years) exposure 
Significant effect of age at first use in midbrain 123 Iβ-
CIT binding ratios. Also a strong significant negative 
correlation between age of first use and midbrain 123 Iβ-
CIT binding ratios in the early exposed group, but not the 
late exposed group. 
   
   
Table 5.1: Summary of studies assessing objective measures of neurotoxicity in ecstasy users 
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de Win et al. (2008a) Structural analysis using radioligand 123 Iβ-CIT to 
assess SERT binding ratios in prospective ecstasy users 
in a longitudinal study: 188 ecstasy naïve participants 
scanned at time 1, with 59 participants subsequently 
using ecstasy by time 2 (12-36 months follow up). 59 
incidental ecstasy users compared to 56 still drug naïve 
controls 
No significant ecstasy related effects on 123 Iβ-CIT 
binding observed. 
   
EEG   
   
Dafters et al. (1999) Functional analysis. Spectral and coherence analysis of 
60s resting (eyes closed) epochs and cognitive/mood 
variables in 23 ecstasy users. 
Level of MDMA use positively correlated with an 
increase in alpha power across left frontal, left posterior 
and right posterior areas. Use also positively correlated 
with beta power in the left posterior region and 
negatively correlated with relative delta power over the 
whole scalp. Coherence analysis revealed weak but 
significant negative correlations between MDMA use 
and sites located over visual tracts (O1-T3, O2-T4). 
   
Gamma et al. (2005) Functional analysis. ERP P3 assessed whilst conducting 
inhibition task (CPT A-X) in 16 ecstasy users and 17 
controls 
Ecstasy users show significantly reduced P3 in relation to 
NoGo trials at midline electrodes Fz and Cz. After 
controlling for age, education and cannabis use, Fz 
became non-significant. No between group differences in 
P3 latencies. No correlation between P3 amplitude or 
latency and lifetime MDMA use. 
   
Mejias et al. (2005) Functional analysis. ERP components assessed while 
conducting visual oddball task: 14 ecstasy users, 14 
controls. 
Ecstasy users showed a greater latency of the P3b 
component compared to controls for rare stimuli. 
   
Casco et al. (2005) Functional analysis. ERP components of VEPs assessed 
during a simple discrimination task: 8 heavy ecstasy 
users, 8 moderate users and 18 drug free controls 
Heavy users showed significantly reduced P2 and P3 
amplitudes at Oz compared to controls. Moderate users 
showed significantly reduced P3 amplitude relative to 
controls. P3 was significantly reduced in both heavy and 
moderate users compared to controls at Fz. N250 
significantly reduced in heavy users relative to controls. 
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de Sola et al. (2008) Functional analysis. ERP components assessed in 
relation to an auditory oddball paradigm in 14 ecstasy 
users, 13 cannabis users and 22 drug naïve controls. 
Longitudinal study. 
No significant between group differences for P3 
amplitude or latency at time 1 or time 2. Correlations 
between MDMA use and P3 response not significant at 
time 1 or time 2. However  lifetime cannabis use and P3 
latency significantly correlated at time 1, with greater 
cannabis use associated with increased neuronal 
processing speed. 
   
Burgess et al. (2011) Functional analysis. ERPs analysed during two 
recognition memory tasks in 15 ecstasy users, 14 
cannabis users and 13non-drug users 
Significantly reduced late positive ERP over left parietal 
sites in ecstasy users compared to both other groups for 
the recollection component of the task. 
   
Nulsen et al. (2011) Functional analysis. ERPs analysed during forward and 
backwards digit span task: 11 ecstasy users, 13 
polydrug controls, 13 non-drug controls 
Both control groups show significantly reduced P3 in the 
digit backwards task than the digit forwards task. This 
difference is not evident in ecstasy users, despite 
showing greatest discrepancy in performance between 
the two tasks. 
   
MRI   
   
Chang et al. (1999) Structural analysis: 21 ecstasy users, 37 non-users Ecstasy users and controls showed normal scans with no 
significant brain atrophy or white matter lesions. 
   
Chang et al. (2000) Structural analysis: 21 ecstasy users, 21 non-users Normal MRI scans for ecstasy users and controls. 
   
Cowan et al. (2003) Structural analysis: 31 ecstasy users, 29 non-users Ecstasy users showed reduced grey matter concentrations 
relative to controls in bilateral BA 18 in the occipital 
lobe, BA 21 in the temporal lobe, and left BA 45 in the 
frontal lobe, as well as a midline region of the brain stem 
and bilateral areas of the cerebellum. 
   
Reneman, Majoie et al. (2001) Structural analysis with conventional T1 weighted 
scans as well as diffusion and perfusion MRI 
(Intravenous bolus injections of gadopentetate 
dimeglumine administered  prior to T2 weighted echo 
planar scans) in 8 ecstasy users and 6 non-user controls 
Perfusion MRI showed ecstasy users had overall higher 
mean rCBV values than controls. This approached 
significance in the globus pallidus. The rCBV ratio in the 
globus pallidus also correlated significantly with extent 
of previous drug use. No differences were observed on 
other MRI measures. 
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Schouw et al. (2012) Structural analysis. Pharmacological MRI, 3.0T T1 
weighted scans performed pre and post infusion  with 
SSRI Citalopram. Haemodynamic response to SSRI 
investigated in 10 male ecstasy users and 7 non-user 
controls 
Ecstasy users displayed a significant cerebral blood flow 
reduction in response to 5-HT challenge, most prominent 
in the left thalamus.  
   
MRS   
   
Chang et al. (1999) Structural analysis from relative concentrations of CNS 
metabolites associated with structural brain integrity: 21 
ecstasy users, 37 non-user controls 
Concentrations of NAA, CR and CHO comparable in all 
3 brain areas measured (mid occipital, mid frontal and 
mid parietal brain regions) between ecstasy users and 
non-users. However ecstasy users showed elevated MI 
and MI to CR ratios in parietal white matter as well as 
MI and MI/CR in parietal white matter. Occipital grey 
matter positively correlated with MDMA use. 
   
Liu et al. (2011) Structural analysis from relative concentrations of CNS 
metabolites associated with structural brain integrity: 25 
ecstasy users, 27 drug naïve controls 
No significant differences in NAA between groups in the 
basal ganglia. However ecstasy users displayed increases 
in MI concentrations. Correlations between CR 
concentration and MDMA dose observed in the right 
basal ganglia. 
   
Reneman, Majoie et al. (2002) Structural analysis from relative concentrations of CNS 
metabolites associated with structural brain integrity: 15 
male ecstasy users, 12 non-user controls 
Ecstasy users show significantly reduced NAA/Cr and 
NAA/CHO ratios in frontal grey matter compared to 
controls. Frontal grey matter binding ratios were 
negatively correlated with MDMA use. No differences 
observed in mid occipital grey matter or right parietal 
white matter between groups. 
   
Obergreisser et al. (2001) Structural analysis from relative concentrations of CNS 
metabolites associated with structural brain integrity. 
Assessment of MDMAs effects on the hippocampus in 
6 ecstasy users and 5 non-user controls. 
No differences in hippocampal NAA or choline 
compounds between ecstasy users and non-users. 
   
Daumann, Fischermann, Pilatus et al. (2004) Structural analysis. 
1
H MRS in the left hippocampus, 
midfrontal and midoccipital cortex of 13 ecstasy users 
and 13 non-user controls 
No significant between group differences in NAA/Cr 
ratios in any brain region observed. No meaningful 
correlations between NAA/Cr ratios and drug use. 
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de Win et al. (2008a) Structural analysis from relative concentrations of CNS 
metabolites associated with structural brain integrity: 
188 ecstasy naïve participants scanned at time 1, with 
59 participants subsequently using ecstasy by time 2 
(12-36 months follow up). 59 incidental ecstasy users 
compared to 56 still drug naïve controls 
No significant effects of MDMA on brain metabolites. 
   
Cowan et al. (2007) Structural analysis, MRS 4T was used to investigate 
absolute concentrations of NAA and MI in the occipital 
lobe in 9 ecstasy users and 7 non-user controls 
No statistical differences in absolute NAA or absolute 
MI levels in the occipital cortex between MDMA users 
and non-users. 
   
fMRI   
   
Daumann, Fimm et al. (2003) Functional analysis during n-back task: 11 heavy 
ecstasy users, 11 moderate ecstasy users, 11 non-user 
controls 
Heavy users showed weaker BOLD responses in left 
frontal and temporal regions on the most difficult level of 
the task (2-back) relative to the other two groups (at 
liberal significance level p<0.01, and p<0.001 
uncorrected). Both user groups showed increased 
activation in the right parietal cortex with 1 and 2 back 
tasks. Extent of previous drug use did not correlate with 
BOLD signal changes. 
   
Daumann, Schnitker et al. (2003) Functional analysis during n-back task: 8 pure ecstasy 
users, 8 polyvalent ecstasy users, 8 non-user controls 
Pure MDMA users showed reduced BOLD activation in 
the temporal gyrus and angular gyrus in the 1-back task 
compared to controls. Pure MDMA users had lower 
signal changes compared to polyvalent users in the striate 
cortex and higher BOLD response in the premotor 
cortex. Pure MDMA users showed lower activation than 
both other groups in the angular gyrus during 2-back 
(more difficult) level of the task. 
   
Daumann, Fischermann, Heekeren et al. (2004) Functional analysis during n-back task, in an 18 month 
longitudinal study: 30 ecstasy users (at time 1, reducing 
to 21 users by time two) 
Continuing users showed increased activation from 
baseline in two clusters in the parietal cortex during the 
most difficult level of the task (2-back) at time 2 
compared to time 1. Increase in haemodynamic 
activation between time 1 and time 2 associated with 
higher one night dose of MDMA. 
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Moeller et al. (2004) Functional analysis during immediate and delayed 
memory task: 15 ecstasy users, 19 non-user controls 
Ecstasy users displayed significantly greater BOLD 
activation compared to controls in three clusters: 1-the 
left medial and superior frontal gyri with extending 
activation to the right medial superior frontal gyri, 
bilateral anterior cingulate gyri, and right middle frontal 
gyrus. 2- left thalamus extending to left caudate and 
putamen, left parahippocampal gyrus, left hippocampus 
and left insula. 3- right hippocampal gyrus extending to 
the right hippocampus, right thalamus, right lentiform 
nucleus, right putamen, right insula, and right temporal 
cortex. Effects remained after controlling for other drugs 
except in the prefrontal cortex after controlling for 
cannabis use. Increased activation due to MDMA users 
being less “efficient” at task, resulting in an increase in 
neuronal activity to perform at a similar level as controls. 
   
Jacobsen et al. (2004) Functional analysis during selective and divided 
attention and verbal working memory: 6 adolescent 
ecstasy users, 6 adolescent ecstasy naïve controls 
Ecstasy users displayed significantly lowered 
hippocampal activity relative to controls during the 
working memory task. Time since last use was 
negatively correlated with left hippocampal activity. 
   
Jager et al. (2008) Functional analysis during working memory, attention 
and associative memory tasks: 33 ecstasy users, 38 non-
user controls 
No significant effects of ecstasy or any other drugs on 
brain activity relating to working memory (modified 
Sternberg task) and attention (SAT task). However in the 
associative learning task ecstasy use predicted lower 
activity in the left DLPFC and higher activation in the 
right middle occipital gyrus, reflecting compensatory 
mechanisms. 
   
Cowan et al. (2006) Functional analysis during photic stimulation using 
specially constructed fibre optic goggles: 20 ecstasy 
users, 23 non-user controls 
No differences in visual cortical activation between the 
two groups. No correlation between MDMA exposure 
and BOLD signal change. 
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Raj et al. (2010) Functional analysis during a semantic recognition task 
in 16 ecstasy polydrug users 
During semantic recognition, but not encoding- lifetime 
episodes of MDMA use and lifetime dose were both 
inversely correlated with %BOLD signal change at BA 9. 
Lifetime episodes of use was inversely correlated with 
BOLD signal change in BA 18 and 21/22. After 
controlling for other drugs the correlation at BA 9 
remained significant. 
   
Roberts and Garavan (2010) Functional analysis during Go/NoGo task in 20 ecstasy 
users and 20 drug naïve controls. 
Ecstasy users displayed greater activity in right middle 
and inferior frontal gyri, right middle frontal gyrus and 
right inferior parietal lobule, during successful response 
inhibitions, compared to controls. Ecstasy users also 
displayed greater error activation in the right middle and 
inferior temporal gyri. It is suggested that increased 
activation despite equivalent performance, shows 
increased neuronal recruitment to inhibit in ecstasy users. 
   
DTI   
   
de Win et al. (2007) Structural analysis: 30 participants scanned before 
ecstasy use and soon after first reported ecstasy use 
0.9% significant increase in FA of white matter in the 
centrum semiovale as well as a significant decrease 
(3.4%) of ADC in the thalamus observed post ecstasy 
use. However increases in FA did not remain after 
correction for multiple comparisons and exclusion of 
participants with continued cocaine use. 
   
de Win et al. (2008a) Structural analysis: 59 novice MDMA users, 56 non-
user controls 
Ecstasy users showed a significant decrease in FA in the 
thalamus and fronto-parietal white matter. Ecstasy users 
also showed an increase in FA in the globus pallidus and 
ADC in the thalamus relative to controls. 
   
Reneman, Majoie et al. (2001) Structural analysis: 8 ecstasy users, 6 non-user controls Ecstasy users displayed a significant increase in ADC in 
the globus pallidus relative to controls. No significant 
correlations were observed between extent of previous 
ecstasy use and ADC values. 
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Moeller et al. (2007) Structural analysis of 6 regions of the corpus callosum 
(Genu, Rostral body, Anterior Midbody, Posterior 
Midbody, Isthmus and Splenium): 12 ecstasy users, 20 
non-user controls  
MDMA users had significantly reduced longitudinal 
diffusivities in the rostral body of the corpus callosum 
relative to controls, consistent with axonal damage in 
MDMA users. No significant differences in FA, Dₐᵥ or 
transverse diffusivity were observed. 
   
Liu et al. (2011) Structural analysis. Whole brain DTI on 25 ecstasy 
users and 27 non-user controls. 
MDMA users showed clusters with significantly 
increased FA in posterior parts of bilateral thalami and 
the retrolenticular parts of internal capsules compared to 
controls. Decreased FA was also observed in MDMA 
users in the genu of the corpus callosum. Furthermore 
MDMA users showed significant decreases in ADCs in 
the bilateral thalami, posterior internal capsule and 
corona radiata along the bilateral corticospinal tracts, as 
well as significantly increased ADC in the bilateral 
anterior internal capsule, the bilateral superior 
longitudinal fasiculus and the splenium and genu of the 
corpus callosum. 
   
de Win et al. (2008b) Structural analysis. DTI of the thalamus in 71 polydrug 
users. 
Extent of MDMA use was significantly correlated with 
decreased FA in the thalamus. No significant effect of 
MDMA on ADC in the basal ganglia. 
   
PET   
   
McCann et al. (1998) Structural analysis using radioligand carbon-11-labelled 
McN-5652 to observe differences in SERT binding 
between 14 ecstasy users and 15 non-user  controls 
DVRs for binding of the radioligand were significantly 
globally decreased in MDMA users relative to controls. 
Decreases in SERT binding correlated significantly with 
extent of previous ecstasy use. 
   
   
   
   
   
   
   
   
 
 
 
 
112 
 
   
 
Buchert et al. (2003) 
Structural analysis using radioligand carbon-11-labelled 
McN-5652 to assess SERT binding in the 
mesencephalon, putamen, caudate and thalamus of 30 
ecstasy users, 29 former users, 29 polydrug controls and 
29 drug naïve controls 
Ecstasy users had significantly lower DVRs in the 
mesencephalon than all other groups. Ecstasy users had 
significantly reduced DVRs in the caudate relative to 
polydrug users and in the thalamus, ecstasy users’ DVRs 
were significantly reduced compared to polydrug users 
and drug naïve controls. Mean DVRs over all areas were 
lowest in current users. However, DVRs for former users 
and drug naïve controls were similar across all areas. 
There were no differences between groups in DVRs in 
the white matter. 
   
Buchert et al. (2004) Structural analysis using radioligand carbon-11-labelled 
McN-5652: 30 ecstasy users, 29 former users, 29 
polydrug controls and 29 drug naïve controls. Follow 
up from the 2003 study 
Ecstasy users had significantly reduced DVRs in the 
posterior cingulate gyrus, left caudate, thalamus, 
occipital cortex, medial temporal lobes including the 
hippocampus and parahippocampal regions and 
brainstem with mesencephalon and pons compared to all 
3 control groups. More pronounced in females than 
males. No significant differences in SERT availability 
between former users and the two other control groups. 
DVRs and MDMA abstention periods were positively 
correlated in the brainstem with mesencephalon and pons 
and the basal forebrain. SERT appeared to normalise in 
this follow up study. 
   
Di lorio et al. (2012) Structural analysis using radioligand [
18
F]setoperone in 
14 female ecstasy users and 10 female non-user 
controls 
Ecstasy users had significantly increased 5-HT2A receptor 
binding in occipital-parietal, temporal, occipito-
temporal-parietal, frontal and fronto-parietal regions. 
Lifetime use was significantly correlated with binding 
increases in fronto-parietal, occipito-temporal, fronto-
limbic, and frontal regions. No significant effects of 
duration of abstinence on binding. 
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Thomasius et al. (2003) Structural analysis using the radioligand [
11
C]McN5652 
to assess SERT density in 30 ecstasy users, 31 former 
users, 29 polydrug controls and 30 drug naïve controls 
Ecstasy users showed significantly reduced DVRs in the 
mesencephalon in relation to all other groups. Number of 
ecstasy exposures was the best predictor of DVRs in the 
thalamus and caudate nucleus, and number of ecstasy 
tablets taken in the year leading up to testing was the best 
predictor of DVRs in the mesencephalon. 
   
McCann et al. (2005) Structural analysis using radioligands [
11
C]McN5652 
and [
11
C]DASB: 23 ecstasy users, 19 non-user controls 
Global reductions in DVRs observed in MDMA users 
compared to controls with both radio ligands. Global 
DVRs correlated with duration of abstinence. Global 
SERT binding DVR was also inversely correlated with 
typical monthly MDMA dose for both radioligands. 
   
McCann et al. (2008) Structural analysis using radioligands [
11
C]DASB to 
investigate SERT binding, alongside [11C]WIN 35,428 
to investigate dopamine transporter binding: 16 ecstasy 
users, 16 non-user controls 
SERT significantly reduced in occipital cortex, parietal 
cortex, temporal cortex, anterior cingulate cortex, 
posterior cingulate cortex, DLPFC and hippocampus for 
ecstasy users. The reductions were greatest in cortical 
regions and there were no significant differences in 
SERT binding in subcortical regions. No differences 
observed between users and controls in DAT binding in 
the caudate or putamen, and no relationship between 
MDMA use and DAT binding.  
   
Sudhakar et al. (2009) Structural analysis using [
11
C]DASB in 12 former 
ecstasy users, 9 polydrug controls and 19 drug naïve 
controls 
No significant differences observed in cerebellar DVRs 
and no correlations between MDMA use and SERT 
binding. 
    
Urban et al. (2012) Structural analysis using SERT ligand [
11
C]DASB and 
the 5-HT2A receptor ligand [
11
C]MDL: 13 ecstasy 
users, 13 non-user controls 
Presynaptic SERT availability reduced overall in ecstasy 
users compared to controls for cortical but not 
subcortical regions. Most pronounced differences in the 
medial prefrontal cortex, occipital cortex and temporal 
cortex. Decreased SERT regionally associated with 
upregulated 5- HT2A receptor binding. 
   
   
   
   
 
 
 
 
114 
 
   
Kish et al. (2010) Structural analysis using [
11
C]DASB in cortical and 
subcortical areas: 49 ecstasy users, 50 non-user controls 
Regional-specific decreases in [
11
C]DASB binding in 
ecstasy users compared to controls was restricted to the 
entire cerebral cortices and hippocampus with the most 
marked reduction (-46%) in the occipital cortex. No 
changes were observed in the SERT rich striatum 
(Caudate, putamen and ventral striatum), thalamus, 
global pallidus or midbrain. 
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Chapter 6: Electrophysiological indices of executive function 
6.1 Chapter overview 
 Chapter 3 reviewed the literature on executive function deficits in relation to MDMA 
use. Furthermore Chapter 5 reviewed the evidence of structural and functional neural 
alterations in relation to MDMA use. It was observed that there was a paucity of 
neurophysiological data systematically assessing Miyake et al.’s (2000) conceptual 
framework of executive function. One of the aims of this thesis is to fully characterise the 
nature of MDMA’s effects upon the central executive of working memory. The following 
chapter investigates each of the four previously defined executive functions with behavioural 
tasks assumed to tap one function and their electrophysiological correlates. Twenty ecstasy 
polydrug users, 20 ecstasy naïve polydrug controls and 20 drug naïve controls were recruited 
and Go/NoGo, number-letter, n-back and semantic association tasks were undertaken.  
ANOVA revealed no significant between group differences on performance measures for the 
Go/NoGo, number-letter and semantic association tasks. There were no differences between 
groups in terms of errors on the n-back task, however reaction time data revealed that drug 
naïve controls were significantly slower to respond than polydrug controls on all levels of the 
task. The ERP data showed drug related atypicalities in the P2 component during, the 
Go/NoGo task. There were also drug related differences in the N2 component in the semantic 
association task, as well as drug effects on positive components (P2 and P3) during the 
number-letter task. There were no between groups differences on the ERP data during the n-
back task. The results from this chapter reflect ecstasy/polydrug related atypicalities of 
processing during tasks that tap inhibitory control, switching and access that may reflect 
compensatory mechanisms/cognitive reallocation of resources to attenuate behavioural 
differences. The results from the data on inhibition, switching and access have been 
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published in three separate journal articles (Roberts et al., 2013a, b and c – in press) and 
copies of these publications can be observed in the appendices of this thesis. 
6.2 Introduction 
Areas that are involved in working memory such as the DLPFC are richly innervated 
with 5-HT receptors; therefore degradation to the serotonergic system via ecstasy use could 
lead to deficits in cognitive processes associated with these forebrain structures. Significant 
deficits have been observed in ecstasy users compared to non-users in components of 
working memory such as spatial working memory (Wareing et al., 2005), access to semantic 
memory, and memory updating (Fisk et al., 2004; Montgomery, Fisk, Newcombe & 
Murphy,2005). Furthermore, ecstasy users perform poorly in information processing tasks 
when cognitive demand is high (Wareing et al., 2000). It has been suggested (Cole et al., 
2002), that a lack of sleep (among other possible lifestyle variables), may exacerbate or 
indeed cause the observed cognitive deficits in ecstasy using populations. Furthermore, 
several characteristics of sleep such as sleep quality, length of sleep (hours) and related 
changes in alertness have been reported to be altered in ecstasy users relative to controls 
(Allen et al., 1993). However such deficits appear to have little mediating effect on ecstasy-
related cognitive deficits (e.g. Montgomery et al., 2010).    
When looking at executive functioning in ecstasy users, some functions appear to be 
more affected than others (See Chapter 3 for a review). There is a differential pattern of 
impairment based on previous drug use history and type of function, with the updating 
function of the executive being particularly susceptible to ecstasy use (Montgomery & Fisk, 
2008; Montgomery, Fisk, Newcombe & Murphy, 2005) along with access to long term 
memory (Montgomery, Fisk, Newcombe & Murphy., 2005). Inhibitory control and set 
switching appear to be more robust to ecstasy-related deficits; however, recent research 
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suggests that even in the absence of behavioural differences, ecstasy users may show 
electrophysiological differences related to task demands (Burgess et al. 2011). Consequently, 
participants in previous studies displaying no impairments in the behavioural tasks may not 
necessarily be exhibiting “normal” functioning. The present study therefore sought to assess 
all aspects of executive functioning (in relation to Miyake et al.’s 2000, and Fisk & Sharp’s 
2004 frameworks) in ecstasy users through behavioural and electrophysiological assessments 
of performance.   
Inhibitory control (see Chapter 3.2.2 for review) requires effortful control over 
instinctive (predominant) responses. Although the DLPFC, ACC and Inferior Frontal Cortex 
are commonly activated during working memory performance (Duncan & Owen, 2000), 
neuroimaging and lesion data indicates that the inferior frontal cortex (IFC) may have a 
particularly important role in inhibitory control (Aron et al., 2004). Furthermore this area 
may also play a role in mental set switching, given that task switching may require inhibition 
of responses to a now inappropriate task (Aron et al., 2004). The Stroop task has been used in 
several studies to test whether ecstasy use impairs inhibitory control (Back-Madruga et al., 
2004; Gouzoulis-Mayfrank et al., 2000; Morgan et al., 2002), with all studies reporting no 
ecstasy-related impairment. Wareing et al. (2000) employed the random letter generation 
measure of inhibitory control and observed performance deficits in ecstasy users compared to 
non-users, however there have been failures to replicate this (Fisk et al., 2004). A review by 
Murphy et al. (2009) found that the literature on inhibition in ecstasy users was unclear, 
although there is little evidence to suggest ecstasy-related impairments. Furthermore any 
perceived impairment can be obscured by confounding variables such as polydrug use and 
although the use of ANCOVA and regression are usually employed to statistically control for 
this, the majority of findings in the literature need to be interpreted with some degree of 
caution. 
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 A commonly used task in the inhibition literature is the Go/NoGo task. This task 
requires participants to only respond to certain stimuli and therefore inhibit prepotent or 
dominant responses. Previous studies using this task with ecstasy users (e.g. Gouzoulis-
Mayfrank et al. 2003), have observed little difference in performance on the task between 
non-users, moderate users and heavy users. However it has been suggested that 5-HT 
depletion, as well as impaired executive functions may play a role in inhibitory control 
(Morgan et al., 2006). One study conducted on ecstasy users with minimal exposure to other 
drugs reported that heavy use of MDMA led to notable impairments in inhibition and 
impulsivity (Halpern et al., 2004).   
Although much of the research on behavioural tasks assessing inhibitory control in 
ecstasy users has provided inconclusive evidence, perhaps such cases where no differences 
have been observed can be attributed to compensatory mechanisms. This was proposed in an 
fMRI study by Roberts and Garavan (2010), where increased activation was seen in right 
middle and inferior frontal gyri, right middle frontal gyrus and right inferior parietal lobule, 
in ecstasy users relative to controls in a Go/NoGo task, despite equivalent task performance 
(see Chapter 5.5). 
Mental set switching (or shifting; as defined in Chapter 3.2.1) is the ability to alternate 
attention as required between two tasks, or between different components of a task. This 
executive function reflects cognitive flexibility and deficits here may have implications for 
real world situations; for example in the work environment where reallocation of attention (or 
switching between tasks) is required continually. The neural basis of this executive function 
is proposed to be localised to the lateral prefrontal cortex (Dove et al., 2000) and left DLPFC, 
parietal and temporal regions (Smith, Taylor et al, 2004). In ecstasy users, research in 
switching is equivocal (Fox et al., 2001; Fox et al., 2002). However tasks used do not always 
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solely assess switching (Fisk & Sharp, 2004). The WCST has been employed frequently to 
assess switching (Reneman et al., 2006; Thomasius et al., 2003) yielding no ecstasy-related 
deficits. The number-letter task (Rogers & Monsell, 1995) has also been used (Montgomery, 
Fisk, Newcombe & Murphy, 2005), showing no clear ecstasy-related deficits. Conversely 
Halpern et al. (2004) observed deficits in switching using the WCST. The cohort in this 
sample had minimal exposure to other drugs and as such potential confounds from polydrug 
use were reduced. However, in a follow up study (Halpern et al., 2011) with a larger sample 
and similar controls for concomitant drug use and other lifestyle variables, no behavioural 
deficits in switching were observed. However, Dafters (2006) did observe deficits in ecstasy 
users relative to cannabis users and controls, in a task switching version of the Stroop task. 
As such the impact of MDMA exposure on this executive function remains unclear. 
The updating component of the central executive involves monitoring and updating 
incoming information and replacing no longer relevant information with salient information. 
This requires active manipulations of incoming information rather than simply acting as a 
short term memory store (Morris & Jones, 1990). The updating memory paradigm (Morris & 
Jones, 1990; Pollack et al., 1959) has been used to investigate the neural basis of the central 
executive and to distinguish between this executive function and slave (storage) systems. 
Neuroimaging studies have confirmed the dissociation between passive storage of 
information and active manipulation of incoming information by localising the two processes 
to separate areas (parietal lobes and frontal lobes respectively) (Smith & Jonides, 1997). 
More recent neuroimaging studies have often used the n-back task to study this executive 
function, finding activation in the left frontopolar cortex, bilateral dorsolateral prefrontal and 
premotor cortex, bilateral intraparietal sulcus, right inferior parietal lobule and the cerebellum 
(Collette et al., 2007). Updating as reviewed in Chapter 3 appears to be more reliably affected 
by ecstasy use (Montgomery & Fisk, 2008: Montgomery, Fisk, Newcombe & Murphy, 2005).  
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However there is still a plethora of studies that observe no ecstasy-related deficits in this area 
(Bhattachary & Powell 2001; Thomasius et al., 2003). The n-back task can be varied for 
difficulty and is ideal for using during EEG as it is computerised with button responses.  
Results from the n-back task in ecstasy using populations have not been as consistent as 
results from consonant updating or spatial updating. Several studies have reported no 
significant differences between users and controls (Daumann, Fimm et al.,2003; Daumann, 
Fischermann, Heekeren et al., 2004; Gouzoulis-Mayfrank et al., 2003). However, the samples 
in these studies were smaller than the present study. Moreover task difficulty has rarely been 
varied to extend further than 2-back and there is evidence to suggest that ecstasy-related 
deficits may be more pronounced with increased cognitive load (Wareing et al., 2000). As 
such this study will include a 4-back condition. Further to this, some of the studies on the n-
back task that yielded no between group differences behaviourally, were combined with 
neurophysiological measures and showed subtle brain functioning alterations in ecstasy users 
(Daumann, Fimm et al., 2003), highlighting the sensitivity of neurophysiological 
measurements for assessment of cognitive impairment.  
Access requires activation of long term memory networks. Although not included in 
the initial conceptualisation of Miyake et al.’s (2000) framework of executive function, 
Baddeley (1996) suggested that temporary activation of long term memory stores was an 
important function of the central executive. Indeed in Fisk and Sharp’s (2004) work on 
cognitive ageing, the factor structure obtained was consistent with Miyake et al. (2000), 
though an additional factor was obtained that reflected the efficiency of access to long term 
memory, as measured by word fluency. Significantly, word fluency has been observed to 
have neurological correlates in the left prefrontal cortex – left inferior frontal gyrus, anterior 
cingulate and superior frontal sulcus (Phelps et al., 1997). For access to semantic memory 
some studies using the COWA task have yielded deficits in ecstasy users compared to 
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controls (Bhattachary & Powell, 2001; Fox et al. 2002), whereas others report no such 
deficits (e.g. Halpern et al., 2004). However, as a written variant of the COWA task, the 
Chicago Word Fluency Test appears to yield more consistent observable deficits in ecstasy 
users (Montgomery, Fisk, Newcombe & Murphy, 2005; Montgomery et al., 2007). It remains 
a possibility that a verbal one minute retrieval task, with no restrictions upon word type or 
length is too simple to require the involvement of the central executive and as such ecstasy 
users may not show any impairment on the COWA. It has been noted that ecstasy users have 
shown impairments on difficult aspects of tasks, yet appear unaffected on simple tasks that 
require relatively automatic processing (Fox et al., 2002). Consequently further investigation 
of ecstasy-related deficits in access to semantic memory is required. 
Whitney et al., (2011) investigated the neuronal network involved in semantic 
retrieval and processing, manipulating strength of semantic association with the cue word 
(low vs. high). Transcranial Magnetic Stimulation (TMS) was employed to disrupt processing 
in the Inferior Frontal Gyrus (IFG) and the posterior middle temporal cortex. Disruption to 
both of these sites produced attenuation of effective processing of executively demanding 
processes. However processing of cue-target stimuli with strong semantic association (that 
are relatively automatic) was unaffected by the disruption. It was concluded that there is a 
network of prefrontal and posterior temporal regions that underlie semantic control, and may 
provide an explanation of why ecstasy users may be unaffected in relatively simple semantic 
retrieval tasks, such as the COWA. As such in this experiment a similar semantic association 
task will be used that has semantic strength manipulation.  
Neuroimaging techniques such as EEG are useful in providing a clearer indication of 
alterations of normal cognitive functioning; for example in patients with Alzheimer’s disease, 
who exhibit increases in prefrontal activity in comparison to controls during executive 
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functioning tasks. Saykin et al. (1998) observed that Alzheimer’s patients displayed 
additional activation in frontal regions which they postulated reflects recruitment of 
additional resources from local and remote regions when conducting a semantic memory task 
(see also Grady et al. 2003; Woodard et al. 1998 for other examples of compensatory 
mechanisms). Similarly, fMRI research in ecstasy users, has revealed increased BOLD 
response, during working memory tasks, despite equivalent performance, which has been 
suggested to reflect compensatory mechanisms due to task inefficiency (Jager et al., 2008; 
Moeller et al., 2004) 
ERP research has demonstrated that cognitive impairment is associated with 
alterations to the P3 amplitude or latency, as the P3 is involved in stimulus processing. Such 
alterations in P3 activity have been reported in ecstasy users, for example, Casco et al. (2005) 
observed a reduction in P3 amplitude in both heavy and moderate ecstasy user groups 
compared to controls in Visually Evoked Potentials (VEP) pertaining to a simple 
discrimination task, though no differences in latency were observed. Furthermore Mejias et al. 
(2005) report longer P3 latencies for detection of target stimuli in a visual oddball task, 
suggesting reduced cognitive processing. de Sola et al. (2008) observed a reduced auditory 
ERP P3 amplitude in ecstasy users compared to non-drug controls and cannabis users, 
although this was non-significant.   
The Go/NoGo task requires continuous attention to the stimuli to effectively make 
(Go) or inhibit (NoGo) responses, and is useful for measuring processing and attentional 
capacity in ERPs (Smith et al., 2004). The P3 component, although a significant component 
in many cognitive tasks due to its involvement in attentional processing, does not appear to 
have a consistent role in response inhibition. This is possibly due to this component occurring 
relatively late and therefore not in the initial early inhibition processes.  
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The N2 component, understood to be important in inhibition, due to this component 
reflecting stimulus discrimination (Ritter et al., 1982), has been observed to be larger in 
inhibition trials (NoGo) than non-inhibition (Go) trials (Kok et al., 2004). This component 
also reflects neuronal processes involved in conflict monitoring, and is determined by the 
processing of distracting information. Therefore the N2 is often increased in high conflict 
trials (Yeung & Cohen, 2006). As such it may be expected that switch trials in the number-
letter task cause an increase in N2 amplitude.  
Low association trials of the semantic association task in the present study possess 
increased conflict compared to high association trials. This task requires participants to link a 
cue word with a target word based on their semantic association, whist ignoring irrelevant 
distractor words. In high association trials the association between the cue and the target is 
very strong, whereas this is much weaker in the low association trials hence producing 
conflict. Related tasks that produce conflict, for example the Stroop task have yielded 
increases in negativity in waveforms of incongruent Stroop trials (West & Alain, 1999) and 
this has been suggested to reflect increases in attention resources (Potter et al., 2002). Indeed, 
studies on participants with mild head injuries have observed equivalent performance to 
controls on cognitive tasks, coupled with increased N2 components that reflect recruitment of 
additional resources (Rugg, et al., 1993). It is suggested by Rugg et al., (1993) that greater 
negativity observed in head injury patients ERPs reflect allocation of attention resources 
necessary to cope with task demands and to achieve similar performance output to controls. 
Furthermore Suwazono et al. (2000) suggest that posterior N2 reflects the degree of attention 
required for processing stimuli. Increases in attentional demand may reflect allocation of 
additional resources. 
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 The P2 wave can be observed at anterior and central sites, and elicits a larger 
response to simple target features that are relatively infrequent (Luck & Hillyard, 1994). This 
component precedes the N2 and is thought to be involved in the initial inhibition from further 
processing in target stimuli (Hansen & Hillyard, 1988). The P2 component is an early 
component in an ERP waveform, and thus is associated with early orienting and stimulus 
evaluation. Furthermore this component has been observed to increase with age (Amendo & 
Diaz, 1999; Ford & Pfefferbaum, 1991). Garcia-Larrea et al. (1992) suggest that in ageing 
populations a growing deficit in ability to withdraw attention from stimuli becomes apparent. 
Increases in the P2 component may reflect early orienting increases in cognitive allocation, or 
fixation as a function of cognitive ageing, or may even reflect increased impulsivity 
(Fritzsche et al., 2011). 
Recently, Burgess et al. (2011) looked at ERPs as evidence for selective impairment 
of verbal recollection in currently abstinent recreational MDMA/polydrug users. Interestingly, 
there appeared to be no significant differences between ecstasy users, polydrug controls and 
drug naïve controls on the behavioural tasks (memory tasks which involved recognition of 
words and faces). However the ecstasy user group showed attenuation of late positivity over 
left parietal scalp sites, which is a component associated with the memory process of 
recollection. Ecstasy users showing a durable abnormality in this ERP component 
exemplifies how EEG is a much more sensitive measure of cognitive impairment than 
behavioural measures alone. This point is further elucidated by Nulsen et al. (2011) where 
ecstasy users displayed alternative patterns of activity in ERPs compared to drug naïve and 
polydrug controls in short term and working memory tasks, despite no significant behavioural 
differences. 
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The aim of the current study was to observe whether there are any behavioural or 
electrophysiological differences between ecstasy users and controls in tasks measuring 
inhibitory control (Go/NoGo), mental set switching (number-letter task), updating (n-back 
task) and access (semantic association task). It is predicted that group differences in 
performance on the Go/NoGo task and the number-letter task will be negligible. However it 
is expected that ecstasy users may show impaired performance on the n-back task and the 
semantic association task. Regardless of behavioural performance observable differences in 
components of the elicited ERPs are predicted. It is envisaged that ecstasy polydrug users 
will show a diminished P3 response, in line with cognitive impairment. Furthermore if 
behavioural differences are silent, ERP responses in line with compensatory 
mechanisms/cognitive impairment are expected. More specifically, increases in N2 and P2 
amplitudes that reflect compensatory mechanisms and recruitment of additional resources. 
6.3 Method 
Design: 
In all analyses, a between groups factor of drug user group with three levels (ecstasy 
user, non-ecstasy polydrug controls and drug naive controls) was employed. Univariate 
ANOVA was conducted on the behavioural data for the Go/NoGo (inhibition) and the 
number-letter task (switching) with scores on the Go/NoGo (NoGo errors) and composite 
scores on the number-letter task (switch cost) as the dependent variables respectively. Mixed 
ANOVA was conducted on the behavioural data for the semantic association (access) and n-
back (updating) tasks, with difficulty level as the within subjects factor (2 levels for semantic 
association – high association vs. low association, and 3 levels for n-back – n=0, n=2 and 
n=4).  
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ERP data on all tasks was analysed using mixed ANOVA, with drug user group as the 
between subjects factor and electrode site as within subjects factors for the three ERP 
components. The n-back task and the semantic association task had an extra within subjects 
factor of difficulty. Mean amplitudes (µvolts) at the selected electrodes for the various 
components were the dependent variables. Where appropriate significant main effects were 
further investigated using ANOVA and Tukey HSD tests. 
Participants: 
Twenty ecstasy users (mean age = 23.95, SD = 0.57, 10 male), 20 non-drug user 
controls (mean age = 23.1, SD = 0.66, 7 male) and 20 non-ecstasy drug user controls (mean 
age = 22.58, SD = 0.79, 9 male) were recruited via direct approach to university students and 
club goers. In terms of statistical power, with 20 participants in each of the three groups, the 
sample is sufficient to detect a difference between pairs of means of at least 1 standard 
deviation at alpha = .05 and beta =.20 (Hinkle et al., 1994).  
Inclusion in the ecstasy user group required participants to have taken ecstasy/MDMA 
on 5 or more occasions over their lifetime (actual minimum = 5 ecstasy tablets). Indices of 
ecstasy use were as follows: total lifetime dose 177.65 tablets ± 301.73; mean amount used in 
last 30 days 0.6 tablets ± 2.26, and frequency of use 0.24 times/week ± 0.42. Furthermore for 
inclusion in both control groups participants must have never used ecstasy/MDMA, however 
all other illicit substances were permitted for the poly drug user control group. 
All participants were asked to abstain from consuming ecstasy for a minimum of 7 
days prior to testing and urine samples were collected upon arrival to the lab to confirm 
abstinence (after ingestion, MDMA is generally accepted to be detectable in urine for 1-3 
days, this is the same for cocaine and amphetamines, with cannabis being detectable for 
anything up to 95 days Verstraete, 2004). Participants were also requested to abstain from use 
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of other illicit drugs for a minimum of 24 hours prior to participating and ideally for 7 days. 
Tobacco smoking was permitted on the day of testing. All participants reported no current or 
last year diagnosis of psychological disorders. 
Materials 
Several questionnaires were issued to participants upon entering the lab, these 
included: A background drug use questionnaire which provides the researcher with indices of 
drug use patterns and other lifestyle variables. In this questionnaire comprehensive details of 
ecstasy use as well as other illicit drug use are requested, such as first and last drug use, 
patterns of drug use, frequencies and doses over time. Using a method employed by 
(Montgomery, Fisk, Newcombe and Murphy, 2005), estimates of total lifetime drug use of 
each drug were calculated. Totals for last 30 days drug use as well as weekly drug use 
estimates were also calculated. This questionnaire also sought information about health, age, 
years of education and changes to mood and cognition amongst other lifestyle variables. 
Measures of sleep quality 
Several questionnaires assessing sleep quality and alertness were employed to 
investigate any possible relationship between sleep quality and cognition. These include a 
sleep quality questionnaire, exploring typical quantities of sleep (how many hours slept 
typically, how many hours over the last 3 nights) and level of quality of sleep. The Epworth 
Sleepiness Scale (ESS, Johns, 1991), explores the chances of dozing or falling asleep in 
various situations. A high total score here is indicative of increased subjective daytime 
sleepiness. The Morningness-Eveningness Questionnaire (MEQ, Terman et al., 2001) is a 
self-assessment of morningness-eveningness in human circadian rhythms (originally 
developed by Horne & Östberg, 1976). A high score on this questionnaire is indicative of a 
morning type person and a low score is indicative of an evening type person. Finally the 
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Karolinska Sleepiness Scale (KSS) (Akerstedt & Gillberg, 1990), is a self-assessment of 
sleepiness at the current moment in time, therefore this can be administered at different time 
points of the experiment to assess sleepiness,  
State mood. 
State Anxiety, Arousal and Depression were measured using scales devised by Fisk & 
Warr (1996) (The UWIST mood adjective checklist – UMACL). Participants are required to 
rate on a 5 point likert scale from 1 = not at all, to 5 = extremely, how they are feeling at the 
time of testing. A high score on each subscale indicates increased hedonic 
tone/anxiety/arousal.  
Raven’s SPM (Raven et al., 1998)     
Raven’s standard progressive matrices (SPM) were used an indicator of fluid 
intelligence. This involves a series of problems (5 sets of 12, 60 in total), presented as a 
symbolic sequence. Participants are required to select an appropriate response to complete the 
sequence from a choice of six options. Successful completion of the task requires an 
understanding of the parts of the sequence and their interaction with one another. Each block 
of 12 problems begins with an intuitively simple problem and the problems become 
progressively more difficult as the task continues. 
NASA-TLX (Hart & Staveland, 1988)   
This is a multi-dimensional scale, consisting of six sub-scales (mental demand, 
physical demand, temporal demand, personal performance rating, effort and frustration). 
Participants are required to place a mark on a 100ml VAS, indicating where they perceive 
their demand to be on the scale. These are administered to observe whether there are any 
differences between ecstasy users and non-users in demand perceived by the participant as it 
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has been suggested that ecstasy users may be more susceptible to stress than non-users 
(Wetherell et al., 2012). 
Tasks 
All behavioural tasks were programmed in Inquisit version 3.0.6.0 (Millisecond 
software, 2011). 
Inhibitory Control: The Go/NoGo task is frequently used in combination with EEG to 
assess inhibitory control (Gamma et al, 2005; Kok, 1986; Oddy & Barry, 2009). Participants 
are required to “Go” (press the space bar) when an X appears on the screen, however they are 
to inhibit their response “NoGo”, when any other letter appears (W, Y or Z). The task is 
designed such that “X” appears 75% of the time and the “NoGo” letters appear only 25% of 
the time. Thus, the task builds up a pre-potent response to “Go”. Furthermore, the first block 
of the task has “X” appearing 100% of the time, again to build up a pre-potent/dominant 
response which participants are required to inhibit. The task therefore comprises of two 
blocks; a practise block with 60 “Go” trials, followed by an interval and then a larger main 
block whereby participants are required to attend to 240 trials (180 Go/ 60 NoGo) lasting a 
total of approximately 15 minutes. The task has an inter-trial interval of 1.5 seconds and 
participants had an epoch of 2.5 seconds from stimulus onset to respond. Participants were 
instructed to respond as quickly and as accurately as possible. 
Mental set switching: This executive function was investigated using the number-
letter task as per Rogers and Monsell (1995). During this task, number-letter pairs e.g. “B6” 
are displayed in one of four quadrants on a screen. If the number-letter pair appears in one of 
the top two quadrants, participants attend to the letter and respond to whether it is a vowel or 
a consonant. If the pair appears in the bottom two quadrants, participants are required to 
attend to the number and respond to whether it is odd or even. In the first block of trials the 
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number-letter pairs alternate between the top two quadrants; in the second block the pairs 
alternate between the bottom two quadrants. In the final block, the pairs are presented in anti-
clockwise rotation, therefore every two responses requires a switch in the mental set between 
letters and numbers. The latency difference between the trials with the switch and those not 
requiring a switch is the “switch cost”. The task is comprised of six blocks, the first two of 
which are practise blocks consisting to 62 trials in each. This is followed by four main blocks, 
each consisting of 64 trials (31 “switch” trials). There were 124 “switch” trials in total. There 
was an inter-trial interval of 1.5 seconds and participants were allocated an epoch of 5 
seconds to respond. Participants were instructed to respond as quickly and as accurately as 
possible, and overall the task took around 20 minutes to complete.  
Access to Semantic Memory: This was assessed using a semantic association task 
based on those used by Whitney et al. (2011) and Badre et al. (2005); two types of semantic 
judgement which differed in their level of difficulty (high association/low association) were 
used. In both difficulty levels participants were presented with a cue word in the centre of a 
computer monitor followed by three target words, one which had a semantic association with 
the cue, and two distracters. Participants had to decide which of the three target words had the 
strongest semantic association with the cue word. Participants selected their answer by 
pressing one of three buttons on a response box which corresponded to their position on 
screen. They were either high association between cue and target words (e.g. candle - flame) 
or low association (e.g. detective - search). The low association judgement is deemed to be 
more difficult and require more processing than the relatively automatic high association 
semantic judgements. As such the low association between cue and targets leads to a less 
obvious dissociation from distracters requiring recruitment of additional executive resources 
in the semantic network (Whitney et al., 2011). The stimuli used were matched for word 
length, frequency and cue-target association strength (Badre et al., 2005; Whitney et al., 2011) 
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and were kindly provided by Whitney et al. The task consisted of a practise round followed 
by 4 blocks of 30 trials, with both high and low association trial types appearing in each 
block pseudo-randomly (15 of each in each block). The cue word was presented for 1-second 
in the centre of a computer screen. After this the three target words appeared below aligned to 
the left, centre and right of the monitor. Participants were instructed to respond by pressing a 
button on the response box corresponding to the position of the target on the screen (left, 
centre, right). The targets remained on screen until a response was made or until the trial 
timed-out (time out set to 8.5 seconds). An inter trial interval of 2 seconds was employed. 
The task took around 20 minutes to complete. Participants were instructed to respond as 
quickly and as accurately as possible. 
Updating: This function was assessed using an n-back task. A variant of the task first 
implemented by Kirchner (1958) was designed, whereby participants were shown a series of 
digits presented singularly (either 7 or 8 digits in a series) followed by a probe requiring 
participants to recall the “nth” digit back in the sequence, if n=0 was the last digit presented.  
A version of the task was used in which after the series of digits were displayed participants 
were required to recall n = 0, n = 2 or n = 4. Three blocks of 65 trials were completed, with 
trial types appearing in each block pseudo randomly. Participants responded by selecting the 
desired number (0-9), via scrolling through the numbers using the arrow keys on a likert scale. 
The scale stayed on the screen until a response was made or until the trial timed-out (time out 
set to 12 seconds). There was an inter trial interval of 3.5 seconds. The task took around 60 
minutes to complete and participants were instructed to respond as quickly and as accurately 
as possible. 
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Equipment 
Electroencephalography (EEG) was recorded using a 64 channel Biosemi Ag-AgCl 
active-two electrode system (Biosemi B.V, Amsterdam, Netherlands) with pin type 
electrodes mounted in a stretch-lycra headcap (Biosemi). Electrodes were positioned 
according to the international 10-20 system. Electrical activity was recorded from the 
following sites: frontal (FPz, FP1, FP2), anterior-frontal (AFz, AF3, AF4, AF7, AF8), frontal 
(Fz, F1, F2, F3, F4, F5, F6, F7, F8), frontocentral (FCz, FC1, FC2, FC3, FC4, FC5, FC6), 
central (Cz, C1, C2, C3, C4, C5, C6), temporal (FT7, FT8, T7, T8, TP7, TP8), parietocentral 
(CPz, CP1, CP2, CP3, CP4, CP5, CP6), parietal (Pz, P1, P2, P3, P4, P5, P6, P7, P8, P9, P10), 
occipitoparietal (POz, PO3, PO4, PO7, PO8) and occipital (Oz, O1, O2, Iz). Sigma 
electrolyte gel was used to ensure contact between scalp and electrodes. Vertical and 
horizontal electro-occulograms were recorded using bipolar, flat Ag-ACl electrodes 
positioned above and below the left eye as well as to the outer side of each eye. Data was 
digitized at a sampling rate of 512Hz and no filters were applied online so that the data could 
be visually inspected for noise and offline filtering could be performed.   
Procedure 
Testing sessions commenced at 9.30am or 1.30pm, and equal amounts of participants 
from each condition were tested in the morning as were in the afternoon. Upon entering the 
lab, participants were given a brief description of the experiment and written consent was 
obtained. Following this, participants were required to give a urine sample. The urine sample 
was frozen at -25 Celsius and later transported to the clinical laboratories for analysis. First, 
participants were required to fill out the battery of questionnaires whilst their head 
circumference and other details were measured, and an electrode cap and electrodes were 
fitted. The questionnaires were administered in the following order: Background drug use 
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questionnaire, Morningness-Eveningness questionnaire, sleep quality questionnaire, mood 
scale, Epworth Sleepiness Scale, Karolinska Sleepiness Scale (pre-test) and fluid intelligence 
was assessed using Raven’s SPM. Following completion of these questionnaires, providing 
the EEG setup was correct and actiview running, the computerised tasks was completed on a 
desktop computer running inquisit version 3.0.6.0 (Millisecond software, 2011). The NASA-
TLX questionnaire was completed after each task. Upon completion of the tasks a final 
Karolinska Sleepiness Scale (after) was administered. Finally participants were fully 
debriefed and paid £20 in store vouchers. The study was approved by the Liverpool John 
Moores University Research Ethics Committee, and was administered in accordance with the 
ethical guidelines of the British Psychological Society. 
EEG Analysis – Go/NoGo 
The EEG data was analysed using BESA 5.3 (MEGIS software GmbH, Gräfelfing, 
Germany). All recordings were visually analysed offline, using high and low pass filters of 
0.1Hz and 40 Hz respectively. Any channels judged to be bad were replaced by interpolation 
and all data were EOG-corrected using BESAs PCA based algorithm. All trials judged to be 
bad after this point were discarded.   
Go/NoGo: EEG was segmented into epochs from -500 to 1000ms from time of 
stimulus onset. Epochs were time-averaged by stimulus type so that ERPs for correctly and 
incorrectly identified stimuli in each condition of each task (e.g. correct “go” responses, 
correct “NoGo” responses and incorrect “NoGo” responses in the Go/NoGo task) could be 
generated for each individual. Only ERPs for correct responses on the “NoGo” condition 
were included in the subsequent analysis. There were 240 trials in the main block of the task, 
60 of which were “NoGo” trials. The mean number of good “NoGo” trials retained for grand 
averaging per subject was 51.92 (average of 13.5% rejected trials), after rejecting incorrect 
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trials (5%) and those containing artefacts (8.5%). Grand averages were made for each group 
(ecstasy user, polydrug user and drug naïve) on each task condition (correct “Go” responses, 
correct “NoGo” responses). The overall P3 response was defined as the mean amplitude 
between 352 and 452ms. This time window was centred on the positive peak latency and the 
duration was chosen due to this epoch containing the majority of positive activity for all 
conditions by observing topographic maps (See Figure 6.1). Midline electrode activity was 
obtained in this epoch from electrodes Fz, FCz, Cz, CPz and Pz, as much of the activity could 
be observed in these sites as well as these midline electrodes being commonly used for this 
task in the literature (Jonkman 2006; Kato et al., 2009). In addition further components were 
analysed for between group differences, including the N2 and P2 components. The N2 of 
subjects in response to the inhibitory condition, was defined as the mean amplitude between 
260 and 330ms, this epoch was based around the mean local negative peak at midline sites 
and encompassed the majority of negative activity for all conditions. The P2 epoch was 
obtained from using a small, 50ms epoch (200-250ms) based around the positive peak from 
the grand averages of all conditions, directly preceding the N2. 
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Figure 6.1. Topographies at midpoints for each component (P2, N2 and P3) for the Go/NoGo 
task. 
  
 
Fig. 6.1: Depicts grand average topographies for the central point of each component. Note that this is from 
grand averages of each group combined. P2 positivity (red) is clustered around the midline electrodes (a). N2 
negativity (blue) is greatest in anterior midline electrodes (b). P3 positivity has a wide spread of activity peaking 
at central electrodes (c). 
Number-Letter: EEG was segmented into epochs from -500 to 1000ms from time of 
stimulus onset. Epochs were time-averaged by stimulus type so that ERPs for correctly and 
incorrectly identified stimuli in each condition of each task (e.g. correct “switches”, correct 
“non-switches” and incorrect “switches” and “non-switches”) could be generated for each 
individual. Only ERPs for correct responses on the “switch” condition were included in the 
subsequent analysis. There were 124 “switch” trials in the entirety of the task. The mean 
number of good “switch” trials retained for grand averaging per subject was 96.37 (average 
22.28% rejected trials), after rejecting incorrect trials (4.48%) and those containing artefacts 
(17.8%). Grand averages were made for each grouping condition (ecstasy user, polydrug user 
and drug naïve) on each task condition (correct “switches”, correct “non-switches”). The 
overall P3 response was defined as the mean amplitude between 290 and 400ms (the window 
was centred on the positive peak latency and the duration was chosen as this epoch contained 
6.56 µv 
-6.56 
µv 
a) 225ms b) 290ms c) 400ms 
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the majority of positive activity for all conditions. See Figure 6.2). Electrode activity was 
analysed in this epoch from parieto-occipital and occipital electrodes POz, PO3, PO4, PO7, 
PO8, Oz, O1 and O2, as the greatest amount of activity in the P3 component could be 
observed at these sites. Further components were also analysed for between group differences, 
including the N2 and P2 components. The N2 component appeared to be largest over 
occipital and parieto-occipital sites P7, P8, POz, PO3, PO4, PO7, PO8, Oz, O1, and O2, 
between 170-220ms, this epoch was based around the mean local negative peak at these sites 
and encompassed the majority of negative activity over all 3 conditions. The P2 epoch was 
most visible as a positive peak between 200-250ms at frontal, fronto-central and central sites 
Fz, FCZ, FC1, FC2, FC3, FC4 and Cz. The mean amplitudes at these sites from the epoch 
based around the positive peak from the grand averages of all conditions were analysed. 
Figure 6.2. Number-letter task topographies at midpoints for each component (P2, N2 and 
P3). 
 
               a) P2 225                      b) N2 195          c) P3 350  
 
 
Fig. 6.2: Grand averaged topographies from the central point of each component during the number-letter task.   
Positivity (red) in the P2 component in fronto-central electrodes can be observed (a). N2 Negativity (in blue) 
can be observed over occipital and parieto-occipital sites (b). P3 positivity is greatest over occipital and parieto-
occipital sites (c). 
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Semantic Association: EEG was segmented into epochs from -500 to 1000ms from 
time of stimulus onset. Epochs were time-averaged by stimulus type so that ERPs for 
correctly and incorrectly identified stimuli in each condition of each task (i.e. correct “high 
associations” and incorrect “high associations” and correct “low associations” and incorrect 
“low associations”) could be generated for each individual. Only ERPs for correct responses 
were included in the subsequent analysis. There were 120 trials in total, the mean number of 
good trials retained for grand averaging per subject was 109.66 (average of 8.6% rejected 
trials), after rejecting incorrect trials (6.1%) and those containing artefacts (2.5%). Grand 
averages were made for each group on each condition (correct “high associations”, correct 
“low associations”). The overall P3 response was defined as the mean amplitude between 280 
and 350ms, for the low association condition and 250-350ms for the high association 
condition. These time windows were centred on the positive peak latency and the duration 
was chosen due to this epoch containing the majority of positive activity for all conditions by 
observing topographic maps (See Figures 6.3 & 6.4). Electrode activity was analysed in this 
epoch from parieto-occipital and occipital electrodes PO7, PO3, O1, OZ, POZ, PO4, PO8 and 
O2, as the greatest amount of activity in the P3 component could be observed at these sites. 
Further components were also analysed for between group differences, including the N2 and 
P2 components. The N2 component was also largest over parieto-occipital and occipital 
electrodes (PO7, PO3, O1, OZ, POZ, , PO4, PO8 and O2) , between 120-190ms in the low 
association condition and 120-200ms in the high association condition, again epochs were 
based around the mean local negative peak at these sites and encompassed the majority of 
negative activity over all 3 groups. The P2 component was most visible as a positive peak 
between 170 and 230ms (for both low and high association) at anterior and midline sites (FZ, 
FCZ, FC1, FC2, CZ, C1 and C2) the mean amplitudes at these sites from the epochs based 
around the peaks from the grand averages of all conditions were analysed. 
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Figure 6.3. Semantic association task topographies at midpoints for each component (P2, N2 
and P3) in the high association condition. 
 
 
 
Fig. 6.3: Grand averaged topographies for central points of each component during high association trials. P2 
positivity is greatest at midline/anterior electrodes (a). N2 negativity is greatest in occipital and parieto-occipital 
electrodes (b). Positivity in the P3 component is greatest around occipital and parieto-occipital electrodes (c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) P2 200ms b) N2 160ms c) P3 315ms 
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Figure 6.4. Semantic association topographies at midpoints for each component (P2, N2 and 
P3) in the low association condition. 
 
 
 
Fig. 6.4: Grand averaged topographies for central points of each component during low association trials. P2 is 
greatest at midline/anterior electrodes (a). N2 negativity is greatest around occipital and parieto-occipital 
electrodes (b). Positivity in the P3 component that is greatest over occipital and parieto-occipital electrodes can 
be observed (c). 
 
N-back: EEG was segmented into epochs from -500 to 1000ms from time of probe 
onset. Epochs were time-averaged by stimulus type so that ERPs for correctly and incorrectly 
identified stimuli in each condition of each (e.g. correct “N = 0” responses, correct “N = 2” 
and correct “N = 4” responses and incorrect “N = 0”, “N = 2” and “N = 4” responses) could 
be generated for each individual. Only ERPs for correct responses were included in the 
subsequent analysis. There were 195 trials in total, the mean number of good trials retained 
for grand averaging per subject was 114.97 (average of 41.03% rejected trials), after rejecting 
incorrect trials (35.15%) and those containing artefacts (5.88%). Grand averages were made 
for each group on each task condition (correct “N = 0”, “N = 2” and “N = 4”responses). The 
overall P3 response was defined as the mean amplitude between 280 and 400ms. This time 
window was centred on the positive peak latency and the duration was chosen due to this 
a) P2 215ms b) N2 200ms c) P3 315ms 
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epoch containing the majority of positive activity for all conditions by observing topographic 
maps (See Figure 6.5). Posterior electrode activity was obtained in this epoch from electrodes 
P7, P5, PO7, PO3, O1, OZ, POZ, PO4, O2, PO8, P8, P6, as much of the activity could be 
observed in these sites. The N2 was defined as the mean amplitude between 140 and 230ms, 
this epoch was based around the mean local negative peak at posterior sites (P6, P8 & PO8) 
and encompassed the majority of negative activity over all 3 conditions. The P2 epoch was 
obtained from using a small, 50ms epoch (200-250ms) based around the positive peak from 
the grand averages of all conditions, here midline and anterior electrodes were used for 
analysis (F1, F3, FC1, Fz, F2, F4, FC2, FCz & C2). 
Figure 6.5: N-back topographies at midpoints for each component (P2, N2 and P3) in the n=2 
condition.  
 
 
 
Fig. 6.5: Grand averaged topographies for central points of each component during n=2 trials. P2 is greatest at 
anterior electrodes (a). N2 negativity is greatest around occipital and parieto-occipital electrodes (b). Positivity 
in the P3 component is greatest over occipital and parieto-occipital electrodes (c). 
 
 
 
 
a) P2 225ms b) N2 185ms c) P3 340ms 
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Urinary Analysis 
Frozen urine samples were delivered to University Hospital Aintree (NHS) and were 
analysed using Solid Phase Extraction (Mixed Mode Phase) followed by Reverse Phase 
HPLC MS/MS detection using BOTH Positive & Negative Ion Multiple Reaction Monitoring 
(MRM). Urine Specimens were been tested for the Synthetic Cannabinoids (JWH-018, JWH-
073, JWH-250, JWH-398, JWH-122, JWH-019, AM-694, WIN 48098 & WIN-55212-2), as 
well as the ‘designer’ drugs ‘Mephedrone’, bk-MDMA or ‘Methylone’, bk-MBDB or 
‘Butylone’, bk-PMMA or ‘Methedrone’, 1-benzylpiperazine, TFMPP, mCPP and MDPV. In 
addition they were tested for were a series of 12 Piperazine compounds, 4 β-Keto 
Amphetamines, a series of 11 Methcathinone compounds, 4-Fluoroamphetamine, Bupropion 
& the Hallucinogenic Amphetamines: D.O.B. (‘bromo-STP’ or ‘Brolamphetamine’), D.O.C. 
and D.O.I. and ‘Traditional’ Drugs of Abuse: Amphetamine(s) including M.D.M.A., M.D.A. 
& M.D.E.A., Barbiturates, Benzodiazepines, THC & Cannabinoids, Buprenorphine, Cocaine 
& metabolites, Methadone & metabolites, Opiates & Opioids (Morphine, Codeine, 
Dihydrocodeine, Tramadol, d-Propoxyphene, Oxymorphone & Oxycodone), LSD, G.H.B. 
(and the Lactone Precursor), Psilocybin, Ketamine and Methaqualone. 
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6.4 Results 
Socio-demographic information about the participants, anxiety, depression and 
arousal scores from the mood scale and sleep measures are shown in Table 6.1. Indices of 
other drug and alcohol use are displayed in Table 6.2.  
Table 6.1 – Indices sleep quality, fluid intelligence and socio-demographic variables 
 Ecstasy 
users 
 
  Polydrug 
controls 
  Drug naïve 
controls 
  
Males:  n ( %) 10 (50)   9 (45)   7 (35)   
Age (SD) 
 
23.94 (2.50)   22.58 (3.45)   23.10 (2.94)   
University degree: n 
(%) 
14 (70)   12 (60)   11 (55)   
          
Employment status          
Student;  n, (%) 12 (60)   14 (70)   17 (85)   
Employed; n (%) 4 (20)   4 (20)   3 (15)   
Unemployed; n (%) 4 (20)   2 (10)   0 (0)   
          
   Mean (SD)    Mean (SD)     Mean (SD)   
          
Ravens Progressive 
Matrices (maximum 
60) 
48.68 (5.96)   48.35 (5.83)   51.35 (5.01)   
          
Sleep – Hours/night 
 
7.13 (1.91)   7.8 (1.39)   7.05 (1.16)   
ESS Score 
(maximum 24) 
 
6.5 (3.3)   6.7 (3.15)   6.5 (3.32)   
KSS before 5.05 (1.93)*   3.75 (1.48)   4.79 (1.23)   
          
KSS after 6.53 (2.03)   5.85 (1.53)   6.56 (1.46)   
          
MEQ total 42.10 (10.15)   45.70 (9.40)   47.90 (8.30)   
          
UMACL anxiety 11.4 (4.08)   12.44 (2.18)   11.75 (2.12)   
          
UMACL depression  13.1 (3.91)   12.61 (2.40)   12.1(3.14)   
          
UMACL arousal 19.7 (4.54)   20.5 (3.68)   20.1 (3.02)   
          
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
 
 
 
 
143 
 
Table 6.2: Indices of other drug use 
 
 
 
 
 
 Ecstasy users   Polydrug 
controls 
  Drug naive 
controls 
  
 Mean (SD)  n Mean (SD)  n Mean (SD)  n 
 
Cannabis 
         
 Frequency 
(times/wk) 
2.67 (3.24)  12 0.95 (1.9)  13 -  - 
 Last 30 
days 
(joints) 
32.77 (53.75)  15 6.09 (15.34)  17 -  - 
 Total use 
(joints) 
5057.88 
(7504.30) 
 16 1091.71 
(2531.65) 
 19 -  - 
          
Cocaine           
Frequency 
(times/wk) 
0.15 (0.14)  11 0.27 (0.34)  2 -  - 
Last 30 
days 
(lines) 
0.4 (1.12)  15 1.60 (3.58)  5 -  - 
Total use 
(lines) 
813.97 (1940.19)  16 107.30 (208.43)  5 -  - 
          
Ketamine          
Frequency 
(times/wk) 
0.26 (0.42)  5  0.02 (-)  1 -  - 
Last 30 
days use 
(grams) 
1 (2.65)  9 -  - -  - 
Total use 
(grams) 
31.26 (70.61)  11 1.13 (1.62)  3 -  - 
          
Alcohol 
units p/w 
 
15.33 (15.29)  20 10.53 (8.37)  20 9.93 (11.58)  20 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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One way ANOVAs revealed that there were no significant between group differences 
on measures such as age, average hours sleep per night, total score on the Epworth Sleepiness 
Scale, Morningness-Eveningness questionnaire total score, post-test Karolinska Sleepiness 
Scale, levels of arousal, depression and anxiety, total score on Ravens SPM or average 
weekly alcohol consumption. However there were between group differences in the pre-
testing Karolinska Sleepiness Scale (i.e. how sleepy the participants felt before the test 
battery) F(2,58)=3.78, p<.05, planned comparison t-tests revealed that the ecstasy user group 
felt significantly more sleepy prior to testing than the polydrug control group t(38)=2.39,  
p<.05, but not the drug naïve control group t(37)=0.50, p>.05. 
t-tests between the ecstasy user group and polydrug controls revealed that the ecstasy 
user group had a larger lifetime total of cannabis joints smoked (5057.88 ± 7504.30) than the 
non-ecstasy drug users (1091.71 ± 2531.65), that is approaching significance t(17.88)=2.02, 
p=.06 (Levene’s test was significant so degrees of freedom have been adjusted accordingly). 
The ecstasy users had also smoked more joints within the last 30 days (32.77 ± 53.75 
compared to 6.09 ± 15.34) and this difference was approaching significance t(16.01)=1.86, 
p=.08. There were however no differences between these two groups on other drug intake 
variables. However as can be seen from table 6.2, the ecstasy user group can be described as 
polydrug users. 
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Urinary analysis 
The following metabolites were found in participants’ urine.    
Table 6.3: Amounts of various drug metabolites found in urine samples (mg/L) 
 
 
 THC ∆9 
THC 
11-
hydroxy-
∆9-THC 
1-
Benzylpiperazine 
TFMPP 
Ecstasy 
users 
N 3 3 3 1 1 
 Mean 0.0083 0.16 0.003 0.84 0.18 
 SD 0.01185 0.18286 0.00346 - - 
Polydrug 
controls 
N 1 1 1 - - 
 Mean 0.001 0.41 0.0020 - - 
 SD - - - - - 
 
As participants were asked to remain abstinent before attending the lab, relatively low 
levels of drug metabolites were found. As such, we re-ran all main analyses excluding the 
participants who had metabolites in their urine. This did not affect the significant and non-
significant results so the analyses reported below contain all participants.   
Behavioural Data Analysis 
All behavioural data was analysed using SPSS (17). Incorrect answers in each case 
were given a score of 0. Therefore an error count could be performed. Furthermore these 
trials were not included in reaction time analysis. Mean reaction times were calculated for 
correct responses only. Reaction time data reduction involved excluding reaction times less 
than 200ms and greater than 5000ms as these reaction times represent pre-emptive 
responding and a loss of concentration respectively. Individual trial reaction times that were 
more than 3 standard deviations above the individual mean were discarded. 
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The Go/NoGo task: Reaction time was not an appropriate measure for correct “NoGo” 
responses. Univariate Analysis of Variance (ANOVA) revealed that there was no significant 
difference between groups in performance on this task F(2,57)=1.15, p>.05. The mean 
“NoGo” errors (i.e. responding to a letter other than an X that required no response/an 
inhibition of response) were used as the measure of performance in this case (ecstasy users: 
2.7± 1.95, polydrug controls: 3.4 ± 2.80, drug naïve: 4.35 ± 4.92).  
Post task NASA TLX scores were analysed using a MANOVA. This revealed no 
overall between group differences in task load F(12,102)=0.52, p>.05, nor any between group 
differences on the individual sub-scales (Mental demand; F(2,55)=0.15, p>.05, Physical 
demand; F(2,55)=0.71, p>.05, Temporal demand; F(2,55)=1.11, p>.05, Effort; F(2,55)=0.09, 
p>.05, Performance; F(2,55)=0.45, p>.05, Frustration; F(2,55)= .01, p>.05). 
Number-Letter task: Mean reaction times were calculated for correct switch trials as 
well as correct non-switch trials so that a switch cost could be calculated. The mean 
percentage of outliers that were discarded from each group were: ecstasy users 1.27 (±0.73) 
(rank = 24.58), polydrug controls 1.64 (± 0.77) (rank = 33.75), drug naïve 6.56 (±22.0) (rank 
= 33.18), Levene’s test was violated so an independent samples Kruskal-Wallis test was 
conducted, there were no between group differences in amount of outliers (H(2) = 3.53, 
p>.05). Switch cost was calculated by subtracting the mean reaction time from two 
preliminary blocks with no switching (all letters, followed by all numbers) from the mean 
reaction time from the switch trials (from letters to numbers) in the main blocks of the task. 
One participant in the drug naïve group had an incomplete dataset for this task and was 
excluded from analysis. ANOVA revealed that there was no significant difference between 
groups on switch cost F(2,56)=0.41, p>.05 (ecstasy users: 303.56 ± 194.15, polydrug controls: 
331.44 ± 229.47, drug naïve controls: 274.09 ± 158.27). 
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Post task NASA TLX scores were analysed using a Multivariate Analysis of Variance 
MANOVA. This revealed no overall between group differences in task load F(12,100)=1.62, 
p>.05 for Pillai’s trace, nor any between group differences on the individual sub-scales 
(Mental demand; F(2,54)=2.21, p>.05, Physical demand; F(2,54)=2.07, p>.05, Temporal 
demand; F(2,54)=2.41, p>.05, Effort; F(2,54)=1.58, p>.05, Frustration; F(2,54)=0.37, p>.05 
with the exception of performance F(2,54)=2.99, p=.06 (approaching significance), multiple 
comparisons revealed that polydrug controls thought they had performed significantly better 
than ecstasy users p<.05. 
Semantic Association Task: The mean percentage of outliers that were discarded from 
each group were; ecstasy users 1.46 (±0.66), polydrug controls 1.42 (± 1.05), drug naïve 
controls 1.71 (±0.92), there were no between group differences in amount of outliers F 
(2,57)=0.63, p>.05. Performance on the semantic retrieval task was measured both in terms 
of number of errors made (incorrect responses) and reaction time. Mixed ANOVA on error 
count revealed no significant effect of difficulty F(1,57)=0.04, p>.05, no main effect of 
group F(2,57)=1.56, p>.05 and no group by difficulty interaction F(2,57)=0.01, p>.05. 
Similarly using reaction time as the dependent variable no significant between group 
differences were observed F(2,57)=0.07 p>.05. Difficulty and group by difficulty 
interactions were non-significant p>.05 in both cases (Table 6.4).  
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Table 6.4: Performance data (means and SDs of error count and reaction times) for all 
participants in both conditions of the semantic association task. 
 
 
 
Ecstasy users  Polydrug controls  Drug naïve controls  
 Mean (SD)  Mean (SD)  Mean (SD)  
 
High 
association 
errors 
 
 
4.00 (2.34) 
 
 
 
 
 
4.60 (2.78) 
 
 
 
 
 
 
5.25 (2.77) 
 
 
 
 
Low 
association 
errors 
 
 
4.10 (2.57) 
 
 
 
 
 
4.60 (2.09) 
 
 
 
 
 
5.35 (2.92) 
 
 
 
 
High 
association 
RT (ms) 
 
 
1282.26 (255.91) 
 
 
 
 
 
1294.43 (354.77) 
 
 
 
 
 
1209.39 (230.89) 
 
 
 
 
Low 
association 
RT (ms) 
 
 
1265.14 (250.85) 
 
 
 
 
 
1294.21(308.44) 
 
 
 
 
 
 
1180.39 (198.60) 
 
 
 
       
 
 
Post task NASA TLX scores were analysed using a multivariate analysis of variance 
MANOVA. This revealed no overall between group differences in perceived demand F 
(12,104)=0.94, p>.05 for Pillai’s trace, nor any between group differences on the individual 
sub-scales of their perception of subjective workload (Mental demand; F(2,56)=1.06, p>.05, 
Physical demand; F(2,56)=0.10, p>.05, Temporal demand; F(2,56)=1.56, p>.05, Effort; 
F(2,56)=0.48, p>.05, Performance; F(2,56)=2.62, p>.05, Frustration; F(2,56)=0.77, p>.05). 
N-back task: The mean percentage of outliers that were discarded from each group 
were; ecstasy users 1.18 (±0.71), polydrug users 6.54 (±22.01), drug naïve controls 6.12 
(±22.11), there were no between group differences in amount of outliers F(2,57)=0.55, p>.05. 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;            
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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A mixed analysis of variance (ANOVA) was conducted on both the mean reaction 
times and number of errors on the n-back task, with between subjects factor of user group (3 
levels) and within subject factor of difficulty (ranging from low difficulty; n=0, to medium 
difficulty; n=2 and high difficulty; n=4). The error count yielded a significant effect of 
difficulty (3 levels) F(2,110)=3.27, p<0.05, but no significant main effect of group 
F(2,55)=1.35, p>0.05 and no group by difficulty interaction F(4,110)=0.30, p>.05. 
Mixed ANOVA on the mean reaction times revealed a significant effect of difficulty 
F(2,110)=16.92, p<0.001, and also a main effect of group F(2,55)=3.80, p<0.05. There was, 
however no group by difficulty interaction F(4,110)=0.22, p>.05. 
To explore the main effect of group further, univariate ANOVAs were conducted on 
each difficulty level for mean reaction time. Significant between group differences in reaction 
time were observed at n=0 F(2,55)=3.18, p<0.05, n=2 F(2,55)=4.50, p<0.05 and n=4 
F(2,55)=4.50, p<0.05. Planned comparisons revealed that drug naïve participants took 
significantly longer to respond than polydrug users at each level (p<.05 in each case), there 
were no significant differences between ecstasy users and the two control groups in reaction 
time at any level of the task (table 6.5). 
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Table 6.5: Performance data (means and SDs of error count and reaction times) on the n-back 
task. 
 
 
 
Ecstasy users Polydrug controls Drug naïve controls 
 Mean (SD) Mean (SD) Mean (SD) 
 
 
N=0 errors 
 
 
21.90 (15.21) 
 
 
15.68 (8.21) 
 
 
17.11 (10.75) 
 
N=2 errors 
 
21.80 (16.11) 
 
 
15.37 (9.26) 
 
17.89 (12.15) 
 
 
N=4 errors 
 
22.65 (14.67) 
 
 
16.95 (8.87) 
 
 
18.63 (10.54) 
 
 
N=0 RT 
(ms) 
 
2895.12 (699.09) 
 
 
2894.72 (678.82)† 
 
 
 
3387.54 (698.82) 
 
N=2 RT 
(ms) 
2755.59 (607.23) 2670.61 (2670.61)† 3205.60 (543.65) 
    
N=4 RT 
(ms) 
2754.19 (651.71) 2674.15 (606.48)† 3162.48 (666.97) 
 
 
Post task NASA TLX scores were analysed using a multivariate analysis of variance 
MANOVA. This revealed no overall between group differences in perceived demand F (12, 
104) = 0.94, p>.05 for Pillai’s trace, nor any between group differences on the individual sub-
scales of their subjective perception of subjective workload (Mental demand; F(2, 56) = 1.06, 
p>.05, Physical demand; F(2, 56) = 0.10, p>.05, Temporal demand; F(2, 56) = 1.56, p>.05, 
Effort; F(2, 56) = 0.48, p>.05, Performance; F(2, 56) = 2.62, p>.05, Frustration; F(2, 56) = 
0.77, p>.05). 
 
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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ERP analysis 
Go/NoGo: Mean amplitudes for each condition and electrode are given in Table 6.6. 
Due to some unusable EEG data, 1 participant is excluded from statistical analysis on the 
EEG data, from the drug naïve group (n=19). 
Table 6.6: Mean amplitudes (µvolts) across components, for each electrode measured 
(Go/NoGo). 
User group CPz   Cz FCz Fz Pz 
 P2     
Ecstasy users 2.17 (1.82) 1.94 (2.69) 2.08 (2.15) *† 1.43 (2.13)* 1.45 (1.84) 
Polydrug controls 1.3 (1.28)                         1.16 (1.9)                        0.29 (2.22)                   0.40 (1.94)                    1.43 (1.92) 
Drug naïve controls 1.49 (3.24)                       0.84 (2.1)                       -0.14 (2.12)                   -.30 (1.79)                 1.64 (2.51) 
      
 N2     
Ecstasy users 1.38 (2.43)                     -0.58 (3.60                       -1.92 (3.27)                     -2.00 (2.14                   2.66 (1.72) 
Polydrug controls 0.78 (2.67)                     -0.82 (2.95)                      -3.21 (3.33)                   -2.87 (2.96)                   2.16 (2.61) 
Drug naïve controls 0.41 (3.50)                     -1.42 (4.37)                      -3.44 (4.33)                   -3.12 (3.20)                   2.16 (2.43) 
      
 P3     
Ecstasy users 4.94 (2.15)                     5.04 (2.82)                        4.06 (2.22)                     1.05 (1.74)                   4.29 (1.95) 
Polydrug controls 4.07 (2.84)                     4.56 (4.20)                        2.91 (3.93)                     0.49 (3.06)                   3.79 (2.50) 
Drug naïve controls 4.76 (2.65)                     5.12 (2.77)                        3.59 (3.23)                     0.93 (3.12)                   4.35 (2.10) 
 
 
Mixed ANOVA
1
 of mean amplitudes at component P3 (352-452ms) revealed a 
significant main effect of electrode site F(2.55, 143.03)=38.01, p<.01. However, the electrode 
by user group interaction was non-significant F(5.11, 143.03)=0.11, p>.05. There was no 
main effect of group F(2,56)=0.61, p>.05. As such this component is not discussed further. 
At the N2 component (260–330ms), mixed ANOVA revealed a significant main 
effect of electrode site F(2.28, 127.64)=59.92, p<.01. However there was no significant 
electrode by group interaction F(4.56, 127.64)=0.25, p>.05. There was no main effect of 
group in this component F(2,56)=0.86, p>.05. 
                                                          
1
 In all mixed ANOVAs (for electrode data in Chapter 6), Mauchley’s test was significant so adjusted degrees of 
freedom are reported in line with the Greenhouse Geisser statistic.  
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Mixed ANOVA on the mean amplitudes measured for the P2 component (200–250ms) 
revealed a significant main effect of electrode site F(2.24, 125.50)=3.56, p<.05. The electrode 
by group interaction was non-significant F(4.48, 125.50)=1.41, p>.05. However there was a 
significant main effect of group F(2,56)=3.27, p<.05. To explore this effect further, a series 
of univariate ANOVAs were conducted at each electrode site. Significant group differences 
were observed at electrode FCz F(2,56)=5.81, p<0.01 and also electrode Fz F(2,56)=3.84, 
p<0.05. Post-hoc Tukey’s test revealed that the ecstasy users had significantly greater mean 
amplitudes than drug naïve controls at electrode site Fz (p<0.05). Furthermore the ecstasy 
users showed significantly greater amplitude than polydrug controls and drug naïve controls 
at electrode FCz (p<.05 in both cases). The grand average waveforms for each group (users, 
polydrug nonusers and drug naïve controls) for the electrodes showing significant differences 
can be observed in Figure 6.6. 
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Figure 6.6. Grand average waveforms for the 3 groups across electrodes: FCz and Fz.(correct trials on Go/NoGo task) 
 
FCz                 Fz 
                             
Fig. 6.6: Depicts the waveforms from FCz and Fz (negative plotted up). The time course of the various components can be observed in the grand averaged data from each 
user group. The significant differences between ecstasy users and drug naïve controls in the P2 component can be observed in Fz from the epoch of 200–250ms (ecstasy users 
shown in blue, polydrug controls in purple and drug naïve controls in red). Also the magnitude and time course of the significant differences in mean amplitude in the P2 
component between ecstasy users and both other control groups can be observed in FCz. 
      Milliseconds    Milliseconds 
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Given the heavy use of cannabis in the ecstasy user group in particular, multiple 
regression analyses were conducted on the data, to observe whether level use of ecstasy (after 
controlling for cannabis use) was a predictor of amplitude at the electrodes Fz and FCz. In the 
first regression, amplitude at Fz was entered as the dependent variable; in the first step 
indices of cannabis use were entered as predictors (frequency of use, total lifetime dose, 
amount smoked in the last 30 days) and in the second step, the same indices of ecstasy use 
were entered as predictors. The overall regression model accounted for a non-significant 9.5% 
(R² = 0.10, R² adjusted = -0.01, F(6,52)=0.91, p>0.05) of the variance in Fz amplitude. 
Cannabis use indices (step 1) did not predict a significant amount of variance in Fz amplitude 
(R² = 0.04, R² adjusted = -0.01, F(3,55)=0.83, p>0.05). With none of the three cannabis use 
variables predicting Fz amplitude; frequency of use (β=-0.70, p>0.05), total lifetime dose 
(β=0.06, p>0.05) and amount smoked in the last 30 days (β=-0.72, p>0.05). The ecstasy use 
indices (step 2) did not predict a significant amount of variance in Fz amplitude, after 
controlling for cannabis use indices (R ²change=0.05, F-change (3,52)=1.00, p>.05). 
Frequency of use (β=-0.01, p>0.05), last 30 day use (β=0.34, p>0.05) and lifetime dose 
(β=0.01, p>0.05) were not significant predictors. 
In the second regression, amplitude at FCz was entered as the dependent variable and 
predictors entered as above. The overall regression model accounted for 14.2% (non-
significant) (R² = 0.14, R² adjusted = 0.04, F(6,52)=1.43, p>0.05) of the variance in FCz 
amplitude. Cannabis use indices (step 1) did not predict a significant amount of variance in 
FCz amplitude (R² = 0.06, R² adjusted = -0.01, F(3,55)=1.09, p>0.05). None of the three 
cannabis use variables predicted FCz amplitude; frequency of use (β=0.60, p>0.05), total 
lifetime dose (β=-0.25, p>0.05) and amount smoked in the last 30 days (β=-0.44, p>0.05). 
The ecstasy use indices (step 2) did not predict a significant amount of variance in FCz 
amplitude, after controlling for cannabis use indices (R ²change=0.09, F-change (3,52)=1.72, 
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p>.05). Frequency of use (β=06, p>0.05) and lifetime dose (β=0.04, p>0.05) were not 
significant predictors. However last 30 days use was a significant predictor of amplitude 
(β=0.42, p<0.05), with greater use associated with increased amplitude. 
Number-Letter: Mean amplitudes for each condition and electrode are given in Table 
6.7. Due to some participants not completing the task and some unusable EEG data 6 
participants are excluded from statistical analysis on the EEG data, 4 from the drug naïve 
group (n=16) and 2 from the ecstasy user group (n=18).  
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Table 6.7: Mean amplitudes (µvolts) across components, for each electrode measured during 
the number-letter task. 
 P3   
 PO7 PO3 O1 Oz POz PO8 PO4 O2   
Ecstasy 
users  
1.25 
(2.13) 
2.59 
(1.63)       
0.68 
(1.84)†      
0.40 
(1.52)      
2.67 
(2.37)†      
1.63 
(2.58)      
2.24 
(1.70)      
0.37 
(1.76) 
  
           
Polydrug 
controls 
1.94 
(2.05) 
2.57 
(1.54)       
0.71 
(1.90) †     
0.27 
(1.72)†    
2.27 
(0.94)†     
0.92 
(3.11)      
1.94 
(1.77)†     
0.32 
(2.82) 
  
           
Drug 
naïve 
controls 
2.03 
(2.20)       
3.56 
(2.61)      
2.37 
(2.41)    
1.66 
(2.33)       
4.50 
(3.26)   
1.56 
(3.49)      
3.61 
(2.75)       
1.93 
(2.72) 
  
           
 N2 
         P7 P8 
Ecstasy 
users 
-2.56 
(0.61)     
-0.90 
(0.46)     
-1.58 
(0.53)      
-0.15 
(0.48)     
0.45 
(0.60)     
-0.66 
(0.78)     
-0.06 
(0.60)    
-0.48 
(0.60)      
-2.81 
(0.46)    
-1.36 
(0.63)             
           
Polydrug 
controls 
-2.08 
(0.57)     
-0.70 
(0.44)     
-1.17 
(0.50)      
0.47 
(0.45)      
0.81 
(0.57)     
-1.44 
(0.74)      
0.12 
(0.57)     
0.39 
(0.57)      
-1.88 
(0.44)      
-0.87 
(0.60)      
           
Drug 
naïve 
controls 
-0.60 
(0.64)     
0.05 
(0.50)       
0.20 
(0.56)       
0.70 
(0.51)     
1.09 
(0.64)      
-0.45 
(0.82)      
0.57 
(0.64)     
0.56 
(0.63)      
-0.66 
(0.49)      
-0.13 
(0.67) 
           
 P2 
 FC3 FC1 Fz FC4 FC2 FCz Cz    
           
Ecstasy 
users  
-0.18 
(4.22)      
1.07 
(1.38)      
1.54 
(1.63)*†     
1.66 
(1.33)      
1.57 
(1.24)     
2.10 
(1.45)*†      
1.78 
(1.24)*† 
   
           
Polydrug 
controls 
0.95 
(1.18)        
0.65 
(1.34)      
0.37 
(1.84)      
1.61 
(1.64)      
1.10 
(1.69)     
0.64 
(1.43)      
0.45 
(2.34) 
   
           
Drug 
naïve 
controls 
0.96 
(2.30)        
0.74 
(1.86)      
0.28 
(1.12)      
0.88 
(1.53)      
0.59 
(1.29)     
0.59 
(1.71)      
0.47 
(1.63) 
   
           
 
 
Mixed ANOVA of mean amplitudes at component P3 (290-400ms) revealed a 
significant main effect of electrode site F(4.04, 206.02)=15.78, p<.01, though the electrode 
by user group interaction was non-significant F(8.08, 206.02)=0.99, p>.05. There was 
however a significant main effect of group F(2,51)=3.35, p<.05. To further explore this 
difference, a series of one-way ANOVAs were conducted. This yielded significant effect of 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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group at electrode O1 F(2,51)=3.80, p<.05, with post-hoc tests indicating that both drug 
using groups had a significantly diminished mean amplitude compared to drug naïve 
participants (p<.05), the two drug user groups did not differ from each other (p>.05). There 
were also significant differences at electrode POz F(2,51)=4.56, p<.05, and again, post-hoc 
analysis showed that both drug groups had significantly lower mean amplitude than drug 
naïve participants (p<.05). The two drug user groups did not differ from each other (p>.05). 
Significant differences were also apparent at PO4 F(2,51)=3.11, p<.05, with post-hoc tests 
indicating that polydrug users had significantly lower mean amplitude than drug naive 
participants (p<.05). Differences at electrode Oz were approaching significance F(2,51)=2.88, 
p=.07. Post-hoc analysis showed that polydrug users had significantly lower mean amplitude 
than drug naïve controls (p<.05). The grand average waveforms for each group (users, 
polydrug controls and drug naïve controls), for the electrodes showing significant differences 
in the P3 component can be observed in Figure 6.7. 
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Figure 6.7. Grand average waveforms for the 3 groups across electrodes: O1, Oz, POz and PO4 (correct switches) 
 
O1                     Oz              POz                                         PO4 
 
 
Fig. 6.7: Depicts the waveforms from electrodes that showed significant group differences in the P3 component. Ecstasy users are displayed in blue, polydrug users are 
displayed in black and drug naïve controls are displayed in lilac. These waveforms are from grand averaged data from each user group. The significant differences between 
drug naïve controls and both drug user groups can be seen in O1and POz (290-400ms). Differences between polydrug users and drug naïve participants can be seen in Oz and 
PO4. 
 
 
    Milliseconds     Milliseconds Milliseconds   Milliseconds 
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Regression analyses were conducted on the four electrodes showing differences, to 
observe whether level use of ecstasy (after controlling for cannabis use) was a predictor of 
amplitude at the electrodes O1, POz, PO4 and Oz. In the first regression, amplitude at O1 was 
entered as the dependent variable; in the first step indices of cannabis use were entered as 
predictors (frequency of use, total lifetime dose, amount smoked in the last 30 days) and in 
the second step, the same indices of ecstasy use were entered as predictors. The overall 
regression model accounted for a significant 24.4% (R² = 0.24, R² adjusted = 0.15, 
F(6,47)=2.53, p<0.05) of the variance in O1 amplitude. However, cannabis use indices (step 
1) did not predict a significant amount of the variance in O1 amplitude (R² = 0.10, R² adjusted 
= 0.04, F(3,50)=1.80, p>0.05); Cannabis use variables; frequency of use (β=-0.72, p>0.05) 
and amount smoked in the last 30 days (β=1.11, p>0.05) did not predict O1 amplitude, 
however total lifetime dose (β=-1.11, p<0.01), was a significant predictor (greater use = 
lower amplitude). The ecstasy use indices (step 2) predicted a significant amount of variance 
in O1 amplitude, after controlling for cannabis use indices (R ²change=0.147, F-change 
(3,47)=3.05, p<.05). Specifically lifetime ecstasy dose was a significant predictor (β=0.74, 
p<.01) with greater ecstasy use being associated with increased amplitude. However 
frequency of use (β=0.02, p>0.05) and last 30 day use (β=0.02, p>0.05) were not significant 
predictors. 
A second regression was conducted with amplitude at POz entered as the dependent 
variable. The overall regression model accounted for a non-significant 6% (R² = 0.06, R² 
adjusted = -0.06, F(6,47)=4.96, p>0.05) of the variance in POz amplitude. Cannabis use 
indices (step 1) did not predict a significant amount of the variance in POz amplitude (R² = 
0.05, R² adjusted = -0.01, F(3,50)=0.92, p>0.05); none of the three cannabis use variables 
predicted POz amplitude; frequency of use (β=-0.15, p>0.05), total lifetime dose (β=-0.42, 
p>0.05) and amount smoked in the last 30 days (β=0.41, p>0.05). The ecstasy use indices 
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(step 2) did not predict significant amount of variance in POz amplitude, after controlling for 
cannabis use indices (R ²change=0.01, F-change (3,47)=0.12, p>.05). None of the ecstasy use 
variables predicted POz amplitude; frequency of use (β=0.06, p>0.05), total lifetime dose 
(β=0.07, p>0.05) and last 30 day use (β=-0.08, p>0.05). 
Amplitude at PO4 was entered as the dependent variable in the third regression. The 
overall regression model accounted for a non-significant 7.7% (R² = 0.08, R² adjusted = -0.04, 
F(6,47)=0.65, p>0.05) of the variance in PO4 amplitude. Cannabis use indices (step 1) did 
not predict a significant amount of the variance in PO4 amplitude (R² = 0.06, R² adjusted = 
0.01, F(3,50)=1.09, p>0.05); none of the three cannabis use variables predicted PO4 
amplitude; frequency of use (β=-0.50, p>0.05), total lifetime dose (β=-0.07, p>0.05) and 
amount smoked in the last 30 days (β=0.53, p>0.05). The ecstasy use indices (step 2) did not 
predict significant amount of variance in PO4 amplitude, after controlling for cannabis use 
indices (R ²change=0.02, F-change (3,47)=0.26, p>.05). None of the ecstasy use variables 
predicted PO4 amplitude; frequency of use (β=0.09, p>0.05), total lifetime dose (β=-0.17, 
p>0.05) and last 30 day use (β=-0.13, p>0.05). 
Amplitude at Oz was entered as the dependent variable in the 4th regression. The 
steps entered were consistent with the previous regressions. The overall regression model 
accounted for 20.3% (R² = 0.20, R² adjusted = 0.10, F(6,47)=1.99, p=0.09) of the variance in 
Oz amplitude (approaching significance). Cannabis use indices (step 1) did not predict a 
significant amount of the variance in Oz amplitude (R² = 0.11, R² adjusted = 0.06, 
F(3,50)=2.11, p>0.05); however total lifetime joints (β=-0.95, p<0.05) significantly predicted 
Oz amplitude (increased dose associated with decreased amplitude), and amount smoked in 
the last 30 days approached significance (β=1.12, p=0.06) (increased use associated with 
increased amplitude). Frequency of use did not predict Oz amplitude (β=-0.54, p>0.05). The 
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ecstasy use indices (step 2) did not predict significant amount of variance in Oz amplitude, 
after controlling for cannabis use indices (R ²change=0.09, F-change (3,47)=1.77, p>.05). 
The ecstasy use variables frequency of use (β=0.09, p>0.05) and last 30 day use (β=-0.17, 
p>0.05) did not predict Oz amplitude; however total lifetime dose (β=0.46, p=0.08) was 
approaching significance (increased use associated with increased amplitude). 
Mixed ANOVA of mean amplitudes at component N2 (170-220) revealed a 
significant main effect of electrode F(4.27, 217.82)=12.23, p<.01. The electrode by user 
group interaction F(8.54, 217.82)=0.76, p>.05, and the main effect of group F(2,51)=1.83, 
p>.05, were however non-significant so this component is not discussed further.  
At component P2 (200-250ms) Mixed ANOVA revealed a non-significant effect of 
electrode F(3.30, 168.44)=1.60, p>.05, though the electrode by user group interaction was 
significant F(6.61, 168.44)=2.12, p<.05. The main effect of group was not significant for this 
component F(2,51)=2.11, p>.05. To further explore the nature of the significant interaction, a 
series of one way ANOVAs were used. These yielded significant group differences at 
electrode Fz F(2,51)=3.52, p<.05, with post-hoc analysis showing that ecstasy users had 
significantly greater mean amplitude compared to both other groups (p<.05); at electrode FCz 
F(2,51)=5.66, p<.01, with ecstasy users having significantly greater mean amplitude than 
both other groups (p<.05); and at electrode Cz F(2,51)=3.14, p<.05, with ecstasy users 
showing greater amplitude than both other groups (p<.05). Inspection of Table 6.7 suggests 
that for all the electrodes, ecstasy users have higher mean P2 amplitudes than the other two 
groups, with the exception of electrode FC3, where the opposite pattern is seen. The grand 
average waveforms of each group, for the electrodes showing significant differences in the P2 
component can be observed in Figure 6.8. 
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Figure 6.8. Grand average waveforms for the 3 groups across electrodes: Fz, FCz and Cz (P2 correct switches) 
 
     Fz                 FCz                    Cz 
 
 
Fig. 6.8: Depicts the waveforms from electrodes that showed significant group differences in the P2 component. Ecstasy users are displayed in blue, polydrug users are 
displayed in black and drug naïve controls are displayed in lilac. The significant differences between ecstasy users and both control groups can be seen in Fz, FCz and Cz 
between 200-250ms. 
          Milliseconds             Milliseconds           Milliseconds 
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Regression analyses were conducted on the three electrodes showing differences, to 
observe whether level use of ecstasy (after controlling for cannabis use) was a predictor of 
amplitude at the electrodes Fz, FCz and Cz. In the first regression, amplitude at Fz was 
entered as the dependent variable; in the first step indices of cannabis use were entered as 
predictors (frequency of use, total lifetime dose, amount smoked in the last 30 days) and in 
the second step, the same indices of ecstasy use were entered as predictors. The overall 
regression model accounted for a non-significant 16.5% (R² = 0.16, R² adjusted = 0.06, 
F(6,47)=1.55, p>0.05) of the variance in Fz amplitude. Cannabis use indices (step 1) did not 
predict a significant amount of the variance in Fz amplitude, although this was approaching 
significance (R² = 0.12, R² adjusted = 0.07, F(3,50)=2.34, p=0.09); none of the three cannabis 
use variables predicted Fz amplitude; frequency of use (β=0.45, p>0.05), total lifetime dose 
(β=-0.23, p>0.05) and amount smoked in the last 30 days (β=-0.19, p>0.05). The ecstasy use 
indices (step 2) did not predict significant amount of variance in Fz amplitude, after 
controlling for cannabis use indices (R ²change=0.04, F-change (3,47)=0.79, p>.05). None of 
the ecstasy use variables predicted Fz amplitude; frequency of use (β=0.00, p>0.05), total 
lifetime dose (β=-0.16, p>0.05) and last 30 day use (β=0.32, p>0.05). 
 FCz was entered as the dependent variable in the second regression. This overall 
regression model accounted for a significant 22.4% (R² = 0.22, R² adjusted = 12.5, 
F(6,47)=2.26, p<0.05) of the variance in FCz amplitude. Cannabis use indices (step 1) 
predicted a significant amount of the variance in FCz amplitude (R² = 0.14, R² adjusted = 
0.09, F(3, 50)=2.80, p<0.05); However none of the three individual cannabis use variables 
predicted  FCz amplitude; frequency of use (β=0.43, p>0.05), total lifetime dose (β=-0.46, 
p>0.05) and amount smoked in the last 30 days (β=-0.17, p>0.05). The ecstasy use indices 
(step 2) did not predict significant amount of variance in FCz amplitude, after controlling for 
cannabis use indices (R ²change=0.08, F-change (3,47)=1.62, p>.05). Individual ecstasy use 
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variables did not predict FCz amplitude; frequency of use (β=0.03, p>0.05), and last 30 day 
use (β=0.32, p>0.05), however total lifetime dose was approaching significance (β=0.46, 
p=0.08) with increased use being associated with increased amplitude. 
 In the third regression Cz was entered as the dependent variable. This overall regres-
sion model accounted for a non-significant 5% (R² = 0.05, R² adjusted = -0.07, F(6,47)=0.43, 
p>0.05) of the variance in Cz amplitude. Cannabis use indices (step 1) did not predict a 
significant amount of the variance in Cz amplitude (R² = 0.03, R² adjusted = -0.03, 
F(3,50)=0.47, p>0.05); None of the three individual cannabis use variables predicted Cz 
amplitude; frequency of use (β=0.18, p>0.05), total lifetime dose (β=-0.39, p>0.05) and 
amount smoked in the last 30 days (β=-0.04, p>0.05). The ecstasy use indices (step 2) did not 
predict significant amount of variance in Cz amplitude, after controlling for cannabis use 
indices (R ²change=0.03, F-change (3,47)=0.42, p>.05). None of the ecstasy use variables 
predicted Cz amplitude; frequency of use (β=0.08, p>0.05), total lifetime dose (β=-0.26, 
p>.05).and last 30 day use (β=0.49, p>0.05). 
Semantic Association: Mean amplitudes for each condition and electrode are given in 
Table 6.8. Due to some unusable EEG data, 1 participant is excluded from statistical analysis 
on the EEG data, from the drug naïve group (n=19). 
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Table 6.8: Mean amplitudes (µvolts) across components, for each electrode measured for the 
semantic association task. 
User group PO7 PO3 O1 Oz POz PO8   PO4 O2 
 P3 high association 
Ecstasy users  2.95 (4.02)      3.94 (2.42)       2.76 (3.01)      1.60 (3.24)      4.19 (2.34)      4.40 (3.23)      4.94 (2.99)      3.31 (3.59) 
Polydrug controls  4.12 (2.83)      2.97 (2.57)       3.52 (4.60)      3.04 (3.40)      3.28 (2.27)      5.72 (3.78)      4.05 (3.27)      3.32 (3.32) 
Drug naïve 
controls  
 
3.62 (3.19)       3.92 (2.39)      2.84 (3.17)      2.13 (3.14)      3.42 (2.56)      5.35 (3.40)      4.00 (2.21)      3.27 (2.75) 
 P3 low association 
Ecstasy users 3.48 (3.74)      4.60 (2.74)      2.32 (3.57)      1.79 (2.90)      4.46 (2.40)      3.78 (2.92)      4.98 (3.33)      2.97 (3.39)    
Polydrug controls   4.16 (3.29)      3.44 (3.16)      2.27 (4.40)      2.70 (2.85)      3.89 (2.26)      5.92 (4.61)      4.41 (3.67)      3.14 (3.90) 
Drug naïve 
controls  
 
4.32 (3.42)      4.40 (2.64)    3.08 (3.46)      2.22 (3.21)      3.93 (2.80)      6.07 (3.32)     4.54 (2.69)      3.78 (2.92)      
 N2 high association 
Ecstasy users -1.66 (3.41)     -1.32 (3.55)     -2.19 (3.53)     -2.51 (3.45)     -0.70 (4.01)    -1.41 (3.20)    -1.04 (3.69)     -2.17 (4.12) 
Polydrug Controls  -2.06 (4.57)     -2.37 (2.90)††   -2.41 (4.36)     -0.59 (4.19)     -0.58 (2.42)    -0.09 (4.11)    -0.44 (2.57)     -1.15 (3.44) 
Drug naïve 
controls   
 
-0.58 (3.11)     0.67 (2.95)     -0.36 (3.43)      0.09 (3.78)      1.22 (3.03)      1.12 (3.50)      0.82 (3.19)     0.33 (3.51)    
 N2 low association 
Ecstasy users -1.40 (3.55)     -0.95 (3.76)     -2.76 (4.19)    -1.98 (3.57)     -0.17 (3.62)     -1.56 (3.53)†     -1.01 (3.67)    -2.40 (3.75)† 
Polydrug controls   -1.69 (4.69)     -1.55 (3.15)     -2.11 (4.47)    -1.09 (3.43)     -0.28 (2.16)     -0.22 (4.02)     -0.29 (1.91)    -0.10 (3.71) 
Drug naïve 
controls  
 
0.01 (3.67)       0.65 (2.97)     -0.33 (4.07)     -0.99 (3.62)       1.55 (2.91)       1.30 (3.58)      0.91 (2.73)       0.67 (3.48) 
 P2 high association 
 Fz FCz FC1 FC2 Cz C1 C2  
Ecstasy users 0.55 (2.15)      1.49 (2.04)      1.15 (1.79)       0.86 (2.09)      1.91 (1.48)      0.89 (2.13)      0.77 (1.53)       
Polydrug controls  1.07 (1.98)      1.85 (1.54)      1.28 (1.52)       1.05 (1.87)      1.53 (1.73)      0.87 (1.87)      0.40 (1.64)       
Drug naïve 
controls   
 
-0.10 (2.43)      0.78 (2.43)     0.61 (1.45)      0.03 (2.75)      0.59 (2.78)       0.22 (2.03)       -0.22 (2.72)       
 P2 low association 
Ecstasy users  0.87 (2.59)      1.64 (2.39)      1.33 (2.54)     0.83 (2.75)       1.55 (1.97)      1.06 (1.45)      0.93 (1.40)      
Polydrug controls 0.51 (1.42)      1.72 (1.62)     1.49 (2.81)      0.98 (1.74)       1.38 (1.77)      0.88 (1.99)      0.62 (1.79)      
Drug naïve 
controls  
0.14 (1.90)      0.72 (2.16)     0.54 (1.98)      0.41 (1.79)       0.81 (2.41)       0.39 (2.22)     0.54 (1.97)      
         
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (PO7, PO3, O1, OZ, POZ, , PO4, 
PO8 and O2) on the P3 component revealed no main effect of difficulty F(1,56) 0.71, p>.05, 
no difficulty by group interaction F(2,56)=0.60, p>.05, no main effect of site F(4.18, 
233.99)=13.97, p>.05, no difficulty by site interaction F(3.42, 191.64)=1.56, p>.05 and no 
difficulty by site by group interaction F(6.84, 191.64)=0.61, p>.05. However there was a 
significant site by user group interaction F(8.36, 233.99)=1.65, p<.05. There were no 
significant between group effects F(2,56)=0.74, p>.05, so these were not investigated further. 
To further explore the site by user group interaction, a series of univariate ANOVAs were run 
with group as the between groups variable and amplitude at the various sites as the dependent 
variable. This yielded no significant differences between the three groups and no significant 
post-hoc comparisons, p>.05 in all cases.  
A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (PO7, PO3, O1, OZ, POZ, , PO4, 
PO8 and O2) on the N2 component revealed no main effect of difficulty F(1,56)=1.05, p>.05, 
no difficulty by group interaction F(2,56)=0.04, p>.05, no main effect of site F(3.82, 
213.92)=6.37, p>.05, no site by group interaction F(7.64, 213.92)=1.10, p>.05, no difficulty 
by site interaction F(4.78, 267.40)=0.81, p>.05 and no difficulty by site by group interaction 
F(9.55, 267.40)=0.73, p>.05. Between group differences approached significance 
F(2,56)=2.78, p=.07. In line with a priori predictions and to further explore this trend on the 
N2 component a series of univariate ANOVAs were conducted. These revealed significant 
between group differences at electrode PO3 in the high association condition F(2,56)=4.68, 
p<.05, post-hoc analysis revealed that polydrug controls were significantly different (greater 
negativity) to drug naïve controls at this electrode (p<.01). Significant between group 
differences were also observed at electrode O2 in the low association condition F(2,56)=3.45, 
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p<.05), post-hoc analysis revealed that ecstasy users differed significantly (greater negativity) 
from drug naive controls here (p<.05). Between group differences were also approaching 
significance at PO8 in the low association condition F(2,56)=2.89, p=.06, again post-hoc 
analysis showed that ecstasy users were significantly different (greater negativity) from drug 
naïve controls here (p<.05). Ecstasy users and polydrug controls did not differ significantly 
from one another at these three sites (p>.05). In all cases, ecstasy users showed a greater 
negativity than drug naïve controls (Table 6.8). The grand average waveforms of each group, 
for the electrodes showing significant differences in the N2 component can be observed in 
Figures 6.9 and 6.10. 
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Figure 6.9. Grand average waveforms for the three groups across electrode PO3 on the high association condition of the semantic association 
task. 
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Fig. 6.9: Depicts the grand average waveform for each user group (ecstasy users in blue, polydrug users in green and drug naïve controls in black) at PO3 for the high 
association condition. Significant differences in mean amplitude in the N2component (120-200ms) between polydrug users and drug naïve controls can be observed. 
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Figure 6.10. Grand average waveforms for the three groups across electrodes O2 and PO8 on the low association condition of the semantic 
association task. 
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Fig. 6.10: Depicts the grand average waveforms for each user group (ecstasy users in blue, polydrug users in green and drug naïve controls in black) for O2 and PO8 during 
the low association condition of the task.. Significant differences in mean amplitude, in the N2component (120-190ms), between ecstasy users and drug naïve controls can be 
observed at both electrodes.   
 
 
 
 
 
 
170 
 
Regression analyses were conducted on the three electrodes showing significant 
differences, to observe whether level use of ecstasy (after controlling for cannabis use) was a 
predictor of amplitude at the electrodes PO3 (high association), O2 (low association) and 
PO8 (low association). In the first regression, amplitude at PO3 (high association) was 
entered as the dependent variable; in the first step indices of cannabis use were entered as 
predictors (frequency of use, total lifetime dose, amount smoked in the last 30 days) and in 
the second step, the same indices of ecstasy use were entered as predictors. The overall 
regression model accounted for a significant 24.9% (R² = 0.25, R² adjusted = 0.16, 
F(6,52)=2.88, p<0.05) of the variance in PO3 amplitude. Cannabis use indices (step 1) did 
not predict a significant amount of the variance in PO3 amplitude, although this was 
approaching significance (R² = 0.12, R² adjusted = 0.08, F(3,55)=2.59, p=0.06); lifetime dose 
of cannabis significantly predicted PO3 amplitude (β=-1.13, p<0.01) (higher dose associated 
with more negative amplitude), however frequency of use (β=0.24, p<0.05) and amount 
smoked in the last 30 days (β=0.29, p>0.05) did not. The ecstasy use indices (step 2) 
predicted a significant amount of variance in PO3 amplitude, after controlling for cannabis 
use indices (R ²change=0.13, F-change (3,52)=2.90, p<.05). Specifically total lifetime dose 
predicted PO3 amplitude (β=0.56, p<0.01) (higher dose associated with higher amplitude). 
However frequency of use (β=0.11, p>0.05) and last 30 day use (β=0.22, p>0.05) did not 
significantly predict PO3 amplitude. 
 For the second regression amplitude at O2 (low association) was entered as the 
dependent variable. This overall regression model accounted for a significant 21.9% of the 
variance in O2 amplitude (R² = 0.22, R² adjusted = 0.13, F(6,52)=2.43, p<0.05). Cannabis use 
indices (step 1) did not predict a significant amount of the variance in O2 amplitude, although 
this was approaching significance (R² = 0.12, R² adjusted = 0.07, F(3,55)=2.42, p=0.08); 
lifetime dose of cannabis significantly predicted O2 amplitude (β=-0.91, p<0.01), with 
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greater use associated with greater negativity, however frequency of use (β=-0.01, p>0.05) 
and amount smoked in the last 30 days (β=0.08, p>0.05) did not. The ecstasy use indices 
(step 2) predicted variance in O2 amplitude that was approaching significance, after 
controlling for cannabis use indices (R ²change=0.10, F-change (3,52)=2.28, p=.09). Total 
lifetime dose predicted O2 amplitude (β=0.51, p<0.05) with greater use associated with 
higher amplitude. However frequency of use (β=-0.13, p>0.05) and last 30 day use (β=0.28, 
p>0.05) did not significantly predict PO3 amplitude. 
PO8 was entered as the dependent variable in the third regression. This regression 
model accounted for a non-significant 6% of the variance in PO8 amplitude (R² = 0.06, R² 
adjusted = -0.05, F(6,52)=0.58, p>0.05). Cannabis use indices (step 1) did not predict a 
significant amount of the variance in PO8 amplitude (R² = 0.05, R² adjusted = -0.00, 
F(3,55)=0.98, p>.05); none of the individual cannabis use variables significantly predicted 
PO8 amplitude; frequency of use (β=-0.03, p>0.05), lifetime dose of cannabis (β=-0.30, 
p>0.05), and amount smoked in the last 30 days (β=-0.08, p>0.05). The ecstasy use indices 
(step 2) did not predict a significant amount of variance in PO8 amplitude, after controlling 
for cannabis use indices (R ²change=0.01, F-change (3,52)=0.23, p>.05). None of the 
individual ecstasy use variables significantly predicted PO8 amplitude; frequency of use (β=-
0.05, p>0.05) total lifetime dose (β=-0.19, p>0.05) and last 30 day use (β=0.05, p>0.05). 
A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (FZ, FCZ, FC1, FC2, CZ, C1 and 
C2) was conducted on the mean amplitudes across the epochs measured (170-230ms in both 
conditions) for the P2 component. This revealed, no main effect of difficulty F(1,56)=0.32, 
p>.05, no difficulty by group interaction F(2,56)=0.35, p>.05, no main effect of site F(4.21, 
236.03)=5.22, p>.05, no site by group interaction F(8.43, 236.03)=0.26, p>.05, no difficulty 
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by site interaction F(4.85, 271.44)=0.51, p>.05 and no difficulty by site by group interaction 
F(9.69, 271.44)=0.48, p>.05. Between group differences were also non-significant 
F(2,56)=1.68, p>.05.  
Updating: Mean amplitudes for each condition, ERP component and electrode are 
given in Tables 6.9, 6.10, and 6.11. Due to some unusable EEG data, one participant from the 
drug naïve group (n=19), one participant from the ecstasy users group (n=19) and two 
participants from the polydrug group (n=18) have their data excluded from statistical analysis. 
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Table 6.9: Mean amplitudes (µvolts) at each electrode measured for the P3 component (n- 
back task) 
 Ecstasy users Polydrug controls Drug naïve controls 
N = 0 electrode:    
P5 1.83 (2.23) 1.36 (3.11) 1.54 (1.89) 
P7 0.16 (3.17) -0.00 (4.17) 0.66 (2.60) 
PO7 1.88 (3.18) 2.29 (3.23) 2.35 (3.15) 
PO3 2.30 (2.50) 2.18 (2.16) 3.69 (3.06) 
O1 0.85 (3.04) 0.51 (2.41) 1.30 (4.24) 
Oz -0.00 (2.25) -0.17 (3.07) 0.71 (4.68) 
POz 1.98 (3.14) 2.06 (1.84) 3.04 (3.43) 
P6 2.74 (1.84) 3.10 (2.96) 2.60 (2.06) 
P8 2.02 (3.25) 2.43 (4.10) 1.71 (1.97) 
PO8 3.07 (2.66) 3.83 (4.11) 2.30 (4.08) 
PO4 3.10 (2.85) 3.53 (2.51) 3.22 (3.17) 
O2 1.23 (3.51) 1.52 (3.15) 1.26 (4.47) 
    
N = 2 electrode:    
P5 1.78 (2.47) 0.62 (3.13) 1.49 (2.69) 
P7 0.42 (3.22) -0.54 (3.26) 0.05 (2.80) 
PO7 2.09 (3.96) 0.62 (3.05) 1.71 (3.08) 
PO3 2.82 (2.76) 2.23 (2.31) 3.21 (3.30) 
O1 1.27 (4.19) -0.20 (3.10) 1.19 (4.20) 
Oz 0.06 (2.22) 0.86 (2.04) 0.81 (4.06) 
POz 2.03 (2.31) 2.34 (1.55) 3.82 (3.81) 
P6 2.70 (2.24) 2.97 (2.04) 2.53 (1.52) 
P8 2.05 (2.76) 2.54 (3.38) 1.98 (1.62) 
PO8 3.73 (3.24) 3.91 (3.63) 3.36 (2.94) 
PO4 2.93 (2.54) 3.61 (2.00) 3.71 (3.08) 
O2 1.33 (3.26) 2.29 (3.06) 1.66 (4.32) 
    
N = 4 electrode:    
P5 2.64 (3.03) 1.28 (2.80) 1.92 (2.68) 
P7 1.01 (3.93) 0.05 (2.76) 0.62 (3.06) 
PO7 3.17 (4.37) 1.97 (2.82) 2.08 (3.32) 
PO3 4.10 (3.11) 2.94 (2.39) 3.54 (2.67) 
O1 2.45 (4.03) 1.43 (3.13) 1.69 (5.04) 
Oz 1.05 (3.70) 1.18 (3.45) 0.51 (4.44) 
POz 3.28 (3.88) 2.20 (2.18) 4.53 (3.87) 
P6 2.05 (2.80) 3.43 (2.05) 2.95 (2.29) 
P8 2.08 (3.68) 3.05 (3.73) 2.00 (2.72) 
PO8 3.83 (3.21) 4.77 (4.09) 3.00 (2.92) 
PO4 4.22 (3.52) 3.88 (2.74) 3.95 (2.84) 
O2 1.64 (4.00) 2.52 (3.34) 2.25 (4.58) 
    
 
 
 
 
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Table 6.10: Mean amplitudes (µvolts) for each electrode measured for the N2 component. 
   Ecstasy users  Polydrug controls Drug naïve controls 
      
N = 0 electrode:      
P6 -0.90 (1.89) -0.47 (20.6) 0.04 (1.45) 
P8 -1.78 (2.68) -0.98 (2.38) -0.43 (2.40) 
PO8 -2.45 (3.55) -1.45 (3.23) -0.95 (3.47) 
       
N=2 electrode:       
P6 -0.48 (1.77) -0.41 (1.78) -0.03 (1.45) 
P8 -1.17 (3.05) -1.37 (2.82) -0.99 (2.40) 
PO8 -1.65 (3.41) -1.87 (3.63) -0.76 (3.37) 
       
N=4 electrode:       
P6 -1.41 (2.17) 0.07 (2.42) 0.29 (1.57) 
P8 -1.67 (3.61) -0.86 (3.03) -0.62 (2.51) 
PO8 -1.73 (4.40) -1.15 (4.10) -0.88 (2.80) 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Table 6.11: Mean amplitudes (µvolts) for each electrode measured for the P2 component. 
 Ecstasy users Polydrug controls Drug naïve controls 
N = 0 electrode:       
F1 1.49 (1.76) 0.69 (2.46)  0.60 (1.32)  
F3 0.34 (1.68) 0.05 (2.32)  0.38 (1.57)  
FC1 2.05 (1.58) 1.19 (2.24)  1.37 (1.87)  
Fz 1.51 (1.65) 1.15 (2.51)  0.85 (2.22)  
F2 1.61 (2.07)  1.07 (3.01)  0.42 (2.69)  
F4 1.54 (1.96)  1.42 (2.47)  1.38 (2.69)  
FC2 2.74 (1.87)  1.76 (3.30)  1.22 (2.00)  
FCz 3.02 (1.51)  1.84 (2.84)  1.72 (2.48)  
C2 2.72 (1.67)  1.58 (2.10)  0.67 (2.11)  
       
N = 2 electrode:        
F1 1.27 (2.37)  1.06 (2.40)  0.94 (1.68)  
F3 0.31 (1.81)  0.15 (2.40)  0.12 (1.82)  
FC1 1.46 (1.79)  0.99 (2.19)  1.26 (1.65)  
Fz 1.59 (3.15)  1.56 (2.29)  0.71 (1.29)  
F2 1.15 (3.42)  1.06 (1.24)  -0.09 (1.87)  
F4 1.42 (2.38)  1.73 (2.29)  0.22 (1.80)  
FC2 2.13 (2.52)  1.52 (2.30)  1.51 (1.96)  
FCz 2.03 (3.99)  2.07 (2.24)  1.23 (2.00)  
C2 1.62 (2.62)  1.27 (2.65)  0.35 (2.11)  
       
N = 4 electrode:        
F1 1.21 (1.60)  0.58 (1.89)  0.32 (2.03)  
F3 0.74 (2.12)  0.12 (2.88)  0.30 (1.73)  
FC1 1.95 (1.75)  1.18 (2.21)  1.12 (2.07)  
Fz 1.71 (2.66)  0.90 (2.29)  1.30 (2.02)  
F2 0.77 (4.64)  0.56 (3.14)  0.16 (2.14)  
F4 1.01 (3.01)  0.96 (2.56)  0.50 (2.27)  
FC2 1.59 (4.38)  1.19 (2.47)  1.33 (2.43)  
FCz 3.57 (2.08)  1.47 (2.62)  1.71 (1.92)  
C2 2.12 (2.52)  1.68 (3.30)  0.74 (1.60)  
 
                 
For the P3 component, a mixed ANOVA, with between subjects factor of group and 
within subjects factors of difficulty (n=0, n=2 and n=4) and site (P5, P7, PO7, PO3, O1, Oz, 
POz, P6, P8, PO8, PO4 and O2) revealed mixed ANOVA revealed there was a significant 
main effect of difficulty indicating that mean amplitudes differed according to condition 
F(2,52)=7.79, p<.01. Inspection of Table 6.9 reveals that this was because amplitude 
increases in line with difficulty. There was also a significant main effect of electrode F(4.48, 
237.40)=16.77, p<.01. The difficulty by user group, electrode by user group, difficulty by 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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electrode and difficulty by electrode by user group interactions were all non-significant 
(p>.05 in all cases). There was no significant effect of user group F(2,53)=0.03, p>.05. 
Therefore this component will not be discussed further. 
               A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty and site (P6, P9 and PO8) on the N2 component revealed a main effect of 
electrode F(2,52)=5.58, p<.01. The effects of difficulty and the difficulty by user group, 
electrode by user group, difficulty by electrode and difficulty by electrode by user group 
interactions were all non-significant p>.05 in all cases. There was no effect of user group 
F(2,53)=1.02, p>.05. Therefore this component will not be discussed further. 
For the P2 component, a mixed ANOVA, with between subjects factor of group and 
within subjects factors of difficulty and site (F1, F3, FC1, Fz, F2, F4, FC2, FCz and C2) 
showed the effects of difficulty were non-significant F(2,52)=0.94, p>.05 as was the 
difficulty by user group interaction F(4,106)=0.39, p>.05. There was however, a main effect 
of electrode F(5.32,282.18)=8.92, p<.01. The electrode by user group, difficulty by electrode 
and difficulty by electrode by user group interactions were all non-significant, p>.05 in all 
cases. Finally, there was no significant effect of group F(2,53)=1.65, p>.05. As such this 
component is not discussed further. 
Implications of Chapter 6 
The ERP results from Chapter 6 support the view that ecstasy/polydrug use does alter 
cognitive processes involved in the executive functions of inhibitory control, switching and 
access. Furthermore these findings are independent of gender, age, fluid intelligence, daytime 
sleepiness, morningness-eveningness types, weekly alcohol intake and state levels of arousal, 
anxiety and depression. Differences between ecstasy users and both control groups in the P2 
component during the Go/NoGo task reflect atypical early processing in ecstasy users (the 
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implications of which will be discussed in more detail in Chapter 10). Moreover recency of 
use may play a role in inhibition, given that amount of ecstasy used in the last 30 days was a 
significant predictor of FCz amplitude after controlling for cannabis use indices.  
Furthermore a diminished P3 response to switching was observed in ecstasy users and 
polydrug controls relative to drug naïve controls at several parieto-occipital and occipital 
electrode sites. The regression analysis on electrode O1 for the P3 component suggested that 
lifetime cannabis use significantly predicted the diminished P3 amplitude in the first step. 
Although lifetime ecstasy use was a significant predictor of P3 amplitude after controlling for 
cannabis use, this appeared to predict amplitude in the opposite direction. This task also 
yielded ecstasy specific alterations in the P2 component at fronto-central sites, perhaps again 
reflecting alterations to early processing suggestive of compensatory mechanisms; lifetime 
dose of ecstasy approached significance for predicting amplitude at FCz in this component.  
The N2 component during the low association (more difficult) level of the semantic 
association task showed ecstasy-related differences in comparison to controls at occipital and 
parieto-occipital sites (O2 and PO8). Ecstasy users were not significantly different from 
polydrug controls so the results need treating with caution. There were no differences in P3 
amplitude between groups in the semantic association task. These results potentially reflect 
evidence of cognitive reallocation, or compensatory mechanisms in ecstasy/polydrug users to 
ameliorate behavioural differences, given that there were no between group differences on 
behavioural performance on these three tasks. Unexpectedly, no between group differences 
were observed in performance (errors) on the n-back task. However there were reaction time 
differences indicating that drug naïve controls were significantly slower to respond than 
polydrug users on the n-back task. Drug naïve controls were also slower than ecstasy users 
for reaction times on the n-back task (although non-significant). Moreover, inspection of 
table 6.5 shows that although non-significant, drug naïve participants made fewer errors on 
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the task than ecstasy users. This data tentatively suggests an accuracy/speed trade off as a 
function of increased impulsivity in ecstasy users, although these differences are non-
significant. Furthermore polydrug controls show the lowest error rates as well as fastest 
reaction time. There were no between group differences in the ERP components during the 
updating task, this was contrary to expectations and potential reasons for this will be 
discussed in Chapter 10. Due to this function showing more consistent deficits in ecstasy 
users in the literature, it will be explored further in Chapter 7, using alternative tasks and 
neuroimaging measures. 
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Chapter 7: fNIRS and Updating 
7.1 Chapter Overview 
Chapter 6 showed electrophysiological differences in the executive functions of inhibitory 
control, switching and access. However no such difference was observed with regards to the 
EEG data from memory updating. This chapter aims to further explore the nature of this 
executive function in relation to ecstasy use. In this chapter the updating function of the 
central executive has been assessed behaviourally using letter updating and spatial updating 
tasks. Furthermore the haemodynamic response to task has been assessed using fNIRS.  
Twenty ecstasy users, 20 polydrug controls and 20 drug naïve controls were recruited for this 
study. Behavioural performance on the letter updating task and the spatial updating task was 
equivalent between the 3 groups. However analysis of fNIRS data showed MDMA related 
alterations to haemodynamic response that may reflect compensatory functioning. 
7.2 Introduction 
The Updating component of working memory as previously discussed has been 
shown to be degraded in ecstasy users. Results from Chapter 6 do not reflect ecstasy-related 
deficits in this function in the sample studied. However the n-back task has been employed in 
the ecstasy literature previously and yielded few observable deficits between users and non-
users (Gouzoulis-Mayfrank et al., 2003; Daumann, Fimm et al., 2003). Nevertheless studies 
employing this task with haemodynamic neurophysiological measures have observed 
haemodynamic correlates that reflect subtle cognitive alterations (Daumann, Fimm et al., 
2003: Daumann, Schnitker et al., 2003). Perhaps electrophysiological differences were 
undetectable in the last chapter due to the variability in response times from the time-locked 
probe, due to the difficulty of the task. The n-back task that was employed would have 
required more protracted mental calculations than the tasks assessing the other executive 
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functions, and as such may have produced a large amount of noise for the time locked ERPs.  
Haemodynamic response to stimuli is not instantaneous. It is understood that the 
haemodynamic response occurs over a 10-12 second epoch (Izzetoglu et al., 2005; Miezin et 
al., 2000). As such, activity over a block of trials may be a better way to measure neuronal 
response. Given that the updating task requires continuous monitoring of information, 
perhaps measurements of neuronal activity over the entire updating process will provide a 
greater understanding of how ecstasy affects this process. 
fNIRS is an emerging non-invasive neuroimaging tool that measures cerebral blood 
flow. Due to cerebral blood flow and neuronal activation being closely linked (Villringer & 
Dirnagl, 1995), fNIRS can be used to assess the haemodynamic response to mental demand. 
More specifically fNIRS uses wavelengths of light in the near infrared range to assess levels 
of oxygenated and deoxygenated haemoglobin in the prefrontal cortex (PFC). Areas of the 
PFC are easily accessed by this type of neuroimaging due to it having a penetration depth of 
2-3mm (Firbank et al., 1998). As such fNIRS is ideal for observing neurological activation 
during tasks that load on the (DL)PFC such as executive functioning tasks. Increases in the 
chromophore oxy-Hb are accepted as reflecting an increase in neuronal activity in certain 
brain regions (Leff et al., 2011). Furthermore it is hypothesised that although blood 
oxygenation is expected to increase with increased workload, this is only if the participant is 
engaged in the task, whereas if the task becomes too difficult and attention shifts (as well as 
performance decline), a decrease in oxygenation will be observed (Izzetoglu et al., 2004). 
The distribution of the activation response is regionally specific i.e. the cortical regions 
underlying the voxels at which the activation is observed are responsible for the activation 
(Leff et al., 2011). Often an increase in oxygenated haemoglobin is coupled with a decrease 
in deoxygenated haemoglobin (Ehlis et al., 2008; Leff et al., 2008; Leff et al., 2011).  
However, increases in oxy-Hb have also been observed to be coupled with increases in 
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deoxy-Hb (Hoshi & Tamura, 1993; Sakatani et al., 1999). The relationship between 
oxygenated and deoxygenated haemoglobin is non-linear and estimates of total haemoglobin 
are sometimes calculated as a correlate of neuronal activation (Ayaz et al., 2012). Total 
haemoglobin is obtained from summating oxygenated and deoxygenated haemoglobin. As 
such increases in deoxy-Hb may reflect increased neuronal activity. However oxy-Hb is 
generally accepted as the best indicator of neuronal activity. 
Although there is currently a paucity of empirical research on substance users with 
this type of technology, there have been studies investigating cognitive impairments 
associated with neurological disease and psychiatric disorders (Ehlis et al., 2008; Falgatter et 
al., 1997; Hermann et al., 2008). Generally, participants with neurological disease such as 
Alzheimer’s are reported as performing worse on cognitive tasks than healthy controls (Ehlis 
et al., 2008; Herrmann et al., 2008), and this is usually coupled with a decrease in oxy-Hb. 
This technology has also been used as a measure of mental workload in human operators 
(Ayaz et al., 2012) to improve efficiency of human-machine systems in critical tasks. 
Although human operators may have similar performance output, fNIRS was incorporated as 
an additional measure of mental workload, given that increased effort (indexed by increased 
oxy-Hb) is predictive of future failure. As such operator efficiency could be predicted from 
their haemodynamic response to demanding tasks.  
 As well as integrating haemodynamic measures to assess this function in ecstasy 
using populations. It may be useful to explore this function in greater depth using tasks that 
are shown in the literature to reliably produce effects in ecstasy users. The letter updating task 
and the spatial updating task have both yielded behavioural deficits in ecstasy users 
previously (Montgomery & Fisk, 2008; Montgomery, Fisk, Newcombe & Murphy, 2005).  
Montgomery, Fisk, Newcombe and Murphy (2005) observed performance deficits in ecstasy 
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users compared to non-users on the letter updating task. The nature of this deficit was 
explored further by Montgomery and Fisk (2008), in which, the analyses explored whether 
the ecstasy/polydrug deficit is more pronounced at specific serial positions, or whether length 
of sequence was a critical factor in performance. In this study, analyses were also varied for 
letter span and spatial span. Deficits in ecstasy users were observed for letter updating, in 
participants with simple spans of 5 and 6 compared to controls, and deficits in spatial 
updating were observed in ecstasy users with a simple span of 5. This study also suggested 
that ecstasy users may display deficits in early serial position recall, with those with spatial 
spans of 4 and 5, and those with letter spans of 6 showing impairment of recall of stimuli at 
early serial positions. The authors suggest that ecstasy use may lead to greater susceptibility 
to chunk destruction during the updating process as an explanation of why early serial 
positions show impairments. Furthermore correlational analysis revealed that indices of 
ecstasy use such as total lifetime dose and average weekly dose had a significant negative 
correlation with letter updating and spatial updating performance. The correlations suggest 
that greater use of ecstasy is associated with poorer updating performance. Moreover indices 
of cannabis and cocaine use were not significantly correlated with letter or spatial updating 
performance.  
The aim of this study is to fully elucidate the effects of ecstasy on the haemodynamic 
response to memory updating by using fNIRS in combination with spatial updating and 
consonant updating tasks. It is predicted that ecstasy users will show performance deficits in 
the updating tasks as well as alterations to their haemodynamic response relative to polydrug 
controls and drug naïve controls. However if performance is equivalent, it is predicted that 
ecstasy users will display evidence of more effortful cognition from their haemodynamic 
response (increases in oxy-Hb). 
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7.3 Method 
Design: 
For analysis of behavioural data and fNIRS data a between groups design was used.  
The between groups factor was drug user group which consisted of three levels (ecstasy users, 
polydrug controls and drug naïve controls). Univariate ANOVA was performed on the 
behavioural data for both letter updating and spatial updating, with composite scores on each 
task as the dependent variables. The fNIRS data was analysed with univariate ANOVAs 
using mean oxy and deoxy-Hb changes from baseline as the dependent variables (voxels 1-
16). Any significant main effects were further investigated using Tukey’s HSD. 
Participants: 
Twenty ecstasy users (mean age = 21.76, SD = 3.19, 11 = male), 20 polydrug controls 
(mean age = 19.75, SD = 1.48, 11 = male) and 20 drug naïve controls (mean age = 19.68, SD 
= 1.89, 9 = male) were recruited via direct approach (e-mail) to Liverpool John Moores 
University students. Inclusion and exclusion criteria were the same as that in Chapter 6. 
Indices of ecstasy use were as follows: total lifetime dose 1305.31 tablets ± 4951.61; mean 
amount used in last 30 days 3.80 tablets ± 4.63, and frequency of use 0.39 times/week ± 0.48. 
Materials 
Questionnaires 
 The Background Drug Use Questionnaire, sleep quality questionnaire, The ESS, The 
MEQ, KSS, UMACL, NASA-TLX and Raven’s SPM were used, as described in Chapter 6. 
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Updating Tasks 
The letter and spatial updating tasks were carried out as per Montgomery and Fisk 
(2008), whereby each participant’s letter and spatial span were first calculated prior to 
conducting the updating tasks. 
 
Letter span: Consonants appeared on a computer monitor sequentially and remained 
on screen for 1.25s each. Following presentation of a sequence of letters, participants were 
required to recall the order in which the letters appeared. To begin with three sets of two 
letters were presented, progressing to three sets of three letters, then three sets of four letters 
and so on up until three sets of seven letters. Participants’ span is noted as the largest string of 
letters they can recall accurately on at least two of the three trials. 
 
Spatial span: Analogous to the letter span task, participants had to recall the positions 
of highlighted blocks in a Corsi block type arrangement in the order that they were presented. 
Highlighted blocks appeared on screen for 1.25s each. 
 
Letter updating: Based on running span memory task (Morris & Jones, 1990) 
consonants appear on the computer screen in random sequences dependent upon the 
participants calculated letter span. Twenty-four sequences were presented and in each trial 
participants were unaware of the number of letters that would appear in the sequence (length 
of list). Participants were required to recall the most recent n consonants in the order in which 
they appeared (where n is the participants calculated letter span). There were four sequence 
lengths; n, n + 2, n + 4 and n + 6 and six trials of each length were presented in randomised 
order. 
 
 
 
 
 
185 
 
Spatial updating: This computer based task was again analogous to the letter updating 
task. Spatial locations were highlighted on a Corsi block type arrangement, in random 
sequences. Twenty-four trials were presented and again participants were unaware of the 
length of the sequence being presented each time, with the exception of six trials, in which 
participants were told how many spatial locations were going to be presented (in each case it 
was always the participant’s span that was the list length for the known length trials).  
Furthermore participants were required to recall the last n (where n is the participant’s spatial 
span) positions in the order that they were presented. There were six trials at each list length; 
known n, unknown n, n + 2, n + 4 and n + 6 and the order in which these appeared was 
randomised. 
Equipment 
Haemodynamic response to task in the PFC was monitored using a continuous wave 
fNIRS system developed by Drexel University (Philadelphia, PA) and supplied by Biopac 
systems (Goleta, CA, USA). The fNIR sensor has a temporal resolution of 500ms per scan 
(2Hz), with a source-detector separation of 2.5cm allowing 1.25cm penetration depth (Ayaz 
et al., 2012). An fNIR100 control box and data acquisition and visualisation software COBI 
studio (Drexel university) were used during data collection (as per Ayaz et al., 2011; Ayaz et 
al., 2012) with a serial cable between display and acquisition PCs to identify task markers.  
Procedure 
Participants were required to attend the lab for a one off session lasting approximately 
2.5 hours. Testing sessions commenced at 9am, 11.30am and 2pm, equal numbers of each 
group were tested at each time. Upon entering the lab participants were given an information 
sheet explaining what was involved in the study and written consent of their participation was 
obtained. Following this, participants completed a battery of questionnaires in the following 
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order; Background drug use questionnaire, sleep quality questionnaire, MEQ, ESS, pre-test 
KSS, UMACL and Raven’s SPM. Participants then completed the letter span task and the 
spatial span task, the order in which these were given was randomised. The fNIRS headband 
was then fitted to the participant’s forehead. The fNIRS signals were displayed on a desktop 
computer running COBI studio (Drexel University) in an adjacent room to the testing room. 
Providing the signals from the fNIRS were stable, a baseline of inactivity was recorded – this 
involved participants watching a video of planet earth accompanied by soothing music.  
Following this the letter updating and spatial updating tasks were completed (a baseline was 
taken prior to each task). After completing the tasks participants completed the post task KSS 
and post task NASA TLX (one for each task). Finally participants were fully debriefed and 
were paid £20 in store vouchers. The study was approved by Liverpool John Moores 
University Research Ethics Committee, and was administered in accordance with the ethical 
guidelines of the British Psychological Society. 
fNIRS Analysis 
fNIRS raw data from COBI studio was pre-processed using fnirSoft (Biopac systems; 
Goleta, CA, USA). All 16 voxels (oxy and deoxy-Hb) were visually inspected for light 
saturation. Saturated channels were discarded. A high-pass filter (0.1Hz cut off) and a linear 
phase filter (order of 20) were used to remove high frequency noise and noise due to 
respiration (Ayaz et al., 2011; Ayaz et al., 2012). Using the modified Beer-Lambert law 
logarithm in fnirSoft (Ayaz et al., 2010), total oxy-Hb and deoxy-Hb changes relative to 
baseline over the entire epoch were calculated for the 16 voxels.   
Statistical analysis 
Behavioural data were analysed using ANOVA, with drug user group as the between 
subjects factor and individual task performance score (A composite overall performance 
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score for each updating task, which was calculated by adding the score on each level of the 
task e.g. n, n + 2, n + 4 and n + 6 in the case of letter updating, and dividing by the number of 
levels to give a mean score) on each of the updating tasks as the dependent variables. For 
analysis of fNIRS data, mean oxygenated and deoxygenated haemoglobin change from 
baseline over the entire epoch of each task, at each voxel was calculated. fNIRS data were 
analysed using ANOVA
2
 with drug user group as the between subjects factor and mean oxy 
and deoxy-Hb change from baseline at each voxel as the dependent variables. Any significant 
main effects were further explored using post-hoc Tukey’s HSD test.  
 
7.4 Results 
Socio-demographic information about the participants, sleep measures and scores of 
anxiety, depression and arousal from the UMACL are shown in Table 7.1. Indices of other 
drug and alcohol use are displayed in Table 7.2. 
 
 
 
 
 
 
 
 
                                                          
2
 Due to small amounts of missing data on different voxels, MANOVA was not appropriate for this analysis.  
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Table 7.1 – Indices sleep quality, fluid intelligence and socio-demographic variables 
 Ecstasy users 
 
 Polydrug controls  Drug naïve controls  
Males:  n, % 11 (55)  11 (55)  9 (45)  
Age (SD) 
 
21.76 (3.19)*†  19.75 (1.48)  19.78 (1.90)  
University degree: 
n (%) 
3 (15)  2 (10)  1 (5)  
       
Employment status       
Student;  n, (%) 19 (95)  20 (100)  20 (100)  
Employed; n (%) 1 (5)  0 (0)  0 (0)  
Unemployed; n (%) 0 (0)  0 (0)  0 (0)  
       
 Mean (SD)    Mean (SD)              Mean (SD)  
       
Ravens Progressive 
Matrices 
(maximum 60) 
47.88 (5.04)  46.90 (6.61)  49.72 (4.70)  
       
Sleep – Hours/night 
 
7.65 (1.51)  8.18 (1.55)  8.39 (1.23)  
ESS Score 
(maximum 24) 
 
7.18 (3.13)  6.15 (3.63)  6.17 (3.13)  
KSS before 5.31 (1.49)†  5.20 (1.47)  4.15 (1.35)  
       
KSS after 6.00 (1.37)  4.79 (1.99)  4.74 (1.88)  
       
MEQ total 40.29 (9.35)  40.70 (9.11)  44.44 (9.67)  
       
UMACL anxiety 7.95 (2.63)  8.10 (1.77)  7.85 (2.39)  
       
UMACL 
depression  
 
9.35 (2.08)  9.26 (1.85)  8.35 (2.41) 
 
 
 
 
UMACL arousal 16.6 (3.45)†  16.5 (2.96)†  19.35 (3.38) 
 
 
      
      
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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 Table 7.2 – Indices of other drug and alcohol use. 
 Ecstasy users  Polydrug controls  Drug naive controls  
 Mean (SD) n Mean (SD) n Mean (SD) n 
Cannabis       
Frequency 
(times/wk) 
2.28 (2.86) 16 2.05 (2.43) 19 - - 
Last 30 days 
(joints) 
33.81 (57.61) 16 24.76 (40.27) 17 - - 
Total use 
(joints) 
4183.42 (6353.33) 16 1137.27 (2516.24) 19 2 (0) 1 
       
Cocaine       
Frequency 
(times/wk) 
0.32 (0.47) 12 0.25 (0.21) 5 - - 
Last 30 days 
(lines) 
9.38 (26.30) 13 2.75 (3.20) 4 - - 
Total use 
(lines) 
964.63 (2876.88) 14 42.9 (67.17) 10 - - 
       
Ketamine       
Frequency 
(times/wk) 
0.39 (0.79) 6 0.08 (0.05) 2 - - 
Last 30 days 
use (grams) 
1.2 (2.68) 5 0.10 (0.14) 2 - - 
Total use 
(grams) 
118.73 (249.71) 9 0.44 (0.47) 5 - - 
Alcohol units 
p/w 
 
23.05 (28.00)† 20 14.82 (13.15) 20 8.33 (6.15) 20 
 
 
One way ANOVA revealed no significant between group differences on several 
background variables including; average hours slept per night, total score on the ESS, total 
score on the MEQ, levels of anxiety, depression and arousal and total score on Raven’s 
SPM. However there were between group differences in age F(2,53)=4.89, p<0.05, KSS 
before F(2,56)=3.94, p<0.05, and arousal  F(2,57)=4.85, p<0.05 and a between group 
difference approaching significance in post task KSS F(2,52)=2.84, p=0.07. Post-hoc t-tests 
revealed that the ecstasy user group was significantly older than both other groups (p<.05 in 
both cases). Ecstasy users were significantly more sleepy prior to testing than drug naïve 
controls (p<.05) but not polydrug users, and drug naïve controls had significantly higher 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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levels of arousal in comparison to both drug user groups (p<.05) in both cases. The post-hoc 
t-tests on the post task KSS were not significant (p>.05).  
t-tests on indices of drug use aside from ecstasy between the ecstasy user group and 
polydrug controls revealed that ecstasy users had smoked a greater mean lifetime amount of 
joints compared to polydrug controls (4183.42±6353.33 compared to 1137.27±2516.24) and 
this difference was approaching significance t(18.95)=1.80, p=.09 (Levene’s test was 
significant so degrees of freedom have been adjusted accordingly). However there were no 
significant between group differences in frequency of cannabis, cocaine or ketamine use, nor 
were there significant between group differences in lifetime total doses for cocaine or 
ketamine, or last 30 day totals for cannabis, cocaine or ketamine. Nevertheless, as can be 
observed in Table 7.2, the ecstasy user group can be described as polydrug users. 
A one way ANOVA on average weekly alcohol consumption revealed a significant 
between group difference F(2,57)=3.29, p<0.05. Multiple comparisons revealed that the 
ecstasy users consumed significantly more alcohol than drug naïve controls on a weekly basis 
(p<.05), there were no significant differences between ecstasy users and polydrug controls, or 
polydrug controls and drug naïve controls in weekly alcohol consumption.  
Behavioural data analysis 
Performance on the updating tasks was compared using overall performance scores on 
each task. For letter updating there were four levels of difficulty depending on the length of 
the sequence presented; the easiest being n (where n is the participants letter span and only n 
amount of letters are presented in the sequence) followed by n + 2 (list length is two letters 
greater than participants span), then n + 4 (list length is four letters greater than participants 
span), and finally n + 6 (list length is six letters greater than participants span). In each case, 
participants had to recall the last n amount of letters in the sequence, in order. Points were 
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awarded for a correctly identified letter recalled, in the correct position of the sequence. The 
spatial updating task follows the same structure. However there is an extra level of difficulty 
in that it has a known n sequence (where participants have to recall their span (n) amount of 
spatial locations, and they are informed that only n amount of spatial locations will be 
presented) and an unknown n sequence (whereby participants have to recall n amount of 
spatial locations, however they are not informed of the sequence length prior to the trial). 
The overall performance scores were a composite of performance on each level of 
difficulty of the task, relative to the participant’s span, divided by the number of levels of 
difficulty, to give a mean score. For example, if a participant had a span of five on the letter 
updating task, this would yield five responses on each trail. Therefore, for each level of 
difficulty on the task, their total score would be divided by their span (in this case five) to 
give a mean score of performance on each level of difficulty. To attain an overall 
performance score, mean totals from each difficulty level are added together and divided by 
the number of levels of difficulty (4 for letter updating, and 5 for spatial updating).     
Task data is displayed in Tables 7.3 and 7.4. ANOVA revealed no between group 
differences on overall performance of letter updating F(2,56)=1.21, p>.05, or spatial updating 
F(2,56)=1.13, p>.05. Mixed ANOVA with list length as within groups and user group as 
between groups was conducted on letter and spatial span separately. As there were no 
significant differences aside from a within groups effect of length, for brevity, a total 
composite score is reported here.  
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Table 7.3: Means and SDs of performance on the letter updating task. 
        Ecstasy users Polydrug controls Drug naïve controls 
Sequence 
length 
Mean (SD)      Mean (SD)  Mean (SD)  
n 4.97 (0.98)      4.85 (0.78)  5.04 (0.75)  
n + 2 3.68 (0.96)   3.76 (1.22)  4.34 (1.02)  
n + 4 3.50 (1.10)   3.68 (0.94)  3.93 (1.09)  
n + 6 3.53 (1.03)      3.75 (1.23)  3.83 (1.10)  
 
 
Table 7.4: Means and SDs of performance on the spatial updating task. 
    Ecstasy users   Polydrug controls Drug naïve controls 
Sequence 
length 
Mean (SD)  Mean (SD)  Mean (SD)  
Kn n 4.85 (1.32)  5.09 (0.73)  5.01 (0.74)  
Ukn n 4.70 (1.00)  5.00 (0.91)  4.70 (1.06)  
n + 2 3.38 (1.41)  3.44 (0.74)  3.36 (1.32)  
n + 4 3.46 (1.44)  4.03 (0.92)  3.07 (1.42)  
n + 6 3.47 (1.31)  3.90 (0.98)  3.34 (1.52)  
 
 
fNIRS Analysis 
Mean averages of oxy and deoxy Hb changes from baseline for the letter updating 
task are displayed in table 7.5, and oxy and deoxy-Hb changes from baseline for the spatial 
updating task are displayed table 7.6. Due to inappropriate recording of baselines, nine 
participant’s data was excluded from analysis (3 ecstasy users, 5 polydrug controls and 1 
drug naïve control). Furthermore channels 4 and 6 failed to obtain any data throughout this 
experiment, so these channels are omitted from analysis. 
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;            
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Letter Updating: 
Table 7.5: Mean oxy-Hb and deoxy-Hb changes from baseline (µmolar) for letter updating.  
 Ecstasy users Polydrug controls Drug naïve controls 
 Mean (SD) Mean (SD) Mean (SD) 
V1 oxy -0.15 (1.38) -0.39 (0.65) -0.09 (1.28) 
V2 oxy    0.93 (1.72)**    -0.60 (0.98) †  0.67 (1.53) 
V3 oxy -0.03 (1.38) -0.08 (0.39) 0.60 (1.14) 
V4 oxy    
V5 oxy 0.01 (1.29) -0.30 (0.62) 0.15 (1.35) 
V6 oxy    
V7 oxy 0.30 (1.37) -0.55 (1.01) -0.52 (1.44) 
V8 oxy 0.42 (1.56) -0.32 (1.14) 0.15 (1.99) 
V9 oxy 0.26 (2.14) -0.55 (1.10) -0.40 (1.48) 
V10 oxy 0.50 (1.76) -0.23 (1.12) -0.30 (1.95) 
V11 oxy -0.05 (1.33) -0.12 (0.77) -0.25 (1.32) 
V12 oxy    1.13 (2.07)*† -0.12 (0.93) -0.40 (1.22) 
V13 oxy 0.31 (1.46) 0.05 (0.69) 0.49 (0.96) 
V14 oxy    0.94 (1.67)** -0.50 (1.15) 0.09 (1.48) 
V15 oxy 0.31 (0.94)   -0.41 (0.64)† 0.39 (1.32) 
V16 oxy  1.49 (3.27)* -0.19 (0.99) 0.44 (1.60) 
    
V1 deoxy  0.46 (1.79)* -0.81 (0.81) -0.60 (1.30 
V2 deoxy 0.39 (1.58) -0.62 (0.91) -0.11 (1.12) 
V3 deoxy 0.04 (1.18) -0.29 (0.86) 0.10 (1.07) 
V4 deoxy    
V5 deoxy 0.12 (0.97) -0.27 (1.00) -0.42 (1.24) 
V6 deoxy    
V7 deoxy            0.34 (1.26) -0.60 (1.22) -0.75 (1.45) 
V8 deoxy 0.43 (1.37) -0.54 (1.02) -0.61 (1.33) 
V9 deoxy 0.33 (1.76) -0.44 (1.16) -0.64 (1.21) 
V10 deoxy 0.36 (1.27) -0.47 (1.15) -0.71 (1.36) 
V11 deoxy 0.02 (1.14) -0.45 (0.91) -0.48 (1.16) 
V12 deoxy   0.79 (1.88)† -0.27 (0.97) -0.76 (1.18) 
V13 deoxy 0.02 (1.03) -0.51 (0.86) -0.18 (0.98) 
V14 deoxy 0.26 (1.22) -0.49 (0.95) -0.54 (1.04) 
V15 deoxy 0.17 (1.24) -0.82 (0.86) -0.52 (1.30) 
V16 deoxy 1.22 (3.24) -0.42 (1.12) -0.28 (1.29) 
 
  
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Univariate ANOVA on the oxy-Hb data during the letter updating task revealed 
significant between group differences at several voxels; V2 F(2,44)=4.62, p<.05, V12 
F(2,45)=4.80, p<.01 and V14 F(2,47)=4.15, p<.05. Group differences also approached 
significance at V15 F(2,45)=2.90, p=.07 and V16 F(2,47)=2.49, p=.09. There were no 
significant differences at any of the other voxels measured (p>.05). 
Planned comparisons revealed that ecstasy users had significantly increased oxy-Hb 
compared to polydrug controls at V2 (p<.01), drug naïve controls also had significantly 
increased oxy-Hb compared to polydrug controls at V2 (p<.05). Ecstasy users and drug naïve 
controls were not significantly different to one another at this voxel (p>.05). At V12, ecstasy 
users displayed significantly increased oxy-Hb compared to both control groups (p<.05 in 
both cases). Polydrug controls and drug naïve controls did not differ significantly at V12. At 
V14, ecstasy users displayed a significant increase in oxy-Hb relative to polydrug controls 
(p<.01), but the difference between ecstasy users and drug naïve controls was non-significant 
(p>.05), as was the difference between the two control groups (p>.05). At V15, ecstasy users 
displayed increased oxy-Hb compared to polydrug controls that was approaching significance 
(p=.07). However, drug naïve controls showed the greatest increase in oxy-Hb at this voxel, 
and the difference between drug naïve controls and polydrug controls was significant (p<.05). 
Differences between ecstasy users and drug naïve controls were non-significant (p>.05). At 
V16, ecstasy users had significantly increased oxy-Hb compared to polydrug controls (p<.05) 
Differences between drug naïve controls and both other groups were non-significant (p>.05). 
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Due to the groups showing differences in age and pre-test sleepiness and given the 
heavy use of cannabis in the ecstasy user group, multiple regression analyses were conducted 
on Voxel 12, at which ecstasy users showed significant increases in oxy-Hb compared to both 
other groups.  This was conducted to observe whether ecstasy use indices predicted oxy-Hb 
increase after controlling for age, sleepiness and cannabis use. Oxy-Hb level at V12 was 
entered as the dependent variable. In the first step, age and pre-test KSS score were entered as 
predictors. In the second step indices of cannabis use were entered as predictors (frequency of 
use, total lifetime dose, amount smoked in the last 30 days) and in the third step the same 
indices of ecstasy use were entered as predictors. 
The overall regression model accounted for a significant 46.9% (R² = 0.47, R² 
adjusted = 0.34, F(8,34)=3.75, p<0.01) of the variance in oxy-Hb. Age and pre-test sleepiness 
(step 1) did not predict a significant amount of variance in oxy-Hb (R² = 0.05, R² adjusted = 
0.00, F(2,40)=1.01, p>0.05). Cannabis use indices (step 2) did not predict a significant 
amount of variance oxy-Hb after controlling for age and pre-test sleepiness (R ²change=0.05, 
F-change (3,37)=0.63, p>.05). Individual indices - frequency of use (β=-0.71, p>0.05) and 
total lifetime dose (β=-0.02, p>0.05) did not predict oxy-Hb, however amount smoked in the 
last 30 days was a significant predictor (β=-1.00, p<0.05), with increased use being 
associated with reduced oxy-Hb. The ecstasy use indices (step 2) predicted a significant 
amount of variance in oxy-Hb, after controlling for cannabis use indices (R ²change=0.37, F-
change (3,34)=7.99, p<.05). Specifically frequency of use (β=0.97, p<0.05) and last 30 day 
use (β=-0.49, p<0.05), were significant predictors of variance in oxy-Hb. Lifetime dose 
(β=0.14, p>0.05) was not a significant predictor. It would appear that frequency of use is the 
most important predictor here as increased frequency is associated with increased level of 
oxy-Hb.  
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ANOVA on the deoxy-Hb data revealed significant between group differences at 
voxels; V1 F(2,44)=3.79, p<.05, V7 F(2,46)=3.41, p<.05, V8 F(2,44)=3.39, p<.05 and V12 
F(2,45)=5.15, p<.01. Group differences were also approaching significance at V10 
F(2,41)=3.04, p=.06, V14 F(2,47)=2.94, p=.06, V15 F(2,45)=2.97, p=.06 and V16 
F(2,46)=3.01, p=.06. There were no significant differences at any of the other voxels 
measured (p>.05). 
Planned comparisons revealed that ecstasy users displayed a significant increase in 
deoxy-Hb compared to drug naïve controls at voxel 12 (p<.01). At V12 ecstasy users also 
showed increased deoxy-Hb compared to polydrug controls that was approaching 
significance (p=.09). At V7, ecstasy users showed a strong trend for increased deoxy-Hb 
compared to drug naïve controls (p=.05), the difference between ecstasy users and polydrug 
controls was non-significant (p>.05). At V1 ecstasy users showed significantly greater deoxy-
Hb compared to polydrug controls (p<.05), and greater deoxy-Hb compared to drug naïve 
controls that was approaching significance (p=.08). At V8 ecstasy users displayed greater 
deoxy-Hb that was approaching significance to drug naïve controls (p=.06) and polydrug 
controls (p=.09). Ecstasy users displayed greater deoxy-Hb than drug naïve controls that was 
approaching significance at V10 (p=.06) and V14 (p=.09). Finally ecstasy users also 
displayed greater deoxy-Hb compared to polydrug controls that was approaching significance 
at V15 (p=.06) and V16 (p=.08). These were all that the 2 tailed level. 
Regression analyses (using the same steps and predictor variables as earlier) were 
conducted for voxels showing significant ecstasy-related increases in deoxy-Hb - V1 and V12.  
With deoxy-Hb at voxel 1 as the dependent variable the overall regression model 
accounted for a non-significant 13.8% (R² = 0.14, R² adjusted = 0.06, F(8,34)=0.68, p>0.05) 
of the variance in deoxy-Hb. Age and pre-test sleepiness (step 1) did not predict a significant 
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amount of variance in deoxy-Hb (R² = 0.03, R² adjusted = -0.02, F(2,40)=0.51, p>0.05). 
Cannabis use indices (step 2) did not predict a significant amount of variance in V1 deoxy-
Hb after controlling for age and pre-test sleepiness (R ²change=0.02, F-change (3,37)=0.27, 
p>.05). None of the individual cannabis indices were significant predictors; frequency of use 
(β=0.01, p>0.05), total lifetime dose (β=-0.12, p>0.05) and amount smoked in the last 30 
days (β=-0.13, p>0.05). The ecstasy use indices (step 2) did not predict a significant amount 
of variance in V1 deoxygenation, after controlling for cannabis use indices (R ²change=0.09, 
F-change (3,34)=1.22, p>.05). Individual indices; frequency of use (β=0.23, p>0.05), lifetime 
dose (β=-0.19, p>0.05) and last 30 day use (β=0.20, p>0.05) did not significantly predict V1 
deoxygenation. 
With deoxy-Hb at V12 as the DV the overall regression model accounted for a non-
significant 26.8% (R² = 0.27, R² adjusted = 0.10, F(8,34)=1.56, p>0.05) of the variance in 
deoxygenation. Age and pre-test sleepiness (step 1) did not predict a significant amount of 
variance in deoxygenation (R² = 0.02, R² adjusted = -0.03, F(2,40)=0.37, p>0.05). Cannabis 
use indices (step 2) did not predict a significant amount of variance in V12 deoxygenation 
after controlling for age and pre-test sleepiness (R ²change=0.03, F-change (3,37)=0.33, 
p>.05). None of the individual cannabis indices were significant predictors; frequency of use 
(β=0.57, p>0.05), total lifetime dose (β=-0.18, p>0.05) and amount smoked in the last 30 
days (β=-0.76, p>0.05). The ecstasy use indices (step 2) did not predict a significant amount 
of variance in V12 deoxy-Hb, after controlling for cannabis use indices (R ²change=0.22, F-
change (3,34)=3.47, p>.05). Individual indices; lifetime dose (β=-0.21, p>0.05) and last 30 
day use (β=0.12, p>0.05) did not significantly predict V12 deoxygenation. However 
frequency of use (β=0.74, p<0.05) was a significant predictor of V12 deoxygenation with 
increased frequency of use being associated with increased deoxygenation. 
 
 
 
 
198 
 
Spatial Updating: 
Table 7.6: Mean oxy-Hb and deoxy-Hb changes from baseline (µmolar) for spatial updating.  
 Ecstasy users Polydrug controls Drug naïve controls 
 Mean (SD) Mean (SD) Mean (SD) 
V1 oxy   0.91 (1.68)*   -0.81 (1.36)† 0.70 (1.42) 
V2 oxy   1.06 (1.79)*   -0.61 (1.18)† 0.76 (1.15) 
V3 oxy 0.53 (1.33) -0.11 (0.70) 0.74 (1.23) 
V4 oxy    
V5 oxy 0.57 (1.74) -0.11 (0.85) 0.71 (1.86) 
V6 oxy    
V7 oxy 0.39 (1.72) -0.14 (0.85) 0.05 (1.54) 
V8 oxy     1.05 (1.80)*† -0.31 (1.04) -0.06 (1.28) 
V9 oxy 0.08 (1.73) -0.32 (0.75) 0.05 (1.57) 
V10 oxy 0.59 (1.80) -0.42 (0.85) -0.11 (1.41) 
V11 oxy 0.34 (1.65) -0.30 (0.72) 0.54 (1.34) 
V12 oxy   0.64 (1.64)* -0.44 (0.93) 0.06 (1.35) 
V13 oxy 0.26 (1.51) -0.19 (1.13) 0.26 (1.11) 
V14 oxy 0.36 (1.79) -0.63 (1.30) 0.13 (1.50) 
V15 oxy 0.12 (1.30) -0.34 (1.09) 0.22 (1.07) 
V16 oxy 0.47 (1.07)   -0.24 (1.17)† 0.83 (1.31) 
    
V1 deoxy 0.07 (1.78) -0.41 (0.80) 0.61 (1.15) 
V2 deoxy 0.12 (0.68) -0.26 (0.72) 0.37 (0.97) 
V3 deoxy 0.09 (1.29) -0.18 (0.77) 0.74 (1.15) 
V4 deoxy    
V5 deoxy 0.22 (1.39) -0.05 (0.69) 0.69 (1.19) 
V6 deoxy    
V7 deoxy 0.13 (1.27) -0.14 (0.88) 0.51 (1.29) 
V8 deoxy 0.34 (0.99) -0.06 (0.68) 0.32 (1.23) 
V9 deoxy -0.13 (1.21) -0.20 (0.75) 0.56 (1.50) 
V10 deoxy 0.27 (0.60) -0.14 (0.69) 0.18 (1.11) 
V11 deoxy -0.03 (1.22) -0.01 (0.48) 0.61 (1.36) 
V12 deoxy 0.16 (1.61) -0.19 (0.58) 0.36 (1.45) 
V13 deoxy -0.05 (1.43) -0.40 (0.88) 0.39 (0.92) 
V14 deoxy -0.06 (1.78) -0.38 (0.85) 0.06 (1.18) 
V15 deoxy -0.45 (1.80) -0.45 (0.96) 0.24 (0.96) 
V16 deoxy -0.09 (1.18) -0.40 (1.04) 0.37 (1.00) 
 
 
Univariate ANOVA on the oxy-Hb data, revealed significant between group 
differences at voxels; V1 F(2,42)=5.89, p<.01, V2 F(2,42)=5.88, p<.01, V8 F(2,42)=3.94, 
p<.05 and V16 F(2,46)=3.47, p<.05. Between group differences were also approaching 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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significance at V12 F(2,44)=2.54, p=.09. There were no significant between group 
differences at any of the other voxels measured (p>.05) 
 Pairwise comparisons revealed that at V1 polydrug users had significantly lower oxy-
Hb that both other groups (p<.05), however the difference between ecstasy users and drug 
naïve controls was non-significant (p>.05). At V2 polydrug users had significantly lower 
oxy-Hb than both other groups (p<.05), however the difference between ecstasy users and 
drug naïve controls was non-significant. At V8 ecstasy users had significantly increased oxy-
Hb relative to polydrug controls and drug naïve controls (p<.05). At V16 polydrug users had 
significantly reduced oxy-Hb relative to drug naïve controls (p<.05). Ecstasy users did not 
differ from either control group significantly (p>.05 in both cases). At V12 ecstasy users had 
significantly increased oxy-Hb compared to polydrug users (p<.05) although they were not 
significantly different to drug naïve controls (p>.05). Polydrug users and drug naïve controls 
did not differ from one another significantly at this voxel. 
A regression analysis with the same steps and indices entered as the letter updating 
regressions with oxy-Hb at V8 as the dependent variable was conducted. This overall regres-
sion model accounted for a non-significant 0.8% (R² = 0.08, R² adjusted = -0.15, 
F(8,31)=0.35, p>0.05) of the variance in oxy-Hb. Age and pre-test sleepiness (step 1) did not 
predict a significant amount of variance in oxy-Hb (R² = 0.00, R² adjusted = -0.05, 
F(2,37)=0.00, p>0.05). Cannabis use indices (step 2) did not predict a significant amount of 
variance in V8 oxygenation after controlling for age and pre-test sleepiness (R ²change=0.01, 
F-change (3,34)=0.09, p>.05). None of the individual cannabis indices were significant 
predictors; frequency of use (β=0.58, p>0.05), total lifetime dose (β=-0.07, p>0.05) and 
amount smoked in the last 30 days (β=-0.70, p>0.05). The ecstasy use indices (step 2) did not 
predict a significant amount of variance in V8 oxy-Hb, after controlling for cannabis use 
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indices (R ²change=0.08, F-change (3,31)=.0.85, p>.05). Individual indices; frequency of use 
(β=0.45, p>0.05), lifetime dose (β=0.02, p>0.05) and last 30 day use (β=-0.29, p>0.05) did 
not significantly predict V8 oxy-Hb level. 
 ANOVA on the deoxy-Hb data during the spatial updating task revealed no 
significant between group differences at any voxel (p>.05 in each case). However differences 
were approaching significance at voxels V1 F(2,44)=2.63, p=.08 and V3 F(2,41)=2.59, p=.09. 
Pairwise comparisons revealed that polydrug users showed decreased deoxy-Hb compared to 
drug naïve controls that was approaching significance at V1 (p=.07) and V3 (p=.09). Ecstasy 
users did not differ significantly from either group at either of these voxels. 
7.5 Discussion and summary 
 Analysis of performance data in Chapter 7 suggest that ecstasy users perform 
equivalently to non-users on letter updating and spatial updating. However the 
haemodynamic response data suggest that ecstasy users may be engaged in more effortful 
cognition to attenuate performance differences. During the letter updating task ecstasy users 
showed significantly increased oxy-Hb compared to both control groups at voxel 12, located 
over the right medial PFC. Furthermore regression analysis revealed that ecstasy use indices 
predicted a significant amount of the variance in oxy-Hb at this voxel after controlling for age, 
sleepiness and cannabis use variables; specifically, frequency of use predicted increased oxy-
Hb level. Furthermore ecstasy users showed increases in deoxy-Hb from baseline compared 
to drug naïve controls at V12, this difference was also approaching significance at V1, V7 
and V8. Ecstasy users also showed significantly increased deoxy-Hb from baseline compared 
to polydrug controls at V1 and this was approaching significance at V12 and V8. This 
indicates that ecstasy users were engaged in more effortful cognition and were perhaps 
relying on additional cognitive resources. Regression analyses on deoxy-Hb data, were 
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generally non-significant, although frequency of MDMA use predicted deoxy-Hb at V12, 
suggesting that more frequent use lead to greater deoxygenation. 
 During spatial updating, the oxy-Hb data again revealed that ecstasy users showed 
significantly increased oxy-Hb compared to both control groups at voxel 8, pertaining to the 
left medial prefrontal cortex. Ecstasy use indices did not significantly predict oxygenation at 
this voxel after controlling for age, sleepiness and cannabis use indices in a regression 
analysis. Nevertheless the between group differences are evidence that increased cognitive 
effort is displayed in ecstasy users compared to non-users during spatial updating. The 
implications of which will be discussed in greater detail in Chapter 10. 
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Chapter 8: fNIRS response to switching, inhibition and access 
8.1 Chapter overview 
Chapter 7 showed that ecstasy users show greater haemodynamic activation than 
control groups when performing memory updating tasks. This chapter assessed the 
haemodynamic response to the other three executive functions – inhibition, switching and 
access. Twenty ecstasy users and 20 controls (polydrug users and drug naïve participants) 
completed a random letter generation (RLG) task (inhibition), a number-letter task (switching) 
and an oral variant of the CWFT (access). No performance differences were observed 
between groups on any of the tasks. However significant increases in oxy-Hb from baseline 
were observed in ecstasy users relative to controls at various sites on every level of every task. 
Significant increases in deoxy-Hb were also observed in ecstasy users relative to controls at 
various sites during the CWFT and the RLG task. 
8.2 Introduction 
As previously discussed research in cognitive psychology suggests that the central 
executive of working memory is not a unified construct and is comprised of separable 
functions including memory updating, mental set switching, inhibitory control and access to 
semantic memory (Fisk and Sharp, 2004; Miyake et al., 2000). In ecstasy users, tasks that are 
proposed to tap the executive function of mental set switching show equivocal results. 
Dafters (2006) observed ecstasy users to be impaired on a switch component of the Stroop 
task compared to cannabis users and non-users and Dafters et al. (1999) found MDMA use to 
be negatively correlated with performance on the BADS rule shift cards test; however, the 
majority of studies suggest that MDMA users are unimpaired on this function (Fox et al.,, 
2001; Back-Madruga et al., 2003: Montgomery, Fisk, Newcombe & Murphy, 2005). Chapter 
6 in this thesis examined performance on the number-letter task in combination with ERP 
analysis. Atypicalities in the P2 component in ecstasy users compared to both polydrug and 
 
 
 
 
203 
 
drug naïve controls despite equivalent behavioural performance, as well as drug related 
alterations to the P3 response (Roberts et al., 2013c in press). This highlights the importance 
of using more sensitive measures of cognitive performance, such as EEG or fNIRS, to gain a 
clearer understanding of the mechanisms underpinning cognitive deficits in substance users, 
as behavioural measures alone may not be sensitive enough to detect subtle ecstasy-related 
cognitive deficits in switching.  
The effects of ecstasy use on inhibition have been reviewed in Chapters 3 and 6. As 
with switching, results of behavioural studies are mixed though the general consensus is that 
this executive function is relatively robust to ecstasy-related decline. Halpern et al., (2004) 
found ecstasy-related deficits on the Stroop task in a relatively pure ecstasy using sample, 
however this was not replicated in a follow up study (Halpern et al., 2011). Moreover, using 
this task more studies have observed ecstasy users to be unimpaired at inhibition (Back-
Madruga et al., 2003; Gouzoulis-Mayfrank et al., 2000). Using the RLG task, Wareing et al. 
(2000) observed performance deficits in ecstasy users compared to non-users, though these 
findings were not replicated by Fisk et al. (2004), using a larger sample and more effective 
controls for concomitant use of other drugs. Nevertheless it has been suggested that depletion 
of Serotonin (5-HT) and impairment of other executive functions may lead to poor inhibitory 
control (Morgan et al., 2006). Moreover, the use of neurophysiological measures may be 
necessary to better understand the impact of MDMA on these cognitive processes. For 
example Roberts and Garavan (2010) observed no performance deficits in ecstasy users on a 
Go/NoGo task, however fMRI data revealed that users showed increased frontal and parietal 
BOLD activation during successful inhibitions and hyperactivity of temporal, frontal and 
cingulate regions during commission errors. Furthermore ERP data in this thesis from 
Chapter 6 support the view that recreational ecstasy use may lead to subtle cognitive 
alterations during this executive function that are more readily detected in neuroimaging data 
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than behavioural data. Atypicalities in early processing (P2 component), during a Go/NoGo 
task suggest that compensatory cognitive mechanisms were being employed to enable 
equivalent behavioural performance to controls (Roberts et al., 2013a).  
While results for switching and inhibitory control are mixed, there appears to be more 
evidence in support of impaired access in ecstasy users. The COWA task has yielded deficits 
in ecstasy users compared to controls (Bhattachary & Powell, 2001; Fox et al., 2002), though 
this is not always a consistent finding (Halpern et al., 2004). Ecstasy users do appear to 
perform at a consistently lower level than controls when the written variant of this task is 
used (CWFT). The CWFT is understood to be more complex than the COWA task as it 
requires participants to name words that fit specific criteria (e.g. four-letter words beginning 
with the letter C) and therefore places more demand on the central executive. Using this task, 
ecstasy-related impairments have been more consistently reported (Montgomery et al., 2007; 
Montgomery, Fisk, Newcombe & Murphy, 2005). Raj et al. (2010) investigated the BOLD 
response to a semantic retrieval task of ecstasy users and suggested that MDMA exposure 
results in reduced BOLD response in neuronal areas relating to verbal memory. Furthermore 
Chapter 6 of this thesis reported evidence of abnormal executive functioning in ecstasy users 
(the N2 ERP component) despite the absence of behavioural differences in a semantic 
association paradigm (Roberts et al., 2013b).   
Consequently studies into cognitive deficits associated with ecstasy use are 
increasingly employing neuroimaging techniques to gain insight into processes underlying 
such deficits. Burgess et al., (2011) observed differences in ecstasy users’ ERPs in a late 
positive component over left parietal scalp sites in a recall task that had yielded no significant 
performance deficits. The amelioration of this late positivity in ecstasy users is accepted as a 
durable abnormality in processing that would not have been detected by behavioural 
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measures alone. fMRI studies (e.g. Daumann, Fimm et al., 2003) have reported increased 
cortical activity in ecstasy users to compensate for behavioural differences. Furthermore 
Moeller et al. (2004) report increases in blood volume in ecstasy users relative to controls in 
several brain regions including the medial frontal gyrus and the thalamus, during a delayed 
memory task. These fMRI studies show increases in cortical activity and blood volume that 
are understood to reflect compensatory mechanisms in ecstasy users. In effect, ecstasy users 
are working harder to achieve the same result behaviourally. Moreover results from Chapter 7 
in this thesis, indicated that differences in haemodynamic response (increases in oxy-Hb and 
deoxy-Hb) were apparent in ecstasy users compared to controls, despite equivalent 
behavioural performance. The findings from Chapter 7 suggest that ecstasy users were 
engaged in more effortful cognition (recruitment of additional resources) to attenuate 
performance deficits, in letter updating and spatial updating. 
 The present chapter sought to investigate the cerebral haemodynamic response (using 
fNIRS) to three executive functioning tasks in ecstasy users and non-user controls. The three 
executive functions investigated were mental set switching, access and inhibitory control. 
Based on previous research that has yielded the most interesting results and compatibility 
with the technology being used, the following tasks have been used to assess each executive 
function – the number-letter task (switching), the CWFT (access) and RLG (inhibition). 
Performance and haemodynamic response were measured on each task. It was hypothesised 
that although performance on each of the executive functions may be equivalent between 
groups, differences will be observed in oxy-Hb and deoxy-Hb haemoglobin changes from 
baseline, in line with findings from Chapter 7, that reflect increased cognitive effort 
(increased oxy-Hb and deoxy-Hb) in ecstasy users.    
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8.3 Method 
Participants: 
Twenty ecstasy users (mean age = 21.85±2.76; 13 = male) and 20 non-user controls 
(mean age = 20.89±2.05; 7 = male) were recruited via email to university students. Inclusion 
criteria for the experiment was similar to that in Chapters 6 and 7, except due to practical 
constraints only one control group was recruited that were ecstasy naïve (although the 
majority of participants in the control group were drug naïve, so there is limited drug use in 
the non-user group). Indices of ecstasy use were as follows: total lifetime dose 431.75 tablets 
± 885.08; mean amount used in last 30 days 2.55 tablets ± 3.23, and frequency of use 0.37 
times/week ± 0.51. 
Materials 
Questionnaires: 
The Background Drug Use Questionnaire, The ESS, The MEQ, KSS, UMACL, 
NASA-TLX and Raven’s SPM were used, as described in Chapter 6. 
Executive function tasks: 
Random Letter Generation (inhibition) (Baddeley, 1966)   
Participants were presented with a bar on the screen that alternated between two 
positions at a set pace, cueing participants to generate a letter. Participants had to produce 
100 letters in each block of the task. There were three blocks and each block represented a 
different production rate (one letter every 4, 2, and 1-seconds). Participants were instructed to 
avoid alphabetical sequences, repetition of sequences of letters and to produce each letter 
with the same overall frequency. Presentation of blocks was randomised and participants’ 
responses were recorded onto a cassette deck with a built in microphone. Four scores were 
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generated – the number of alphabetically ordered pairs, the number of repeat sequences, 
“redundancy” (the extent to which all letters are produced equally with 0% being truly 
random) and the number of letters produced. A high score on the first three indicates poor 
performance whereas the opposite is true in the fourth case. All scores were standardised and 
a single score for each random generation measure was obtained by calculating the mean 
standardised scores for the three production rates (as per Montgomery, Fisk, Newcombe & 
Murphy, 2005) 
The Number Letter Task (switching) (Rogers & Monsell, 1995) – as described in Chapter 6. 
The Chicago Word Fluency Task (access) (Thurstone, 1938)   
A variation of the original Thurstone word fluency task, this task consisted of three 
blocks in which participants had to verbally produce as many words as they could in one 
minute. In the first block (semantic fluency), participants were instructed to name as many 
animals as they could during the time period. Following this they were instructed to produce 
as many words possible beginning with the letter “S”, and in the third and final block they 
were required to name as many four letter words beginning with the letter “C” as possible 
(word fluency). Participants were informed that place names, people’s names and plurals 
were prohibited. Responses were recorded on a cassette deck with a built in microphone. 
Scores for each of the fluency tasks were counted as the number of appropriate words in each 
case. 
Equipment 
A continuous wave fNIRS system (developed by Drexel University, Philadelphia, PA) 
supplied by Biopac systems (Goleta, CA, USA) was used for collecting haemodynamic 
response to task data from the PFC as described in Chapter 7. 
 
 
 
 
208 
 
Procedure 
Participants attended the lab for a single session lasting approximately 2 hours. 
Testing sessions commenced at 9am, 11am and 1pm and 3pm, with equal numbers of each 
group tested at each session time. Upon arrival participants were given an information sheet 
explaining what was involved in the study, and written consent was obtained. Questionnaires 
were administered in the following order: background drug use questionnaire, MEQ, ESS, 
pre-test KSS, UMACL and Raven’s SPM. The fNIRS headband was then fitted to the 
participant’s forehead. fNIRS signals were displayed on a desktop computer running COBI 
studio (Drexel University) in an adjacent room to the testing room. Once stability of fNIRS 
signals was obtained, a baseline of inactivity was recorded. Baselines were recorded prior to 
each task. Participants watched a video of planet earth accompanied by soothing music and 
the baselines were recorded during this period. Participants then completed one of the three 
tasks (number-letter task, CWFT or RLG). After each task participants completed the NASA 
TLX then the process was repeated for the other tasks starting with baseline recording. Task 
order was randomised. After all three tasks had been completed participants were 
administered the post task KSS. Participants were fully debriefed after the testing procedure 
and were paid £20 in store vouchers. The study was approved by Liverpool John Moores 
University Research Ethics Committee, and was administered in accordance with the ethical 
guidelines of the British Psychological Society. 
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fNIRS analysis 
 Pre-processing and analysis followed the same procedure as that described in Chapter 
7. fNIRS data was analysed using ANOVA
3
 in blocks of discrete epochs on each task. The 
number-letter task was analysed over two switching blocks, the CWFT had three blocks 
(animals, “S” letter words and four-letter long words beginning with “C”) and RLG had three 
blocks where the speed at which letters had to be produced differed (every 4, 2, or 1-seconds). 
Due to the various blocks in these tasks relating to the level of difficulty of the task, mean 
oxy-Hb and deoxy-Hb changes from baseline at each channel were calculated for each block. 
8.4 Results 
Socio-demographic information about the participants, sleep measures and scores of 
anxiety, depression and arousal are shown in Table 8.1. Indices of other drug and alcohol use 
are displayed in Table 8.2.  
  
                                                          
3
 Due to small amounts of missing data on different voxels, MANOVA was not appropriate for this analysis.  
 
 
 
 
210 
 
Table 8.1- Indices sleep quality, fluid intelligence and socio-demographic variables 
 Ecstasy users 
 
     Non-users   
Males:  n, (%) 13 (65)       8 (40)  
Age (SD) 
 
21.85 (2.76)     20.89 (2.05)  
University 
degree: n (%) 
4 (20)     5 (25)  
        
Employment 
status 
       
Student;  n, (%) 17 (85)     20 (100)  
Employed; n 
(%) 
2 (10)     0 (0)  
Unemployed; n 
(%) 
1 (5)     0 (0)  
        
      Mean (SD)     Mean (SD)  
        
Ravens 
Progressive 
Matrices 
(maximum 60) 
47.20 (5.64)     48.00 (6.79)  
        
ESS Score 
(maximum 24) 
 
5.00 (2.81)     5.25 (2.81)  
KSS before 4.30 (1.49)     4.75 (1.74)  
        
KSS after 5.33 (2.15)     4.06 (2.05)  
        
MEQ total 45.33 (9.31)     50.00 (9.95)  
        
UWIST anxiety 8.70 (2.56)     8.75 (2.24)  
        
UWIST 
depression  
 
9.05 (3.22)     8.70 (2.00)  
        
UWIST arousal 17.35 (5.38)     17.75 (3.29)  
       
       
 
 
 
 
 
 
*Indicates a significant difference from controls at the .05 level, and ** at the .01 level. 
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Table 8.2: Indices of Drug use 
 Ecstasy users 
 Mean (SD) n 
Cannabis   
Frequency (times/wk) 1.42 (1.94) 19 
Last 30 days (joints) 23.03 (40.19) 19 
Total use (joints) 1607.88 (2212.54) 19 
   
Cocaine   
Frequency (times/wk) 1.15 (2.96) 11 
Last 30 days (lines) 6.42 (14.80) 12 
Total use (lines) 294.64 (465.18) 14 
   
Ketamine   
Frequency (times/wk) 0.24 (0.32) 10 
Last 30 days use (grams) 0.33 (0.71) 9 
Total use (grams) 7.16 (9.56) 11 
   
 
t-tests on background variables revealed there was no significant difference between 
the two groups in age t(36)=1.21, p>.05, total scores on the ESS t(37)=-0.28, p>.05, MEQ 
t(30)=-.1.37, p>.05, Raven’s SPM t(38)=-0.41, p>.05, pre-test KSS t(38)=-0.88, p>.05, post-
test KSS t(26)=1.59, p>.05, or levels of arousal t(38)=-0.28, p>.05, depression t(38)=0.41, 
p>.05 and anxiety t(38)=-0.07, p>.05. However ecstasy users did drink significantly more 
units of alcohol per week than non-users (18.6±11.91 units p/w compared to 9.75±8.63 units 
p/w) t(38)=2.71, p<.01, and it is clear from Table 8.2 that there is concomitant drug use this 
cohort. Perhaps it would be more appropriate to call the current sample of ecstasy users, 
ecstasy/polydrug users. 
Behavioural Data Analysis: See Table 8.3 for descriptive statistics. 
Random Letter Generation: Standardised scores for alphabetically ordered pairs, 
repeat sequences and redundancy were added together and the standardised score for the 
number of letters produced was subtracted from this total, this new total was then divided by 
four, to give a single standardised performance score for each rate (1s, 2s and 4s) for each 
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participant. MANOVA was conducted on the performance scores for this task, this revealed 
no significant main effect of group, F(3,36)=0.85, p>.05 for Pillai’s trace. Univariate 
ANOVA revealed no significant between group differences on performance at each 
individual rate; 1s F(1,38)=0.01, p>.05, 2s F(1,38)=1.75, p>.05 or 4s F(1,38)=0.93, p>.05. 
Number-Letter Task: Incorrect answers were given a score of 0 and were not 
investigated any further. Responses before 200ms and after 4000ms were excluded from 
analysis as these represent pre-emptive responding and loss of concentration respectively and 
individual reaction times that were 3 standard deviations or more above the individual mean 
were excluded. The mean percentage of outliers discarded from each group were: ecstasy 
users 1.51 ±0.73, drug naïve 1.48 ±0.91, there were no between group differences in amount 
of outliers F(1,37)=0.02, p>.05. One participant from the ecstasy user group had an 
incomplete dataset and therefore was excluded from the final analysis. ANOVA revealed no 
significant between groups difference on switch cost F(1,37)=0.31, p>.05. 
Chicago Word Fluency Task: A mixed ANOVA was conducted on the CWFT data 
with group as the between subjects variable and level of difficulty as the within subjects 
variable (the easiest being “animals” followed by words beginning with “S” and the most 
difficult being 4 letter words beginning with “C”).  There was a significant main effect of 
difficulty on the task F(1.59, 60.23)=158.33, p<.01 (the sphericity assumption was violated 
so Greenhouse-Geisser adjusted stats are reported), however there was no group by difficulty 
interaction F(1.59, 60.23)=0.75, p>.05. Furthermore there were no significant between group 
differences in performance on the task F(1,38)=0.64, p>.05. 
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Table 8.3: Means and SDs for behavioural measures for ecstasy users and non-users 
     Ecstasy users           Non-users 
 Mean (SD)  Mean (SD)  
RLG 4-second rate     
Redundancy 0.087 (0.02)  0.087 (0.02)  
Repeat Sequences 11.70 (6.13)  11.10 (3.00)  
Alphabetical Sequences 5.10 (3.61)  4.30 (2.36)  
Number of Letters Produced 97.15 (11.38)  99.95 (0.22)  
     
RLG 2-second rate     
Redundancy 0.093 (0.03)  0.095 (0.02)  
Repeat Sequences 14.90 (7.35)  14.30 (3.98)  
Alphabetical Sequences 8.65 (8.22)  6.75 (3.43)  
Number of Letters Produced 95.50 (11.94)  99.20 (1.01)  
     
RLG 1-second rate     
Redundancy 0.113 (0.03)  0.11 (0.03)  
Repeat Sequences 13.95 (5.99)  15.75 (6.16)  
Alphabetical Sequences 9.95 (4.38)  10.50 (4.50)  
Number of Letters Produced 82.60 (15.09)  86.95 (12.66)  
     
Number/letter Switch Cost (ms) 358.61 (161.79)  323.40 (227.34)  
     
CWFT     
Animals 42.10 (9.24)  38.55 (7.27)  
Words beginning with “S” 37.95 (11.26)  35.75 (11.49)  
4 letter words beginning with “C” 15.45 (7.12)  15.55 (8.17)  
     
 
 
 
 
 
 
 
 
*Indicates a significant difference from controls at the .05 level, and ** at the .01 level. 
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fNIRS Analysis 
RLG: Changes in oxy-Hb and deoxy-Hb from baseline are displayed in table 8.4. 
Table 8.4: Mean changes in oxy-Hb and deoxy-Hb (µmolar) from baseline, for ecstasy users 
and non-user controls during the random letter generation task. 
 Ecstasy users Non-users 
 RLG4 RLG2 RLG1 RLG4 RLG2 RLG1 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
V1oxy 0.56 (0.84) 0.78 (1.32) 0.85 (1.27) 1.04 (1.13) 0.74 (0.86) 1.16 (1.51) 
V2oxy 0.10 (1.82) 0.52 (1.49) 0.57 (1.44) 0.29 (1.36) 0.13 (1.49) 0.58 (1.59) 
V3oxy 0.29 (1.07) 0.36 (1.03) 0.55 (1.17) 0.28 (0.94) 0.04 (0.82) 0.53 (1.45) 
V4oxy 0.23 (1.42) 0.75 (1.44)* 1.14 (1.83) -0.19 (0.70) -0.36 (0.76) 0.27 (1.12) 
V5oxy 0.18 (1.63) 0.30 (1.81) 0.50 (1.82) 0.54 (1.08) 0.34 (1.26) 0.55 (1.53) 
V6oxy 0.06 (1.74) 0.37 (1.88) 0.33 (2.18) 0.16 (1.23) 0.24 (1.81) 0.40 (1.56) 
V7oxy 0.25 (1.61) 0.32 (1.34) 0.35 (1.80) 0.67 (1.22) 0.49 (1.50) 0.71 (1.53) 
V8oxy 0.84 (2.12) 1.31 (1.84) 1.22 (2.47) 0.49 (1.37) 0.53 (1.95) 0.64 (1.57) 
V9oxy 0.47 (1.62) 0.42 (1.76) 0.62 (1.88) 0.52 (1.32) 0.21 (1.48) 0.56 (1.55) 
V10oxy 1.21 (2.17)* 1.37 (2.31)* 1.11 (2.66) 0.14 (1.22) -0.02 (1.85) 0.23 (1.59) 
V11oxy 0.47 (1.17) 0.88 (1.34) 0.96 (1.26) 0.42 (1.08) -0.02 (1.25) 0.34 (1.19) 
V12oxy 0.49 (1.62) 0.84 (1.35)* 0.97 (1.62)* -0.07 (0.91) -0.17 (1.40) 0.08 (1.24) 
V13oxy 0.41 (1.09) 0.37 (1.77) 1.03 (1.34) 0.35 (1.25) 0.37 (1.20) 0.44 (1.34) 
V14oxy 0.51 (1.74) 0.64 (1.65) 0.93 (1.68)* 0.00 (1.08) -0.27 (1.65) -0.06 (1.52) 
V15oxy 0.45 (1.30) 0.43 (1.82) 0.68 (1.53) 0.56 (1.40) 0.35 (1.17) 0.61 (1.79) 
V16oxy 0.51 (1.43) 0.50 (1.71) 0.82 (1.60) 0.07 (0.84) 0.10 (1.14) 0.30 (1.13) 
       
V1deoxy 0.17 (1.27) 0.13 (1.83) 0.04 (1.49) -0.34 (0.96) -0.55 (2.00) -0.38 (1.02) 
V2deoxy -0.14 (1.46) 0.03 (1.55)* -0.03 (1.29)* -0.83 (0.98) -1.12 (1.65) -0.90 (1.17) 
V3deoxy 0.18 (1.19)* -0.01 (1.39) -0.01 (1.10)* -0.79 (1.33) -0.94 (2.11) -0.81 (1.66) 
V4deoxy 0.10 (1.58)* 0.30 (1.55)* 0.49 (1.59)** -1.45 (1.71) -1.91 (2.91) -1.59 (1.59) 
V5deoxy 0.24 (1.37)* 0.14 (1.31) 0.25 (1.35)* -0.48 (1.22) -0.66 (1.91) -0.60 (1.56) 
V6deoxy 0.16 (1.32) 0.18 (1.34) 0.16 (1.32) -0.40 (1.38) -0.45 (2.11) -0.33 (1.59) 
V7deoxy 0.25 (1.70) 0.10 (1.73) 0.11 (1.54) 0.03 (0.88) -0.12 (1.45) -0.06 (1.15) 
V8deoxy 0.31 (1.52) 0.55 (2.54) 0.21 (1.53) -0.25 (1.25) -0.36 (1.79) -0.30 (1.35) 
V9deoxy 0.25 (1.70) 0.15 (1.76) 0.03 (1.57) -0.22 (1.35) -0.49 (2.18) -0.29 (1.46) 
V10deoxy 0.53 (1.92) 0.61 (2.76) 0.17 (1.84) -0.49 (1.79) -0.72 (2.43) -0.60 (1.90) 
V11deoxy 0.18 (2.09) 0.28 (1.96)* 0.16 (1.80)* -1.07 (1.86) -1.53 (2.97) -1.34 (2.21) 
V12deoxy 0.50 (1.91) 0.45 (1.86) 0.45 (1.88) -0.29 (0.62) -0.28 (1.06) -0.42 (1.08) 
V13deoxy 0.34 (1.46)** 0.43 (1.56)* 0.57 (1.57)** -0.72 (1.18) -0.85 (1.91) -0.83 (1.61) 
V14deoxy 0.66 (2.09)* 0.61 (1.84)* 0.71 (1.98)** -0.27 (0.62) -0.35 (1.00) -0.51 (0.83) 
V15deoxy 0.56 (1.75)* 1.10 (3.99)* 0.53 (1.64)** -0.62 (1.41) -0.98 (2.52) -0.84 (1.67) 
V16deoxy 0.20 (1.44)* -0.09 (1.79) 0.04 (1.82) -0.89 (1.42) -0.85 (1.98) -0.88 (1.65) 
 
 
ANOVA on oxy-Hb change from baseline on the first level of difficulty of the task 
(4s rate) revealed that ecstasy users showed increased oxy-Hb compared to controls at V10 
F(1,30)=2.96, p<.05 and this difference was approaching significance at V1 F(1,33)=2.00, 
p=.08. There were no significant differences at any of the other voxels measured (p>.05). 
*Indicates a significant difference from controls at the .05 level, and ** at the .01 level 
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There were also significant differences in the amount of deoxy-Hb change from baseline at 
V3 F(1,35)=5.42, p<.05, V4 F(1,16)=3.90, p<.05, V5 F(1,36)=2.92, p<.05, V13 
F(1,36)=6.11, p<.01, V14 F(1,34)=3.11, p<.05, V15 F(1,34)=4.93, p<.05 and V16 
F(1,35)=5.37, p<.05, whereby ecstasy users showed greater deoxygenation than controls. 
This difference was also approaching significance at V2 F(1,32)=2.64, p=.06, V10 
F(1,30)=2.44, p=.06, V11 F(1,20)=2.19, p=.08 and V12 F(1,31)=2.37, p=.07. No other 
differences were observed for the other voxels measured (p>.05 in each case).  
At the 2
nd
 level of difficulty in this task (2s rate) ANOVA revealed between group 
differences in oxy-Hb at V4 F(1,16)=3.47, p<.05, V10 F(1,30)=3.52, p<.05, and V12 
F(1,31)=4.45, p<.05 whereby ecstasy users showed greater oxy-Hb increase from baseline 
than controls. This difference was approaching significance at V11 F(1,20)=2.65, p=.06 and 
V14 F(1,34)=2.75, p=.06. There were no differences at any other voxels (p>.05). ANOVA on 
deoxy-Hb changes at the 2-s rate revealed that ecstasy users showed significantly greater 
deoxy-Hb increase than controls at V2 F(1,32)=4.33, p<.05, V4 F(1,16)=4.47, p<.05, V11 
F(1,20)=2.84, p<.05, V13 F(1,36)=5.12, p<.05, V14 F(1,34)=3.67, p<.05 and V15 
F(1,34)=3.48, p<.05. This difference was also approaching significance at V3 F(1,35)=2.56, 
p=.06, V5 F(1,36)=2.27, p=.07, V10 F(1,30)=2.10, p=.08 and V12 F(1,31)=1.83, p<.09. No 
other significant differences were observed (p>.05 in each case). 
For the 3
rd
 and most difficult level of the task (1s rate) ANOVA revealed that ecstasy 
users displayed significantly increased oxy-Hb from baseline relative to controls at V12 
F(1,31)=3.08, p<.05 and V14 F(1,34)=3.42, p<.05. This difference was also approaching 
significance at V13 F(1,36)=1.83, p=.09. There were no other significant differences at any 
of the voxels measured (p>.05 in each case). ANOVA on the deoxy-Hb data in this block 
revealed that ecstasy users displayed significantly greater deoxy-Hb than controls at V2 
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F(1,32)=4.24, p<.05, V3 F(1,35)=3.07, p<.05, V4 F(1,16)=7.20, p<.01, V5 F(1,36)=3.18, 
p<.05, V11 F(1,20)=3.05, p<.05, V13 F(1,36)=7.28, p<.01, V14 F(1,34)=5.55, p<.01 and 
V15 F(1,34)=6.14, p<.01. This difference was also approaching significance at V12 
F(1,31)=2.50, p=.06 and V16 F(1,35)=2.59, p=.06. There were no significant differences at 
the other voxels measured (p>.05 in each case). 
Overall these results show a general increase in oxy-Hb and deoxy-Hb from baseline 
for ecstasy users compared to controls that is significant at several voxels in each level of the 
task.   
Multiple regression analyses were conducted on all voxels showing significant 
between group differences in oxy-Hb and deoxy-Hb. This was conducted to observe whether 
ecstasy use indices predicted oxy-Hb and deoxy-Hb increase after controlling for cannabis 
use. Values of oxy-Hb or deoxy-Hb (µmolar) were entered as dependent variables. In step 
one indices of cannabis use were entered as predictors (frequency of use, total lifetime dose, 
amount smoked in the last 30 days), in step two the same indices of ecstasy use were entered 
as predictors. The results from these regression analyses can be seen in Appendix 1, for 
brevity, only regressions yielding notable results are reported here. 
Using deoxy-Hb at V14 during the 4s rate as the dependent variable, this overall 
regression model accounted for a significant 43.8% (R² = 0.44, R² adjusted = 0.32, 
F(6,29)=3.76, p<0.01) of the variance in deoxy-Hb. Cannabis use indices (step 1) did not 
predict a significant amount of variance in V14 deoxygenation (R² = 0.05, R² adjusted = -0.04, 
F(3,32)=0.56, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=-0.10, p>0.05), total lifetime dose (β=0.24, p>0.05) and 
amount smoked in the last 30 days (β=-0.39, p>0.05). The ecstasy use indices (step 2) did, 
however, predict a significant amount of variance in V14 deoxy-Hb, after controlling for 
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cannabis use indices (R² change=0.39, F-change (3,29)=6.66, p<.01). Individual indices; 
frequency of use (β=-0.42, p<0.05) and last 30 day use (β=0.82, p<0.05) predicted V14 
deoxy-Hb level at the 4s rate, with increased frequency being associated with decreased 
deoxy-Hb and increased last 30 day use being associated with increased deoxy-Hb. Lifetime 
dose (β=0.02, p>0.05) was not a significant predictor. 
Using deoxy-Hb at V14 during the 2s rate as the dependent variable this overall 
regression model accounted for a non-significant 25.1% (R² = 0.25, R² adjusted = 0.10, 
F(6,29)=1.62, p>0.05) of the variance in deoxy-Hb. Cannabis use indices (step 1) did not 
predict a significant amount of variance in V14 deoxygenation (R² = 0.03, R² adjusted = -0.07, 
F(3,32)=0.28, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=-0.01, p>0.05), total lifetime dose (β=0.24, p>0.05) and 
amount smoked in the last 30 days (β=-0.31, p>0.05). There was a strong trend for ecstasy 
use indices (step 2) to predict variance in V14 deoxy-Hb, after controlling for cannabis use 
indices (R² change=0.23, F-change (3,29)=2.92, p=.05). Individual indices; frequency of use 
(β=-0.35, p>0.05) and lifetime dose (β=0.04, p>0.05) did not predict V14 deoxy-Hb level at 
the 2s rate, whereas last 30 day use (β=0.62, p<0.01) was a significant predictor, with 
increased use being associated with increased deoxy-Hb. 
Using oxy-Hb at V12 during the 1s rate as the dependent variable this overall regres-
sion model accounted for a significant 38.9% (R² = 0.39, R² adjusted = 0.25, F(6,26)=2.76, 
p<0.05) of the variance in oxy-Hb. Cannabis use indices (step 1) did not predict a significant 
amount of variance in V12 oxy-Hb (R² = 0.23, R² adjusted = 0.15, F(3,29)=2.90, p>0.05). 
None of the individual cannabis use indices were significant predictors; frequency of use 
(β=0.73, p>0.05), total lifetime dose (β=0.39, p>0.05) and amount smoked in the last 30 days 
(β=-0.31, p>0.05). Ecstasy use indices (step 2) did not predict a significant amount of 
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variance in V12 oxy-Hb, after controlling for cannabis use indices (R² change=0.16, F-
change (3,26)=2.25, p>.05). Individual indices; frequency of use (β=-0.27, p>0.05) and 
lifetime dose (β=0.03, p>0.05) did not predict V12 oxy-Hb increase at the 1s rate. However 
last 30 day use (β=0.52, p<0.05) was a significant predictor with increased use being 
associated with increased oxy-Hb. 
Using oxy-Hb level at V14 during the 1s rate as the dependent variable this overall 
regression model accounted for a significant 33.8% (R² = 0.34, R² adjusted = 0.20, F(6, 
29)=2.47, p<0.05) of the variance in oxy-Hb. Cannabis use indices (step 1) did not predict a 
significant amount of variance in V14 oxy-Hb (R² = 0.18, R² adjusted = 0.11, F(3,32)=2.38, 
p>0.05). None of the individual cannabis use indices were significant predictors; frequency of 
use (β=0.11, p>0.05), total lifetime dose (β=0.16, p>0.05) and amount smoked in the last 30 
days (β=0.21, p>0.05). Ecstasy use indices (step 2) did not predict a significant amount of 
variance in V14 oxy-Hb, after controlling for cannabis use indices (R² change=0.16, F-
change (3,29)=2.28, p>.05). Individual indices; frequency of use (β=-0.27, p>0.05) and 
lifetime dose (β=-0.19, p>0.05) did not predict V14 oxy-Hb level at the 1s rate. However, last 
30 day use (β=0.49, p<0.05) was a significant predictor, with increased use being associated 
with increased oxy-Hb change. 
Using deoxy-Hb at V14 during the 1
st
 rate as the dependent variable this overall 
regression model accounted for a non-significant 30.7% (R² = 0.31, R² adjusted = 0.16, F(6, 
29)=2.14, p>0.05) of the variance in deoxy-Hb. Cannabis use indices (step 1) did not predict 
a significant amount of variance in V14 deoxy-Hb (R² = 0.03, R² adjusted = -0.06, 
F(3,32)=0.34, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=-0.09, p>0.05), total lifetime dose (β=0.38, p>0.05) and 
amount smoked in the last 30 days (β=-0.25, p>0.05). However, ecstasy use indices (step 2) 
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did predict a significant amount of variance in V14 deoxy-Hb, after controlling for cannabis 
use indices (R² change=0.28, F-change (3,29)=3.85, p<.05). Individual indices; frequency of 
use (β=-0.37, p>0.05) and lifetime dose (β=-0.86, p>0.05) did not predict V14 deoxy-Hb 
level at the 1s rate. However, last 30 day use (β=0.69, p<0.01) was a significant predictor, 
with increased use being associated with increased deoxy-Hb level.  
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Number-Letter Task: The fNIRS data from the two switching blocks of this task is 
displayed in table 8.5. 
Table 8.5: Mean changes in oxy-Hb and deoxy-Hb (µmolar) from baseline, for ecstasy users 
and non-user controls on the switching blocks of the number/letter task. 
 Ecstasy users Non-users 
 NL1 NL2 NL1 NL2 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
V1oxy 0.71 (1.78) 0.57 (1.74) 1.07 (2.37) 1.22 (2.53) 
V2oxy 1.59 (2.57) 1.52 (2.50) 1.10 (1.45) 1.45 (1.51) 
V3oxy 0.89 (1.70) 0.78 (1.73) 0.22 (1.37) 0.24 (1.38) 
V4oxy 1.26 (2.17) 1.17 (2.23) 0.57 (1.47) 0.76 (1.40) 
V5oxy 1.36 (2.57)* 1.29 (2.49) 0.10 (1.43) 0.26 (1.47) 
V6oxy 1.70 (3.38) 1.68 (3.44) 0.57 (1.10) 0.57 (1.14) 
V7oxy 0.95 (3.15) 0.89 (3.03) 0.69 (2.03) 0.96 (2.27) 
V8oxy 3.33 (7.04) 3.51 (7.09) 1.11 (1.72) 1.52 (1.80) 
V9oxy 1.05 (2.12) 0.91 (2.08) 0.27 (1.81) 0.60 (1.97) 
V10oxy 1.26 (2.76) 1.60 (3.07) 0.88 (3.33) 1.36 (3.30) 
V11oxy 0.64 (2.75) 0.52 (2.75) 0.40 (1.70) 0.78 (1.61) 
V12oxy 0.59 (2.61) 0.48 (2.66) 0.50 (1.58) 0.80 (1.42) 
V13oxy 1.34 (2.49) 1.29 (2.42) 0.39 (1.06) 0.49 (1.22) 
V14oxy 0.90 (1.42) 0.88 (1.44) 0.66 (1.32) 0.81 (1.29) 
V15oxy 0.94 (1.91) 0.83 (2.23) 1.11 (1.69) 1.21 (1.83) 
V16oxy 1.22 (2.02) 1.20 (2.02) 1.05 (1.25) 1.11 (1.33) 
     
V1deoxy -0.21 (2.23) -0.20 (2.29) 1.21 (3.57) 0.75 (2.78) 
V2deoxy 0.17 (1.97) 0.28 (2.05) 0.35 (1.71) 0.11 (1.27) 
V3deoxy -0.17 (1.54) -0.13 (1.52) 0.60 (1.96) 0.21 (0.91) 
V4deoxy 0.43 (1.65) 0.45 (1.68) -0.01 (0.96) 0.05 (1.06) 
V5deoxy 0.39 (1.81) 0.45 (1.86) 0.45 (2.03) 0.09 (1.04) 
V6deoxy 0.54 (1.98) 0.60 (2.03) 0.33 (2.03) -0.06 (1.04) 
V7deoxy 0.69 (3.35) 0.74 (3.41) 0.73 (2.87) 0.30 (1.79) 
V8deoxy 2.25 (5.52) 2.63 (5.56) 1.18 (2.48) 1.02 (2.23) 
V9deoxy 0.10 (1.81) 0.11 (1.75) 0.64 (2.85) 0.17 (1.68) 
V10deoxy 0.63 (2.25) 1.14 (2.82) 0.95 (2.87) 0.70 (2.59) 
V11deoxy -0.32 (1.55) -0.27 (1.60) 0.88 (2.83) 0.18 (1.23) 
V12deoxy -0.46 (1.09) -0.44 (1.05) 0.28 (2.09) -0.06 (1.05) 
V13deoxy -0.16 (1.27) -0.12 (1.28) 0.36 (2.34) -0.10 (1.03) 
V14deoxy -0.40 (1.49) -0.31 (1.50) 0.08 (1.73) -0.22 (1.00) 
V15deoxy -0.33 (1.53) -0.34 (1.54) 0.91 (3.19) 0.43 (2.22) 
V16deoxy -0.32 (1.17) -0.20 (1.27) 0.07 (1.78) -0.28 (1.12) 
  
*Indicates a significant difference from controls at the .05 level, and ** at the .01 level 
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Using the oxy-Hb data, ANOVA revealed that in the first switching block ecstasy 
users showed a significant increase in oxy-Hb compared to non-user controls at voxel 5 
F(1,36)=3.57, p<.05, and this difference was approaching significance at voxels 6 
F(1,36)=1.99, p=.08 and 13 F(1,35)=2.41, p=.06. There were no significant differences at any 
of the other voxels measured (p>.05 in all cases). 
There were no significant differences in the deoxy-Hb data at any of the voxels 
measured. However, there were differences that approached significance at V1 F(1,35)=2.02, 
p=.08, V11 F(1,26)=2.03, p=.08 and V15 F(1,35)=2.15, p=.08, whereby ecstasy users had 
decreased deoxy-Hb compared to controls.  
ANOVA on the oxy-Hb data during the second switching block revealed that ecstasy 
users displayed greater oxy-Hb at V5 compared to controls and this difference was 
approaching significance F(1,35)=2.37, p=.07. There were no significant differences at any 
voxels (p>.05). Analysis of the deoxy-Hb change during the second switching block also 
revealed no significant between group differences on any of the voxels measured (p>.05 in 
each case). 
Multiple regression analyses were conducted on the voxel (V5) showing significant 
between group differences in oxy-Hb. Oxy-Hb (µmolar) level at V5 during block 1 of the 
number-letter task was entered as the dependent variable. In step one indices of cannabis use 
were entered as predictors (frequency of use, total lifetime dose, amount smoked in the last 
30 days), in step two the same indices of ecstasy use were entered as predictors. The overall 
regression model accounted for a non-significant 18.8% (R² = 0.19, R² adjusted = 0.03, 
F(6,31)=1.20, p>0.05) of the variance in oxy-Hb. Cannabis use indices (step 1) did not 
predict a significant amount of variance in oxy-Hb (R² = 0.15, R² adjusted = 0.08, 
F(3,34)=2.07, p>0.05). Individual cannabis use indices; frequency of use (β=-0.07, p>0.05) 
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and amount smoked in the last 30 days (β=-0.12, p>0.05), did not significantly predict oxy-
Hb. However total lifetime dose (β=0.56, p<0.05) was a significant predictor, with increased 
dose being associated with increased oxy-Hb. Ecstasy use indices (step 2) did not predict a 
significant amount of variance in oxy-Hb, after controlling for cannabis use indices (R² 
change=0.03, F-change (3,31)=0.43, p>.05). None of the individual ecstasy use indices were 
significant predictors of oxy-Hb at V5 during the first switching block; frequency of use 
(β=0.07, p>0.05) and lifetime dose (β=-0.16, p>0.05) and last 30 day use (β=-0.17, p>0.05).  
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CWFT: Mean oxy-Hb and deoxy-Hb changes from baseline are displayed in table 8.6. 
Table 8.6. Mean changes in oxy-Hb and deoxy-Hb (µmolar) from baseline, for ecstasy users 
and non-users for the CWFT. 
 Ecstasy users Non-users 
 CWFT1 CWFT2 CWFT3 CWFT1 CWFT2 CWFT3 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
V1oxy 0.80 (1.42) 0.71 (1.24) 0.78 (1.33) 1.23 (1.31) 1.12 (1.46) 1.05 (2.48) 
V2oxy 2.36 (2.12)* 1.84 (2.24)* 1.59 (2.02)* 1.04 (1.35) 0.82 (1.30) 0.50 (1.49) 
V3oxy 1.45 (1.65)* 1.08 (1.46) 0.94 (1.51)* 0.68 (1.00) 0.45 (0.90) 0.14 (1.35) 
V4oxy 2.03 (1.99)* 1.99 (1.75)* 2.07 (1.83)* 0.67 (1.54) 0.31 (1.58) 0.36 (1.70) 
V5oxy 1.27 (1.61) 0.83 (1.62) 0.63 (2.13) 0.67 (1.37) 0.47 (1.10) 0.12 (1.33) 
V6oxy 1.67 (2.62) 1.24 (2.36) 1.19 (2.21) 1.07 (2.11) 0.59 (1.62) 0.30 (1.80) 
V7oxy 0.93 (1.65) 0.90 (1.44) 0.68 (1.71) 0.79 (1.53) 0.95 (1.55) 0.66 (1.62) 
V8oxy 1.71 (2.61) 1.72 (2.56) 1.70 (2.34) 1.18 (2.42) 0.93 (1.97) 0.60 (2.41) 
V9oxy 1.05 (1.70) 0.87 (1.63) 0.47 (2.08) 0.79 (1.53) 0.74 (1.59) 0.30 (1.65) 
V10oxy 2.54 (2.38)* 2.59 (2.30)** 2.17 (2.29)** 1.04 (2.35) 0.60 (1.69) -0.06 (1.99) 
V11oxy 1.35 (1.94) 1.00 (1.56) 0.76 (1.66) 0.56 (1.23) 0.60 (1.09) 0.17 (1.31) 
V12oxy 1.48 (2.33) 1.38 (2.35)* 1.49 (1.79)** 0.37 (1.78) 0.13 (1.75) -0.32 (1.82) 
V13oxy 1.26 (1.48) 0.78 (1.51) 0.65 (1.55) 0.81 (1.09) 0.57 (1.15) 0.21 (1.25) 
V14oxy 1.08 (1.80) 0.76 (1.66) 0.74 (1.41) 0.60 (1.62) 0.42 (1.64) 0.08 (1.87) 
V15oxy 0.83 (1.56) 0.61 (1.36) 0.58 (1.40) 1.27 (2.19) 1.36 (2.41) 1.14 (2.25) 
V16oxy 1.83 (1.90) 1.38 (2.41) 1.24 (1.29) 1.16 (1.60) 1.21 (1.61) 0.86 (1.78) 
       
V1deoxy 0.06 (2.79) 0.60 (3.42) 0.94 (3.60) -0.19 (1.40) -0.07 (1.50) 0.52 (2.39) 
V2deoxy 0.70 (2.01)* 0.77 (2.74)* 0.88 (2.83) -0.32 (1.19) -0.42 (1.21) -0.17 (1.17) 
V3deoxy 0.47 (2.39) 0.61 (2.78) 0.82 (2.99) -0.14 (1.06) -0.18 (1.00) 0.14 (1.10) 
V4deoxy 0.89 (2.83) 1.34 (3.37) 1.42 (3.71) -0.38 (1.14) -0.26 (1.16) 0.07 (1.07) 
V5deoxy 0.45 (2.39) 0.54 (2.76) 0.64 (2.98) -0.10 (0.92) -0.19 (1.01) 0.03 (1.05) 
V6deoxy 0.22 (2.36) 0.43 (2.67) 0.45 (2.77) -0.01 (1.27) -0.14 (1.20) 0.13 (1.29) 
V7deoxy 0.27 (2.53) 0.82 (2.94) 0.93 (3.16) -0.11 (1.25) 0.26 (1.49) 0.51 (1.42) 
V8deoxy -0.01 (2.59) 0.60 (3.03) 0.84 (3.14) 0.18 (1.59) 0.14 (1.57) 0.32 (1.78) 
V9deoxy 0.66 (2.90) 1.06 (3.37) 1.03 (3.56) 0.16 (1.42) 0.29 (1.66) 0.49 (1.54) 
V10deoxy 0.49 (2.74) 1.21 (3.54) 1.25 (3.73) 0.19 (1.33) 0.04 (1.48) 0.07 (1.42) 
V11deoxy 0.57 (3.04) 0.71 (3.48) 0.65 (3.80) -0.01 (1.49) -0.01 (1.47) 0.21 (1.40) 
V12deoxy 0.25 (2.51) 0.44 (2.89) 0.56 (3.10) -0.48 (2.10) -0.51 (1.98) -0.33 (1.95) 
V13deoxy 0.33 (2.34) 0.38 (2.66) 0.53 (2.89) -0.12 (1.11) -0.16 (1.03) 0.11 (0.98) 
V14deoxy -0.12 (2.09) 0.10 (2.36) 0.29 (2.50) -0.84 (1.56) -0.78 (1.50) -0.51 (1.48) 
V15deoxy 0.35 (2.73) 0.43 (3.06) 0.57 (3.37) 0.13 (1.81) 0.31 (1.79) 0.58 (1.71) 
V16deoxy 0.42 (2.30) 0.24 (2.46) 0.47 (2.56) -0.22 (0.99) -0.19 (1.04) -0.07 (0.96) 
 
 
 
 
 
*Indicates a significant difference from controls at the .05 level, and ** at the .01 level. 
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 Analysis of oxy-Hb change in block one of the CWFT (“animals”) revealed that 
ecstasy users displayed a significant increase in oxy-Hb compared to controls at V2 
F(1,37)=5.27, p<.05, V3 F(1,36)=2.94, p<.05, V4 F(1,18)=2.91, p<.05 and V10 
F(1,31)=3.28, p<.05. All other differences were non-significant (p>.05). ANOVA on the 
deoxy-Hb data revealed that ecstasy users showed greater deoxygenation compared to 
controls at V2 F(1,37)=3.63, p<.05. No other differences were observed here for any other 
voxel measured (p>.05 in each case).  
The more difficult criteria of naming words beginning with the letter “S” yielded 
significant increased oxy-Hb change in ecstasy users relative to controls at V2 F(1,37)=2.98, 
p<.05, V4 F(1,18)=5.09, p<.05, V10 F(1,31)=8.06, p<.01 and V12 F(1,33)=3.14, p>.05. 
This difference was also approaching significance at V3 F(1,36)=2.49, p=.06. There were no 
significant between group differences at any of the other voxels measured (p>.05 in each 
case). ANOVA on deoxy-Hb change during this block of the task revealed ecstasy users had 
significantly greater deoxy-Hb at V2 F(1,37)=3.05, p<.05, with trends at V4 F(1,18)=2.01, 
p=.09 and V14 F(1,37)=1.94, p=.09. There were no significant differences at any of the other 
voxels measured (p>.05 in each case).  
In the 3
rd
 and most difficult block of this task ANOVA on oxy-Hb change from 
baseline revealed that ecstasy users displayed a significant increase in oxy-Hb compared to 
controls at V2 F(1,37)=3.65, p<.05, V3 F(1,36)=2.96, p<.05, V4 F(1,18)=4.69, p<.05, V10 
F(1,31)=9.01, p<.01 and V12 F(1,33)=8.68, p<.01. There were no significant differences at 
any of the other voxels measured (p>.05 in each case). There were no significant between 
group differences in deoxy-Hb change during this part of the task (p>.05 in all cases). 
However ecstasy users displayed a greater deoxygenation compared to controls that was 
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approaching significance at V2 F(1,37)=2.26, p=.07. There were no significant differences at 
any of the other voxels measured (p>.05 in each case). 
As with the data from the other two tasks, multiple regression analyses were 
conducted on the fNIRS data, at voxels showing between group differences, to observe 
whether ecstasy use predicted oxy/deoxy-Hb level after controlling for cannabis use. Oxy-
Hb/deoxy-Hb (µmolar) change level was entered as the dependent variable in each case. In 
step one indices of cannabis use were entered as predictors (frequency of use, total lifetime 
dose, amount smoked in the last 30 days), in step two the same indices of ecstasy use were 
entered as predictors. The results from these regression analyses can be seen in Appendix 2, 
for brevity, only regressions yielding notable results are reported here. 
Using oxy-Hb at V3 during the first block of the task (animals) as the dependent 
variable, this overall regression model accounted for 30.8% of the variance in oxy-Hb and 
this was approaching significance (R² = 0.31, R² adjusted = 0.17, F(6,31)=2.30, p=0.06). 
Cannabis use indices (step 1) did not predict a significant amount of variance in oxy-Hb (R² = 
0.10, R² adjusted = 0.02, F(3,34)=1.28, p>0.05). None of the individual cannabis use indices 
were significant predictors; frequency of use (β=0.40, p>0.05), total lifetime dose (β=-0.29, 
p>0.05) and amount smoked in the last 30 days (β=-0.19, p>0.05). The ecstasy use indices 
(step 2) did, however, predict a significant amount of variance in oxy-Hb, after controlling 
for cannabis use indices (R² change=0.21, F-change (3,31)=3.07, p<.05). Individual indices; 
last 30 day use (β=-0.28, p>0.05) and lifetime dose (β=0.37, p>0.05) did not predict oxy-Hb. 
However frequency of use (β=0.44, p<0.05) was a significant predictor with increased 
frequency being associated with increased oxy-Hb. 
Using oxy-Hb at V4 during the first block of the task (animals) as the dependent 
variable, this overall regression model accounted for a non-significant 52.4% (R² = 0.52, R² 
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adjusted = 0.30, F(6,13)=2.38, p>.05) of the variance in oxy-Hb. Cannabis use indices (step 1) 
did not predict a significant amount of variance in oxy-Hb (R² = 0.13, R² adjusted = -0.03, 
F(3,16)=0.80, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=-0.04, p>0.05), total lifetime dose (β=0.54, p>0.05) and 
amount smoked in the last 30 days (β=-0.38, p>0.05). The ecstasy use indices (step 2) did, 
however, predict a significant amount of variance in oxy-Hb, after controlling for cannabis 
use indices (R² change=0.39, F-change (3,13)=3.58, p<.05). Individual indices; frequency of 
use (β=0.62, p<0.05) and lifetime dose (β=0.46, p<0.05) did significantly predict oxy-Hb 
level, with increased frequency and increased dose being associated with increased oxy-Hb. 
However last 30 day use (β=-0.35, p>0.05) was not a significant predictor. 
Using deoxy-Hb at V2 during the first block of the task (animals) as the dependent 
variable, this overall regression model accounted for a non-significant 14.8% (R² = 0.15, R² 
adjusted = -0.01, F(6, 32)=0.92, p>.05) of the variance in oxy-Hb. Cannabis use indices (step 
1) did not predict a significant amount of variance in deoxy-Hb (R² = 0.03, R² adjusted = -
0.01, F(3,35)=0.35, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=0.05, p>0.05), total lifetime dose (β=-0.14, p>0.05) and 
amount smoked in the last 30 days (β=-0.01, p>0.05). The ecstasy use indices (step 2) did not 
predict a significant amount of variance in deoxy-Hb, after controlling for cannabis use 
indices (R² change=0.12, F-change (3,32)=1.48, p>.05). Individual indices; frequency of use 
(β=0.44, p>0.05) and last 30 day use (β=-0.28, p>0.05) did not predict deoxy-Hb level. 
However lifetime dose (β=0.34, p=0.06) approached significance as a predictor, with 
increased use being associated with increased deoxy-Hb. 
Using oxy-Hb at V4 during the second block of the task (S letter words) as the 
dependent variable, this overall regression model accounted for a non-significant 52.1% (R² = 
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0.52, R² adjusted = 0.30, F(6, 13)=2.35, p>.05) of the variance in oxy-Hb. Cannabis use 
indices (step 1) did not predict a significant amount of variance in oxy-Hb (R² = 0.31, R² 
adjusted = 0.18, F(3,16)=2.35, p>0.05). Individual cannabis use indices; frequency of use 
(β=-.029, p>0.05), and amount smoked in the last 30 days (β=-0.47, p>0.05) did not predict 
oxy-Hb, however total lifetime dose (β=0.91, p<0.05) was a significant predictor, with 
increased use being associated with increased oxy-Hb. The ecstasy use indices (step 2) did 
not predict a significant amount of variance in oxy-Hb, after controlling for cannabis use 
indices (R² change=0.22, F-change (3,13)=1.94, p>.05). Individual indices; frequency of use 
(β=-0.03, p>0.05) and last 30 day use (β=0.29, p>0.05) did not predict oxy-Hb. However 
lifetime dose (β=0.42, p=0.06) approached significance as a predictor, with increased use 
being associated with increased oxy-Hb change. 
Using deoxy-Hb at V2 during the second block of the task (S letter words) as the 
dependent variable, this overall regression model accounted for a non-significant 14.1% (R² = 
0.14, R² adjusted = -0.02, F(6, 32)=2.35, p>.05) of the variance in deoxy-Hb. Cannabis use 
indices (step 1) did not predict a significant amount of variance in deoxy-Hb (R² = 0.03, R² 
adjusted = -0.05, F(3,35)=0.35, p>0.05). None of the individual cannabis use indices were 
significant predictors; frequency of use (β=-0.08, p>0.05), total lifetime dose (β=-0.15, 
p>0.05) and amount smoked in the last 30 days (β=0.04, p>0.05). The ecstasy use indices 
(step 2) did not predict a significant amount of variance in deoxy-Hb, after controlling for 
cannabis use indices (R² change=0.11, F-change (3,32)=1.38, p>.05). Individual indices; 
frequency of use (β=-0.00, p>0.05) and last 30 day use (β=0.06, p>0.05) did not predict 
deoxy-Hb. However lifetime dose (β=0.44, p=0.06) approached significance as a predictor, 
with increased use being associated with increased deoxy-Hb. 
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Using oxy-Hb at V3 during the third block of the task (4 letter C words) as the 
dependent variable, this overall regression model accounted for a non-significant 26.7% (R² = 
0.27, R² adjusted = 0.13, F(6, 31)=1.88, p>.05) of the variance in oxy-Hb. Cannabis use 
indices (step 1) did not predict a significant amount of variance in oxy-Hb (R² = 0.03, R² 
adjusted = -0.06, F(3,34)=0.33, p>0.05). None of the individual cannabis use indices were 
significant predictors; frequency of use (β=0.01, p>0.05), total lifetime dose (β=-0.02, p>0.05) 
and amount smoked in the last 30 days (β=-0.05, p>0.05). The ecstasy use indices (step 2) did 
predict a significant amount of variance in oxy-Hb, after controlling for cannabis use indices 
(R² change=0.24, F-change (3,31)=3.36, p<.05). Individual indices; lifetime dose (β=0.29, 
p>0.05) and last 30 day use (β=-0.09, p>0.05) did not predict oxy-Hb level. However 
frequency of use (β=0.48, p<0.05) was a significant predictor, with increased use being 
associated with increased oxy-Hb. 
Using oxy-Hb at V4 during the third block of the task (4 letter C words) as the 
dependent variable, this overall regression model accounted for a non-significant 46.3% (R² = 
0.46, R² adjusted = 0.22, F(6, 13)=1.87, p>.05) of the variance in oxy-Hb. Cannabis use 
indices (step 1) did not predict a significant amount of variance in oxy-Hb (R² = 0.27, R² 
adjusted = 0.14, F(3,16)=2.01, p>0.05). However individual cannabis use indices: total 
lifetime dose (β=0.94, p<0.05) and amount smoked in the last 30 days (β=-1.17, p<0.05) were 
significant predictors of oxy-Hb, with increased lifetime dose being associated with increased 
oxy-Hb and increased amount smoked in last 30 days being associated with decreased oxy-
Hb. Frequency of use (β=0.31, p>0.05), was not a significant predictor. The ecstasy use 
indices (step 2) did not predict a significant amount of variance in oxy-Hb, after controlling 
for cannabis use indices (R² change=0.19, F-change (3,13)=1.53, p>.05). None of the 
individual ecstasy use indices predicted oxygenation at V4; frequency of use (β=-0.07, 
p>0.05) lifetime dose (β=0.33, p>0.05) and last 30 day use (β=0.39, p>0.05). 
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Implications of Chapter 8 
The results from this chapter indicate that ecstasy users show an increase in effortful 
cognition during all three executive functioning tasks, despite having similar behavioural 
output to controls. Ecstasy users displayed significantly increased oxy-Hb changes from 
baseline relative to controls over several voxels during the inhibition (RLG) task. At the 
slowest rate (4second rate), that is understood to be the easiest level of the task, increases 
were observed in V10 relating to the right medial PFC in ecstasy users. As difficulty 
increased, a more pronounced difference between ecstasy users and controls was observed. 
During the second block of the task (2 second rate) ecstasy users displayed significant 
increases in oxy-Hb relative to controls at voxels 4, 10 and 12. This indicates a bilateral 
induction of oxy-Hb increase. At the most difficult level of the task (1 second rate), ecstasy 
users displayed significant increases in oxy-Hb in voxels relating to inferior parts of the right 
medial PFC and right DLPFC (V12 and V14). Although, this is a less pronounced difference 
than in block two, there were complimentary increases in deoxy-Hb that suggest more 
pronounced differences between users and non-users as a function of difficulty. A total of 
eight voxels, showed significant between group differences in deoxy-Hb at the one second 
rate, compared to six voxels at the two second rate and seven voxels at the four second rate. 
In each case, increases in deoxy-Hb, were observed over the breadth of the prefrontal cortex, 
suggesting that induction of haemoglobin in ecstasy users during inhibition is bilateral. The 
majority of the regression analyses, on voxels showing significant between group differences, 
to observe whether ecstasy use predicted oxy and deoxy-Hb increases after controlling for 
cannabis use indices, were non-significant. However ecstasy use indices predicted a 
significant amount of the variance in deoxy-Hb at voxel 14, in the four second rate of the task.  
Specifically frequency of use and last 30 days use were significant predictors, with increased 
frequency being associated with reduced deoxy-Hb, and increased last 30 day use being 
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associated with increased deoxy-Hb. Last 30 days use was also a significant predictor of oxy-
Hb increase at V12 and V14 in the 1 second rate block, with increased use being associated 
with increased oxygenation. Last 30 days use also predicted deoxy-Hb increase at V14 at the 
two and one second rates. The results from regression analyses suggest that recency of 
ecstasy use may play an important role in the observed cognitive function alterations during 
inhibition. 
Ecstasy users displayed increases in oxy-Hb relative to controls in voxels pertaining 
to the left medial PFC during switching. Indeed voxel 5 in the first switching block saw 
significant increases in oxygenated haemoglobin for ecstasy users relative to controls. 
Moreover V5 also displayed differences in block two that were approaching significance. 
Regression analyses did not show ecstasy use indices as significant predictors of oxy-Hb 
change at V5 (block 1) after controlling for cannabis use. However lifetime dose of cannabis 
was a significant predictor of oxygenation at V5, in block one, with increased use being 
associated with increased oxy-Hb. Increases in oxy-Hb relative to controls were observed 
consistently in several sites over the left DLPFC and right PFC during tasks that tap the 
executive function of “access”. Furthermore the number of voxels showing differences here 
increased as a function of difficulty. Ecstasy users also displayed significant increases in 
deoxy-Hb compared to controls at V2 relating to the left DLPFC in blocks one (semantic 
fluency – “animals”) and two (first level of word fluency – “s” letter words). Frequency of 
ecstasy use was a significant predictor of oxy-Hb after controlling for cannabis use indices at 
V3 and V4 of block one and V3 in block three. Increased frequency is associated with 
increased oxy-Hb at these sites. Lifetime dose of ecstasy was also a significant predictor of 
oxy-Hb at V4 in block one. Lifetime dose was also approaching significance (p=.06 in each 
case) as a predictor of oxy-Hb at V4 in block two and of deoxy-Hb in V2 in blocks one and 
two. Again increased lifetime dose was associated with increases in oxy and deoxy-Hb. 
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Lifetime dose of cannabis was also a significant predictor of oxy-Hb at V4 in blocks two and 
three. These results suggest that frequency of use and lifetime dose of ecstasy may play a role 
in neurocognitive alterations associated with access. 
Thus far it appears that ecstasy users are engaged in more effortful cognition in terms 
of haemodynamic response than non-users, during executive function tasks. This is consistent 
across Chapters 7 and 8. Furthermore the results from this chapter corroborate the results 
from Chapter 6 that suggest atypical processing of inhibition, switching and access in ecstasy 
users. All three chapters thus far have a dissociation between behavioural output and 
cognitive effort reflecting neuroimaging measures’ greater sensitivity to cognitive 
impairment, and the results are consistent with ecstasy users relying on recruitment of 
additional resources to attenuate performance deficits. The next chapter will assess the 
haemodynamic response to a multitasking paradigm alongside cortisol sampling data as a 
measure of the integrity of the HPA axis in ecstasy users. 
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Chapter 9: fNIRS multitasking and neuroendocrine response  
9.1 Chapter overview 
Thus far it appears that fNIRS has provided clear observable differences in relation to 
effortful cognition exhibited between ecstasy users and controls. This chapter further explores 
haemodynamic response in ecstasy users relative to controls. However this time a multi-
tasking paradigm has been employed. Furthermore a diurnal cortisol profile has been 
completed by all participants to assess the integrity of the HPA axis. Twenty ecstasy users, 17 
polydrug controls and 19 drug naïve controls were recruited for this study. Again 
performance on the task was equivalent between groups. However, fNIRS data show 
differences in haemodynamic response to task between groups. The cortisol profiling data 
show generally increased levels of cortisol in ecstasy users compared to controls, which was 
significant compared to both control groups at time 3 on day 1 of the study protocol and also 
significantly increased compared to polydrug controls at time 1 of day 1 of the protocol. 
9.2 Introduction 
  
Recreational drug use is argued to be detrimental to normal physiological and 
psychological functioning. As documented in this thesis, working memory deficits – 
particularly those associated with higher level executive functioning tasks appear to be most 
prominent in the literature (Fisk et al., 2004; Montgomery, Fisk, Newcombe & Murphy, 
2005). However ecstasy produces its acute psychological and physiological effects by being a 
powerful indirect serotonin agonist, whilst also having stimulatory effects on dopamine 
amongst other neurotransmitters (McDowell & Kleber, 1994). After exposure, rebound 
neurotransmitter depletion is common, leading to anhedonia (Curran & Travill, 1997), 
amongst other psychobiological alterations to cognition sleep and mood (Parrott & Lasky, 
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1998; Parrott, 2006). Repeated exposure of MDMA may lead to long lasting effects on 
monoamine mediated psychobiological functions. 
MDMA’s agonist action on serotonin also leads to stimulation of the hypothalamic-
adrenal-axis (HPA) axis, resulting in altered neuroendocrine function (Parrott et al., 2008). 
The neurohormone cortisol is understood to be produced in response to stress, and has been 
used as an indicator of neuroendocrine function. In ecstasy users, acute effects of MDMA 
combined with dancing in hot environments, have been reported to increase salivary cortisol 
levels by up to 800% compared to clubbing without taking the drug (Parrott et al., 2008). 
This combination of drug use and prolonged dancing in hot environments is proposed to have 
an interactive effect on psychobiological functions, which has been termed the Bioenergetic 
Stress Model of recreational MDMA use (Parrott, 2006; Parrott et al., 2008). Moreover 
MDMA has been described as an acute metabolic stressor, due to its actions on cortisol 
(Parrott, 2006; Parrott et al., 2008). Further evidence for acute increases of cortisol after 
MDMA use comes from de la Torre et al. (2000) who observed marked elevation of plasma 
cortisol and prolactin after doses of MDMA that are equivalent to recreational doses (50-
150mg). Peak cortisol concentration was observed 2 hours post ingestion. Harris et al. (2002) 
report similar significant increases in plasma cortisol after administration (1.5mg/kg) of 
MDMA in humans. 
 The most marked increases in cortisol have been observed in the field environment 
where recreational MDMA users are predominantly using these drugs, such as night clubs 
(Parrott et al., 2008). It is in these ‘real world’ situations where ecstasy users are exposed to 
multiple stimulatory factors (heat, crowding, loud music, intense light), which can cause high 
levels of bioenergetic stress (Parrott, 2009). Moreover, it has been suggested that repeated 
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exposure to such hyperstimulation will have cumulative effects and result in chronic 
bioenergetic distress (Parrott, 2006; Parrott, 2009). 
 Gerra et al., (2000) investigated long lasting effects of MDMA use on cortisol and 
prolactin. Ecstasy users’ basal cortisol levels appeared equivalent to controls, three weeks 
post MDMA exposure. However a significantly reduced cortisol response to D-fenfluramine 
challenge was observed in ecstasy users, three weeks post administration, though cortisol 
responses appeared to normalise after 12 months abstinence. The same research group (Gerra 
et al., 2001) observed significantly elevated baseline cortisol levels in MDMA users, who had 
been free from MDMA for at least three weeks, compared to controls. A possibility for this 
increase was suggested to be MDMA related alterations to basal HPA-axis function, due to 
serotonergic changes produced by repeated MDMA exposure. Basal cortisol plasma levels 
were again observed to be elevated in drug free ecstasy users compared to controls in a study 
by Gerra et al. (2003); ecstasy users and controls were exposed to psychosocial stressors 
(Stroop interference task, mental arithmetic and public speaking) and MDMA users showed a 
blunted cortisol response to psychological stress compared to controls. It was suggested that 
increased basal levels of cortisol may reflect increased worry about the tasks and perception 
of them being more stressful. Alternatively, perhaps elevated basal cortisol due to MDMA 
exposure exhausts HPA axis leading to blunted responses to stress (Gerra et al., 2003). 
Nevertheless there is evidently a complex relationship between drug use and HPA-axis 
function. 
Cortisol release follows an established diurnal pattern, increasing rapidly within the 
first 30 minutes of awakening (cortisol awakening response) (Pruessner et al., 1997), and 
remaining elevated for up to 60 minutes. Following this a general decline in cortisol levels 
throughout the day is normal. Hyperactivity of the HPA-axis has real health implications, 
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given that it is associated with susceptibility to infectious disease (Sapolsky, 1996) and 
depression (Wong et al., 2000). Cortisol also increases as a response to stress and allostatic 
load in normal individuals (McEwen, 1998). Thus investigation of diurnal cortisol profiles in 
ecstasy users in the days leading up to a psychological stressor may yield more information 
about basal cortisol levels and stress reactivity. 
Wetherell et al., (2012) recently investigated psychological stress reactivity in ecstasy 
users and controls using a multi-tasking stressor framework (including tasks that require 
executive function resources). Self-reported feelings of calmness were significantly reduced 
in ecstasy users compared to drug naïve controls in response to the stressor task. This is 
suggestive that ecstasy use can have long lasting ill effects on the psychological response to 
stress. This in turn has real life implications for recreational drug users and also warrants 
further investigation. 
The aims of this study were to investigate changes in prefrontal blood oxygenation in 
response to a demanding task in ecstasy users, polydrug controls and drug naïve controls. The 
acute stressor is provided in the form of a multitasking stressor task (Purple Research 
Solutions, UK), with four higher-level processing tasks (Stroop task, two visual monitoring 
tasks and mental arithmetic). The cerebral hemodynamic response to conducting several tasks 
at once was measured as well as performance on the task behaviourally. Moreover a diurnal 
cortisol profile was obtained from all participants in the day preceding the multitasking 
stressor and the test day. Pre and post test samples were also collected (saliva samples) to 
assess cortisol levels in response to a psychological stressor. It was hypothesised that 
performance on the multitasking stressor task may be equivalent, as with other measures of 
performance in this thesis, but MDMA users will again show increased haemodynamic 
response to the task, reflective of increased cognitive effort. Furthermore in line with 
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previous research on cortisol, it was predicted that ecstasy users will show increased basal 
cortisol levels from their diurnal cortisol profiles and as such will not display marked cortisol 
increase in response to the multitasking stressor. 
9.3 Method 
Participants: 
Twenty ecstasy users (mean age = 21.61, SD = 0.52, 12 = male), 17 non-ecstasy, 
polydrug controls (mean age = 21.23, SD = 0.79, 12 = male) and 19 drug naïve controls 
(mean age = 21.60, SD = 0.84, 6 = male) were recruited via direct approach (e-mail) to 
Liverpool John Moores University students. Inclusion criteria were the same as that in 
Chapter 6. Indices of ecstasy use were as follows: total lifetime dose 253.86 tablets ± 376.20; 
mean amount used in last 30 days 2 tablets ± 3.46, and frequency of use 0.22 times/week ± 
0.21. 
Materials 
Questionnaires: 
The Background Drug Use Questionnaire, NASA-TLX and Raven’s SPM were used, 
as described in Chapter 6. 
The SAI VAS (State Anxiety Inventory – Visual Analogue Scale) was completed pre 
and post testing period, this comprises 6 statements (I feel calm, I feel tense, I feel upset, I 
feel relaxed, I feel content, I feel worried) and participants have to indicate on a 100mm line 
how much they agree with the statement, ranging from 0 – not at all, to 100 – very much. To 
attain a measure of perceived stress in the lab, the Perceived Stress Scale (PSS4) was used. 
This is a four item scale that asks participants about their perceived stress, for example “How 
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often have you felt difficulties were piling up so high that you could not overcome them?” 
Participants are required to respond from 0 = Never, to 4 = very often. 
The HADS (Hospital Anxiety and Depression Scale) (Zigmond & Snaith, 1983), is a 
14-item scale with seven items relating to anxiety and seven items relating to depression.  
This scale includes items such as “I still enjoy things that I used to enjoy” and participants are 
required to state how much they agree with this from for example 1 = definitely as much, to 4 
= hardly at all. A high score for the anxiety related items reflects high levels of anxiety and a 
high level on depression related items reflect high levels of depression.  
Multitasking stress test 
The multi-tasking framework (Purple Research Solutions, UK) is a PC run platform 
used to elicit acute psychological stress (Wetherell & Sidgreaves, 2005). The same 
combination of four stressor modules (Stroop, mental arithmetic, tracking/target area – visual 
monitoring and warning/rising bars – visual monitoring) was used for all participants, at a 
medium intensity workload. The task requires participants to attend to the four different 
components/modules of the task simultaneously. The instructions on screen inform 
participants of how points are scored and the participants were instructed to achieve the 
highest score possible. The set of tasks included a mental arithmetic task whereby 
participants were required to calculate a series of 2 x 3 digit addition sums; visual monitoring 
(target area) whereby participants monitor the position of a moving cursor and reset this 
cursor when it entered a points zone; a second visual monitoring module (rising bars) 
comprises of a set of six bars that rise towards a target line at varying speeds. Once the bars 
reach the target, participants select the order in which the bars reached the target, fastest first. 
Finally a Stroop task module involved colour names appearing onscreen in various colours, 
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participants had to select the colour the word appeared in, rather than read the word. For more 
information on the different modules of the framework, see Wetherell and Sidgreaves (2005) 
Equipment 
fNIRS: Haemodynamic response to task in the PFC was monitored as in Chapter 7. 
Cortisol: Saliva samples were obtained by instructing participants to chew on a 
salivette (Sarstedt Ltd, Germany) for one minute. Participants collected labelled salivettes 
from the laboratory prior to commencing the study. Sample 1 was taken on day 1 on 
awakening, sample 2 was taken 30 minutes after waking, sample 3 was taken in the afternoon 
between 1-3 pm and a fourth sample was taken in the evening (between 9-11pm). The 
following day (test day) a sample was again taken upon waking, a second sample was taken 
30 minutes later, a third sample was taken upon entering the lab for testing, a fourth sample 
was taken post-test and a final sample was collected in the evening (between 9-11pm). Saliva 
samples were frozen until they were assayed for salivary cortisol using Neogen cortisol 
ELISA kits (Neogen Corporation, USA). Assays were conducted by Northumbria University. 
Procedure 
Participants were required to attend the lab on two occasions. Upon entering the lab 
for the first day participants were informed of what the study would entail and written 
consent was obtained. Participants were given questionnaires in the following order: 
background drug use questionnaire, PSS4, HADS and Raven’s SPM and informed of the 
saliva sampling protocol (outlined above). The following day, participants did not attend the 
lab, but did collect cortisol samples (day 1 of cortisol profile protocol). One day later (test 
day, day 2 of sampling protocol), a pre-task SAI-VAS and HADS were given upon entering 
the lab, and a pre–test cortisol sample was taken. After this the fNIRS sensor pad was 
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attached to the participants’ forehead whilst they read instructions on how to complete the 
task. Participants were then instructed to complete a two minute practise trial of the task after 
which any questions that the participant had about the task could be answered. The fNIRS 
signals were displayed on a desktop computer running COBI studio (Drexel University) in an 
adjacent room to the testing room. Providing the signals from the fNIRS were stable, a 
baseline of inactivity was recorded before the participants were instructed to complete a 20 
minute session of the multi-tasking stressor task on a desktop computer running the purple 
framework (Purple Solutions, UK). After the 20 minutes had elapsed, participants completed 
a post task SAI-VAS and gave post-test cortisol sample. The NASA TLX was also completed 
post task. Finally participants were fully debriefed and were paid £20 in store vouchers. The 
study was approved by Liverpool John Moores University Research Ethics Committee, and 
was administered in accordance with the ethical guidelines of the British Psychological 
Society. 
fNIRS analysis 
 Pre-processing and analysis followed the same procedure as that described in Chapter 
7.  
Statistical analysis 
Behavioural data was analysed using ANOVA with group as the between subjects 
factor and total scores on each component of the task (Stroop, mental arithmetic, 
tracking/target area – visual monitoring and warning/rising bars – visual monitoring) as well 
as overall score on the task as the dependent variables. ANOVA4 was conducted on oxy-Hb 
                                                          
4
 Due to small amounts of missing data on different voxels, MANOVA was not appropriate for this analysis. 
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and deoxy-Hb changes from baseline (µmolar) at each voxel, for the whole epoch of the 
multitasking test (20 minutes). ANOVA was also conducted on the cortisol data
5
. 
Any significant main effects were further explored using post-hoc Tukey’s HSD test.  
 
9.4 Results 
Perceived stress scores, HADS scores and pre and post task SAI-VAS scores are 
displayed in Table 9.1. Indices of other drug and alcohol use are displayed in Table 9.2.   
Table 9.1: Indices sleep quality, fluid intelligence and socio-demographic variables 
    Ecstasy Users  Polydrug Controls       Drug Naïve Controls 
       
Males:  n, (%)  13 (65)  13 (76)  6 (32) 
Age (SD)    21.61 (2.20)    21.23 (2.83)  21.60(3.27) 
University degree: n (%)  5 (25)         5 (30)           3 (15) 
Employment status       
Student;  n, (%)  18 (90)   11 (65)  18 (95) 
Employed; n (%)  1 (5)  6 (35)  3 (15) 
Unemployed; n (%)  1 (5)  0 (0)  1 (5) 
   Mean (SD)  Mean (SD)     Mean (SD) 
Ravens Progressive 
Matrices (maximum 60) 
 49.70 (5.12)  51.82 (5.42)  49.58 (6.94) 
PSS4 (1)  1.55 (0.83)  1.41 (0.94)  1.32 (0.95) 
PSS4 (2)  1.90 (0.55)  1.82 (0.64)  2.00 (0.67) 
PSS4 (3)  2.45 (0.60)  2.35 (0.49)  2.37 (0.50) 
PSS4 (4)  1.45 (0.89)  1.41 (0.80)  1.21 (0.79) 
HADS anxiety Day 1 
HADS depression Day 1 
HADS anxiety Day 2 
HADS depression Day 2 
SAIVAS pre calm 
SAIVAS post calm 
SAIVAS pre tense 
SAIVAS post tense 
SAIVAS pre upset 
SAIVAS post upset 
SAIVAS pre relaxed 
SAIVAS post relaxed 
SAIVAS pre content 
SAIVAS post content 
SAIVAS pre worried 
SAIVAS post worried 
 17.92 (1.64) 
10.80 (1.97) 
10.14 (3.53) 
10.33 (2.13) 
63.80 (24.25) 
70.00 (17.27) 
20.30 (15.89) 
25.10 (15.97) 
11.70 (9.59) 
12.50 (9.55) 
66.05 (20.35) 
64.30 (17.93) 
71.60 (16.54) 
71.25 (11.84) 
22.40 (17.27) 
19.70 (12.68) 
 
 18.13 (1.46) 
10.57 (1.70) 
9.93 (2.55) 
10.79 (2.83) 
84.06 (10.29) 
74.24 (30.68) 
15.71 (19.09) 
22.35 (24.89) 
14.65 (23.17) 
8.00 (9.97) 
68.29 (28.76) 
69.00 (29.54) 
76.76 (21.33) 
82.00 (14.90) 
19.12 (24.76) 
13.71 (17.75) 
 
 18.50 (1.62) 
10.06 (2.88) 
9.39 (2.97) 
9.17 (2.62) 
79.00 (19.44) 
78.37 (20.28) 
16.14 (16.84) 
14.32 (16.24) 
11.00 (11.69) 
10.37 (10.65) 
79.47 (16.52) 
78.89 (16.70) 
74.21 (24.67) 
73.89 (21.21) 
14.79 (17.69) 
12.37 (13.80) 
 
 
 
                                                          
5
 Due to missing data at each time point it was not appropriate to perform mixed ANOVA on the cortisol data. 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;           
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Table 9.2: Indices of drug use.  
 
 
 
 Ecstasy Users  Polydrug 
Controls 
 Drug Naïve 
Controls 
 
 Mean (SD) n Mean (SD) n Mean (SD) n 
 
Cannabis 
      
 Frequency 
(times/wk) 
2.74 (2.81)*  20 1.11 (1.56) 16 - - 
       
 Last 30 
days 
(joints) 
46.56 (59.89) 17 19.34 (46.36) 16 - - 
       
 Total use 
(joints) 
3613.80 
(4469.70) 
20 1562.96 
(3021.05) 
17 - - 
       
Cocaine        
Frequency 
(times/wk) 
0.06 (0.08) 2 0.05 (0.06) 2 - - 
       
Last 30 
days 
(lines) 
0.00 (0.00) 2 0.00 (0.00) 2 - - 
       
Total use 
(lines) 
415.00 (43.84) 2 7.50 (0.71) 2 - - 
       
Ketamine       
Frequency 
(times/wk) 
0.19 (0.19) 5 - - - - 
       
Last 30 
days use 
(grams) 
0.00 (0.00) 5 - - - - 
       
Total use 
(grams) 
21.72 (16.90) 
 
5 - - - - 
       
Alcohol 
units p/w 
 
13.20 (6.68) 20 12.44 (9.70) 16 6.99 (9.14) 19 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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One way ANOVA revealed that there were no significant between group differences 
on measures such as age and fluid intelligence or on measures of perceived stress (PSS4 
pretesting), (p>.05 in all cases). Pre and post task SAI-VAS scores for each of the six 
subscales (calm, tense, relaxed, content, upset and worried) were analysed using a mixed 
ANOVA, with user group as the between subject factor and time point (pre/post-test) as the 
within subjects factor. Using the score on the visual analogue scale as the DV, for calm there 
was no significant main effect of time point F(1,53)=0.19, p>.05, no time point by group 
interaction F(2,53)=1.97, p>.05, but there was a strong trend for main effect of group 
F(2,53)=3.08, p=05. Pairwise comparisons showed that ecstasy users reported feeling less 
calm than both other groups overall (p<.05) in both cases. For tense there was a strong trend 
for main effect of time point F(1,53)=3.95, p=.05, with all three groups showing increases in 
tenseness post-task. There was no time point by group interaction F(2,53)=0.32, p>.05.  
There was no main effect of group F(2,53)=1.75, p>.05. 
The subscale upset showed no main effect of time point F(1,53)=1.69, p>.05, no time 
point by group interaction F(2,53)=1.82, p>.05 and no main effect of group F(2,53)=0.07, 
p>.05. The subscale of relaxed also showed no main effect of time point F(1,53)=0.03, p>.05 
and no time point by group interaction F(2,53)=0.05, p>.05, but does show a significant main 
effect of group F(2,53)=3.04, p<.05, pairwise comparisons revealed that drug naïve controls 
were significantly more relaxed than ecstasy users (p<.05). The content subscale revealed no 
significant main effect of time point F(1,53)=0.25, p>.05, no time point by group interaction 
F(2,53)=0.33, p>.05 and no main effect of group F(2,53)=1.39, p>.05. Finally, worried 
revealed a main effect of time point, that was approaching significance F(2,53)=3.04, p=06, 
with worry being greatest pre task, but no time point by group interaction F(2,53)=0.27, 
p>.05 and there was no main effect of group F(2,53)=1.06, p>.05. 
 
 
 
 
 
243 
 
Mixed ANOVA was also performed on the HADS with user group as the between 
subject factor and time point (day1/test day awakening) as within subjects. For anxiety there 
was a significant main effect of time point F(1,44)=232.12, p<.05 with reduced anxiety on 
the day of testing. There was however no group by time point interaction F(2,44)=0.53, 
p>.05, or main effect of group F(2,44)=0.02, p>.05. For depression there was no main effect 
of time point F(1,44)=1.98, p<.05, no time point by group interaction F(2,44)=1.41, p>.05 
and no main effect of group F(2,44)=1.14, p>.05. 
ANOVA revealed a significant between group difference in the amount of alcohol 
consumed (weekly) F(2,52)=3.28, p<.05. Pairwise comparisons revealed a strong trend for 
ecstasy users to drink more than drug naïve controls p=.05. t-tests between ecstasy users and 
polydrug controls on drug use other than ecstasy revealed that ecstasy users reported smoking 
cannabis more frequently than polydrug controls (2.74 ± 2.81 compared to 1.11 ± 1.56) 
t(30.74)=2.20, p<.05 (Levene’s test was significant so degrees of freedom have been adjusted 
accordingly). However there were no differences in total lifetime joints smoked or total joints 
smoked in the last 30 days. The ecstasy user group showed greater total cocaine use (415 ± 
43.84 compared to 7.5 ± 0.71) though only 2 participants in each group reported taking 
cocaine. Ketamine was used by 5 participants in the ecstasy user group, though there were no 
polydrug users who reported using ketamine, so a statistical comparison cannot be made. 
However as seen in Table 9.2, the ecstasy user group can be considered a polydrug user 
group. No differences were observed on other drug intake variables. 
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Behavioural data analysis 
Due to eight participants (4 ecstasy users, 3 polydrug users and 1 drug naïve control) 
not following instructions correctly on the Stroop task and consistently answering incorrectly, 
their data on this component of the task was not analysed any further. These participants are 
also excluded from fNIRS analysis. Performance data can be observed in table 9.3. 
 
Table 9.3: Performance data (means and SDs of total scores) multitasking components. 
 
 
 
Ecstasy users Polydrug controls Drug naïve controls 
 Mean Mean Mean 
 
 
Stroop 
 
 
4443.75 (1653.38) 
 
 
4222.14 (1683.38) 
 
 
4500.28 (2545.14) 
 
 
Warning 
 
 
550.50 (43.71) 
 
 
566.47 (28.93) 
 
 
533.16 (141.07) 
 
 
Tracking 
 
 
392.80 (112.39) 
 
 
437.29 (58.23) 
 
 
386.11 (203.88) 
 
 
Maths 
 
 
Total 
 
 
414.35 (235.65) 
 
 
5847.75 (1721.07) 
 
 
463.65 (230.06) 
 
 
5691.29 (1727.09) 
 
 
371.05 (293.16) 
 
 
6382.22 (2357.42) 
    
 
 
Univariate ANOVA with a between subjects factor of group and score on task 
component as the dependent variables revealed that there were no significant differences 
between groups on any of the components of the task; Stroop F(2,45)=0.08, p>.05; Maths 
F(2,53)=0.56, p>.05; Tracking/target are visual monitoring F(2,53)=0.50, p>.05. Levene’s 
statistic was violated on the warning/rising bars scores, therefore an independent samples 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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Kruskall-Wallace test was conducted. This revealed that there were no significant differences 
between ecstasy users (rank = 560), polydrug controls (rank = 570) and drug naïve controls 
(rank = 580) on this component of the task; (H(2) =1.43, p>.05). On the composite total score, 
ANOVA revealed no significant between group differences F(2,45)=0.55, p>.05. 
  Post task NASA TLX scores were analysed using MANOVA. This revealed no 
overall between group differences in task load F(12,96)=1.25, p>.05 for Pillai’s trace, nor 
any between group differences on the individual sub-scales (Mental demand; F(2,52)=1.32, 
p>.05, Physical demand; F(2,52)=0.11, p>.05, Temporal demand; F(2,52)=0.10, p>.05, 
Effort; F(2,52)=1.97, p>.05, Performance; F(2,52)=2.39, p>.05, Frustration; F(2,52)=2.65, 
p>.05). 
fNIRS Analysis 
Averaged oxy-Hb and deoxy-Hb changes (µmolar) from baseline are displayed in 
table 9.4. A series of ANOVAs were used to assess group differences in changes from 
baseline.  
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Table 9.4: Oxy-Hb and deoxy-Hb changes from baseline (µmolar) for each group during the 
multitasking test. 
 Ecstasy users Polydrug controls Drug naïve controls 
 Mean (SD) Mean (SD) Mean (SD) 
    
V1oxy 1.03 (2.27) 0.85 (1.17) 1.06 (0.91) 
V2oxy    0.34 (0.88) † 1.22 (1.16) 1.51 (1.18) 
V3oxy 0.68 (1.85) 0.69 (1.02) 0.79 (0.82) 
V4oxy 0.26 (2.25) 1.40 (1.22) 0.92 (1.01) 
V5oxy 0.22 (2.12) 0.02 (1.75) 1.12 (0.91) 
V6oxy 0.23 (2.57) 1.36 (1.35) 1.06 (1.09) 
V7oxy 0.22 (1.56) 0.20 (1.44) 0.78 (1.14) 
V8oxy 0.37 (2.56) 0.91 (1.38) 1.14 (0.86) 
V9oxy -0.02 (1.65) 0.13 (1.11) 0.65 (1.53) 
V10oxy 0.20 (2.06) 0.99 (1.36) 1.11 (1.52) 
V11oxy 0.75 (1.84) 0.32 (0.97) 0.38 (1.31) 
V12oxy -0.06 (1.90) 0.58 (1.29) 1.05 (0.98) 
V13oxy 0.51 (1.77) 0.94 (1.66) 1.10 (1.06) 
V14oxy         -0.27 (1.61)** † 1.74 (2.06) 1.37 (1.13) 
V15oxy 0.58 (1.82) 1.01 (1.33) 0.55 (1.01) 
V16oxy    0.17 (1.33) † 1.20 (1.55) 1.35 (1.19) 
    
V1deoxy -0.74 (1.00)    0.41 (2.02) † -0.81 (0.67) 
V2deoxy   -1.11 (0.77)* 0.15 (1.65) -0.75 (0.80) 
V3deoxy -0.12 (1.28) -0.08 (1.03) -0.59 (0.57) 
V4deoxy -0.67 (1.58)   0.42 (1.63) † -1.24 (1.12) 
V5deoxy -0.23 (1.44) -0.54 (1.34) -0.31 (0.68) 
V6deoxy -0.64 (1.71) 0.31 (1.50) -0.48 (1.44) 
V7deoxy -0.26 (0.69) -0.10 (1.68) -0.46 (0.52) 
V8deoxy -0.33 (1.67) 0.13 (1.78) -0.88 (1.29) 
V9deoxy -0.66 (1.04) -0.02 (1.26) -0.48 (0.84) 
V10deoxy -0.83 (1.41) 0.15 (1.93) -1.08 (1.42) 
V11deoxy -0.51 (1.04) 0.44 (2.45) -0.55 (1.03) 
V12deoxy   -1.07 (1.22)*    0.71 (2.03) † -1.09 (1.03) 
V13deoxy -0.49 (1.01) 0.08 (1.02) -0.20 (0.61) 
V14deoxy     -1.28 (1.21)** 0.28 (1.65) -0.80 (1.14) 
V15deoxy -0.62 (1.50) -0.00 (1.10) -0.74 (0.54) 
V16deoxy            -0.88 (1.09) 0.08 (1.81) -0.76 (0.80) 
 
 
 
 
*Indicates a significant difference from polydrug controls at the .05 level, and ** at the .01 level;          
† indicates a significant difference from drug naïve controls at the .05 level and †† at the .01 level. 
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ANOVA revealed significant between group differences in average oxy-Hb changes 
at voxel 2 F(2,43)=4.78, p<.05; V14 F(2,43)=6.37, p<.01 and V16 F(2,42)=3.32, p<.05. 
There were no significant between group differences at any of the other voxels measures 
(p>.05).  
 Pairwise comparisons revealed that at V2 ecstasy users showed a significantly 
reduced oxy-Hb change compared to drug naïve controls (p<.05). At V14 ecstasy users show 
significantly lower oxy-Hb than both polydrug controls (p<.01) and drug naïve controls 
(p<.05). At V16 ecstasy users again show significantly lower oxy-Hb than drug naïve 
controls (p<.05).    
ANOVA on deoxy-Hb changes from baseline revealed significant between group 
differences at V1 F(2,42)=3.96, p<.05, V2 F(2,43)=4.71, p<.05, V4 F(2,30)=3.66, p<.05, 
V12 F(2,30)=5.04, p<.05 and V14, F(2,43)=5.09, p<.01. There were no significant between 
group differences at any of the other voxels measured (p>.05). 
 Pairwise comparisons revealed that at V1, polydrug controls showed significantly 
greater deoxy-Hb than drug naïve controls (p<.05), and this difference approached 
significance compared to ecstasy users (p=.07). At V2, polydrug controls showed 
significantly greater deoxy-Hb increase than ecstasy users (p<.05) and this difference 
approached significance compared to drug naïve controls (p=.08). At V4 polydrug controls 
showed significantly increased deoxy-Hb compared to drug naïve controls (p<.05). At V12 
polydrug controls showed significantly increased deoxy-Hb compared to both ecstasy users 
and drug naïve controls (p<.05 in both cases) and at V14 polydrug controls showed 
significantly greater deoxy-Hb compared to ecstasy users (p<.01). Ecstasy users and drug 
naïve controls did not differ significantly from each other at any of these voxels. 
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Cortisol Analysis 
 Mean salivary cortisol levels for each group over the time course of the sampling 
protocol can be observed in figure 9.1. 
Figure 9.1. Diurnal cortisol profile for each group over the two-day protocol. 
 
 
  
 
ANOVA was conducted for cortisol levels at each time point. Significant between 
group differences were observed at day 1 time 3 F(2,45) = 3.60, p<.05, and between group 
differences were approaching significance at day 1 time 1 F(2,44) = 2.92, p=.06. There were 
no significant between group differences in salivary cortisol at any of the other time points 
measured (p>.05 in each case). Planned comparisons revealed that at day 1 time 3 ecstasy 
users had significantly increased cortisol levels compared to both other groups (p<.05 in each 
case). At day 1 time 1, ecstasy users had significantly increased cortisol levels compared to 
polydrug controls (p<.05), there was no significant difference between ecstasy users and drug 
Fig. 9.1: Depicts mean salivary cortisol levels (nmol/l) for each group over the time course for the two day protocol. Note 
the steep increase in cortisol levels 30 minutes after waking on day 1, then gradual decline throughout the day. This 
increase was not as pronounced in day 2, perhaps reflecting elevated cortisol levels at waking itself, due to anxiety about 
attending the lab to undertake a stressor task. On day1 ecstasy users’ cortisol levels remain elevated throughout the day 
compared to control groups. This is significant compared to both groups at time 3 on day 1. Ecstasy users had significantly 
increased cortisol levels at time 1 of day 1 compared to polydrug controls. 
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controls at this time (p>.05). Furthermore, as can be observed in figure 9.1, ecstasy users and 
polydrug users display decreased cortisol level post task compared to pre task. 
9.5 Implications of Chapter 9 
The results from this chapter show that there were no performance differences 
between groups on any of the subscales of multitasking, or on total score for the task. In 
addition, there were no significant differences on self-report measures of perceived workload 
(indexed by the NASA – TLX). There were differences between groups in their 
haemodynamic response to the task. However these were contrary to expectations. Analysis 
of oxy-Hb change from baseline revealed that ecstasy users showed a blunted increase 
compared to controls in response to the task. Indeed, at voxel 14 (pertaining to the right 
DLPFC) ecstasy users showed significantly less oxy-Hb compared to both control groups.  
Moreover drug naïve controls displayed a significant increase in oxy-Hb from baseline 
compared to ecstasy users at V2 (left DLPFC), and V16 (right DLPFC). Polydrug controls 
showed the greatest increase in deoxy-Hb. This was significant compared to ecstasy users at 
V2, 12 and 14, and both ecstasy users and drug naïve controls at V12. Polydrug controls also 
showed increases compared to drug naïve controls at V1 and V4. There were no differences 
between ecstasy users and drug naïve controls in deoxy-Hb at any voxel. These results 
provide difficulty for interpretation given what has preceded them in this thesis. Perhaps the 
individual tasks that comprise the multitasking framework were not executive function 
specific, rather they require other neuronal areas for performance. If this is the case, perhaps 
ecstasy users showed a decrease in oxy-Hb compared to controls in the PFC due to 
reallocating resources to other brain regions. This will be discussed in greater depth in 
Chapter 10. However, the act of multitasking itself, should load on the central executive.  
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The results from cortisol sampling were more in line with predictions and current 
knowledge of MDMA’s effects on the HPA axis. Observation of figure 9.1 shows a general 
elevation in salivary cortisol levels in ecstasy users. However it was only at time 3 on day one 
that ecstasy users displayed significantly increased cortisol levels compared to both other 
groups. Ecstasy users did however show significant increase in salivary cortisol levels 
compared to polydrug controls at time 1 day 1. These results reflect increased basal cortisol 
levels in MDMA users relative to controls. Ecstasy users report significantly reduced feelings 
of calmness, on the day of testing compared to both control groups on the SAI-VAS, and 
significantly reduced feelings of being relaxed than drug naïve controls. Waking cortisol 
levels are increased in control groups on the day of the test, by a greater amount than the 
ecstasy user group. However the ecstasy users still show the greatest levels of cortisol at this 
point. Perhaps such a high level of cortisol upon waking, reflects elevated anxiety about 
undertaking the stressor task, and this increased level of cortisol is unsustainable, hence a 
continuing drop in cortisol levels (as in day 1) rather than an increase post task. The 
following chapter will discuss these results, along with the other results from the empirical 
chapters in this thesis in greater depth. 
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10. General Discussion 
The aim of the current thesis was to examine the neurophysiological response to 
executive functioning in MDMA users. This was investigated using EEG and fNIRS, to aid 
the current understanding of MDMA related cognitive deficits, due to potential serotonergic 
neurotoxicity. Degradation to the serotonin system via repeated use of MDMA may also have 
profound implications for other psychobiological functions. To this end a secondary aim of 
this thesis was to examine neuroendocrine function in ecstasy users, and their neurohormonal 
response to stressful events.  
Chapter 6 of this thesis investigated the executive functions of inhibitory control, 
switching, updating and, access to semantic memory and their behavioural and 
electrophysiological correlates. Background variables such as fluid intelligence, age, 
measures of sleep (apart from pre-test differences between polydrug controls and ecstasy 
users on KSS), level of arousal, depression and anxiety showed no significant differences 
between ecstasy users, polydrug controls and drug naïve controls. There were no behavioural 
differences between groups in terms of number of errors for the Go/NoGo, N-back task and 
semantic association tasks and there were no switch cost differences on the number-letter task. 
No between group differences were observed in terms of reaction time on the semantic 
association task. Furthermore ecstasy users did not differ significantly to the control groups 
with respect to subjective mental workload on any of the tasks. However there were 
differences in reaction time data on the n-back task, whereby drug naïve controls were 
significantly slower to respond than polydrug controls. Although ecstasy users were not 
significantly different in terms of reaction times compared to either control group, they did 
show generally increased reaction times compared to drug naïve controls. Furthermore the 
error count was generally higher for ecstasy users compared to controls (although not 
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significant) perhaps reflecting an accuracy versus speed trade off, that reflects increased 
impulsivity in ecstasy users. The results here are non-significant however, and the polydrug 
users show less errors than drug naïve controls as well as faster reaction times, so this 
interpretation needs treating with caution. The lack of performance differences between 
groups in response inhibition and switching was to be expected. Several studies have shown 
that ecstasy users appear unimpaired at inhibitory control (Gouzoulis-Mayfrank et al., 2003; 
Hanson & Luciana, 2010; Roberts & Garavan, 2010) and mental set switching (Back-
Madruga et al., 2003; Fox et al., 2001; Montgomery, Fisk, Newcombe & Murphy, 2005). It 
was predicted that ecstasy users may show performance deficits in the semantic association 
task. However, ecstasy users have been reported to display unimpaired performance in tasks 
that assess access previously (Bedi & Redman, 2008; Halpern et al., 2004). Furthermore, it 
was expected that ecstasy users may show performance deficits on the n-back task. 
Nevertheless, the lack of performance impairment in updating on this task is in line with 
previous research (Daumann, Fimm et al., 2003). Moreover as has been stipulated previously, 
it was a central aim of this thesis to examine the neurophysiological response to executive 
functioning tasks, as this may be more sensitive in exposing cognitive deficits. 
Despite the lack of between-group differences on behavioural measures, there were 
differences in EEG measures in line with our predictions that reflect atypical processing in 
ecstasy users in response to executive function tasks involving inhibitory control, switching 
and access. The following parts of this discussion will summarise the findings from EEG and 
their relationship to the existing literature and implications for each executive function 
separately. First to be discussed are the findings from the inhibitory control (Go/NoGo) task. 
The ERP results from performing the Go/NoGo task are suggestive of changes in 
attentional processes between the components involved in early inhibition processing (P2). 
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Ecstasy users exhibited significantly higher mean amplitudes than both control groups at 
anterior midline site FCz and significantly higher amplitudes than drug-naïve controls at 
another anterior midline site Fz. Furthermore regression analyses revealed that the amount of 
ecstasy consumed in the last 30 days was a significant predictor of FCz amplitude after 
controlling for cannabis use, suggesting that recent use of ecstasy may play a role in response 
inhibition. It is interesting to observe such differences in the P2 component, given that it has 
been suggested that problems with early orienting or preparation may have consequences for 
later processing stages (Pliszka et al., 2000). Differences in this component have been 
observed previously in attention deficit hyperactivity disorder (ADHD) subjects (Johnstone et 
al., 2001; Lazzaro et al., 2001) who display greater amplitude in this component relative to 
controls. This has been interpreted as atypical inhibition of sensory input in ADHD subjects 
(Johnstone et al., 2001). In addition, research has shown that the P2 component is elevated in 
unexpected versus expected inhibition trials (Gajewski et al., 2008). Research has also 
investigated the P2 component in inhibitory control in high and low functional impulsives (i.e. 
individuals whose impulsivity may facilitate performance). High functional impulsives show 
an increase in P2 amplitude as a function of task demand (higher demand=increased 
amplitude) whereas low functional impulsives do not (Fritzsche et al., 2011). Taken together, 
this suggests a number of explanations for the elevation of P2 during performance of this 
function. Firstly, ecstasy users have elevated impulsivity compared to nonusers and this 
impulsivity may be masking performance deficits. Fritzsche et al. (2011) suggest that this 
steeper P2 slope, as seen in the ecstasy-polydrug users, reflects earlier and more efficient 
evaluation of stimuli as a result of impulsivity. This seems a reasonable assumption given 
that elevated impulsivity has been noted in ecstasy users in previous research (e.g. Butler and 
Montgomery, 2004). The heightened P2 has been shown to be associated with stimulus 
evaluation and response (Gajewski et al., 2008). It is notable that Gajewski et al., (2008) only 
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reported elevated P2 when they increased the demands of their task, which tentatively 
suggests that, in the present study, the task was more demanding for ecstasy users. Secondly 
in line with the ADHD research cited above, the atypical early inhibitory processing 
displayed in the P2 ERP component in ecstasy users could be due to recruitment of additional 
compensatory resources, similar to the increased activity in prefrontal areas associated with 
executive functioning deficits in Alzheimer’s disease patients (Grady, et al., 2003; Saykin et 
al., 1998; Woodard et al., 1998). This proposal could also help explain the lack of observed 
behavioural differences on the task. Moreover the recruitment of additional resources at this 
early stage in processing could offset any further waveform modulation at later processing 
stages. 
Although some previous studies report differences between ecstasy users and controls 
in the P3 component on a Go/NoGo task (Gamma et al., 2005), these have conceded that 
between-group differences were lower after age, education level and cannabis use were 
controlled for. Debates have arisen about the contribution of the P3 and N2 components in 
response inhibition. For example, although often cited as being reflections of inhibitory 
control (Kok, 1986; Kopp et al., 1996), the N2 has also been argued to have a role in conflict 
monitoring, rather than response inhibition (Donkers and Boxtel, 2004; Nieuwenhuis et al., 
2003). Furthermore, the P3 has been suggested to be insensitive to performance differences in 
inhibitory control and not necessarily involved in response inhibition (Falkenstein et al., 1999; 
Kopp et al., 1996). If this is the case then perhaps the task used in the current study, which 
was employed due to it tapping the executive function of inhibitory control only, would not 
highlight any differences in these components. 
Moving on to mental set switching in Chapter 6, ERP data during the number-letter 
task also provide support for MDMA related disturbances to cognitive processing. The P3 
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component, thought to play an important role in the allocation of attentional resources and as 
such an important role in the ability to switch between mental sets, showed significant 
between group differences at several parieto-occipital and occipital electrode sites. Drug 
naïve controls displayed significantly higher mean amplitude in this component compared to 
ecstasy users as well as polydrug controls at O1 and POz. A diminished P3 component is 
thought to reflect cognitive impairment, and as such these findings are consistent with those 
of Casco et al. (2005) and Mejias et al. (2005) who observed reduced P3 in ecstasy users 
compared to controls in other cognitive tasks. Interestingly, the polydrug control group 
appear to have a reduced P3 in a further two sites (PO4 and Oz) compared to drug naïve 
controls, suggesting some evidence of atypical processing that is related to the use of drugs in 
general and not just ecstasy i.e. a polydrug effect. Furthermore, it has been suggested 
previously that concomitant cannabis use may account in part or fully for cognitive deficits 
observed in ecstasy users (Dafters et al., 2004; Gamma et al., 2005). Further to this point the 
regression analyses suggested that lifetime dose of cannabis significantly predicted lower 
mean amplitude at O1 and Oz. Although polydrug users did not differ from ecstasy users in 
amplitude at PO4 and Oz, these results provide evidence for cannabis contributing to 
processing atypicalities in mental set switching.   
Ecstasy specific differences were also apparent in the P2 component, involved in 
early processing of stimuli. It was observed that ecstasy users displayed a significantly higher 
mean amplitude than both control groups at frontal, central and fronto-central sites; Fz, Cz 
and FCz. Atypicalities at this early stage of processing in ecstasy users provide evidence that 
suggest additional resources are being recruited as a compensatory mechanism as described 
above. Perhaps additional recruitment of resources at this stage allowed for similar results 
behaviourally, despite diminished P3 amplitude at a later stage of processing. These ERP 
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results are in line with our predictions and suggest evidence for an ecstasy/polydrug effect on 
the degradation of the executive function of mental set switching.  
 In the semantic association task, there were no main effects of difficulty or site, or 
any interactions with these and group, or difficulty by site by group for the N2 component. 
There were however between group trends that warranted further exploration. In the low 
association condition of the task ecstasy users displayed a significantly larger negativity in 
the N2 component compared to drug naïve controls in occipital electrode site O2 and parieto-
occipital electrode PO8 although non-ecstasy polydrug users did not differ from either group.   
The supposedly easier high association condition showed significant differences in 
negativity at the N2 component in polydrug controls compared to drug naïve controls at 
parieto-occipital site PO3. Components that reflect positivity’s (P2 and P3) showed no main 
effects of difficulty or site, or any interactions with these and group, or difficulty by site by 
group (except in P3 where there was a site by group interaction) and there were no between 
group differences. Thus these components are less informative about access to semantic 
memory in ecstasy users. However, the group difference in the N2 component does provide 
some interesting points to consider. The N2 component has been reported as having a source 
in the anterior cingulate cortex (Bekker et al., 2005; Nieuwenhuis et al., 2003) and to reflect 
neural processes engaged during conflict monitoring, thus being increased in high conflict 
trials (Yeung & Cohen, 2006), for example when incongruence between targets and 
cues/distracters elicits a conflict of response in a Stroop task (Kopp et al., 1996). Firstly, 
considering why the N2 was more pronounced in ecstasy users compared to drug naïve 
controls in those trials where there was a lower semantic association between target and cue 
words, it is possible that at this level of processing, the ecstasy users required the recruitment 
of additional resources in order to access the semantic network of long term memory 
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compared to drug naïve controls. Previous research has provided evidence that ecstasy users’ 
performance can be more greatly impaired under higher task difficulty. For example 
Montgomery, Fisk, Newcombe and Murphy (2005) observed a decline in performance in a 
word fluency task when more rules were imposed, suggesting that deficits are more 
prominent in tasks that place more demand on the central executive. Given that participants 
reported no perceived differences in cognitive effort on the NASA-TLX it is possible that 
compensatory cognitive processing at neurological sites is correcting for deficits in executive 
function to eradicate behavioural differences and other research reporting null results, with 
respect to performance may reflect similar reallocation of cognitive resources. This aspect of 
the results was in line with our predictions.  
Ecstasy users did not show significant differences to controls on the high association 
condition of the task. It is generally accepted (Jefferies et al., 2004; Rossell et al., 2001; 
Shiffrin & Schneider, 1977) that information processing involves two modes of processing: 
automatic and controlled. Controlled processing, unlike automatic processing, involves 
selectively and consciously attending to a stimulus, suggesting that controlled processing 
involves higher level mental processes. As such automatic processing is proposed to rely on 
long-term memory, whilst controlled processing loads more on working memory (Jeffries et 
al. 2004), suggesting separable neural substrates. Indeed Rossell et al. (2001) used fMRI to 
investigate differences in effortful and automatic processing in a similar lexical decision 
priming experiment, and found that distinct sub regions of the anterior cingulate cortex 
showed activation dependent on the processing type involved. The N2 component in a 
semantic classification task was argued to reflect controlled processing by Ritter et al. (1982). 
This could help explain why the magnitude of effects was larger under the more difficult low 
association condition, as this was more effortful and as such required recruitment of 
additional resources. Furthermore it has been observed that patients with mild head injuries 
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will display greater N2 amplitudes whilst performing at a similar level of performance on 
cognitive tasks (Rugg et al., 1993). This is proposed as evidence for reallocation of cognitive 
resources to cope with task demands and to achieve similar performance.  
While the above discusses possible N2-related differences in access, it is possible that 
the N2 here reflects changes in other cognitive processes additional to semantic access (See 
Folstein & van Petten, 2008, for a review). The N2 in the current study was prominent in 
more posterior electrodes which Suwazono et al. (2000) suggest is reflective of increased 
attention demands in the visual cortex required for stimulus processing. In the study by 
Suwazono et al. (2000) posterior N2 was eliminated by eliminating target novelty (i.e. 
making targets completely predictable). Luck and Hillyard (1994) investigated 
subcomponents of the N2 component using visual search tasks. It was found that the bilateral 
posterior N2 as seen in the present study was related to visual search and target probability, 
with an increased posterior N2 when participants could not predict a target before 
presentation. Taken together this provides evidence that in the present study the posterior N2 
may reflect increased demands on visual search and maintenance of visual representations, 
with greater negativity in ecstasy polydrug users showing that they require increased 
attentional resources for this. Durable abnormalities of the N2 component observed over 
occipital and parieto-occipital sites of drug users compared to drug naïve controls are 
indicative of compensatory mechanisms, or reallocation of cognitive resources to attenuate 
any observable behavioural differences caused by ecstasy-related disturbances to traditional 
processing of semantic information and allocation of attention during visual search. 
Contrary to expectations, the n-back task yielded no observable ERP differences 
between groups. It was predicted that ecstasy users would show alterations to ERP 
components that reflect cognitive impairment/compensatory mechanisms, given that 
 
 
 
 
259 
 
performance was not significantly reduced. Furthermore, previous research combining this 
task with neuroimaging methods has suggested neuronal alterations despite equivalent 
performance (Daumann, Fimm et al., 2003). One possible explanation for the current lack of 
differences may be the design of the n-back task employed. In several ERP studies using the 
n-back task, a paradigm is employed whereby participants are presented with a series of 
stimuli (letters or numbers) and are required to respond when a stimulus in the series matches 
a stimulus presented n stimuli back in the series (Chen et al., 2008; Watter et al., 2001). This 
would therefore elicit an ERP on each response, whereas the task used in the current thesis 
required participants to select (from a display of numbers) which number was presented n 
digits back. In this case the task is more difficult and requires more protracted mental 
processing to calculate which digit was presented. As such this task may lend itself better to 
imaging methods that are not time-locked, but rather evaluate the induction of neuronal 
activity over time, for example ERD/ERS or measures or haemodynamic response such as 
fMRI/fNIRS. Indeed the ecstasy-related activation differences observed by Daumann, Fimm 
et al. (2003), were observed in an fMRI study. 
To summarise the results from chapter 6, the ERP evidence suggests that 
ecstasy/polydrug users are showing evidence of atypical cognitive processing during tasks 
that require response inhibition, switching of the mental set and access of semantic/long term 
memory stores. The durable abnormalities observed in these tasks in P2 and N2 components, 
in line with predictions, reflect potential recruitment of additional resources to attenuate 
behavioural differences. Whereas the diminished P3 response associated with mental set 
switching may reflect general cognitive deficiencies that have been observed in ecstasy using 
populations in the past. The lack of MDMA related differences in the ERPs elicited from the 
n-back task are contrary to expectations. However the next part of this discussion focuses on 
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the results from haemodynamic response to memory updating tasks, which provide more 
evidence consistent with expectations. 
Chapter 7 investigated the haemodynamic response to memory updating using letter 
updating and spatial updating tasks. Functional near-infrared spectroscopy was employed to 
assess the haemodynamic response to task in ecstasy users, polydrug controls and drug naïve 
controls. To summarise the results, performance was equivalent between groups on both 
updating measures. Whilst this was again contrary to expectations due to previous research 
suggesting that ecstasy users were consistently impaired on this function, it was in line with 
results from updating performance in Chapter 6. Furthermore it was predicted that in the 
absence of behavioural differences, haemodynamic measures would provide evidence of 
ecstasy users being engaged in more effortful cognition as an index of cognitive 
reallocation/compensatory mechanisms. The results from fNIRS showed that during the 
letter-updating task ecstasy users showed significant increases in oxy-Hb from baseline 
compared to both control groups at voxel 12, situated over the right medial PFC. Furthermore 
significant increases in deoxy-Hb were observed in ecstasy users relative to drug naïve 
controls at V12. At V12 the difference was approaching significance compared to polydrug 
users. At V7 ecstasy users had greater deoxy-Hb compared to drug naïve controls that was 
approaching significance. At V1 ecstasy users displayed significant increases in deoxy-Hb 
compared to polydrug users, and differences compared to drug naïve controls that were 
approaching significance and at V8 ecstasy users showed greater deoxy-Hb compared to both 
control groups that was approaching significance. These voxels are located across the breadth 
of the PFC showing a bilateral haemodynamic response to letter updating. This is consistent 
with previous neuroimaging studies that suggest memory updating requires bilateral neuronal 
response (e.g. Collette et al., 2007). During the spatial updating task ecstasy users showed 
significant increases in oxy-Hb compared to both groups at voxel 8, situated over the left 
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medial prefrontal cortex. No significant between group differences were observed for deoxy-
Hb during the spatial updating task. Regression analyses were generally non-significant. 
However frequency of MDMA use predicted oxy-Hb and deoxy-Hb at V12 during letter 
updating, suggesting that frequency of use may affect haemodynamic response to memory 
updating.  
Increases in oxy-Hb compared to both control groups, are indicative of increased 
cognitive effort displayed by ecstasy users to attenuate behavioural differences and are in line 
with expectations. These results suggest that although performing at a similar level, the tasks 
were more demanding for ecstasy users. Increases in oxygenated haemoglobin are understood 
to reflect increases in neuronal activity (Leff et al., 2011), and levels of oxy-Hb increase with 
increased demand (Izzetoglu et al., 2004). The importance of measuring haemodynamic 
response to tasks where subjects perform at a similar level behaviourally has been explored 
previously in human operators (for example, air traffic control operators – Ayaz et al., 2012). 
Such studies highlight the dissociation between cognitive effort and performance output, 
arguing that performance can be maintained at necessary levels via increased mental effort or 
perhaps strategic alterations. However increased mental workload is also suggested to be 
predictive of future performance failure (with increased demand or task changes). Increases 
in oxy-Hb are accepted as increases in cognitive effort despite behaviourally similar 
performance, and can be used as an assessment of operators’ ability (Ayaz et al., 2012). This 
is an interesting distinction to make, as in previous studies neurological disorders are coupled 
with task performance deficits and reductions in oxy-Hb (Ehlis et al., 2008). However given 
that the current sample does not suffer from neurological impairment it is not appropriate to 
compare results from this sample with those in studies such as that conducted by Ehlis et al. 
(2008). The explanation of increasing cognitive effort to maintain similar behavioural 
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performance is more applicable and may reflect recruitment of additional cognitive resources 
compared to controls and predict future cognitive decline. 
The post-hoc statistical comparisons of means for the deoxy-Hb data in this chapter 
were assessed at the 2 tailed level. This is because it is suggested that during neurovascular 
coupling, increases in cerebral blood flow and cerebral blood volume are caused by 
reductions in local glucose and oxygen due to increased consumption of these from the local 
capillary bed (Irani et al., 2007). Thus increases in oxygenated haemoglobin delivery will 
outweigh consumption leading to an excess of oxygenated haemoglobin in the activated area 
(Fox et al., 1988). The excess of oxy-Hb is argued to cause decreases in deoxy-Hb, however 
this has been the subject of much debate, as equally, increases in deoxy-Hb may be observed 
in the capillary bed due to increased oxygen consumption (Irani et al., 2007). Previous 
research has suggested that increases in oxy-Hb are often complimented by a decrease in 
deoxy-Hb in the same area (Ehlis et al., 2008; Leff et al., 2008). However oxygenated and 
deoxygenated haemoglobin do not necessarily have a linear relationship, rather they are 
separate sources of haemodynamic response. Furthermore several studies have shown 
increases in deoxy-Hb alongside increases in oxy-Hb (Hoshi & Tamura, 1993; Sakatani et al., 
1999). As such deoxy-Hb appears to be a less reliable measure of neuronal activation than 
oxy-Hb in fNIRS. Nevertheless these results are better understood as an increase in total 
haemoglobin to the areas of the prefrontal cortex that are involved in this executive function, 
given that total-Hb is understood to be the sum of oxy-Hb and deoxy-Hb (Steinbrink et al., 
2006). 
To summarise results from Chapter 7, there is evidence from fNIRS that ecstasy users 
are engaged in more effortful cognition indexed by increases in oxy-Hb to areas of the 
prefrontal cortex in letter-updating (V12 in the right medial PFC) and spatial updating (V8 
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left medial PFC). Increases in neuronal activation, reflect a compensatory mechanism due to 
degradation of 5HT neurons in the PFC via MDMA use. Furthermore this may predict future 
cognitive failure with increasing task demands. This is in line with our predictions and 
supports previous research suggesting that ecstasy users show performance deficits in 
updating (Montgomery & Fisk, 2008; Montgomery, Fisk, Newcombe & Murphy, 2005). 
Moreover, these results are consistent with neural activation changes that have been observed 
in ecstasy users during memory updating tasks in fMRI studies that are suggested to reflect 
MDMA-induced neurotoxicity (Daumann, Fimm et al., 2003; Daumann, Schnitker et al., 
2003; Daumann, Fischermann, Heekeren et al., 2004). 
 
 Chapter 8 investigated the effects of ecstasy/MDMA on the haemodynamic response 
to the remaining executive functions that were not covered in Chapter 7; inhibition, switching 
and access. Ecstasy users were compared to a non-ecstasy control group (largely of drug 
naïve participants) on performance of RLG, number-letter task and CWFT and their 
haemodynamic response was assessed using fNIRS. The ecstasy users in this sample did not 
differ significantly from controls in fluid intelligence, sleep measures or levels of arousal, 
depression or anxiety. However, they did report drinking significantly more alcohol per week 
than controls and due to their concomitant use of other drugs, it may be more adequate to 
refer to them as polydrug users. 
As in previous chapters behavioural data did not yield any significant differences at 
any level of any of the tasks used. However, as predicted ecstasy users did display alterations 
to neuronal activation on all three tasks used, which is consistent with findings from Chapter 
6. Typically ecstasy users displayed increases in oxy-Hb compared to controls that reflect 
increases in effortful cognition, which is in line with findings from Chapter 7. Furthermore 
 
 
 
 
264 
 
increases in deoxy-Hb were again observed in ecstasy users relative to controls during the 
RLG task and the CWFT. 
Inhibitory control was measured using RLG and analysis of fNIRS data during this 
task revealed that on the easier level of the task (generation rate of 4s), ecstasy users showed 
significant increases in oxy-Hb at one voxel (V10) in the right medial PFC and one voxel that 
was approaching significance in the left DLPFC (V1). However deoxy-Hb was also increased 
in ecstasy users relative to controls at several voxels relating the left DLPFC and the right 
DLPFC. When difficulty was increased (2 second rate) a stronger haemodynamic response 
was observed in the ecstasy user group. Increased levels of oxy-Hb were observed in V4 
relating to the left DLPFC, and V10 and V12 relating to the (inferior) right medial PFC 
compared to controls. A further two voxels (V1 and V14) also approached significance. 
Significantly more deoxy-Hb was observed in six voxels in ecstasy users compared to 
controls, covering the spectrum of the PFC. This marked increase in significantly different 
voxels, suggest that neuronal activation is increasing as a function of difficulty. Again in the 
most difficult block of the task (generation rate of 1s) ecstasy users display significant 
increases in oxy-Hb at two voxels V12 (located on the inferior part on the right medial PFC) 
and V14 (relating to the right DLPFC), with a third (V13) approaching significance. This was 
a less pronounced difference than at the two second rate, however there was an increase in 
the number of voxels showing increased deoxy-Hb (a total of 8 voxels, primarily relating to 
the left DLPFC and right DLPFC, with a further two approaching significance).This shows a 
general increase in neuronal activity at this rate, if we consider that the total amount of 
haemoglobin to the prefrontal cortex appears increased. This supports the existing evidence 
that suggests ecstasy users are more greatly affected when greater cognitive load is placed 
upon them (Wareing et al., 2000; Montgomery, Fisk, Newcombe & Murphy, 2005).  
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The increase in neuronal activation observed in this inhibitory control task is bilateral 
and suggests that ecstasy polydrug users find this task more difficult than non-users. Meta-
analysis of neuroimaging data during cognitive functions suggest a network of PFC regions 
are regularly active, including bilateral activation of the DLPFC, inferior frontal cortex and 
anterior cingulate cortex (Duncan & Owen, 2000). Interestingly, a review of lesion studies 
(Aron et al., 2004), suggested that although the network of PFC areas described above is 
necessary for inhibitory control, the right inferior frontal cortex is of particular importance in 
this function. This is consistent with the current results that observe consistently increased 
oxy-Hb in inferior voxels relating to the right of the PFC (V10 and V12), for ecstasy users. If 
MDMA damages 5-HT neurons, which are abundant in the PFC, it is logical that these areas 
that are necessary for performing executive tasks would require additional resources, or 
would show increased activation as a function of increased demand. This is further support 
for the argument that ecstasy users are recruiting additional resources to perform at a similar 
level as controls on the task. This supports results from the ERP data on inhibition from 
Chapter 6 (Roberts et al., 2013a), which suggests atypical processing, despite equivalent 
behavioural performance. These results are also in agreement with those of Roberts and 
Garavan (2010), who observed that ecstasy users displayed increased frontal and temporal 
BOLD activation compared to controls during a Go/NoGo task, in an fMRI study. Morgan et 
al. (2006) suggested that depletion of serotonin and impairment of other executive functions 
may lead to poor inhibitory control. Taken together these results potentially reflect evidence 
of MDMA related serotonergic neurotoxicity. The regression analyses on the present dataset 
showed that last 30 day use significantly predicted oxy-Hb increase in voxels 12 and 14 
during the one second rate of the task, after controlling for cannabis use indices. This is 
indicative of recency of MDMA use having implications for inhibitory control. Indeed Hoshi 
et al. (2007) observed impaired inhibitory control in ecstasy users which they suggest is 
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related to recency of use, given that current users were impaired, but former users were not. It 
is suggested that abstention may lead to recovery of this function. Furthermore, last 30 day 
use also predicted P2 amplitude during the Go/NoGo task in Chapter 6, this provides further 
evidence that recency of use may be an important factor for inhibitory control. 
In the first switching block of the number-letter task ecstasy users displayed 
significantly more oxy-Hb than drug naïve controls in voxel 5 relating to the left medial PFC. 
Increases in oxy-Hb were also approaching significance at V6 and V13. In the second block 
ecstasy users showed increased oxy-Hb compared to controls that was approaching 
significance at V5 again. There were no significant differences in the deoxy-Hb data. 
Nevertheless, significant increases in oxy-Hb again suggest that ecstasy users are engaging in 
more effortful cognition during mental set switching than non-users. The increase in oxy-Hb, 
typically in the left medial PFC reflects recruitment of additional resources to attenuate 
performance deficits. This is consistent with our predictions, and findings of atypical 
processing during this task in Chapter 6 (Roberts et al., 2013c in press). This reflects an 
increase in cognitive effort at the same level of performance that may predict future cognitive 
failures (Ayaz et al., 2012). Interestingly, the regression analysis conducted on oxy-Hb 
increase at V5, showed that lifetime dose of cannabis significantly predicted oxy-Hb increase. 
Furthermore none of the ecstasy use indices predicted level of oxy-Hb after controlling for 
cannabis use indices. This is particularly salient, given the observed contribution of cannabis 
to the diminished P3 response during this executive function in Chapter 6. Dafters and Hoshi 
(2004) have previously highlighted the contribution of cannabis to memory performance in 
MDMA users. However work from the same lab (Dafters 2006), suggested that MDMA users 
(who also used cannabis) were impaired in switching performance compared to cannabis only 
users and drug naïve controls. The contribution of cannabis to the results on switching in this 
thesis highlight the importance of understanding potential drug interactions that may affect 
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cognition. It is advised that the results here are treated with caution and are described as 
polydrug effects due to the concomitant use of other drugs. However the interaction between 
MDMA use and cannabis use appears to be particularly salient in relation to task switching.   
fNIRS analysis during the CWFT (access) yielded some interesting results; as 
predicted, ecstasy users displayed increases in oxy-Hb compared to controls in three voxels 
relating to the left DLPFC as well as one voxel relating to the right medial PFC on what is 
considered to be the easiest level of difficulty on the task (naming animals). As difficulty 
increased, ecstasy users displayed a significantly greater increase in oxy-Hb relative to 
controls at two voxels, and a third approaching significance relating to the left DLPFC and a 
further two voxels relating to the right medial PFC. This increase in oxygenation is 
complimented by an increase in deoxy-Hb compared to controls at V2 (and V4 that was 
approaching significance) in the left DLPFC and V14 in the right DLPFC that was 
approaching significance. In the final and most difficult phase of the task (4 letter words 
beginning with C) ecstasy users displayed significant increases in oxy-Hb compared to 
controls at three voxels (and a further 1 voxel approaching significance) that pertain to the 
left DLPFC and two voxels relating to the right medial PFC. 
 Thus ecstasy users show consistently increased levels of oxy-Hb in the LDLPFC and 
RPFC regions during the access executive function. Moreover the haemodynamic response to 
the task increases with task difficulty, with ecstasy users displaying more significant 
differences in oxy-Hb in more voxels as the task progresses. This supports previous 
arguments that ecstasy users perform worse as cognitive demand increases (Wareing et al., 
2000). Further to this point Montgomery, Fisk, Newcombe and Murphy (2005) observed that 
ecstasy users perform worse in word fluency tasks as more rules are imposed, as a function of 
difficulty. Although the current task elicited no behavioural differences, oxy-Hb differences 
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were more pronounced as a function of difficulty, suggesting that, in agreement with 
Montgomery, Fisk, Newcombe and Murphy (2005), ecstasy users are showing a greater 
departure from normal cognitive functioning as difficulty increases. This highlights the 
greater sensitivity of neurophysiological measures to detect cognitive impairment. 
Compensatory mechanisms may explain the lack of behavioural differences observed using 
this task in the literature (Bedi & Redman, 2008; Halpern et al., 2004; Morgan et al., 2002). 
Especially if we consider that these studies, employed simpler word fluency measures, than 
those yielding performance differences (Montgomery, Fisk, Newcombe & Murphy, 2005; 
Montgomery et al., 2007). Moreover Montgomery, Fisk, Newcombe and Murphy (2005) 
used a much longer time frame than the task employed in this thesis (and those in the studies 
mentioned above), suggesting that longer periods of sustained load on the central executive 
produce more pronounced effects. This is consistent with the current findings, as has been 
previously stated, the increased neuronal activity that reflects increased cognitive effort to 
attain equivalent performance, potentially predicts future failure with increasing task demand 
(Ayaz et al., 2012). 
 Increases in oxy-Hb to both the left and right hemispheres reflect the need for more 
cognitive resources to attenuate behavioural performance decline and that this effect is 
bilateral. It is interesting to note this consistent increase in oxy-Hb in the left DLPFC and 
right medial PFC over all three levels of CWFT, as these areas have been implicated in 
semantic and word fluency previously. Stuss et al. (1998) observed that in patients with brain 
lesions, those to the left DLPFC caused the most severe impairments on letter based word 
fluency measures. The same lesion sites produced impairments in category based fluency, but 
so did lesions to right medial and DLPFC regions. Indeed the left inferior frontal gyrus, has 
been consistently associated with semantic and phonologic processing in functional 
neuroimaging studies (Costafreda et al., 2006), so it is interesting that these areas should 
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show the greatest differences in the word fluency task in this thesis. These areas appear to be 
working much harder in ecstasy users compared to controls to achieve similar performance. 
Likewise, Raj et al. (2010) observed that ecstasy users displayed cognitive processing 
aberrations that relate to areas of the DLPFC during semantic recognition, despite equivalent 
task performance, in an fMRI study, that is broadly consistent with the present findings. This 
potentially reflects MDMA induced neurotoxicity. The results from this study were in line 
with our predictions as well as our interpretation of the results from Chapter 6 with ERP 
correlates of semantic retrieval (Roberts et al., 2013b). Furthermore regression analyses 
suggested that frequency of use and lifetime dose of ecstasy predicted oxy-Hb levels after 
controlling for cannabis use indices at voxels (V3 and V4) relating to the left DLPFC. 
Due to ecstasy using populations invariably using other recreational drugs, as well as 
drinking significantly more alcohol than controls on weekly estimates, it cannot be ruled out 
that other drugs, or alcohol or concomitant use of substances with ecstasy are not responsible 
for the effects observed in this study. Nevertheless the ecstasy using sample did show a 
differential pattern of PFC activation on the CWFT and RLG compared to non-users, which 
is indicative of cognitive impairment in ecstasy using populations. This study provides 
evidence of atypical executive functioning in ecstasy users compared to controls on tasks 
relating to the executive functions of mental set switching, access and inhibitory control. All 
three tasks invoke an increased haemodynamic response in ecstasy users that is bilateral in 
the prefrontal cortex. These results show that ecstasy users are engaged in more effortful 
cognition than non-users to achieve equivalent performance. This is indicative of recruitment 
of additional cognitive resources in the prefrontal cortex, and perhaps predictive of future 
cognitive decline.   
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Chapters 6, 7 and 8 provide evidence of altered cognitive processing in ecstasy users 
relative to controls during executive functioning tasks that reflect compensatory mechanisms. 
As previously noted in this thesis, differences in activation observed from neuroimaging 
measures, despite equivalent performance reflect the increased sensitivity of neuroimaging 
techniques to detect cognitive deficits than behavioural measures alone. Indeed, information 
provided in this thesis may help explain the inconsistency in results from previous 
behavioural studies in this area. This point is interesting to consider as the executive 
functioning tasks in this thesis yielded no behavioural differences between ecstasy users and 
controls throughout. This is not surprising given that the tasks used in this thesis are relatively 
simple tasks of executive function and have been inconsistent in producing behavioural 
effects in the literature.  
There is however, a wealth of literature in other areas of memory and cognition that 
show ecstasy related performance differences, particularly with tasks that involve higher 
cognitive processing and mental reasoning. For example McCann et al. (1999) observed 
ecstasy users to perform worse than controls in the Logical Reasoning task (correctly 
identifying statements that accurately describe transformational grammar, from active/passive, 
positive/negative statements), yet performance on several simpler cognitive tasks was 
equivalent. These results lead the authors to suggest that ecstasy related alterations to 
cognitive function are quite subtle and are only detected on sensitive tasks that place high 
demand on the central executive. Montgomery, Fisk, Newcombe, Wareing and Murphy 
(2005) observed MDMA users to be significantly impaired in syllogistic reasoning relative to 
controls. Syllogistic reasoning involves participants drawing inferences from a set of 
premises. Reasoning is suggested to be the most cognitively demanding of all intellectual 
abilities and requires operation of working memory processes (Montgomery, Fisk, 
Newcombe, Wareing & Murphy, 2005). Therefore consistency in these measures, that are 
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more demanding than simpler executive measures, yielding ecstasy related performance 
differences may be expected. Indeed, Fisk et al. (2005) observed reasoning deficits in ecstasy 
users relative to controls, particularly when problems are more difficult. These studies offer 
consistent MDMA related difficulties in thinking and reasoning, that Fisk et al. (2005) 
conclude is a result of working memory limitations.  
Immediate and delayed recall has been investigated extensively in ecstasy users. Early 
reports showed differences between ecstasy users (novice and regular users) and controls, in 
both immediate and delayed memory that suggest performance deficits in ecstasy users 
(Parrott et al., 1998). However, this study was criticised for not reporting use of other illicit 
drugs (Parrott, 2000). The Rivermead Behavioural Memory Task (RBMT) was used to 
investigate immediate and delayed memory in ecstasy users, polydrug controls and drug 
naïve controls by Morgan (1999). This task requires a passage of prose to be remembered and 
to be recalled as accurately as possible, immediately and then again 40-50 minutes later. This 
study observed that ecstasy users recalled significantly less prose than both control groups in 
both immediate and delayed recall conditions. Morgan (1999) suggests that impaired recall 
performance may be an early sign of global, age related cognitive impairment, due to 5-HT 
function declining with age. The author argues that ecstasy use may lead to exacerbation of 
cognitive ageing. Similarly, Morgan (2002) observed ecstasy users (current and former) to be 
impaired in recall on the RBMT, particularly in the delayed recall condition compared to 
non-user controls. The results from this study suggest that ecstasy has protracted 
neuropsychological impairment, due to abstinence not reversing recall deficits. A longitudinal 
study by Zakzanis et al. (2003) suggested that continued ecstasy use was associated with 
progressive decline in immediate and delayed recall. Furthermore, after observing ecstasy 
users performing poorly in immediate and delayed recall, McCardle et al. (2004) posit that 
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ecstasy users have problems coding information into long term memory and are less able to 
focus attention on complex tasks. 
   Studies into declarative memory have also frequently observed ecstasy related 
deficits. Measures of ‘everyday’ memory, in particular prospective memory (remembering to 
do something in the future) appear to have consistent impairment following regular ecstasy 
use (Heffernan et al., 2001; Zakzanis et al., 2003). Prospective memory is understood to be 
underpinned by central executive resources. Measures of prospective memory produce more 
consistent evidence of behavioural deficits than simple executive tasks. Perhaps, such robust 
impairment behaviourally in declarative memory, higher cognitive processing and mental 
reasoning reflect how ecstasy related deficits are more apparent when greater demand is 
placed on the central executive. This is consistent with findings from fNIRS data in Chapter 8, 
which suggests haemodynamic response is greater when task difficulty increases, as well as 
other studies that have observed greater ecstasy related performance deficits as difficulty 
increases (Montgomery, Fisk, Newcombe & Murphy, 2005; Wareing et al., 2000). 
Furthermore, such behavioural tests as those mentioned above are markedly more complex 
than the relatively simple executive tasks employed throughout this thesis, which may 
explain the lack of performance deficits in the current sample. With this in mind, it may be 
interesting to observe neurophysiological correlates from fNIRS and EEG in future research 
of these more complex measures of cognitive processing. 
McCann et al. (1999) observed that cognitive function differences between ecstasy 
users and non-users are quite subtle, and performance differences are only observed in tasks 
that are more sensitive than those used in this thesis. However, they argue that this may lead 
users to unwittingly continue MDMA use, oblivious to potential cumulative damage. It is 
also suggested that difficulties may become manifest with aging and diminished neuronal 
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reserve. Indeed studies from the clinical literature into ageing and dementia may aid the 
current understanding of the implications of the effects of increased cognitive load. For 
example, it has been reported that early prefrontal connectivity abnormalities are modulated 
by cognitive demand in pre Huntingdon’s disease subjects (Wolf et al., 2008). Furthermore 
impairment in verbal memory and executive function are associated with the development of 
dementia in those with Parkinson’s disease (Levy et al., 2002). Moreover studies into 
cognitive ageing and prospective memory suggest that event-based prospective memory tasks 
that require greater cognitive demand produce significantly larger age effects than event-
based prospective memory tasks that rely on more automatic processes (Henry et al., 2004). 
Taken together the results from the current thesis that suggest that ecstasy users are engaged 
in more effortful cognition to perform at similar levels to controls, and that this can be 
modulated as a function of cognitive load, suggest that ecstasy use may exacerbate cognitive 
ageing. 
Chapter 9 investigated the effects of ecstasy use on neuroendocrine function and 
neurohormonal response to stress, using a multitasking stressor task. Performance on the task 
and the haemodynamic response was assessed, between ecstasy users, polydrug controls and 
drug naïve controls. A diurnal cortisol profile was obtained from salivary cortisol samples 
over a two day period, as well as pre and post stressor. The ecstasy users in this study did not 
differ significantly from controls on background variables such as perceived stress, fluid 
intelligence or age. Nor did they differ significantly on any of the individual components that 
made up the multi-tasking stressor task. There were also no significant between group 
differences on perceived workload as measured by the NASA TLX. There were however 
differences on subscales of the SAI VAS, indicating that ecstasy users felt less calm than both 
other groups overall and less relaxed than drug naïve controls. Furthermore as to be expected, 
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all groups showed a decrease in worry post task. Analysis of the HADS showed no 
significant differences between groups on states of anxiety or depression. 
Despite an absence of between group differences on behavioural measures the fNIRS 
data revealed several significant differences that are worthy of discussion. Ecstasy users 
displayed a significant reduction in oxy-Hb compared to both polydrug users and drug naïve 
controls at voxel 14. At voxels 2 and 16, ecstasy users had significantly less oxy-Hb relative 
to drug naïve controls. As such the results infer reduced activation of the right dorsolateral 
prefrontal cortex in ecstasy users compared to both control groups. Polydrug users displayed 
significant increases in deoxy-Hb compared to ecstasy users at voxels 2 and 14 and to both 
ecstasy users and drug naïve controls at V12. The results from the fNIRS data are contrary to 
expectation and are also in opposition to those observed from fNIRS data in Chapters 7 and 8. 
Although reductions in oxy-Hb have been associated with cognitive impairment in fNIRS 
studies previously (e.g. Ehlis et al., 2008; Herrmann et al., 2008), these are usually coupled 
with task performance deficits. As the ecstasy user group in this experiment performed to 
similar levels to controls, and given the interpretation of fNIRS results from Chapter 7 and 8, 
this does not seem an adequate explanation of the fNIRS results during multi-tasking.   
One possible explanation for these findings could be that the individual tasks that 
comprise the multi-tasking paradigm are not executive tasks and perhaps do not load on the 
PFC. Indeed two of the component tasks are visual monitoring tasks, which may induce more 
activation of the visual cortex in the occipital lobe. Neuroimaging studies that have attempted 
to define the neural substrates of mental arithmetic, suggest a widespread network of 
activation that includes activation of the lateral prefrontal cortex, cingulate cortex, occipital 
cortex and of particular salience the parietal cortex (Kong et al., 2005). Indeed Grabner et al. 
(2007) observed that activation in the parietal cortex (particularly the left angular gyrus) 
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predicts mathematical competence using fMRI. Although the prefrontal cortex does appear to 
play a role in mathematical calculation (Burbaud et al., 1995), it is reported to lie in a circuit 
involving bilateral intraparietal, prefrontal and anterior cingulate components (Chochon et al., 
1999). The final component of the multi-tasking framework is a Stroop task which measures 
inhibition (see Chapter 3.2.2). Potentially the diversity of the tasks used would require 
widespread neuronal network activation; this may lead ecstasy users to reallocate resources to 
other brain regions that this task requires that are not measured by prefrontal fNIRS. If this is 
the case it may be possible that a reduction in oxy-Hb to the PFC reflects cognitive decline. 
For example, when resources are reallocated to other regions, the PFC shows a deficit in 
activation due to exhausted resources. However if this were the case it may be expected that 
performance on the subcomponent of the Stroop task would decline, which is not the case. So 
the results are difficult to interpret in terms of our hypothesis. However, it is noteworthy that 
7 of the 8 participants’ data that were excluded from analysis of the Stroop task module, due 
to incorrect interpretation of instructions were drug users (4 ecstasy users). It has been 
observed previously that ecstasy users make more errors when completing a web based 
questionnaire compared to other drug users and drug naïve controls (Rodgers et al., 2003). 
Therefore it is possible that there are deficits in the processing of instructional information 
associated with ecstasy use. 
The results from analysis of salivary cortisol were more in line with our hypotheses. It 
was observed that ecstasy users displayed significant increases in cortisol levels compared to 
both other groups at time three of day one of the cortisol profiling protocol. Furthermore they 
exhibited greater cortisol upon waking (time 1) on day one of the cortisol profile compared to 
polydrug controls. These results reflect that ecstasy users show elevated basal cortisol levels 
compared to healthy controls, suggesting that MDMA use has adverse effects on the HPA-
axis. This is in agreement with previous reports of acute, on drug elevation of cortisol level in 
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ecstasy users (Parrott et al., 2008), as well as longer lasting basal increases in plasma cortisol 
secretion observed in ecstasy users (Gerra et al., 2003). Gerra et al., (2003) report a blunted 
cortisol response to stress in ecstasy users comparative to controls from plasma cortisol levels, 
the results from post task salivary cortisol analysis in our sample suggest that the current 
sample had steadily declining cortisol levels throughout the day. Perhaps the multi-tasking 
framework used in this thesis was not sufficiently stressful to observe elevated cortisol levels 
post task. Alternatively, perhaps the HPA-axis becomes exhausted, due to high basal levels of 
cortisol, and as such appears unresponsive to experimental stressors. This is a potential 
explanation of the current findings that is in concordance with suggestions by Gerra et al. 
(2003). In summary it appears that ecstasy users display increases in basal salivary cortisol 
levels, which reflects damage to the integrity of the HPA-axis. Repeated doses of the acute 
metabolic stressor MDMA (Parrott, 2006; Parrott et al., 2008), hyperstimulation (from 
crowding, intense lighting, heat) and prolonged physical activity (dancing), may have 
cumulative effects, resulting in chronic bioenergetic distress (Parrott, 2006; Parrott, 2009). 
Such effects may lead to long lasting alterations to neuroendocrine function, which is 
potentially what is being observed in the current ecstasy using sample. 
Limitations:  
Unlike the relatively “pure” MDMA user groups in the two studies by Halpern et al. 
(2004 & 2011), the ecstasy user groups in this thesis tended to take several other drugs – in 
particular cannabis. Although attempts to control for this have been made with the addition of 
a polydrug control group in three out of the four experimental chapters, it was apparent that 
the ecstasy user group generally smoked more cannabis and consumed more cocaine than 
polydrug users in each case. This is problematic for our results as cocaine has been shown to 
have strong associations with deficits in inhibitory control (Fillmore & Rush, 2002). As such 
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any observed differences could still be attributed to the use of these other drugs, or indeed a 
synergistic effect of concomitant use of other drugs. Furthermore, in Chapter 6 there were 9 
participants in the ecstasy user group who reported using ketamine in the last 30 days. This is 
potentially problematic for the interpretation of the results given the association between 
ketamine use and executive function deficits in humans (for a review see Morgan & Curran, 
2006). Specifically, switching has been shown to be impaired in animals with ketamine 
exposure (Stoet & Snyder, 2006). The polydrug control group showed a diminished P3 
response compared to drug naïve controls in several sites in the switching task, also in the 
semantic association task ecstasy users, although showing greater negativities in the N2 in the 
low association condition of the task, compared to drug naïve controls, were not significantly 
different to polydrug controls. Regression analyses were conducted to try and control for 
cannabis use (as this was the primary co-used substance in the ecstasy using samples). 
However statistical analysis and polydrug control groups cannot account for potentially 
additive effects that concurrent drug use may have. Perhaps it would be more accurate to call 
the observed effects “polydrug effects”. With this in mind, it can also not be ruled out that 
premorbid factors do not predict drug use, and that such factors (for example differences in 
sensation seeking) contribute to the observed differences in the present thesis. In addition, the 
self-reporting of psychological state is potentially problematic and in future research, a 
structured psychiatric assessment may be more appropriate. Tobacco use was also not 
controlled for in this thesis, there has been previous research to suggest that tobacco smoking 
has an effect on EEG measures (Gilbert et al., 2004; Illan & Polich, 2001). In particular 
abstinence from tobacco is associated with performance and activity decline that can last for 
up to 31 days (Gilbert et al., 2004). However, smokers were permitted to smoke tobacco on 
the day of testing so this is unlikely to have affected the results reported here. The quasi-
experimental design employed in each study also means it cannot be ruled out that the 
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differences observed are not the result of factors other than drug use. Attempts have been 
made to control for many of these such as sleep patterns, sleepiness, fluid intelligence, age, 
state mood and residual intoxication of drugs. In most cases there were no between group 
differences on these measures. However in Chapter 7, ecstasy users were significantly older 
than both control groups and also reported being sleepier than drug naïve controls prior to 
testing. These factors were entered into the regression analyses for this chapter and did not 
predict significant amounts of variance in haemodynamic response in any case. Residual 
intoxication of alcohol was self-report, but in future studies it would be advantageous to 
verify this with a breathalyser to ensure no residual alcohol intoxication. Self-report measures 
for background drug use are also problematic, however because of the legal status of the 
drugs consumed, this remains the most appropriate measure of background drug use, and is 
also the most commonly used in this area of research (Fox et al., 2001; Montgomery et 
al.,2010). The purity of the tablets consumed by the current set of participants as well as the 
strength of the cannabis being consumed is questionable. However, Parrott (2004) reported 
that the purity of ecstasy tablets collected from amnesty bins in nightclubs in the UK is 
approaching 100%. However if this is not the case then this raises additional concerns over 
the magnitude of cognitive deficits incurred (Montgomery et al., 2010). Furthermore 
although confirmation of drug abstinence (apart from cannabis) was sought through 
collecting urine samples from participants in every experiment, these have only been 
analysed from the participants in Chapter 6. This is due to the analysis being performed at 
NHS hospitals, and relying on the time of our collaborator. Thus confirmation of abstinence 
from illicit drug use (apart from cannabis) for 7 days prior to testing, again relies upon self-
report for Chapters 7, 8 and 9. However many of the published research articles in this area 
do not report objective measures of drug use (Montgomery, Fisk, Newcombe & Murphy, 
2005; Fisk & Montgomery 2009; Burgess et al., 2011). 
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Implications: 
 There are several implications from the research conducted in this thesis, firstly, the 
neuroimaging results suggest that ecstasy users are employing compensatory mechanisms to 
make up for shortcomings in executive functioning. Neuronal activity aberrations are 
suggestive of potential serotonergic neurotoxicity due to repeated pharmacological 
interference to the serotonin system by administration of MDMA. It has been suggested that 
the evidence of compensatory mechanisms and increased effortful cognition predict future 
failures. This is in line with the suggestion that MDMA use potentially exacerbates cognitive 
ageing. Furthermore the atypicalities in processing observed in this thesis also reflect 
cognitive inflexibility. These have real world implications as cognitive flexibility is a 
desirable trait in every-day life. Serotonin is involved in the regulation of many 
psychobiological functions; as such degradation to the serotonin system from MDMA use has 
other psychobiological implications that stretch further than cognitive deficits. As already 
shown in this thesis, MDMA use may have adverse effects on neuroendocrine function. 
Neurohormonal activation has a role in moderating immune responses. Indeed increased 
basal cortisol levels reflect elevated levels of physiological stress. Such physiological stress 
can lead to exacerbation of infectious disease (Sapolsky, 1996). Furthermore pronounced and 
sustained load on the HPA-axis can increase incidence of depression (Wong et al., 2000). 
Work related stress, along with anxiety and depression accounted for the majority of sick 
days from work taken in 2011/2012 (Labour Force Survey for 2011/2012, HSE). Indeed 
Connor (2004) has already reported MDMA’s effects as a stressor on the immune system. 
Therefore findings of this thesis could be used for educational purposes and could inform 
prospective users or individuals who have used ecstasy in the past of the potential harms in 
terms of neurohormonal changes and cognitive function alterations before consideration of 
use.  
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 The research from this thesis has implications for cognitive and psychobiological 
health and well-being. It contributes to the existing knowledge about MDMA’s potential as a 
selective serotonergic neurotoxin; as such it can aid the current understanding and treatment 
of drug related disorders involving HPA axis dysfunction, and cognitive decline. The results 
are useful for health education and have potential use in harm reduction strategies and 
interventions for drug use disorders. This is of particular salience given the government’s 
recent discussions about drug reclassification, information provided in this thesis could prove 
beneficial when assessing the relative harms of ecstasy for reclassification under the Misuse 
of Drugs Act (MDA). 
Future Research: 
 There are a number of suggestions for future research that arise from the current thesis. 
Firstly, in Chapters 6 and 8 it was observed that ecstasy users show differences to controls in 
their neurophysiological response to inhibition. In both cases there were significant results 
from regression analyses to suggest that recency of use may play a role in this executive 
function. It would be interesting to conduct research into this function with ecstasy users that 
have been abstinent from drug use for a reasonably long period of time, for example 12 
months. Hoshi et al., (2007) conducted behavioural research into this area and observed 
former users to be unimpaired compared to current users. Morgan et al. (2002) also compared 
former users to current users and controls, observing little performance differences. However 
as has been shown in this thesis, neuroimaging techniques provide more sensitive measures 
of impairment and greater information about the nature of such impairments. Thus it would 
be beneficial to observe former users performance on inhibitory control relative to current 
users and controls in combination with fNIRS, EEG and fMRI. Indeed Reneman, Lavalaye et 
al. (2001) have reported that MDMA’s neurotoxic effects on SERT may be reversible after 
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long periods of abstinence. A multi-faceted neuroimaging approach combining several 
methods with strict inclusion criteria for group assignment might help address the 
contribution to prolonged abstinence to this function. 
 In the switching tasks in chapters 6 and 8, there is evidence to suggest that cannabis 
may be an important factor in ecstasy-related neuronal activation differences for this function. 
Indeed the contribution on drug use besides ecstasy is always problematic for research in this 
area. Few studies have the purity of the ecstasy user group observed in Halpern et al.’s 2004 
and 2011 studies. Concomitant drug use is at least partially controlled for in the literature 
with the inclusion of non-ecstasy polydrug users and various statistical controls. However, 
ideally future research should concentrate on sampling techniques that recruit participants 
that are ecstasy only users, cannabis only users etc. This may help aid the understanding of 
the relative contributions of each drug to potential cognitive deficits. That said, in the real-
world environment of recreational drug use, where individuals are using ecstasy, it appears 
that use is frequently coupled with co-use of other drugs. As such the results from studies 
such as those in this thesis do offer validity in terms of understanding the nature of drug 
interactions and the effects arising from drug use that is commonplace in recreational 
environments. 
 The use of fNIRS in this thesis has been beneficial in aiding our understanding of 
PFC activation in executive functioning tasks, and MDMA related changes to haemodynamic 
responses in these areas. However this technology in the current thesis has been limited to the 
PFC only. The whole head fNIRS systems would provide more information about 
haemodynamic response across the cortex. This may be advantageous for gaining information 
about connections with other neural areas that may be involved in some working memory 
tasks. Indeed this may provide more information that is necessary to understand the results 
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from the multi-tasking neuronal response. To this end, it may also be beneficial to incorporate 
fMRI into some of the protocols in the current thesis. fNIRS is a valuable and upcoming 
portable technology that is easy to set up and is more robust to noise and movement artefacts 
than fMRI. However it does not have the spatial resolution to provide the rich information 
about specific neuronal areas showing activation during tasks across the whole brain that 
fMRI affords. fMRI has been employed in the past to observe ecstasy-related changes to 
neuronal activation during updating (Daumann, Fischermann, Heekeren et al., 2004), 
inhibitory control (Roberts & Garavan, 2010) and semantic recognition (Raj et al., 2010). 
However, future research could use this technology with greater task specificity such as that 
employed by Raj et al. (2010) and with control groups (including drug naïve, cannabis only, 
former drug users) that may provide more complete assessment of the executive functions 
used in all three of the aforementioned studies. 
 The interesting results that have been observed in this thesis from salivary cortisol 
levels in ecstasy users also have scope for future research. The long lasting effects of 
bioenergetic stress on the HPA axis could be explored by conducting diurnal cortisol profiles 
on participants who report taking ecstasy in environments with high levels of sensory 
stimulation (hot environments, crowding, and intense lighting) and prolonged dancing, and 
those who report taking the drug in more ambient environments with less physiological stress. 
 Although this thesis did attempt to control for a number of background factors that 
may influence results (intelligence, sleep, age etc.), it may be that there are other individual 
differences and lifestyle variables that have not been controlled for that may contribute to the 
effects observed. Future research should aim to focus on protective factors (such as that 
mentioned in the previous paragraph), to observe whether these may be useful in reducing 
harm when on drug. Regular breaks from dancing, adequate nutrition and more research into 
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the effects of bingeing and higher nightly doses may lead future research to produce 
neuroprotective strategies for drug users. 
Thesis Summary: 
 This thesis sought to evaluate the neurophysiological response to executive functions 
in a sample of recreational ecstasy users. This was investigated using Miyake et al.’s (2000) 
conceptual framework of executive functioning with the additions made by Fisk and Sharp 
(2004) with EEG and fNIRS. It was found that ecstasy users show atypical processing in ERP 
components during inhibition, switching and access tasks that reflect cognitive 
impairment/compensatory mechanisms. Furthermore the haemodynamic response to each of 
the four proposed executive functions was altered in ecstasy users reflecting increased 
cognitive effort and recruitment of additional resources as a result of potential degradation to 
the serotonin system via MDMA related neurotoxicity. In most cases neuronal activation 
changes appear to be due to ecstasy. However cannabis use emerged as an important 
predictor of ERP amplitude and oxygenated haemoglobin increase during switching. The 
changes to neuronal activation reflect compensatory mechanisms/reallocation of cognitive 
resources to enable equivalent performance to controls in executive functioning as a whole.   
 There is also evidence of MDMA related alterations to HPA-axis function, whereby 
increased salivary cortisol levels in ecstasy users from diurnal cortisol profiles reflect 
elevated basal stress levels. The neurophysiological changes observed in this thesis suggest 
that ecstasy is damaging to the human brain. This is likely to be a result of damage to the 
serotonergic system. As such results from this thesis should be used to educate individuals 
considering using ecstasy. 
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Appendix 1 
The table below shows results from regression analyses on voxels showing significant between group differences during the RLG task in 
Chapter 8. Cannabis use indices and ecstasy use indices are entered as predictors of oxy-Hb and deoxy-Hb increases from baseline (µmolar). 
        
DV IV R² ∆R² F-change B SE β 
 Step 1       
4s V10 oxy Cannabis frequency of use 0.12 0.03 1.29 0.22 0.26 0.20 
 Lifetime dose (cannabis)    0.00 0.00 -0.18 
 Last 30 days dose (cannabis)    0.01 0.02 0.09 
        
4s V3 deoxy Cannabis frequency of use 0.06 -0.03 0.65 0.08 0.19 0.09 
 Lifetime dose (cannabis)    1.51 0.00 0.02 
 Last 30 days dose (cannabis)    -0.01 0.01 -0.30 
        
4s V4 deoxy Cannabis frequency of use 0.07 -0.13 0.34 0.07 0.56 0.06 
 Lifetime dose (cannabis)    0.00 0.00 0.46 
 Last 30 days dose (cannabis)    -0.03 0.03 -0.79 
        
4s V5 deoxy Cannabis frequency of use 0.10 0.03 1.31 0.19 0.18 0.22 
 Lifetime dose (cannabis)    1.94 0.00 0.03 
 Last 30 days dose (cannabis)    -0.02 0.01 -0.47 
        
4s V13 deoxy  Cannabis frequency of use 0.09 0.01 1.16 0.15 0.20 0.16 
 Lifetime dose (cannabis)    0.00 0.00 0.19 
 Last 30 days dose (cannabis)    -0.02 0.01 -0.48 
        
4s V14 deoxy Cannabis frequency of use 0.50 -0.04 0.56 -0.10 0.19 -0.10 
 Lifetime dose (cannabis)    0.00 0.00 0.24 
 Last 30 days dose (cannabis)    -0.02 0.01 -0.39 
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4s V15 deoxy Cannabis frequency of use 0.50 -0.04 0.56 -0.27 0.43 -0.21 
 Lifetime dose (cannabis)    0.00 0.00 0.19 
 Last 30 days dose (cannabis)    -0.00 0.02 -0.03 
        
4s V16 deoxy Cannabis frequency of use 0.09 0.00 1.05 -0.08 0.22 -0.08 
 Lifetime dose (cannabis)    0.00 0.00 0.36 
 Last 30 days dose (cannabis)    -0.01 0.01 -0.25 
        
2s V4 oxy Cannabis frequency of use 0.43 0.30 3.47* -0.40 0.35 -0.50 
 Lifetime dose (cannabis)    0.00 0.00 0.59 
 Last 30 days dose (cannabis)    0.01 0.02 0.39 
        
2s V10 oxy Cannabis frequency of use 0.09 -0.01 0.88 0.24 0.32 0.18 
 Lifetime dose (cannabis)    -7.73 0.00 -0.06 
 Last 30 days dose (cannabis)    0.01 0.02 0.08 
        
2s V12 oxy Cannabis frequency of use 0.09 -0.01 0.91 -0.09 0.20 -0.10 
 Lifetime dose (cannabis)    6.04 0.00 0.08 
 Last 30 days dose (cannabis)    0.01 0.01 0.23 
        
2s V14 oxy Cannabis frequency of use 0.07 -0.02 0.75 0.04 0.24 0.04 
 Lifetime dose (cannabis)    0.00 0.00 0.15 
 Last 30 days dose (cannabis)    0.01 0.02 0.10 
        
2s V2 deoxy Cannabis frequency of use 0.12 0.03 1.34 0.04 0.25 0.04 
 Lifetime dose (cannabis)    8.30 0.00 0.09 
 Last 30 days dose (cannabis)    -0.02 0.02 -0.41 
        
2s V4 deoxy Cannabis frequency of use 0.05 -0.15 0.26 -0.02 0.81 -0.01 
 Lifetime dose (cannabis)    0.00 0.00 0.50 
 Last 30 days dose (cannabis)    -0.03 0.04 -0.50 
 
 
 
 
318 
 
        
2s V11 deoxy  Cannabis frequency of use 0.04 -0.12 0.24 0.00 0.41 0.00 
 Lifetime dose (cannabis)    0.00 0.00 0.32 
 Last 30 days dose (cannabis)    -0.04 0.03 -0.57 
        
2s V13 deoxy Cannabis frequency of use 0.07 -0.02 0.82 0.23 0.27 0.19 
 Lifetime dose (cannabis)    0.00 0.00 0.15 
 Last 30 days dose (cannabis)    -0.02 0.02 -0.37 
        
2s V14 deoxy Cannabis frequency of use 0.03 -0.07 0.28 -0.01 0.21 -0.01 
 Lifetime dose (cannabis)    0.00 0.00 0.24 
 Last 30 days dose (cannabis)    -0.02 0.01 -0.31 
        
2s V15 deoxy Cannabis frequency of use 0.01 -0.08 0.11 0.16 0.93 0.06 
 Lifetime dose (cannabis)    0.00 0.00 0.06 
 Last 30 days dose (cannabis)    -0.02 0.04 -0.15 
        
1s V12 oxy Cannabis frequency of use 0.23 0.15 2.90* 0.07 0.19 0.07 
 Lifetime dose (cannabis)    0.00 0.00 -0.17 
 Last 30 days dose (cannabis)    0.02 0.01 0.39 
        
1s V14 oxy Cannabis frequency of use 0.18 0.11 2.38 0.11 0.21 0.11 
 Lifetime dose (cannabis)    0.00 0.00 0.16 
 Last 30 days dose (cannabis)    0.01 0.01 0.21 
        
1s V2 deoxy Cannabis frequency of use 0.10 0.01 1.12 -0.01 0.20 -0.01 
 Lifetime dose (cannabis)    8.12 0.00 0.12 
 Last 30 days dose (cannabis)    -0.01 0.01 -0.34 
        
1s V3 deoxy Cannabis frequency of use 0.03 -0.05 0.38 0.11 0.21 0.12 
 Lifetime dose (cannabis)    -9.90 0.00 -0.01 
 Last 30 days dose (cannabis)    -0.01 0.01 -0.16 
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1s V4 deoxy Cannabis frequency of use 0.18 0.00 1.02 -0.52 0.57 -0.46 
 Lifetime dose (cannabis)    0.00 0.00 0.65 
 Last 30 days dose (cannabis)    -0.00 0.03 -0.12 
        
1s V5 deoxy Cannabis frequency of use 0.11 0.03 1.36 0.34 0.21 0.35 
 Lifetime dose (cannabis)    4.46 0.00 0.05 
 Last 30 days dose (cannabis)    -0.02 0.01 -0.45 
        
1s V11 deoxy Cannabis frequency of use 0.03 -0.13 0.21 0.01 0.33 0.01 
 Lifetime dose (cannabis)    0.00 0.00 0.29 
 Last 30 days dose (cannabis)    -0.03 0.02 -0.56 
        
1s V13 deoxy Cannabis frequency of use 0.07 -0.02 0.81 0.24 0.25 0.22 
 Lifetime dose (cannabis)    0.00 0.00 0.20 
 Last 30 days dose (cannabis)    -0.02 0.02 -0.37 
        
1s V14 deoxy Cannabis frequency of use 0.03 -0.06 0.34 -0.09 0.21 -0.09 
 Lifetime dose (cannabis)    0.00 0.00 0.38 
 Last 30 days dose (cannabis)    -0.01 0.01 0.25 
        
1s V15 deoxy Cannabis frequency of use 0.08 -0.01 0.87 -0.51 0.45 -0.37 
 Lifetime dose (cannabis)    0.00 0.00 0.20 
 Last 30 days dose (cannabis)    0.01 0.02 0.21 
        
 Step 2       
        
4s V10 oxy Ecstasy frequency of use 0.21 0.02 0.91 -0.01 0.92 -0.00 
 Lifetime dose (tablets)    0.00 0.00 -0.07 
 Last 30 days dose (tablets)    0.20 0.15 0.31 
        
4s V3 deoxy Ecstasy frequency of use 0.14 -0.03 0.99 0.16 0.69 0.05 
 Lifetime dose (tablets)    0.00 0.00 0.28 
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 Last 30 days dose (tablets)    0.08 0.11 0.16 
        
4s V4 deoxy Ecstasy frequency of use 0.34 -0.03 1.47 -0.34 1.15 -0.10 
 Lifetime dose (tablets)    0.00 0.00 0.38 
 Last 30 days dose (tablets)    0.31 0.23 0.50 
        
4s V5 deoxy Ecstasy frequency of use 0.19 0.04 1.13 0.12 0.67 0.04 
 Lifetime dose (tablets)    0.00 0.00 0.25 
 Last 30 days dose (tablets)    0.10 0.12 0.20 
        
4s V13 deoxy  Ecstasy frequency of use 0.16 -0.00 0.82 -0.03 0.73 -0.01 
 Lifetime dose (tablets)    0.00 0.00 0.13 
 Last 30 days dose (tablets)    0.13 0.12 0.25 
        
4s V14 deoxy Ecstasy frequency of use 0.44 0.32 6.66** -1.63 0.69 -0.42* 
 Lifetime dose (tablets)    9.37 0.00 0.04 
 Last 30 days dose (tablets)    0.49 0.11 0.82** 
        
4s V15 deoxy Ecstasy frequency of use 0.09 -0.10 0.38 0.02 0.91 0.00 
 Lifetime dose (tablets)    0.00 0.00 0.10 
 Last 30 days dose (tablets)    0.11 0.15 0.18 
        
4s V16 deoxy Ecstasy frequency of use 0.16 -0.01 0.07 -0.45 0.78 -0.12 
 Lifetime dose (tablets)    0.00 0.00 0.06 
 Last 30 days dose (tablets)    0.19 0.13 0.34 
        
2s V4 oxy Ecstasy frequency of use 0.53 0.28 0.84 -0.87 0.72 -0.36 
 Lifetime dose (tablets)    0.00 0.00 0.12 
 Last 30 days dose (tablets)    0.22 0.14 0.47 
        
2s V10 oxy Ecstasy frequency of use 0.12 -0.09 0.36 0.64 1.17 0.13 
 Lifetime dose (tablets)    0.00 0.00 -0.13 
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 Last 30 days dose (tablets)    0.06 0.19 0.08 
        
2s V12 oxy Ecstasy frequency of use 0.19 0.00 1.12 -0.39 0.74 -0.12 
 Lifetime dose (tablets)    1.47 0.00 -0.01 
 Last 30 days dose (tablets)    0.21 0.12 0.40 
        
2s V14 oxy Ecstasy frequency of use 0.14 -0.04 0.84 -0.41 0.88 -0.10 
 Lifetime dose (tablets)    0.00 0.00 -0.16 
 Last 30 days dose (tablets)    0.20 0.14 0.32 
        
2s V2 deoxy Ecstasy frequency of use 0.18 -0.00 0.70 -0.06 0.91 -0.01 
 Lifetime dose (tablets)    0.00 0.00 0.24 
 Last 30 days dose (tablets)    0.12 0.15 0.19 
        
2s V4 deoxy Ecstasy frequency of use 0.24 -0.18 0.87 0.06 1.66 0.01 
 Lifetime dose (tablets)    0.00 0.00 0.30 
 Last 30 days dose (tablets)    0.29 0.33 0.36 
        
2s V11 deoxy  Ecstasy frequency of use 0.27 -0.03 1.55 3.12 2.63 0.36 
 Lifetime dose (tablets)    0.00 0.00 0.31 
 Last 30 days dose (tablets)    0.05 0.25 0.06 
        
2s V13 deoxy Ecstasy frequency of use 0.10 -0.07 0.37 -0.04 0.98 -0.01 
 Lifetime dose (tablets)    0.00 0.00 0.13 
 Last 30 days dose (tablets)    0.11 0.16 0.16 
        
2s V14 deoxy Ecstasy frequency of use 0.25 0.10 2.92 -1.31 0.76 -0.35 
 Lifetime dose (tablets)    9.77 0.00 0.04 
 Last 30 days dose (tablets)    0.36 0.12 0.62** 
        
2s V15 deoxy Ecstasy frequency of use 0.02 -0.18 0.12 0.11 1.95 0.01 
 Lifetime dose (tablets)    0.00 0.00 0.08 
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 Last 30 days dose (tablets)    0.10 0.31 0.08 
        
1s V12 oxy Ecstasy frequency of use 0.39 0.25 2.25 -0.93 0.67 -0.27 
 Lifetime dose (tablets)    6.03 0.00 0.03 
 Last 30 days dose (tablets)    0.28 0.11 0.52* 
        
1s V14 oxy Ecstasy frequency of use 0.34 0.20 2.28* -1.06 0.76 -0.27 
 Lifetime dose (tablets)    0.00 0.00 -0.19 
 Last 30 days dose (tablets)    0.30 0.12 0.49* 
        
1s V2 deoxy Ecstasy frequency of use 0.12 -0.07 0.22 0.07 0.73 0.02 
 Lifetime dose (tablets)    0.00 0.00 0.18 
 Last 30 days dose (tablets)    0.02 0.12 0.04 
        
1s V3 deoxy Ecstasy frequency of use 0.09 -0.09 0.66 -0.02 0.77 -0.01 
 Lifetime dose (tablets)    0.00 0.00 0.29 
 Last 30 days dose (tablets)    0.06 0.12 0.11 
        
1s V4 deoxy Ecstasy frequency of use 0.39 0.05 1.24 0.00 1.16 0.00 
 Lifetime dose (tablets)    0.00 0.00 0.34 
 Last 30 days dose (tablets)    0.24 0.23 0.37 
        
1s V5 deoxy Ecstasy frequency of use 0.15 -0.02 0.50 -0.14 0.78 -0.04 
 Lifetime dose (tablets)    0.00 0.00 0.17 
 Last 30 days dose (tablets)    0.10 0.12 0.18 
        
1s V11 deoxy Ecstasy frequency of use 0.29 0.01 1.80 1.94 2.08 0.28 
 Lifetime dose (tablets)    0.00 0.00 0.40 
 Last 30 days dose (tablets)    0.07 0.20 0.11 
1s V13 deoxy Ecstasy frequency of use 0.11 -0.07 0.46 -0.23 0.91 -0.06 
 Lifetime dose (tablets)    0.00 0.00 0.09 
 Last 30 days dose (tablets)    0.15 0.15 0.23 
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1s V14 deoxy Ecstasy frequency of use 0.31 0.16 3.85 -1.44 0.77 -0.37 
 Lifetime dose (tablets)    0.00 0.00 -0.09 
 Last 30 days dose (tablets)    0.42 0.12 0.69** 
        
1s V15 deoxy Ecstasy frequency of use 0.11 -0.07 0.40 0.11 0.95 0.03 
 Lifetime dose (tablets)    0.00 0.00 0.07 
 Last 30 days dose (tablets)    0.11 0.15 0.17 
        
        
        
        
        
 
*Indicates significance at the .05 level, and ** at the .01 level. 
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Appendix 2 
The table below shows results from regression analyses on voxels showing significant between group differences during the CWFT in Chapter 8. 
Cannabis use indices and ecstasy use indices are entered as predictors of oxy-Hb and deoxy-Hb increases from baseline (µmolar). 
        
DV IV R² ∆R² F-change B SE β 
 Step 1       
V2 animals oxy Cannabis frequency of use 0.02 -0.07 0.22 0.17 0.27 0.14 
 Lifetime dose (cannabis)    0.00 0.00 -0.11 
 Last 30 days dose (cannabis)    -0.01 0.02 -0.08 
        
V3 animals oxy Cannabis frequency of use 0.10 0.02 1.28 0.37 0.18 0.40 
 Lifetime dose (cannabis)    0.00 0.00 -0.29 
 Last 30 days dose (cannabis)    -0.01 0.01 -0.19 
        
V4 animals oxy Cannabis frequency of use 0.13 -0.03 0.80 -0.05 0.49 -0.04 
 Lifetime dose (cannabis)    0.00 0.00 0.54 
 Last 30 days dose (cannabis)    -0.02 0.02 -0.38 
        
V10 animals oxy Cannabis frequency of use 0.15 0.06 1.70 0.47 0.34 0.32 
 Lifetime dose (cannabis)    0.00 0.00 0.36 
 Last 30 days dose (cannabis)    -0.04 0.03 -0.55 
        
V2 animals deoxy Cannabis frequency of use 0.03 -0.05 0.35 0.06 0.25 0.05 
 Lifetime dose (cannabis)    0.00 0.00 -0.14 
 Last 30 days dose (cannabis)    -0.00 0.02 -0.01 
        
V2 “S” words oxy Cannabis frequency of use 0.01 -0.07 0.16 0.00 0.28 0.00 
 Lifetime dose (cannabis)    -4.06 0.00 -0.04 
 Last 30 days dose (cannabis)    -0.00 0.02 -0.02 
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V4 “S” words oxy Cannabis frequency of use 0.31 0.18 2.35 -0.34 0.48 -0.29 
 Lifetime dose (cannabis)    0.00 0.00 0.91** 
 Last 30 days dose (cannabis)    -0.02 0.02 -0.47 
        
V10 “S” words oxy  Cannabis frequency of use 0.13 0.04 1.48 0.45 0.31 0.33 
 Lifetime dose (cannabis)    0.00 0.00 0.30 
 Last 30 days dose (cannabis)    -0.03 0.03 -0.46 
        
V12 “S” words oxy  Cannabis frequency of use 0.30 0.23 4.31** 0.42 0.28 0.32 
 Lifetime dose (cannabis)    0.00 0.00 -0.42 
 Last 30 days dose (cannabis)    0.03 0.02 0.44 
        
V2 “S” words deoxy  Cannabis frequency of use 0.03 -0.05 0.35 -0.11 0.31 -0.08 
 Lifetime dose (cannabis)    0.00 0.00 -0.15 
 Last 30 days dose (cannabis)    0.00 0.02 0.04 
        
V2 “C” words oxy  Cannabis frequency of use 0.03 -0.06 0.32 -0.08 0.28 -0.07 
 Lifetime dose (cannabis)    8.30 0.00 0.08 
 Last 30 days dose (cannabis)    -0.01 0.02 -0.09 
        
V3 “C” words oxy  Cannabis frequency of use 0.03 -0.06 0.33 0.01 0.20 0.01 
 Lifetime dose (cannabis)    -1.41 0.00 -0.02 
 Last 30 days dose (cannabis)    -0.00 0.01 -0.05 
        
V4 “C” words oxy Cannabis frequency of use 0.27 0.14 2.01 0.38 0.54 0.31 
 Lifetime dose (cannabis)    0.00 0.00 0.94* 
 Last 30 days dose (cannabis)    -0.06 0.03 -1.17* 
        
V10 “C” words oxy  Cannabis frequency of use 0.08 -0.02 0.84 0.32 0.35 0.22 
 Lifetime dose (cannabis)    0.00 0.00 0.26 
 Last 30 days dose (cannabis)    -0.03 0.03 -0.36 
 
 
 
 
326 
 
        
V12 “C” words oxy Cannabis frequency of use 0.21 0.13 2.71 0.26 0.27 0.21 
 Lifetime dose (cannabis)    0.00 0.00 -0.18 
 Last 30 days dose (cannabis)    0.02 0.02 0.34 
        
 Step 2       
        
V2 animals oxy Ecstasy frequency of use 0.12 -0.04 1.29 1.64 0.98 0.36 
 Lifetime dose (ta-0.blets)    0.00 0.00 0.21 
 Last 30 days dose (tablets)    -0.16 0.16 -0.23 
        
V3 animals oxy Ecstasy frequency of use 0.31 0.17 3.07 1.52 0.66 0.44* 
 Lifetime dose (tablets)    0.00 0.00 0.37 
 Last 30 days dose (tablets)    -0.15 0.11 -0.28 
        
V4 animals oxy Ecstasy frequency of use 0.52 0.30 3.58* 2.22 1.00 0.62* 
 Lifetime dose (tablets)    0.00 0.00 0.46* 
 Last 30 days dose (tablets)    -0.23 0.20 -0.35 
        
V10 animals oxy Ecstasy frequency of use 0.27 0.10 1.36 0.97 1.48 0.17 
 Lifetime dose (tablets)    0.00 0.00 0.34 
 Last 30 days dose (tablets)    -0.19 0.30 -0.18 
        
V2 animals deoxy Ecstasy frequency of use 0.15 -0.01 1.48 0.25 0.89 0.06 
 Lifetime dose (tablets)    0.00 0.00 0.44 
 Last 30 days dose (tablets)    0.03 0.14 0.04 
        
V2 “S” words oxy Ecstasy frequency of use 0.04 -0.14 0.34 0.30 1.03 0.07 
 Lifetime dose (tablets)    0.00 0.00 0.22 
 Last 30 days dose (tablets)    -0.02 0.16 -0.03 
        
V4 “S” words oxy Ecstasy frequency of use 0.52 0.30 1.94 -0.09 0.99 -0.03 
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 Lifetime dose (tablets)    0.00 0.00 0.42 
 Last 30 days dose (tablets)    0.20 0.20 0.29 
        
V10 “S” words oxy  Ecstasy frequency of use 0.23 0.05 1.11 -0.42 1.37 -0.08 
 Lifetime dose (tablets)    0.00 0.00 0.33 
 Last 30 days dose (tablets)    0.10 0.28 0.10 
        
V12 “S” words oxy  Ecstasy frequency of use 0.31 0.16 0.22 -0.16 1.23 -0.03 
 Lifetime dose (tablets)    0.00 0.00 0.17 
 Last 30 days dose (tablets)    0.00 0.24 0.00 
        
V2 “S” words deoxy  Ecstasy frequency of use 0.14 -0.02 1.38 -0.02 1.13 -0.00 
 Lifetime dose (tablets)    0.00 0.00 0.44 
 Last 30 days dose (tablets)    0.05 0.18 0.06 
        
V2 “C” words oxy  Ecstasy frequency of use 0.04 -0.14 0.19 0.03 1.00 0.01 
 Lifetime dose (tablets)    0.00 0.00 0.14 
 Last 30 days dose (tablets)    0.05 0.16 0.07 
        
V3 “C” words oxy  Ecstasy frequency of use 0.27 0.13 3.36 1.72 0.71 0.48* 
 Lifetime dose (tablets)    0.00 0.00 0.29 
 Last 30 days dose (tablets)    -0.05 0.11 -0.09 
        
V4 “C” words oxy Ecstasy frequency of use 0.46 0.22 1.53 -0.25 1.10 -0.07 
 Lifetime dose (tablets)    0.00 0.00 0.33 
 Last 30 days dose (tablets)    0.27 0.22 0.39 
        
V10 “C” words oxy  Ecstasy frequency of use 0.17 -0.02 0.95 -0.45 1.54 -0.08 
 Lifetime dose (tablets)    0.00 0.00 0.30 
 Last 30 days dose (tablets)    0.16 0.31 0.16 
        
V12 “C” words oxy Ecstasy frequency of use 0.25 0.09 0.48 0.21 1.20 0.04 
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 Lifetime dose (tablets)    0.00 0.00 0.21 
 Last 30 days dose (tablets)    0.06 0.23 0.07 
        
        
 
*Indicates significance at the .05 level, and ** at the .01 level. 
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